2017 State Profile — United States and Other Jurisdictions National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

The 2017 N-SSATS included 13,585 substance abuse treatment facilities, which reported a total of 1,356,015 clients in substance abuse treatment on March 31, 2017. The survey response rate was 89.2 percent overall.

Facility operation, by number and percent						
	Clients in treatment of				t on March 31	2017
	Faciliti	es	All clie	nts	Clients under age 18	
	No.	%	No.	%	No.	%
Private non-profit	7,163	52.7	658,896	48.6	40,235	64.0
Private for-profit	4,931	36.3	550,992	40.6	15,582	24.8
Local, county, or community government	640	4.7	66,577	4.9	3,942	6.3
State government	304	2.2	28,529	2.1	1,173	1.9
Federal government	289	2.1	34,435	2.5	372	0.6
Tribal government	258	1.9	16,586	1.2	1,558	2.5
Total	13,585	100.0	1,356,015	100.0	62,862	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
_	Faciliti	es¹	Client	Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	11,555	92.1	500,948	37.0	184	
Clients with drug abuse only	10,571	84.2	642,713	47.4	244	
Clients with alcohol abuse only	9,759	77.8	211,460	15.6	79	
Total			1,355,121	100.0	507	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and pe	rcent								
			Clients in treatment on March 31, 2017						
	Faci	lities¹			All clients		Clients	Clients age < 18	
					Median no.	Median no. of			
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%	
Outpatient	11,184	82.3	1,238,654	91.3	305	40	55,613	88.5	
Regular	10,437	76.8	599,290	44.2	40	30			
Intensive	6,241	45.9	133,850	9.9	20	15			
Day treatment/partial hospitalization	1,805	13.3	23,310	1.7	20	12			
Detoxification	1,366	10.1	11,839	0.9	5	7			
Methadone maintenance	3,395	25.0	470,365	34.7	290	20			
Residential (non-hospital)	3,125	23.0	99,881	7.4	30	19	6,539	10.4	
Short term (<30 days)	1,738	12.8	32,156	2.4	21	14			
Long term (30+ days)	2,513	18.5	56,787	4.2	28	16			
Detoxification	908	6.7	10,938	8.0	14	6			
Hospital inpatient	715	5.3	17,480	1.3	21	14	710	1.1	
Treatment	532	3.9	9,929	0.7	16	13			
Detoxification	655	4.8	7,551	0.6	14	8			
Total	13,585		1,356,015	100.0	285	36	62,862	100.0	

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	1,317	100.0
Clients in facilities with OTPs ²		
	440.000	400.0
Any MAT	413,930	100.0
Methadone	382,867	100.0
Buprenorphine	27,665	100.0
Naltrexone	3,398	100.0
Clients in facilities without OTPs ²		
Any MAT	104,225	100.0
Buprenorphine	84,558	100.0
Naltrexone	19,667	100.0

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. some j parjimoni opinono, arj maninon sin		
	No.	%
Cash or self-payment	12,248	90.2
Private health insurance	9,531	70.2
Medicare	4,767	35.1
Medicaid	8,685	63.9
State-financed health insurance	6,415	47.2
Federal military insurance	4,638	34.1
No payment accepted	422	3.1
Access to Recovery (ATR) vouchers ²	1,146	8.4
IHS/Tribal/Urban (ITU) funds	1,079	7.9
Other payments	70	0.5
Sliding fee scale	8,024	59.1
Treatment at no charge for clients who can't pay	6,036	44.4
1 == 1141 == ==== 4		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	12,763	93.9
State substance abuse agency	10,848	79.9
State mental health department	5,468	40.3
State department of health	6,368	46.9
Hospital licensing authority	854	6.3
The Joint Commission	2,666	19.6
Commission on Accreditation of Rehabilitation Facilities	3,952	29.1
National Committee for Quality Assurance	351	2.6
Council on Accreditation	670	4.9
Healthcare Facilities Accreditation Program	130	1.0
Other state/local agency/organization	416	3.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 7,238 53.3

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
	Fac	ilities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	13,069	96.2
Screening for mental health disorders	10,051	74.0
Comprehensive substance abuse assessment or diagnosis	12,654	93.1
Comprehensive mental health assessment or diagnosis	6,999	51.5
Screening for tobacco use	8,960	66.0
Outreach to persons in the community who may need treatment	8,331	61.3
Interim services for clients when immediate admission is not possible	6,381	47.0
No services offered	134	1.0
Testing		
Breathalyzer or other blood alcohol testing	8,637	63.6
Drug or alcohol urine screening	11,727	86.3
Screening for hepatitis B	3,265	24.0
Screening for hepatitis C	3,739	27.5
HIV testing	3,841	28.3
STD testing	2,970	21.9
TB screening	5,218	38.4
No services offered	1,421	10.5
Counseling	,	
Individual counseling	13,387	98.5
Group counseling	12,785	94.1
Family counseling	11,318	83.3
Marital/couples counseling	8,628	63.5
Transitional services		
Discharge planning	13,133	96.7
Aftercare/continuing care	11,771	86.6
No services offered	158	1.2
Pharmacotherapies		
Disulfiram (Antabuse®)	2,605	19.2
Naltrexone (oral)	3,557	26.2
Extended-release, injectable naltrexone/Vivitrol®	3,197	23.5
Acamprosate (Campral®)	2,691	19.8
Nicotine replacement	3,683	27.1
Non-nicotine smoking/tobacco cessation medications	2,888	21.3
Medications for psychiatric disorders	5,976	44.0
Methadone	1,271	9.4
Buprenorphine with naloxone (Suboxone®)	3,720	27.4
Buprenorphine without naloxone	2,438	17.9
Buprenorphine subdermal implant (Probuphine®)	154	1.1
No services offered	5,622	41.4
Ancillary services		
Case management services	11,282	83.0
Social skills development	10,427	76.8
Mentoring/peer support	7,677	56.5
Child care for clients' children	874	6.4
Assistance with obtaining social services	8,113	59.7
Employment counseling or training for clients	5,250	38.6
Continued	,	

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	7,346	54.1
Domestic violence services	5,511	40.6
Early intervention for HIV	3,255	24.0
HIV or AIDS education, counseling, or support	7,434	54.7
Hepatitis education, counseling, or support	6,491	47.8
Health education other than HIV/AIDS or hepatitis	7,240	53.3
Substance abuse education	13,155	96.8
Transportation assistance to treatment	5,928	43.6
Mental health services	9,210	67.8
Acupuncture	741	5.5
Residential beds for clients' children	385	2.8
Self-help groups	6,277	46.2
Smoking/tobacco cessation counseling	6,724	49.5
No services offered	40	0.3
Other services		
Treatment for gambling disorder	3,283	24.2
Treatment for Internet use disorder	1,725	12.7
Treatment for other addiction disorder	3,915	28.8
No services offered	8,517	62.7

	Faci	lities
	No.	%
Substance abuse counseling	13,423	98.8
Relapse prevention	13,073	96.2
Cognitive behavioral therapy	12,744	93.8
Motivational interviewing	12,579	92.6
Anger management	11,264	82.9
Brief intervention	11,147	82.1
Frauma-related counseling	10,792	79.4
12-step facilitation	9,929	73.1
Contingency management/motivational incentives	7,563	55.7
Dialectical behavior therapy	7,402	54.5
Rational emotive behavioral therapy	6,234	45.9
Matrix model	5,903	43.5
Computerized substance abuse treatment	2,082	15.3
Community reinforcement plus vouchers	1,614	11.9
Other treatment approaches	1,016	7.5

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	2,752	473			
Number of clients ²	86,046	12,495			
Number of designated beds	91,601	12,707			
Utilization rate ³	93.9	98.3			
Average number of designated beds per facility	33	27			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	126
Methadone	116
Buprenorphine	8
Naltrexone	1

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	4,480	33.0
Any language other than English	6,718	49.5
Non-English language provided by		
Staff counselor only	1,804	26.9
On-call interpreter only	3,179	47.3
Both staff counselor and on-call interpreter	1,735	25.8
Languages provided by staff counselor ¹		
Spanish	3,271	92.4
American Indian/Alaskan Native		
languages	81	2.3
Other	724	20.5

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ities
	No.	%
Any program or group	11,291	83.1
Adult women	6,576	48.4
Clients with co-occurring disorders	6,719	49.5
Adult men	6,235	45.9
Clients who have experienced trauma	5,164	38.0
Criminal justice clients	4,765	35.1
DUI/DWI clients	3,672	27.0
Young adults	3,966	29.2
Adolescents	3,537	26.0
Clients who have experienced domestic violence	3,436	25.3
Clients who have experienced sexual		
abuse	3,421	25.2
Pregnant or postpartum women	3,040	22.4
Seniors or older adults	2,669	19.6
LGBT ¹	2,550	18.8
Veterans	2,555	18.8
Clients living with HIV/AIDS	2,379	17.5
Members of military families	1,569	11.5
Active duty military	1,383	10.2
Other	464	3.4
No program or group offered	2,294	16.9

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Alabama National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Alabama, 129 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 13,771 clients in substance abuse treatment on March 31, 2017. The survey response rate in Alabama was 92.2 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	77	59.7	3,926	28.5	377	84.3
Private for-profit	40	31.0	9,072	65.9	70	15.7
Local, county, or community government	4	3.1	434	3.2	_	-
State government	2	1.6	101	0.7	_	-
Federal government	6	4.7	238	1.7	_	-
Tribal government	_	_	_	_	_	_
Total	129	100.0	13,771	100.0	447	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 100,0			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	109	89.3	3,391	24.6	85	
Clients with drug abuse only	110	90.2	9,435	68.5	244	
Clients with alcohol abuse only	89	73.0	945	6.9	24	
Total			13,771	100.0	353	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	102	79.1	12,821	93.1	309	36	328	73.4
Regular	83	64.3	2,996	21.8	102	35		
Intensive	49	38.0	1,611	11.7	35	22		
Day treatment/partial hospitalization	7	5.4	62	0.5	62	_		
Detoxification	14	10.9	27	0.2	7	1		
Methadone maintenance	27	20.9	8,125	59.0	292	7		
Residential (non-hospital)	26	20.2	920	6.7	95	24	119	26.6
Short term (<30 days)	11	8.5	357	2.6	72	23		
Long term (30+ days)	18	14.0	518	3.8	_	18		
Detoxification	2	1.6	45	0.3	23	_		
Hospital inpatient	7	5.4	30	0.2	_	5	_	_
Treatment	3	2.3	4	*	_	4		
Detoxification	7	5.4	26	0.2	<u> </u>	5		
Total	129		13,771	100.0	292	34	447	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	23	1.7
Clients in facilities with OTPs ²		
Cheffic in facilities with OTPS		
Any MAT	7,630	1.8
Methadone	7,441	1.9
Buprenorphine	130	0.5
Naltrexone	59	1.7
Clients in facilities without OTPs ²		
Any MAT	881	0.8
Buprenorphine	839	1.0
Naltrexone	42	0.2

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	118	91.5
Private health insurance	86	66.7
Medicare	33	25.6
Medicaid	78	60.5
State-financed health insurance	44	34.1
Federal military insurance	49	38.0
No payment accepted	4	3.1
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	5	3.9
Other payments	1	0.8
Sliding fee scale	79	61.2
Treatment at no charge for clients who can't pay	69	53.5
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	125	96.9
State substance abuse agency	106	82.2
State mental health department	101	78.3
State department of health	22	17.1
Hospital licensing authority	5	3.9
The Joint Commission	24	18.6
Commission on Accreditation of Rehabilitation Facilities	24	18.6
National Committee for Quality Assurance	3	2.3
Council on Accreditation	4	3.1
Healthcare Facilities Accreditation Program	1	0.8
Other state/local agency/organization	3	2.3

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 79 61.2

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of convices effected, by framiber and percent	Fac	ilities
	No.	%
Assessment and pre-treatment services	1101	
Screening for substance abuse	125	96.9
Screening for mental health disorders	84	65.1
Comprehensive substance abuse assessment or diagnosis	119	92.2
Comprehensive mental health assessment or diagnosis	47	36.4
Screening for tobacco use	57	44.2
Outreach to persons in the community who may need treatment	106	82.2
Interim services for clients when immediate admission is not possible	78	60.5
No services offered	_	_
Testing		
Breathalyzer or other blood alcohol testing	87	67.4
Drug or alcohol urine screening	126	97.7
Screening for hepatitis B	23	17.8
Screening for hepatitis C	27	20.9
HIV testing	45	34.9
STD testing	28	21.7
TB screening	95	73.6
No services offered	3	2.3
Counseling		
Individual counseling	129	100.0
Group counseling	127	98.4
Family counseling	119	92.2
Marital/couples counseling	87	67.4
Transitional services		
Discharge planning	126	97.7
Aftercare/continuing care	116	89.9
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	15	11.6
Naltrexone (oral)	27	20.9
Extended-release, injectable naltrexone/Vivitrol®	26	20.2
Acamprosate (Campral®)	18	14.0
Nicotine replacement	18	14.0
Non-nicotine smoking/tobacco cessation medications	14	10.9
Medications for psychiatric disorders	54	41.9
Methadone	21	16.3
Buprenorphine with naloxone (Suboxone®)	17	13.2
Buprenorphine without naloxone	13	10.1
Buprenorphine subdermal implant (Probuphine®)	_	_
No services offered	43	33.3
Ancillary services		
Case management services	105	81.4
Social skills development	96	74.4
Mentoring/peer support	89	69.0
Child care for clients' children	7	5.4
Assistance with obtaining social services	63	48.8
Employment counseling or training for clients	48	37.2

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	56	43.4
Domestic violence services	48	37.2
Early intervention for HIV	50	38.8
HIV or AIDS education, counseling, or support	102	79.1
Hepatitis education, counseling, or support	71	55.0
Health education other than HIV/AIDS or hepatitis	79	61.2
Substance abuse education	125	96.9
Transportation assistance to treatment	47	36.4
Mental health services	74	57.4
Acupuncture	1	0.8
Residential beds for clients' children	1	8.0
Self-help groups	64	49.6
Smoking/tobacco cessation counseling	54	41.9
No services offered	_	_
Other services		
Treatment for gambling disorder	9	7.0
Treatment for Internet use disorder	6	4.7
Treatment for other addiction disorder	19	14.7
No services offered	108	83.7

	Faci	lities
	No.	%
Substance abuse counseling	126	97.7
Relapse prevention	124	96.1
Cognitive behavioral therapy	124	96.1
Motivational interviewing	122	94.6
Anger management	112	86.8
Brief intervention	99	76.7
Trauma-related counseling	88	68.2
12-step facilitation	110	85.3
Contingency management/motivational incentives	85	65.9
Dialectical behavior therapy	65	50.4
Rational emotive behavioral therapy	82	63.6
Matrix model	70	54.3
Computerized substance abuse treatment	22	17.1
Community reinforcement plus vouchers	17	13.2
Other treatment approaches	1	0.8

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	26	5		
Number of clients ²	920	29		
Number of designated beds	1,073	64		
Utilization rate ³	85.7	45.3		
Average number of designated beds per facility	41	13		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	157
Methadone	153
Buprenorphine	3
Naltrexone	1

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	66	51.2
Any language other than English	57	44.2
Non-English language provided by		
Staff counselor only	2	3.5
On-call interpreter only	49	86.0
Both staff counselor and on-call interpreter	6	10.5
Languages provided by staff counselor ¹		
Spanish	8	100.0
American Indian/Alaskan Native		
languages	_	_
Other	2	25.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	91	70.5
Adult women	40	31.0
Clients with co-occurring disorders	47	36.4
Adult men	47	36.4
Clients who have experienced trauma	26	20.2
Criminal justice clients	29	22.5
DUI/DWI clients	14	10.9
Young adults	28	21.7
Adolescents	32	24.8
Clients who have experienced domestic violence	23	17.8
Clients who have experienced sexual		
abuse	24	18.6
Pregnant or postpartum women	32	24.8
Seniors or older adults	21	16.3
LGBT ¹	23	17.8
Veterans	26	20.2
Clients living with HIV/AIDS	29	22.5
Members of military families	13	10.1
Active duty military	13	10.1
Other	2	1.6
No program or group offered	38	29.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Alaska National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Alaska, 89 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 3,556 clients in substance abuse treatment on March 31, 2017. The survey response rate in Alaska was 95.7 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	53	59.6	1,872	52.6	137	54.2
Private for-profit	12	13.5	483	13.6	7	2.8
Local, county, or community government	3	3.4	160	4.5	10	4.0
State government	_	_	_	_	_	_
Federal government	3	3.4	354	10.0	_	
Tribal government	18	20.2	687	19.3	99	39.1
Total	89	100.0	3,556	100.0	253	100.0

Substance abuse problem treated, by number and percent							
Clients in treatment on March 31, 2017							
	Faciliti	es¹	Clients ² Clients ² per 100,000				
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	83	97.6	1,823	51.3	303		
Clients with drug abuse only	63	74.1	618	17.4	104		
Clients with alcohol abuse only	73	85.9	1,115	31.4	188		
Total			3,556	100.0	595		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	73	82.0	3,235	91.0	150	25	198	78.3
Regular	73	82.0	2,075	58.4	_	20		
Intensive	47	52.8	634	17.8	_	11		
Day treatment/partial hospitalization	10	11.2	28	8.0	_	6		
Detoxification	8	9.0	15	0.4	_	7		
Methadone maintenance	15	16.9	483	13.6	150	21		
Residential (non-hospital)	27	30.3	304	8.5	_	12	55	21.7
Short term (<30 days)	12	13.5	78	2.2	_	11		
Long term (30+ days)	23	25.8	226	6.4	_	11		
Detoxification	3	3.4	_	_	_	_		
Hospital inpatient	2	2.2	17	0.5	_	9	_	_
Treatment	1	1.1	12	0.3	<u>—</u>	6		
Detoxification	2	2.2	5	0.1	_	3		
Total	89		3,556	100.0	150	22	253	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	3	0.2
Clients in facilities with OTPs ²		
Any MAT	369	0.1
Methadone	364	0.1
Buprenorphine	4	*
Naltrexone	1	*
Clients in facilities without OTPs ²		
Any MAT	137	0.1
Buprenorphine	133	0.2
Naltrexone	4	*

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. activity paryment options, by manner and	. po. oo	
	No.	%
Cash or self-payment	82	92.1
Private health insurance	85	95.5
Medicare	40	44.9
Medicaid	71	79.8
State-financed health insurance	51	57.3
Federal military insurance	67	75.3
No payment accepted	_	_
Access to Recovery (ATR) vouchers ²	17	19.1
IHS/Tribal/Urban (ITU) funds	35	39.3
Other payments	_	_
Sliding fee scale	74	83.1
Treatment at no charge for clients who can't pay	49	55.1
1 = -1141		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	87	97.8
State substance abuse agency	67	75.3
State mental health department	52	58.4
State department of health	39	43.8
Hospital licensing authority	6	6.7
The Joint Commission	29	32.6
Commission on Accreditation of Rehabilitation Facilities	41	46.1
National Committee for Quality Assurance	2	2.2
Council on Accreditation	10	11.2
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	5	5.6

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Foreign for substance abuse 86 96.6 Screening for substance abuse 86 96.6 Comprehensive substance abuse assessment or diagnosis 84 94.4 Comprehensive substance abuse assessment or diagnosis 66 74.2 Comprehensive substance abuse assessment or diagnosis 66 74.2 Correcting for tobacco use 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interior services for clients when immediate admission is not possible 54 60.7 No services for clients when immediate admission is not possible 53 59.6 No services for clients when immediate admission is not possible 53 59.6 No services forfered 53 59.6 70.7 Put services 53 59.6 70.7 Screening for hepatitis B 25 28.1 Screening for hepatitis B 26 28.1 Screening for hepatitis B 26 28.1 Screening for hepatitis B 26 28.1 B services 28 28.5	Types of services offered, by number and percent		
Assessment and pre-treatment services 86 96.6 Screening for substance abuse 86 96.6 Screening for mental health disorders 79 88.8 Comprehensive substance abuse assessment or diagnosis 66 74.2 Comprehensive mental health assessment or diagnosis 66 74.2 Screening for tobacco use 72 80.9 Outreach to persons in the community who may need treatment Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 1.1 Testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis B 25 28.1 Screening for hepatitis B 26 29.2 HIV testing 23 25.8 STD testing 8 98.9 Table screening for hepatitis B 8 98.9 Group counseling 8 98.9 B creening for hepatitis B 8 98.9 <t< th=""><th>Types of services offered, by flumber and percent</th><th>Faci</th><th>litios</th></t<>	Types of services offered, by flumber and percent	Faci	litios
Screening for substance abuse \$6 \$96.6 \$6.5			
Screening for substance abuse 86 96.6 Screening for mental health disorders 79 88.8 Comprehensive substance abuse assessment or diagnosis 84 94.4 Comprehensive mental health assessment or diagnosis 66 74.2 Screening for tobacco use 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interin services for clients when immediate admission is not possible 54 60.7 No services offered 3 59.6 Treating 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis B 8 98.9 STD testing 8 98.9 STD testing 8 98.9 STO services offered 8	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 79 88.8 Comprehensive substance abuse assessment or diagnosis 84 94.4 Comprehensive mental health assessment or diagnosis 66 74.2 Screening for tobacco use 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 No services offered 17 19.1 Counseling 88 98.9 Group counseling 88 98.9 Group counseling 88 98.9 Group counseling 87 87.6 <td< td=""><td></td><td>86</td><td>96.6</td></td<>		86	96.6
Comprehensive substance abuse assessment or diagnosis 84 94.4 Comprehensive mental health assessment or diagnosis 66 74.2 Screening for tobacco uses 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis B 8 98.9 TD testing 8 98.9 TD testing 8 98.9			
Comprehensive mental health assessment or diagnosis 66 74.2 Screening for tobacco use 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 25 28.1 No services offered 19 21.3 TB screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 25 28.1 No services offered 70 19.1 Testing 88 98.9 Group counseling 85 95.5 Family counseling 87	-		
Screening for tobacco use 72 80.9 Outreach to persons in the community who may need treatment 64 71.9 Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 55 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 23 25.8 STD testing 19 21.3 TB screening 23 25.8 STD testing 19 21.3 TB screening 85 95.5 STD testing 88 98.9 TB screening for hepatitis C 17 19.1 Versieng 23 25.8 STD testing 19 21.3 TB screening for hepatitis C 28 28.1 No services offered 17 19.1 Counseling 86 98.5 <td< td=""><td>· ·</td><td></td><td></td></td<>	· ·		
Outreach to persons in the community who may need treatment 64 71.9 Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 85 95.5 Family counseling 87 87.6 Marital/couples counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered 78 87.6 <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Interim services for clients when immediate admission is not possible 54 60.7 No services offered 1 1.1 Testing Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 19 21.3 TB screening 85 28.1 No services offered 17 19.1 Councesting Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 85 95.5 Family counseling 87 87.6 Marital/couples counseling 87 97.8 Family counseling 87 97.8 Family counseling 87 97.8 Patients 87 97.8 Family counseling 87 97.8	-		
No services offered 1 1.1 Testing 3 59.6 Breathalyzer or other blood alcohol testing 59.6 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 19 21.3 TB screening 25 28.1 No services offered 25 28.1 No services offered 88 98.9 Group counseling 85 95.5 Family counseling 85 95.5 Family counseling 87 87.6 Marital/couples counseling 87 97.8 Family counseling 87 97.8 Marital/couples counseling 87 97.8 Family counseling 87 97.8 Marital/couples counseling 87 97.8 Marital/couples counseling			
Testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 19 21.3 No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 85 95.5 Family counseling 87 87.6 Marital/couples counseling 87 87.6 Marital/couples counseling 87 97.8 Aftercare/continuing care 87 97.8 Aftercare/continuing care 87 97.8 No services offered 7 7 Pharmacotherapies Disulfiram (Antabuse*) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol* 15	·		
Breathalyzer or other blood alcohol testing 53 59.6 Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 88 98.9 Group counseling 88 96.9 Family counseling 88 87.6 Araital/couples counseling 87 87.6 Araity counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered <			
Drug or alcohol urine screening 70 78.7 Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 83 87.6 Marital/couples counseling 87 97.8 Family counseling 87 97.8 Marital/couples counseling 87 97.8 Marital/couples counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered 7 7 Pharmacotherapies 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 15 <		53	59.6
Screening for hepatitis B 25 28.1 Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 85 95.5 Family counseling 63 70.8 Marital/couples counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered 78 87.6 <td></td> <td></td> <td></td>			
Screening for hepatitis C 26 29.2 HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 63 70.8 Brailt couples counseling 63 70.8 Marital/couples counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered 79 97.8 Marital/couples counseling 10			
HIV testing 23 25.8 STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling 88 98.9 Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services 87 97.8 Discharge planning care 87 87.6 No services offered 78 87.6 No services offered 78 87.6 No services offered 10 11.2 Patamacotherapies 10 11.2 Native cone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatr	~ .		
STD testing 19 21.3 TB screening 25 28.1 No services offered 17 19.1 Counseling Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Tissufficial services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered 7 - Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 3 42.7 Methadone			
TB screening 25 28.1 No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 63 70.8 Barital/couples counseling 63 70.8 Marital/couples counseling 87 97.8 Aftercare/continuing care 78 87.6 No services offered 78 87.6 Pharmacotherapies 10 11.2 Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine with naloxone (Suboxone®) 9 10.1 Buprenorphine without naloxone <	-		
No services offered 17 19.1 Counseling 88 98.9 Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered 10 11.2 Nalternacy 10 11.2			
Counseling 88 98.9 Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Usual services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered - - No services offered - - No services offered 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine without naloxone 1 1.1 1.1	S .		
Individual counseling 88 98.9 Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Use planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered 78 87.6 Pharmacotherapies Use planning 10 11.2 Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®)<			10.1
Group counseling 85 95.5 Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Usual services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1		88	98.9
Family counseling 78 87.6 Marital/couples counseling 63 70.8 Transitional services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1			
Marital/couples counseling 63 70.8 Transitional services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies U U Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1	· · · · · · · · · · · · · · · · · · ·		
Transitional services Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1	·		
Discharge planning 87 97.8 Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1			7 0.0
Aftercare/continuing care 78 87.6 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1		87	97.8
No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 10 11.2 Naltrexone (oral) 20 22.5 Extended-release, injectable naltrexone/Vivitrol® 15 16.9 Acamprosate (Campral®) 8 9.0 Nicotine replacement 19 21.3 Non-nicotine smoking/tobacco cessation medications 14 15.7 Medications for psychiatric disorders 38 42.7 Methadone 3 3.4 Buprenorphine with naloxone (Suboxone®) 14 15.7 Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1			
Disulfiram (Antabuse®)1011.2Naltrexone (oral)2022.5Extended-release, injectable naltrexone/Vivitrol®1516.9Acamprosate (Campral®)89.0Nicotine replacement1921.3Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		_	_
Disulfiram (Antabuse®)1011.2Naltrexone (oral)2022.5Extended-release, injectable naltrexone/Vivitrol®1516.9Acamprosate (Campral®)89.0Nicotine replacement1921.3Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1	Pharmacotherapies		
Naltrexone (oral)2022.5Extended-release, injectable naltrexone/Vivitrol®1516.9Acamprosate (Campral®)89.0Nicotine replacement1921.3Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		10	11.2
Extended-release, injectable naltrexone/Vivitrol®1516.9Acamprosate (Campral®)89.0Nicotine replacement1921.3Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1	·	20	22.5
Acamprosate (Campral®)89.0Nicotine replacement1921.3Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		15	16.9
Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		8	9.0
Non-nicotine smoking/tobacco cessation medications1415.7Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		19	21.3
Medications for psychiatric disorders3842.7Methadone33.4Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		14	15.7
Buprenorphine with naloxone (Suboxone®)1415.7Buprenorphine without naloxone910.1Buprenorphine subdermal implant (Probuphine®)11.1		38	42.7
Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1	Methadone	3	3.4
Buprenorphine without naloxone 9 10.1 Buprenorphine subdermal implant (Probuphine®) 1 1.1	Buprenorphine with naloxone (Suboxone®)	14	15.7
	· · · · · · · · · · · · · · · · · · ·	9	10.1
	Buprenorphine subdermal implant (Probuphine®)	1	1.1
No services offered 44 49.4	No services offered	44	49.4
Ancillary services	Ancillary services		
Case management services 75 84.3	Case management services	75	84.3
Social skills development 76 85.4	Social skills development	76	85.4
Mentoring/peer support 46 51.7	Mentoring/peer support	46	51.7
Child care for clients' children 7.9	Child care for clients' children	7	7.9
Assistance with obtaining social services 70 78.7	Assistance with obtaining social services	70	78.7
Employment counseling or training for clients 34 38.2	Employment counseling or training for clients	34	38.2

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	53	59.6
Domestic violence services	54	60.7
Early intervention for HIV	24	27.0
HIV or AIDS education, counseling, or support	63	70.8
Hepatitis education, counseling, or support	62	69.7
Health education other than HIV/AIDS or hepatitis	61	68.5
Substance abuse education	87	97.8
Transportation assistance to treatment	50	56.2
Mental health services	76	85.4
Acupuncture	2	2.2
Residential beds for clients' children	6	6.7
Self-help groups	44	49.4
Smoking/tobacco cessation counseling	51	57.3
No services offered	-	_
Other services		
Treatment for gambling disorder	20	22.5
Treatment for Internet use disorder	18	20.2
Treatment for other addiction disorder	32	36.0
No services offered	55	61.8

	Fac	ilities
	No.	%
Substance abuse counseling	89	100.0
Relapse prevention	88	98.9
Cognitive behavioral therapy	88	98.9
Motivational interviewing	88	98.9
Anger management	78	87.6
Brief intervention	72	80.9
Trauma-related counseling	80	89.9
12-step facilitation	57	64.0
Contingency management/motivational incentives	57	64.0
Dialectical behavior therapy	64	71.9
Rational emotive behavioral therapy	50	56.2
Matrix model	53	59.6
Computerized substance abuse treatment	29	32.6
Community reinforcement plus vouchers	17	19.1
Other treatment approaches	15	16.9

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	24	1				
Number of clients ²	285	13				
Number of designated beds	382	32				
Utilization rate ³	74.6	41				
Average number of designated beds per facility	16	32				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	50
Methadone	49
Buprenorphine	1
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	18	20.2
Any language other than English	32	36.0
Non-English language provided by		
Staff counselor only	7	21.9
On-call interpreter only	13	40.6
Both staff counselor and on-call interpreter	12	37.5
Languages provided by staff counselor ¹		
Spanish	11	57.9
American Indian/Alaskan Native		
languages	11	57.9
Other	3	15.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	73	82.0
Adult women	36	40.4
Clients with co-occurring disorders	42	47.2
Adult men	32	36.0
Clients who have experienced trauma	43	48.3
Criminal justice clients	19	21.3
DUI/DWI clients	27	30.3
Young adults	25	28.1
Adolescents	28	31.5
Clients who have experienced domestic violence	26	29.2
Clients who have experienced sexual		
abuse	21	23.6
Pregnant or postpartum women	15	16.9
Seniors or older adults	10	11.2
LGBT ¹	9	10.1
Veterans	12	13.5
Clients living with HIV/AIDS	6	6.7
Members of military families	8	9.0
Active duty military	9	10.1
Other	6	6.7
No program or group offered	16	18.0

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Arizona National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Arizona, 341 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 41,929 clients in substance abuse treatment on March 31, 2017. The survey response rate in Arizona was 90.5 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Facilities All clients Clients under age 18					
	No.	%	No.	%	No.	%
Private non-profit	175	51.3	25,180	60.1	1,547	70.1
Private for-profit	134	39.3	13,265	31.6	365	16.5
Local, county, or community government	3	0.9	411	1.0	3	0.1
State government	1	0.3	30	0.1	4	0.2
Federal government	9	2.6	809	1.9	66	3.0
Tribal government	19	5.6	2,234	5.3	221	10.0
Total	341	100.0	41,929	100.0	2,206	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
_	Faciliti	es¹	Clients ² Clients ² per 100,0			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	293	91.8	16,478	39.3	285	
Clients with drug abuse only	267	83.7	16,849	40.2	301	
Clients with alcohol abuse only	244	76.5	8,563	20.4	151	
Total			41,889	100.0	737	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹		All clients Clien				
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	277	81.2	39,317	93.8	300	45	1,865	84.5
Regular	247	72.4	22,048	52.6	51	33		
Intensive	165	48.4	6,570	15.7	25	21		
Day treatment/partial hospitalization	38	11.1	556	1.3	_	12		
Detoxification	42	12.3	442	1.1	2	5		
Methadone maintenance	75	22.0	9,701	23.1	300	7		
Residential (non-hospital)	78	22.9	2,024	4.8	_	16	321	14.6
Short term (<30 days)	43	12.6	437	1.0	_	12		
Long term (30+ days)	67	19.6	1,417	3.4	_	14		
Detoxification	20	5.9	170	0.4	_	5		
Hospital inpatient	24	7.0	588	1.4	_	17	20	0.9
Treatment	18	5.3	296	0.7	_	18		
Detoxification	24	7.0	292	0.7	<u>—</u>	15		
Total	341		41,929	100.0	300	36	2,206	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	29	2.2
Clients in facilities with OTPs ²		
Any MAT	9,544	2.3
Methadone	8,621	2.3
Buprenorphine	724	2.6
Naltrexone	199	5.9
Clients in facilities without OTPs ²		
Any MAT	928	0.9
Buprenorphine	639	8.0
Naltrexone	289	1.5

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r dome, paymont options, by named and		
	No.	%
Cash or self-payment	295	86.5
Private health insurance	220	64.5
Medicare	147	43.1
Medicaid	220	64.5
State-financed health insurance	154	45.2
Federal military insurance	112	32.8
No payment accepted	2	0.6
Access to Recovery (ATR) vouchers ²	15	4.4
IHS/Tribal/Urban (ITU) funds	83	24.3
Other payments	2	0.6
Sliding fee scale	170	49.9
Treatment at no charge for clients who can't pay	132	38.7
1 = -114		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	313	91.8
State substance abuse agency	148	43.4
State mental health department	180	52.8
State department of health	277	81.2
Hospital licensing authority	28	8.2
The Joint Commission	73	21.4
Commission on Accreditation of Rehabilitation Facilities	101	29.6
National Committee for Quality Assurance	9	2.6
Council on Accreditation	21	6.2
Healthcare Facilities Accreditation Program	2	0.6
Other state/local agency/organization	8	2.3

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent Facilities No. % Assessment and pre-treatment services Screening for substance abuse 321 94.1 Screening for mental health disorders 261 76.5 Comprehensive substance abuse assessment or diagnosis 312 91.5
No.%Assessment and pre-treatment services8Screening for substance abuse32194.1Screening for mental health disorders26176.5
Assessment and pre-treatment services Screening for substance abuse 321 94.1 Screening for mental health disorders 261 76.5
Screening for substance abuse32194.1Screening for mental health disorders26176.5
Screening for mental health disorders 261 76.5
Completelisive substance abuse assessment of diadriosis
Comprehensive mental health assessment or diagnosis 221 64.8
Screening for tobacco use 215 63.0
Outreach to persons in the community who may need treatment 201 58.9
Interim services for clients when immediate admission is not possible 167 49.0
No services offered 5 1.5
Testing
Breathalyzer or other blood alcohol testing 164 48.1
Drug or alcohol urine screening 242 71.0
Screening for hepatitis B 96 28.2
Screening for hepatitis C 102 29.9
HIV testing 104 30.5
STD testing 103 30.2
TB screening 131 38.4
No services offered 81 23.8
Counseling
Individual counseling 321 94.1
Group counseling 325 95.3
Family counseling 288 84.5
Marital/couples counseling 237 69.5
Transitional services
Discharge planning 330 96.8
Aftercare/continuing care 270 79.2
No services offered 6 1.8
Pharmacotherapies
Disulfiram (Antabuse®) 59 17.3
Naltrexone (oral) 90 26.4
Extended-release, injectable naltrexone/Vivitrol® 80 23.5
Acamprosate (Campral®) 68 19.9
Nicotine replacement 92 27.0
Non-nicotine smoking/tobacco cessation medications 95 27.9
Medications for psychiatric disorders 185 54.3
Methadone 29 8.5
Buprenorphine with naloxone (Suboxone®) 86 25.2
Buprenorphine without naloxone 66 19.4
Buprenorphine subdermal implant (Probuphine®) 4 1.2
No services offered 131 38.4
Ancillary services
Case management services 284 83.3
Social skills development 285 83.6
Mentoring/peer support 237 69.5
Child care for clients' children 12 3.5
Assistance with obtaining social services 213 62.5
Employment counseling or training for clients 181 53.1

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	220	64.5
Domestic violence services	186	54.5
Early intervention for HIV	60	17.6
HIV or AIDS education, counseling, or support	125	36.7
Hepatitis education, counseling, or support	128	37.5
Health education other than HIV/AIDS or hepatitis	184	54.0
Substance abuse education	322	94.4
Transportation assistance to treatment	226	66.3
Mental health services	271	79.5
Acupuncture	30	8.8
Residential beds for clients' children	8	2.3
Self-help groups	172	50.4
Smoking/tobacco cessation counseling	149	43.7
No services offered	4	1.2
Other services		
Treatment for gambling disorder	69	20.2
Treatment for Internet use disorder	55	16.1
Treatment for other addiction disorder	127	37.2
No services offered	206	60.4

	Faci	Facilities		
	No.	%		
Substance abuse counseling	337	98.8		
Relapse prevention	320	93.8		
Cognitive behavioral therapy	320	93.8		
Motivational interviewing	309	90.6		
Anger management	284	83.3		
Brief intervention	279	81.8		
Trauma-related counseling	278	81.5		
12-step facilitation	202	59.2		
Contingency management/motivational incentives	200	58.7		
Dialectical behavior therapy	213	62.5		
Rational emotive behavioral therapy	153	44.9		
Matrix model	180	52.8		
Computerized substance abuse treatment	81	23.8		
Community reinforcement plus vouchers	38	11.1		
Other treatment approaches	49	14.4		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	53	12			
Number of clients ²	1,581	450			
Number of designated beds	1,562	416			
Utilization rate ³	101.2	108.2			
Average number of designated beds per facility	29	35			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	136
Methadone	123
Buprenorphine	10
Naltrexone	3

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	163	47.8
Any language other than English	219	64.2
Non-English language provided by		
Staff counselor only	38	17.4
On-call interpreter only	72	32.9
Both staff counselor and on-call interpreter	109	49.8
Languages provided by staff counselor ¹		
Spanish	133	90.5
American Indian/Alaskan Native		
languages	18	12.2
Other	7	4.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	303	88.9
Adult women	164	48.1
Clients with co-occurring disorders	201	58.9
Adult men	159	46.6
Clients who have experienced trauma	146	42.8
Criminal justice clients	117	34.3
DUI/DWI clients	89	26.1
Young adults	109	32.0
Adolescents	109	32.0
Clients who have experienced domestic violence	114	33.4
Clients who have experienced sexual		
abuse	100	29.3
Pregnant or postpartum women	60	17.6
Seniors or older adults	67	19.6
LGBT ¹	72	21.1
Veterans	65	19.1
Clients living with HIV/AIDS	44	12.9
Members of military families	39	11.4
Active duty military	33	9.7
Other	11	3.2
No program or group offered	38	11.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Arkansas National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Arkansas, 118 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 6,089 clients in substance abuse treatment on March 31, 2017. The survey response rate in Arkansas was 89.3 percent.

Facility operation, by number and percer	nt					
			Clients	in treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	93	78.8	3,617	59.4	428	93.7
Private for-profit	19	16.1	1,186	19.5	29	6.3
Local, county, or community government	_	_	_	_	_	_
State government	2	1.7	418	6.9	_	_
Federal government	4	3.4	868	14.3	_	_
Tribal government	_	_	_	_	_	_
Total	118	100.0	6,089	100.0	457	100.0

Substance abuse problem treated, by number and percent							
	nt on March 31, 2017						
	Facilities ¹ Clients ²						
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	92	87.6	2,543	41.8	102		
Clients with drug abuse only	87	82.9	2,535	41.6	104		
Clients with alcohol abuse only	75	71.4	1,011	16.6	39		
Total			6,089	100.0	245		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report substance abuse problem treated in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clients in treatment on March 31, 20				
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	104	88.1	5,124	84.2	221	20	378	82.7
Regular	102	86.4	3,172	52.1	_	19		
Intensive	54	45.8	534	8.8	_	13		
Day treatment/partial hospitalization	24	20.3	143	2.3	_	8		
Detoxification	8	6.8	28	0.5	1	14		
Methadone maintenance	10	8.5	1,247	20.5	220	49		
Residential (non-hospital)	25	21.2	869	14.3	_	17	79	17.3
Short term (<30 days)	22	18.6	364	6.0	_	15		
Long term (30+ days)	23	19.5	466	7.7	_	13		
Detoxification	11	9.3	39	0.6	_	5		
Hospital inpatient	9	7.6	96	1.6	_	8	_	_
Treatment	4	3.4	53	0.9	_	9		
Detoxification	9	7.6	43	0.7	_	4		
Total	118		6,089	100.0	221	21	457	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	4	0.3
Clients in facilities with OTPs ²		
Any MAT	895	0.2
Methadone	754	0.2
Buprenorphine	141	0.5
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	410	0.4
Buprenorphine	379	0.4
Naltrexone	31	0.2

 $^{^{\}rm 1}$ Percentage of all OTP facilities in the U.S. $^{\rm 2}$ Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	-	
	No.	%
Cash or self-payment	104	88.1
Private health insurance	85	72.0
Medicare	42	35.6
Medicaid	47	39.8
State-financed health insurance	61	51.7
Federal military insurance	55	46.6
No payment accepted	5	4.2
Access to Recovery (ATR) vouchers ²	10	8.5
IHS/Tribal/Urban (ITU) funds	5	4.2
Other payments	1	0.8
Sliding fee scale	71	60.2
Treatment at no charge for clients who can't pay	73	61.9

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	107	90.7
State substance abuse agency	91	77.1
State mental health department	57	48.3
State department of health	37	31.4
Hospital licensing authority	3	2.5
The Joint Commission	21	17.8
Commission on Accreditation of Rehabilitation Facilities	81	68.6
National Committee for Quality Assurance	8	6.8
Council on Accreditation	7	5.9
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	3	2.5

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 71 60.2

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by fidiliber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	115	97.5
Screening for mental health disorders	101	85.6
Comprehensive substance abuse assessment or diagnosis	103	87.3
Comprehensive mental health assessment or diagnosis	63	53.4
Screening for tobacco use	64	54.2
· · · · · · · · · · · · · · · · · · ·	69	54.2 58.5
Outreach to persons in the community who may need treatment		56.5 55.9
Interim services for clients when immediate admission is not possible	66	
No services offered	1	0.8
Testing Provide the state of th	40	05.0
Breathalyzer or other blood alcohol testing	42	35.6
Drug or alcohol urine screening	95	80.5
Screening for hepatitis B	13	11.0
Screening for hepatitis C	14	11.9
HIV testing	21	17.8
STD testing	17	14.4
TB screening	26	22.0
No services offered	21	17.8
Counseling		
Individual counseling	114	96.6
Group counseling	110	93.2
Family counseling	109	92.4
Marital/couples counseling	72	61.0
Transitional services		
Discharge planning	114	96.6
Aftercare/continuing care	100	84.7
No services offered	1	0.8
Pharmacotherapies		
Disulfiram (Antabuse®)	9	7.6
Naltrexone (oral)	13	11.0
Extended-release, injectable naltrexone/Vivitrol®	9	7.6
Acamprosate (Campral®)	4	3.4
Nicotine replacement	26	22.0
Non-nicotine smoking/tobacco cessation medications	13	11.0
Medications for psychiatric disorders	48	40.7
Methadone	4	3.4
Buprenorphine with naloxone (Suboxone®)	10	8.5
Buprenorphine without naloxone	10	8.5
Buprenorphine subdermal implant (Probuphine®)		-
No services offered	55	46.6
Ancillary services	30	
Case management services	110	93.2
Social skills development	81	68.6
Mentoring/peer support	49	41.5
Child care for clients' children	3	2.5
Assistance with obtaining social services	51	43.2
Employment counseling or training for clients	38	32.2
Continued	30	JZ.Z

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	52	44.1		
Domestic violence services	38	32.2		
Early intervention for HIV	22	18.6		
HIV or AIDS education, counseling, or support	62	52.5		
Hepatitis education, counseling, or support	42	35.6		
Health education other than HIV/AIDS or hepatitis	49	41.5		
Substance abuse education	96	81.4		
Transportation assistance to treatment	35	29.7		
Mental health services	83	70.3		
Acupuncture	1	0.8		
Residential beds for clients' children	6	5.1		
Self-help groups	46	39.0		
Smoking/tobacco cessation counseling	52	44.1		
No services offered	_	_		
Other services				
Treatment for gambling disorder	30	25.4		
Treatment for Internet use disorder	19	16.1		
Treatment for other addiction disorder	32	27.1		
No services offered	75	63.6		

	Faci	ilities
	No.	%
Substance abuse counseling	115	97.5
Relapse prevention	104	88.1
Cognitive behavioral therapy	107	90.7
Motivational interviewing	100	84.7
Anger management	105	89.0
Brief intervention	93	78.8
Trauma-related counseling	94	79.7
12-step facilitation	85	72.0
Contingency management/motivational incentives	58	49.2
Dialectical behavior therapy	66	55.9
Rational emotive behavioral therapy	45	38.1
Matrix model	76	64.4
Computerized substance abuse treatment	20	16.9
Community reinforcement plus vouchers	9	7.6
Other treatment approaches	8	6.8

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	19	5		
Number of clients ²	725	63		
Number of designated beds	563	96		
Utilization rate ³	128.8	65.6		
Average number of designated beds per facility	30	19		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	30
Methadone	25
Buprenorphine	5
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facil	ities
	No.	%
Sign language	54	45.8
Any language other than English	64	54.2
Non-English language provided by		
Staff counselor only	2	3.1
On-call interpreter only	59	92.2
Both staff counselor and on-call interpreter	3	4.7
Languages provided by staff counselor ¹		
Spanish	5	100.0
American Indian/Alaskan Native languages	_	_
Other	_	_

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	84	71.2
Adult women	34	28.8
Clients with co-occurring disorders	47	39.8
Adult men	36	30.5
Clients who have experienced trauma	28	23.7
Criminal justice clients	25	21.2
DUI/DWI clients	37	31.4
Young adults	32	27.1
Adolescents	48	40.7
Clients who have experienced domestic violence	14	11.9
Clients who have experienced sexual		
abuse	20	16.9
Pregnant or postpartum women	14	11.9
Seniors or older adults	13	11.0
LGBT ¹	12	10.2
Veterans	17	14.4
Clients living with HIV/AIDS	11	9.3
Members of military families	9	7.6
Active duty military	10	8.5
Other	4	3.4
No program or group offered	34	28.8

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — California National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In California, 1,311 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 118,607 clients in substance abuse treatment on March 31, 2017. The survey response rate in California was 87.6 percent.

Facility operation, by number and percent						
	Clients in treatment				t on March 31	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	699	53.3	44,125	37.2	2,355	47.0
Private for-profit	443	33.8	62,358	52.6	1,885	37.6
Local, county, or community government	110	8.4	8,390	7.1	690	13.8
State government	5	0.4	255	0.2	23	0.5
Federal government	33	2.5	2,556	2.2	16	0.3
Tribal government	21	1.6	923	8.0	44	0.9
Total	1,311	100.0	118,607	100.0	5,013	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
_	Faciliti	es¹	Clients ² Clients ² per 100,000 p			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	1,117	90.0	37,448	31.6	115	
Clients with drug abuse only	1,018	82.0	60,463	51.0	192	
Clients with alcohol abuse only	895	72.1	20,696	17.4	65	
Total			118,607	100.0	373	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	rcent							
			Clients in treatment on March 31, 2017					
	Facil	ities¹		All clients				age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	921	70.3	104,972	88.5	271	33	4,745	94.7
Regular	829	63.2	48,501	40.9	49	28		
Intensive	517	39.4	8,361	7.0	5	12		
Day treatment/partial hospitalization	242	18.5	3,170	2.7	20	8		
Detoxification	207	15.8	1,755	1.5	5	7		
Methadone maintenance	262	20.0	43,185	36.4	287	17		
Residential (non-hospital)	490	37.4	13,020	11.0	127	17	268	5.3
Short term (<30 days)	324	24.7	2,758	2.3	31	7		
Long term (30+ days)	440	33.6	9,289	7.8	96	15		
Detoxification	197	15.0	973	8.0	_	4		
Hospital inpatient	29	2.2	615	0.5	47	11	_	_
Treatment	24	1.8	362	0.3	_	3		
Detoxification	28	2.1	253	0.2	47	5		
Total	1,311		118,607	100.0	271	29	5,013	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	139	10.6
Clients in facilities with OTPs ²		
Any MAT	40,790	9.9
Methadone	39,376	10.3
Buprenorphine	489	1.8
Naltrexone	925	27.2
Clients in facilities without OTPs ²		
Any MAT	4,682	4.5
Buprenorphine	2,896	3.4
Naltrexone	1,786	9.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

11 13 11 11 11 11 11 11 11 11		
	No.	%
Cash or self-payment	1,121	85.5
Private health insurance	734	56.0
Medicare	273	20.8
Medicaid	461	35.2
State-financed health insurance	326	24.9
Federal military insurance	189	14.4
No payment accepted	66	5.0
Access to Recovery (ATR) vouchers ²	55	4.2
IHS/Tribal/Urban (ITU) funds	137	10.5
Other payments	3	0.2
Sliding fee scale	802	61.2
Treatment at no charge for clients who can't pay	611	46.6
4= """		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	1,215	92.7
State substance abuse agency	1,018	77.7
State mental health department	217	16.6
State department of health	582	44.4
Hospital licensing authority	47	3.6
The Joint Commission	182	13.9
Commission on Accreditation of Rehabilitation Facilities	366	27.9
National Committee for Quality Assurance	52	4.0
Council on Accreditation	68	5.2
Healthcare Facilities Accreditation Program	12	0.9
Other state/local agency/organization	44	3.4

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 683 52.1

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Fact	lities
	No.	"
Assessment and pre-treatment services	140.	70
Screening for substance abuse	1,271	96.9
Screening for mental health disorders	845	64.5
Comprehensive substance abuse assessment or diagnosis	1,179	89.9
Comprehensive mental health assessment or diagnosis	487	37.1
Screening for tobacco use	699	53.3
Outreach to persons in the community who may need treatment	909	69.3
Interim services for clients when immediate admission is not possible	600	45.8
No services offered	14	1.1
Testing		
Breathalyzer or other blood alcohol testing	913	69.6
Drug or alcohol urine screening	1,197	91.3
Screening for hepatitis B	262	20.0
Screening for hepatitis C	339	25.9
HIV testing	433	33.0
STD testing	285	21.7
TB screening	533	40.7
No services offered	75	5.7
Counseling	10	0.1
Individual counseling	1,299	99.1
Group counseling	1,222	93.2
Family counseling	991	75.6
Marital/couples counseling	701	53.5
Transitional services		
Discharge planning	1,260	96.1
Aftercare/continuing care	1,090	83.1
No services offered	19	1.4
Pharmacotherapies		
Disulfiram (Antabuse®)	246	18.8
Naltrexone (oral)	274	20.9
Extended-release, injectable naltrexone/Vivitrol®	250	19.1
Acamprosate (Campral®)	183	14.0
Nicotine replacement	275	21.0
Non-nicotine smoking/tobacco cessation medications	221	16.9
Medications for psychiatric disorders	407	31.0
Methadone	138	10.5
Buprenorphine with naloxone (Suboxone®)	331	25.2
Buprenorphine without naloxone	210	16.0
Buprenorphine subdermal implant (Probuphine®)	20	1.5
No services offered	687	52.4
Ancillary services		
Case management services	1,200	91.5
Social skills development	1,111	84.7
Mentoring/peer support	919	70.1
Child care for clients' children	170	13.0
Assistance with obtaining social services	819	62.5
Employment counseling or training for clients	604	46.1
Continued		

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	837	63.8		
Domestic violence services	565	43.1		
Early intervention for HIV	396	30.2		
HIV or AIDS education, counseling, or support	800	61.0		
Hepatitis education, counseling, or support	696	53.1		
Health education other than HIV/AIDS or hepatitis	767	58.5		
Substance abuse education	1,292	98.6		
Transportation assistance to treatment	665	50.7		
Mental health services	740	56.4		
Acupuncture	107	8.2		
Residential beds for clients' children	63	4.8		
Self-help groups	821	62.6		
Smoking/tobacco cessation counseling	579	44.2		
No services offered	_	_		
Other services				
Treatment for gambling disorder	193	14.7		
Treatment for Internet use disorder	144	11.0		
Treatment for other addiction disorder	297	22.7		
No services offered	964	73.5		

	Faci	ilities
	No.	%
Substance abuse counseling	1,304	99.5
Relapse prevention	1,281	97.7
Cognitive behavioral therapy	1,184	90.3
Motivational interviewing	1,224	93.4
Anger management	1,079	82.3
Brief intervention	1,079	82.3
Trauma-related counseling	1,049	80.0
12-step facilitation	1,014	77.3
Contingency management/motivational incentives	836	63.8
Dialectical behavior therapy	660	50.3
Rational emotive behavioral therapy	502	38.3
Matrix model	644	49.1
Computerized substance abuse treatment	190	14.5
Community reinforcement plus vouchers	210	16.0
Other treatment approaches	120	9.2

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	438	23			
Number of clients ²	12,340	565			
Number of designated beds	13,180	594			
Utilization rate ³	93.6	95.1			
Average number of designated beds per facility	30	26			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	103
Methadone	100
Buprenorphine	1
Naltrexone	2

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	320	24.4
Any language other than English	726	55.4
Non-English language provided by		
Staff counselor only	342	47.1
On-call interpreter only	102	14.0
Both staff counselor and on-call interpreter	282	38.8
Languages provided by staff counselor ¹		
Spanish	603	96.6
American Indian/Alaskan Native languages	5	0.8
Other	120	19.2
Outo	120	10.2

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	1,158	88.3
Adult women	715	54.5
Clients with co-occurring disorders	720	54.9
Adult men	686	52.3
Clients who have experienced trauma	629	48.0
Criminal justice clients	523	39.9
DUI/DWI clients	117	8.9
Young adults	436	33.3
Adolescents	279	21.3
Clients who have experienced domestic violence	424	32.3
Clients who have experienced sexual		
abuse	423	32.3
Pregnant or postpartum women	389	29.7
Seniors or older adults	343	26.2
LGBT ¹	355	27.1
Veterans	319	24.3
Clients living with HIV/AIDS	342	26.1
Members of military families	179	13.7
Active duty military	148	11.3
Other	49	3.7
No program or group offered	153	11.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Colorado National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Colorado, 381 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 32,213 clients in substance abuse treatment on March 31, 2017. The survey response rate in Colorado was 90.2 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Facilities All clients Clients under age 18				ler age 18	
	No.	%	No.	%	No.	%
Private non-profit	166	43.6	11,910	37.0	369	29.4
Private for-profit	192	50.4	17,205	53.4	667	53.2
Local, county, or community government	3	8.0	1,192	3.7	151	12.0
State government	12	3.1	1,047	3.3	49	3.9
Federal government	6	1.6	717	2.2	_	_
Tribal government	2	0.5	142	0.4	18	1.4
Total	381	100.0	32,213	100.0	1,254	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
_	Faciliti	Facilities ¹ Clients ² Clients ²		Clients ² Clients ² per 100,00		
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	313	96.9	13,485	41.9	297	
Clients with drug abuse only	269	83.3	9,077	28.2	199	
Clients with alcohol abuse only	284	87.9	9,651	30.0	216	
Total			32,213	100.0	712	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients age < 1	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	344	90.3	30,867	95.8	301	55	1,189	94.8
Regular	340	89.2	25,198	78.2	101	50		
Intensive	169	44.4	2,177	6.8	20	10		
Day treatment/partial hospitalization	20	5.2	197	0.6	_	12		
Detoxification	15	3.9	32	0.1	1	3		
Methadone maintenance	65	17.1	3,263	10.1	221	8		
Residential (non-hospital)	53	13.9	1,224	3.8	26	15	58	4.6
Short term (<30 days)	26	6.8	349	1.1	16	11		
Long term (30+ days)	41	10.8	717	2.2	3	13		
Detoxification	16	4.2	158	0.5	17	5		
Hospital inpatient	10	2.6	122	0.4	_	10	7	0.6
Treatment	10	2.6	82	0.3	<u> </u>	8		
Detoxification	9	2.4	40	0.1	_	5		
Total	381		32,213	100.0	301	50	1,254	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	11	0.8
Clients in facilities with OTPs ²		
Any MAT	2,790	0.7
Methadone	2,468	0.6
Buprenorphine	313	1.1
Naltrexone	9	0.3
Clients in facilities without OTPs ²		
Any MAT	736	0.7
Buprenorphine	421	0.5
Naltrexone	315	1.6

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	368	96.6
Private health insurance	199	52.2
Medicare	100	26.2
Medicaid	216	56.7
State-financed health insurance	108	28.3
Federal military insurance	126	33.1
No payment accepted	7	1.8
Access to Recovery (ATR) vouchers ²	134	35.2
IHS/Tribal/Urban (ITU) funds	18	4.7
Other payments	3	8.0
Sliding fee scale	287	75.3
Treatment at no charge for clients who can't pay	135	35.4

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	367	96.3
State substance abuse agency	349	91.6
State mental health department	160	42.0
State department of health	131	34.4
Hospital licensing authority	11	2.9
The Joint Commission	37	9.7
Commission on Accreditation of Rehabilitation Facilities	17	4.5
National Committee for Quality Assurance	3	0.8
Council on Accreditation	3	0.8
Healthcare Facilities Accreditation Program	1	0.3
Other state/local agency/organization	7	1.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 193 50.7

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	372	97.6
Screening for mental health disorders	295	77.4
Comprehensive substance abuse assessment or diagnosis	360	94.5
Comprehensive mental health assessment or diagnosis	201	52.8
Screening for tobacco use	241	63.3
Outreach to persons in the community who may need treatment	217	57.0
Interim services for clients when immediate admission is not possible	186	48.8
No services offered	100	0.3
		0.3
Testing Draethal was an other blood clock of testing	075	72.2
Breathalyzer or other blood alcohol testing	275	
Drug or alcohol urine screening	265	69.6
Screening for hepatitis B	106	27.8
Screening for hepatitis C	111	29.1
HIV testing	42	11.0
STD testing	39	10.2
TB screening	113	29.7
No services offered	65	17.1
Counseling		
Individual counseling	380	99.7
Group counseling	374	98.2
Family counseling	292	76.6
Marital/couples counseling	262	68.8
Transitional services		
Discharge planning	366	96.1
Aftercare/continuing care	325	85.3
No services offered	8	2.1
Pharmacotherapies		
Disulfiram (Antabuse®)	151	39.6
Naltrexone (oral)	112	29.4
Extended-release, injectable naltrexone/Vivitrol®	79	20.7
Acamprosate (Campral®)	89	23.4
Nicotine replacement	83	21.8
Non-nicotine smoking/tobacco cessation medications	75	19.7
Medications for psychiatric disorders	133	34.9
Methadone	11	2.9
Buprenorphine with naloxone (Suboxone®)	79	20.7
Buprenorphine without naloxone	41	10.8
Buprenorphine subdermal implant (Probuphine®)	1	0.3
No services offered	163	42.8
Ancillary services		
Case management services	317	83.2
Social skills development	284	74.5
Mentoring/peer support	217	57.0
Child care for clients' children	15	3.9
Assistance with obtaining social services	154	40.4
Employment counseling or training for clients	133	34.9
Continued		

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	147	38.6
Domestic violence services	131	34.4
Early intervention for HIV	48	12.6
HIV or AIDS education, counseling, or support	102	26.8
Hepatitis education, counseling, or support	92	24.1
Health education other than HIV/AIDS or hepatitis	121	31.8
Substance abuse education	369	96.9
Transportation assistance to treatment	120	31.5
Mental health services	275	72.2
Acupuncture	41	10.8
Residential beds for clients' children	6	1.6
Self-help groups	108	28.3
Smoking/tobacco cessation counseling	173	45.4
No services offered	1	0.3
Other services		
Treatment for gambling disorder	67	17.6
Treatment for Internet use disorder	46	12.1
Treatment for other addiction disorder	131	34.4
No services offered	228	59.8

	Faci	lities
	No.	%
Substance abuse counseling	380	99.7
Relapse prevention	375	98.4
Cognitive behavioral therapy	367	96.3
Motivational interviewing	362	95.0
Anger management	317	83.2
Brief intervention	304	79.8
Trauma-related counseling	313	82.2
12-step facilitation	164	43.0
Contingency management/motivational incentives	197	51.7
Dialectical behavior therapy	254	66.7
Rational emotive behavioral therapy	119	31.2
Matrix model	156	40.9
Computerized substance abuse treatment	66	17.3
Community reinforcement plus vouchers	75	19.7
Other treatment approaches	38	10.0

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	46	8		
Number of clients ²	1,008	71		
Number of designated beds	1,265	111		
Utilization rate ³	79.7	64.0		
Average number of designated beds per facility	28	14		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	50
Methadone	44
Buprenorphine	6
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	100	26.2
Any language other than English	173	45.4
Non-English language provided by		
Staff counselor only	61	35.3
On-call interpreter only	57	32.9
Both staff counselor and on-call interpreter	55	31.8
Languages provided by staff counselor ¹		
Spanish	115	99.1
American Indian/Alaskan Native		
languages	_	_
Other	5	4.3

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	356	93.4
Adult women	202	53.0
Clients with co-occurring disorders	221	58.0
Adult men	189	49.6
Clients who have experienced trauma	195	51.2
Criminal justice clients	219	57.5
DUI/DWI clients	242	63.5
Young adults	153	40.2
Adolescents	137	36.0
Clients who have experienced domestic violence	108	28.3
Clients who have experienced sexual		
abuse	99	26.0
Pregnant or postpartum women	92	24.1
Seniors or older adults	88	23.1
LGBT ¹	82	21.5
Veterans	64	16.8
Clients living with HIV/AIDS	63	16.5
Members of military families	41	10.8
Active duty military	40	10.5
Other	7	1.8
No program or group offered	25	6.6

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

O CHIMINAN SERVICES USA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Connecticut National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Connecticut, 210 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 41,873 clients in substance abuse treatment on March 31, 2017. The survey response rate in Connecticut was 92.2 percent.

Facility operation, by number and percent						
	Clients in treatment on March 31, 201			2017		
	Facilities		All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	181	86.2	37,416	89.4	674	97.3
Private for-profit	16	7.6	2,773	6.6	19	2.7
Local, county, or community government	2	1.0	30	0.1	_	_
State government	6	2.9	644	1.5	_	_
Federal government	3	1.4	981	2.3	_	_
Tribal government	2	1.0	29	0.1	_	_
Total	210	100.0	41,873	100.0	693	100.0

Substance abuse problem treated, by number and percent					
			Clients i	n treatmer	nt on March 31, 2017
	Faciliti	es¹	Clients ² Clients ² per 100,000		Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	189	94.5	15,766	37.7	542
Clients with drug abuse only	173	86.5	20,565	49.1	715
Clients with alcohol abuse only	158	79.0	5,542	13.2	191
Total			41,873	100.0	1,448

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent									
				Clie	nts in treatmen	t on March 31, 20	17		
_	Facili	ities¹		All clients				Clients age < 18	
					Median no. of clients per	Median no. of clients per			
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%	
Outpatient	167	79.5	39,513	94.4	491	76	645	93.1	
Regular	146	69.5	18,769	44.8	45	67			
Intensive	96	45.7	3,339	8.0	24	25			
Day treatment/partial hospitalization	25	11.9	270	0.6	50	15			
Detoxification	26	12.4	58	0.1	4	5			
Methadone maintenance	77	36.7	17,077	40.8	488	25			
Residential (non-hospital)	49	23.3	2,024	4.8	29	16	31	4.5	
Short term (<30 days)	29	13.8	1,038	2.5	18	20			
Long term (30+ days)	31	14.8	700	1.7	45	11			
Detoxification	9	4.3	286	0.7	13	111			
Hospital inpatient	10	4.8	336	0.8	34	8	17	2.5	
Treatment	8	3.8	241	0.6	24	7			
Detoxification	10	4.8	95	0.2	10	3			
Total	210		41,873	100.0	477	60	693	100.0	

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	34	2.6
Clients in facilities with OTPs ²		
Any MAT	14,618	3.5
Methadone	13,793	3.6
Buprenorphine	789	2.9
Naltrexone	36	1.1
Clients in facilities without OTPs ²		
Any MAT	1,714	1.6
Buprenorphine	1,261	1.5
Naltrexone	453	2.3

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	192	91.4
Private health insurance	169	80.5
Medicare	115	54.8
Medicaid	180	85.7
State-financed health insurance	143	68.1
Federal military insurance	83	39.5
No payment accepted	2	1.0
Access to Recovery (ATR) vouchers ²	38	18.1
IHS/Tribal/Urban (ITU) funds	9	4.3
Other payments	_	_
Sliding fee scale	152	72.4
Treatment at no charge for clients who can't pay	99	47.1
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	205	97.6
State substance abuse agency	133	63.3
State mental health department	131	62.4
State department of health	191	91.0
Hospital licensing authority	12	5.7
The Joint Commission	75	35.7
Commission on Accreditation of		
Rehabilitation Facilities	60	28.6
National Committee for Quality Assurance	5	2.4
Council on Accreditation	21	10.0
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	12	5.7

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 152 72.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by number and persont	Faci	lities
	No.	%
Assessment and pre-treatment services	1101	70
Screening for substance abuse	202	96.2
Screening for mental health disorders	191	91.0
Comprehensive substance abuse assessment or diagnosis	197	93.8
Comprehensive mental health assessment or diagnosis	150	71.4
Screening for tobacco use	172	81.9
Outreach to persons in the community who may need treatment	102	48.6
Interim services for clients when immediate admission is not possible	63	30.0
No services offered	4	1.9
Testing		
Breathalyzer or other blood alcohol testing	172	81.9
Drug or alcohol urine screening	199	94.8
Screening for hepatitis B	56	26.7
Screening for hepatitis C	61	29.0
HIV testing	69	32.9
STD testing	47	22.4
TB screening	68	32.4
No services offered	8	3.8
Counseling		
Individual counseling	204	97.1
Group counseling	197	93.8
Family counseling	185	88.1
Marital/couples counseling	150	71.4
Transitional services		
Discharge planning	204	97.1
Aftercare/continuing care	166	79.0
No services offered	2	1.0
Pharmacotherapies		
Disulfiram (Antabuse®)	80	38.1
Naltrexone (oral)	90	42.9
Extended-release, injectable naltrexone/Vivitrol®	73	34.8
Acamprosate (Campral®)	83	39.5
Nicotine replacement	97	46.2
Non-nicotine smoking/tobacco cessation medications	83	39.5
Medications for psychiatric disorders	153	72.9
Methadone	33	15.7
Buprenorphine with naloxone (Suboxone®)	79	37.6
Buprenorphine without naloxone	45	21.4
Buprenorphine subdermal implant (Probuphine®)	2	1.0
No services offered	36	17.1
Ancillary services		
Case management services	165	78.6
Social skills development	159	75.7
Mentoring/peer support	116	55.2
Child care for clients' children	15	7.1
Assistance with obtaining social services	163	77.6
Employment counseling or training for clients	82	39.0

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	118	56.2
Domestic violence services	84	40.0
Early intervention for HIV	54	25.7
HIV or AIDS education, counseling, or support	97	46.2
Hepatitis education, counseling, or support	77	36.7
Health education other than HIV/AIDS or hepatitis	104	49.5
Substance abuse education	204	97.1
Transportation assistance to treatment	95	45.2
Mental health services	194	92.4
Acupuncture	39	18.6
Residential beds for clients' children	6	2.9
Self-help groups	110	52.4
Smoking/tobacco cessation counseling	123	58.6
No services offered	_	_
Other services		
Treatment for gambling disorder	81	38.6
Treatment for Internet use disorder	33	15.7
Treatment for other addiction disorder	78	37.1
No services offered	106	50.5

	Fac	ilities
	No.	%
Substance abuse counseling	210	100.0
Relapse prevention	206	98.1
Cognitive behavioral therapy	201	95.7
Motivational interviewing	195	92.9
Anger management	181	86.2
Brief intervention	172	81.9
Trauma-related counseling	183	87.1
12-step facilitation	147	70.0
Contingency management/motivational incentives	103	49.0
Dialectical behavior therapy	113	53.8
Rational emotive behavioral therapy	69	32.9
Matrix model	65	31.0
Computerized substance abuse treatment	13	6.2
Community reinforcement plus vouchers	25	11.9
Other treatment approaches	9	4.3

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	46	4		
Number of clients ²	1,641	246		
Number of designated beds	1,333	226		
Utilization rate ³	123.1	108.8		
Average number of designated beds per facility	29	57		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	407
Methadone	384
Buprenorphine	22
Naltrexone	1

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	58	27.6
Any language other than English	129	61.4
Non-English language provided by		
Staff counselor only	47	36.4
On-call interpreter only	25	19.4
Both staff counselor and on-call interpreter	57	44.2
Languages provided by staff counselor ¹		
Spanish	103	99.0
American Indian/Alaskan Native		
languages	_	_
Other	24	23.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	180	85.7
Adult women	123	58.6
Clients with co-occurring disorders	148	70.5
Adult men	123	58.6
Clients who have experienced trauma	120	57.1
Criminal justice clients	73	34.8
DUI/DWI clients	16	7.6
Young adults	66	31.4
Adolescents	37	17.6
Clients who have experienced domestic violence	59	28.1
Clients who have experienced sexual		
abuse	66	31.4
Pregnant or postpartum women	46	21.9
Seniors or older adults	49	23.3
LGBT ¹	46	21.9
Veterans	42	20.0
Clients living with HIV/AIDS	53	25.2
Members of military families	26	12.4
Active duty military	22	10.5
Other	9	4.3
No program or group offered	30	14.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

PHITTERS OF THE PROPERTY OF TH

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Delaware National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Delaware, 34 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 7,738 clients in substance abuse treatment on March 31, 2017. The survey response rate in Delaware was 79.2 percent.

Facility operation, by number and percen	nt					
			Clients	in treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	18	52.9	5,406	69.9	7	7.6
Private for-profit	15	44.1	2,041	26.4	85	92.4
Local, county, or community government	_	_	_	_	_	_
State government	_	_	_	_	_	_
Federal government	1	2.9	291	3.8	_	_
Tribal government	_	_	_	_	_	_
Total	34	100.0	7,738	100.0	92	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 1		Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	30	93.8	2,350	30.4	304	
Clients with drug abuse only	30	93.8	4,279	55.3	561	
Clients with alcohol abuse only	24	75.0	1,109	14.3	145	
Total			7,738	100.0	1,009	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	32	94.1	7,603	98.3	435	70	92	100.0
Regular	30	88.2	2,687	34.7	55	55		
Intensive	15	44.1	162	2.1	20	15		
Day treatment/partial hospitalization	3	8.8	28	0.4	20	8		
Detoxification	9	26.5	535	6.9	30	1		
Methadone maintenance	18	52.9	4,191	54.2	400	19		
Residential (non-hospital)	3	8.8	115	1.5	74	21	_	_
Short term (<30 days)	3	8.8	29	0.4	3	26		
Long term (30+ days)	2	5.9	70	0.9	55	15		
Detoxification	1	2.9	16	0.2	16	_		
Hospital inpatient	1	2.9	20	0.3	_	20	_	_
Treatment	1	2.9	10	0.1	_	10		
Detoxification	1	2.9	10	0.1	_	10		
Total	34		7,738	100.0	435	60	92	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	9	0.7
Clients in facilities with OTPs ²		
Any MAT	5,390	1.3
Methadone	3,555	0.9
Buprenorphine	1,382	5.0
Naltrexone	453	13.3
Clients in facilities without OTPs ²		
Any MAT	545	0.5
Buprenorphine	445	0.5
Naltrexone	100	0.5

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

· acmed parameters, and manufacture personne		
	No.	%
Cash or self-payment	33	97.1
Private health insurance	28	82.4
Medicare	15	44.1
Medicaid	31	91.2
State-financed health insurance	18	52.9
Federal military insurance	16	47.1
No payment accepted	_	_
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	_	_
Other payments	_	_
Sliding fee scale	25	73.5
Treatment at no charge for clients who can't pay	11	32.4
1 = -114		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	27	79.4
State substance abuse agency	23	67.6
State mental health department	10	29.4
State department of health	8	23.5
Hospital licensing authority	3	8.8
The Joint Commission	13	38.2
Commission on Accreditation of Rehabilitation Facilities	10	29.4
National Committee for Quality Assurance	_	_
Council on Accreditation	4	11.8
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	_	_

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services effered, by fluitiber and percent	Facilities	
-	No.	%
Assessment and pre-treatment services	140.	70
Screening for substance abuse	31	91.2
Screening for mental health disorders	30	88.2
Comprehensive substance abuse assessment or diagnosis	32	94.1
Comprehensive mental health assessment or diagnosis	18	52.9
Screening for tobacco use	21	61.8
Outreach to persons in the community who may need treatment	17	50.0
Interim services for clients when immediate admission is not possible	15	44.1
No services offered	_	
Testing		
Breathalyzer or other blood alcohol testing	18	52.9
Drug or alcohol urine screening	27	79.4
Screening for hepatitis B	9	26.5
Screening for hepatitis C	13	38.2
HIV testing	13	38.2
STD testing	12	35.3
TB screening	14	41.2
No services offered	7	20.6
Counseling		20.0
Individual counseling	34	100.0
Group counseling	31	91.2
Family counseling	32	94.1
Marital/couples counseling	25	73.5
Transitional services		
Discharge planning	31	91.2
Aftercare/continuing care	28	82.4
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	8	23.5
Naltrexone (oral)	15	44.1
Extended-release, injectable naltrexone/Vivitrol®	19	55.9
Acamprosate (Campral®)	10	29.4
Nicotine replacement	7	20.6
Non-nicotine smoking/tobacco cessation medications	6	17.6
Medications for psychiatric disorders	18	52.9
Methadone	8	23.5
Buprenorphine with naloxone (Suboxone®)	13	38.2
Buprenorphine without naloxone	11	32.4
Buprenorphine subdermal implant (Probuphine®)	_	_
No services offered	9	26.5
Ancillary services		
Case management services	21	61.8
Social skills development	23	67.6
Mentoring/peer support	16	47.1
Child care for clients' children	_	_
Assistance with obtaining social services	21	61.8
Employment counseling or training for clients	12	35.3

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	20	58.8
Domestic violence services	12	35.3
Early intervention for HIV	11	32.4
HIV or AIDS education, counseling, or support	16	47.1
Hepatitis education, counseling, or support	16	47.1
Health education other than HIV/AIDS or hepatitis	16	47.1
Substance abuse education	28	82.4
Transportation assistance to treatment	11	32.4
Mental health services	28	82.4
Acupuncture	_	_
Residential beds for clients' children	_	_
Self-help groups	13	38.2
Smoking/tobacco cessation counseling	12	35.3
No services offered	1	2.9
Other services		
Treatment for gambling disorder	11	32.4
Treatment for Internet use disorder	5	14.7
Treatment for other addiction disorder	10	29.4
No services offered	21	61.8

	Fac	Facilities	
	No.	%	
Substance abuse counseling	34	100.0	
Relapse prevention	34	100.0	
Cognitive behavioral therapy	32	94.1	
Motivational interviewing	33	97.1	
Anger management	27	79.4	
Brief intervention	22	64.7	
Frauma-related counseling	32	94.1	
12-step facilitation	23	67.6	
Contingency management/motivational incentives	17	50.0	
Dialectical behavior therapy	14	41.2	
Rational emotive behavioral therapy	15	44.1	
Matrix model	14	41.2	
Computerized substance abuse treatment	5	14.7	
Community reinforcement plus vouchers	5	14.7	
Other treatment approaches	1	2.9	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	3	1		
Number of clients ²	115	20		
Number of designated beds	78	35		
Utilization rate ³	147.4	57.1		
Average number of designated beds per facility	26	35		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	560
Methadone	370
Buprenorphine	144
Naltrexone	47

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	8	23.5
Any language other than English	14	41.2
Non-English language provided by		
Staff counselor only	8	57.1
On-call interpreter only	2	14.3
Both staff counselor and on-call interpreter	4	28.6
Languages provided by staff counselor ¹		
Spanish	12	100.0
American Indian/Alaskan Native languages	_	_
Other	2	16.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	28	82.4
Adult women	14	41.2
Clients with co-occurring disorders	18	52.9
Adult men	13	38.2
Clients who have experienced trauma	10	29.4
Criminal justice clients	5	14.7
DUI/DWI clients	11	32.4
Young adults	10	29.4
Adolescents	5	14.7
Clients who have experienced domestic violence	5	14.7
Clients who have experienced sexual		
abuse	6	17.6
Pregnant or postpartum women	11	32.4
Seniors or older adults	6	17.6
LGBT ¹	5	14.7
Veterans	5	14.7
Clients living with HIV/AIDS	5	14.7
Members of military families	5	14.7
Active duty military	3	8.8
Other	_	_
No program or group offered	6	17.6

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — District of Columbia National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In the District of Columbia, 27 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 2,763 clients in substance abuse treatment on March 31, 2017. The survey response rate in the District of Columbia was 77.1 percent.

Facility operation, by number and percer	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	20	74.1	1,912	69.2	61	100.0
Private for-profit	5	18.5	686	24.8	_	—
Local, county, or community government	-	_	_	_	_	—
State government	-	_	_	_	_	—
Federal government	2	7.4	165	6.0	_	—
Tribal government	_	_	_	-	_	_
Total	27	100.0	2,763	100.0	61	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
_	Faciliti	es¹	Clients ² Clients ² per 100,000			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	20	83.3	470	17.0	81	
Clients with drug abuse only	15	62.5	2,070	74.9	355	
Clients with alcohol abuse only	16	66.7	223	8.1	39	
Total			2,763	100.0	474	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	22	81.5	2,326	84.2	464	22	61	100.0
Regular	22	81.5	957	34.6	588	20		
Intensive	12	44.4	167	6.0	10	20		
Day treatment/partial hospitalization	1	3.7	10	0.4	10	-		
Detoxification	1	3.7	_	_	_	-		
Methadone maintenance	7	25.9	1,192	43.1	339	25		
Residential (non-hospital)	8	29.6	437	15.8	_	48	_	_
Short term (<30 days)	8	29.6	251	9.1	_	40		
Long term (30+ days)	6	22.2	186	6.7	_	40		
Detoxification	_	_	_	_	_	_		
Hospital inpatient	_	_	_	_	_	_	_	_
Treatment	_	_	_	_	_	_		
Detoxification	_	_	_	_	_	-		
Total	27		2,763	100.0	464	40	61	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	4	0.3
Clients in facilities with OTPs ²		
Any MAT	1,751	0.4
Methadone	1,736	0.5
Buprenorphine	15	0.1
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	52	*
Buprenorphine	52	0.1
Naltrexone	_	_

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. domey paymont options, by mannes and		
	No.	%
Cash or self-payment	12	44.4
Private health insurance	9	33.3
Medicare	13	48.1
Medicaid	22	81.5
State-financed health insurance	10	37.0
Federal military insurance	5	18.5
No payment accepted	_	_
Access to Recovery (ATR) vouchers ²	6	22.2
IHS/Tribal/Urban (ITU) funds	_	_
Other payments	_	_
Sliding fee scale	6	22.2
Treatment at no charge for clients who can't pay	11	40.7
1 Facilities may assent more than one time of normant		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	25	92.6
State substance abuse agency	21	77.8
State mental health department	13	48.1
State department of health	18	66.7
Hospital licensing authority	1	3.7
The Joint Commission	3	11.1
Commission on Accreditation of Rehabilitation Facilities	4	14.8
National Committee for Quality Assurance	_	_
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	1	3.7
Other state/local agency/organization	1	3.7

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 19 70.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Residence of the control of	Types of services offered, by number and percent		
No. No.	Types of services offered, by flumber and percent	Facilities	
Assessment and pre-treatment services 24 88.9 Screening for substance abuse 24 88.9 Screening for mental health disorders 18 66.7 Comprehensive substance abuse assessment or diagnosis 25 92.6 Comprehensive mental health assessment or diagnosis 14 51.9 Screening for tobacco use 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interim services for clients when immediate admission is not possible 8 29.6 No services offered 23 85.2 Preathalyzer or other blood alcohol testing 23 85.2 Screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 11 40.7 HIV testing 15 55.6 STD testing 11 40.7 To screening for hepatitis B 9 33.3 No services offered 12 44.4 HIV testing <th></th> <th></th> <th></th>			
Screening for substance abuse 24 88.9 Screening for mental health disorders 18 66.7 Comprehensive substance abuse assessment or diagnosis 14 51.9 Comprehensive mental health assessment or diagnosis 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interim services for citents when immediate admission is not possible 8 29.6 No services offered — — Testing Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 13 48.1 IN services offered 26 96.3 Group counseling 26 96.3 Fam	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 18 66.7 Comprehensive substance abuse assessment or diagnosis 25 92.6 Comprehensive mental health assessment or diagnosis 14 51.9 Screening for tobacco use 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interim services for clients when immediate admission is not possible a 29.6 No services offered 2 85.2 Presting 23 85.2 Breathalyzer or other blood alcohol testing 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 12 44.4 IVI Vising 15 55.6 STD testing 11 40.7 TB screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 16 96.3 STD testing 11		24	88.9
Comprehensive substance abuse assessment or diagnosis 25 92.6 Comprehensive mental health assessment or diagnosis 14 51.9 Screening for tobacco use 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interim services offered - - No services offered - - Testing - - Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 2 96.3 TSD testing 11 40.7 TS screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 16 96.3 TS besting 16 96.3			
Comprehensive mental health assessment or diagnosis 14 51.9 Screening for tobacco use 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interin services for clients when immediate admission is not possible 8 29.6 No services offered — — Testing Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis B 9 33.3 Screening for hepatitis B 12 44.4 IVI Vesting 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 2 96.3 Group counseling 26 96.3 Group counseling 26 96.3 Family counseling 26 96.3 Martial Couples counseling 26 96.3 Family counseling 26 <	~		
Screening for tobacco use 13 48.1 Outreach to persons in the community who may need treatment 20 74.1 Interim services for clients when immediate admission is not possible 8 29.6 No services offered — — Testing 23 85.2 Breathalyzer or other blood alcohol testing 25 92.6 Breathalyzer or other blood alcohol testing 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Group counseling 26 96.3 Family counseling 26 96.3 Family counseling 26 96.3 Family counseling 26 96.3 Palloty counseling 26 96.3	·		
Outreach to persons in the community who may need treatment 20 74.1 Interim services for clients when immediate admission is not possible 8 29.6 No services offered - - Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Family counseling 26 96.3	·		
Interim services for clients when immediate admission is not possible 8 29.6 No services offered — — Testing Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening of repatitis B 13 48.1 No services offered 1 3.7 Testening 13 48.1 No services offered 26 96.3 Group counseling 26 96.3 Family counseling 26 96.3 Testing time all testing services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 Discharge planning 5 18.5 No services offered 2 3	~		
No services offered — — Testing 85.2 Breathalyzer or other blood alcohol testing 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling Individual counseling 26 96.3 Group counseling 26 96.3 Group counseling 26 96.3 Family counseling 26	·		
Totalinalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Group counseling 18 66.7 Branity counseling 18 66.7 Branity counseling 26 96.3 Family counseling 18 66.7 Branity counseling 26 96.3 Transitional services Transitional services Bush contains an expression 2 96.3 Aftercare/continuing care 23 85.2 No services offered 2 96.3 Na services offered 2 18.5	·	_	
Breathalyzer or other blood alcohol testing 23 85.2 Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Group counseling 26 96.3 Family counseling 16 59.3 Testilional services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered 2 9 Pharmacotherapies Disulfiram (Antabuse*) 5 18.5 Naltrexone (coral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol* 3 11.1 Acamprosate (Campra*)* 3 11.1 </td <td></td> <td></td> <td></td>			
Drug or alcohol urine screening 25 92.6 Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Courseling Individual counseling 26 96.3 Family counseling		23	85.2
Screening for hepatitis B 9 33.3 Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Family counseling 26 96.3 Family counseling 16 59.3 Family counseling 26 96.3 Family counseling 26 96.3 Marital/couples counseling 16 59.3 Transitional services 3 86.2 Marital/couples counseling 26 96.3 Aftercare/continuing care 3 85.2 No services offered 2 3 No services offered 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Mcan-ricotine smoking/to	·		
Screening for hepatitis C 12 44.4 HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Courseling Individual counseling 26 96.3 Group counseling 26 96.3 Family counseling 16 59.3 Family counseling 26 96.3 Aftercare/continuing care 26 96.3 Aftercare/continuing care 26 96.3 Aftercare/continuing care 3 85.2 No services offered			
HIV testing 15 55.6 STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered 2 6 Pharmacotherapies Disulfram (Antabuse*) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol* 3 11.1 Acamprosate (Campral*) 3 11.1 Acamprosate (Campral*) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 </td <td>· ·</td> <td></td> <td></td>	· ·		
STD testing 11 40.7 TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 18 66.7 Marital/couples counseling 18 66.7 Marital/couples counseling 26 96.3 Family counseling 26 96.3 Family counseling 26 96.3 Transitional services 23 85.2 Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered 23 85.2 Discharge planning 5 18.5 Naitreare/continuing care 23 85.2 Discharge planning 5 18.5 Naitreare/continuing care 3 11.1 Extended-release, injectable naitrexone/vivitrol® <th< td=""><td></td><td></td><td></td></th<>			
TB screening 13 48.1 No services offered 1 3.7 Counseling 26 96.3 Individual counseling 26 96.3 Group counseling 18 66.7 Marital/couples counseling 18 66.7 Marital/couples counseling 18 66.7 Marital/couples counseling 26 96.3 Family counseling 26 96.3 Marital/couples counseling 26 96.3 Transitional services 22 96.3 Aftercare/continuing care 26 96.3 Aftercare/continuing care 23 85.2 No services offered 2 96.3 Pharmacotherapies 5 18.5 Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Medications for			
No services offered 1 3.7 Counseling 26 96.3 Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services **** **** Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered - - Pharmacotherapies *** - Disulfiram (Antabuse*) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol** 3 11.1 Acamprosate (Campral**) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone**) 5 18.5<			
Counseling 26 96.3 Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 5 18.5 Buprenorphine subderma			
Individual counseling 26 96.3 Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services Userlange planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered - - Pharmacotherapies Pharmacotherapies 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Acamprosate (Campral®) 3 11.1 Acamprosate (Campral®) 3 11.1 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 5 18.5 Buprenorphine without naloxone 5 18.5 Buprenorphi			0
Group counseling 26 96.3 Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services Usualization provided in a literature (continuing care) 26 96.3 Aftercare/continuing care 23 85.2 No services offered Pharmacotherapies Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 4 4.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) - - No services offered		26	96.3
Family counseling 18 66.7 Marital/couples counseling 16 59.3 Transitional services Transitional services Transitional services Discharge planning care 26 96.3 Aftercare/continuing care 23 85.2 No services offered Pharmacotherapies Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®)	•		
Marital/couples counseling 16 59.3 Transitional services Transitional services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered — — Pharmacotherapies — — Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 2 2 Rocal actions for general services 22 81.5 Social skills devel			
Transitional services Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 26 96.3 Aftercare/continuing care 23 85.2 No services offered — — Pharmacotherapies Usulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 22 81.5 Ancillary services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — <td></td> <td></td> <td></td>			
Aftercare/continuing care 23 85.2 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 5 18.5 Buprenorphine without naloxone 5 22 No services offered 6 22.2 Accillary services 2 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children - -	Discharge planning	26	96.3
No services offered — — Pharmacotherapies — — Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —			
Disulfiram (Antabuse®) 5 18.5 Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 2 81.5 Case management services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	· · · · · · · · · · · · · · · · · · ·	_	_
Naltrexone (oral) 3 11.1 Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 2 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 3 11.1 Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 2 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Disulfiram (Antabuse®)	5	18.5
Acamprosate (Campral®) 3 11.1 Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Naltrexone (oral)	3	11.1
Nicotine replacement 9 33.3 Non-nicotine smoking/tobacco cessation medications 5 18.5 Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Extended-release, injectable naltrexone/Vivitrol®	3	11.1
Non-nicotine smoking/tobacco cessation medications518.5Medications for psychiatric disorders1659.3Methadone414.8Buprenorphine with naloxone (Suboxone®)1037.0Buprenorphine without naloxone518.5Buprenorphine subdermal implant (Probuphine®)——No services offered622.2Ancillary services2281.5Case management services2281.5Social skills development2177.8Mentoring/peer support2074.1Child care for clients' children——	Acamprosate (Campral®)	3	11.1
Medications for psychiatric disorders 16 59.3 Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Case management services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Nicotine replacement	9	33.3
Methadone 4 14.8 Buprenorphine with naloxone (Suboxone®) 10 37.0 Buprenorphine without naloxone 5 18.5 Buprenorphine subdermal implant (Probuphine®) — — No services offered 6 22.2 Ancillary services 22 81.5 Case management services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Non-nicotine smoking/tobacco cessation medications	5	18.5
Buprenorphine with naloxone (Suboxone®)1037.0Buprenorphine without naloxone518.5Buprenorphine subdermal implant (Probuphine®)——No services offered622.2Ancillary servicesCase management services2281.5Social skills development2177.8Mentoring/peer support2074.1Child care for clients' children——	Medications for psychiatric disorders	16	59.3
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) No services offered 6 22.2 Ancillary services Case management services 22 81.5 Social skills development Mentoring/peer support Child care for clients' children 5 18.5 18.5 22 7 18.5 22 81.5 22 81.5 77.8 77.8 77.8	Methadone	4	14.8
Buprenorphine subdermal implant (Probuphine®) — — — No services offered 6 22.2 Ancillary services Case management services 22 81.5 Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Buprenorphine with naloxone (Suboxone®)	10	37.0
No services offered622.2Ancillary services2281.5Case management services2281.5Social skills development2177.8Mentoring/peer support2074.1Child care for clients' children——	Buprenorphine without naloxone	5	18.5
Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children 22 81.5 77.8 21 77.8 — —	Buprenorphine subdermal implant (Probuphine®)	_	<u> </u>
Case management services2281.5Social skills development2177.8Mentoring/peer support2074.1Child care for clients' children——	No services offered	6	22.2
Social skills development 21 77.8 Mentoring/peer support 20 74.1 Child care for clients' children — —	Ancillary services		
Mentoring/peer support Child care for clients' children 20 74.1 — —	Case management services	22	81.5
Child care for clients' children — — —	Social skills development	21	77.8
	Mentoring/peer support	20	74.1
Assistance with obtaining social services 19 70.4	Child care for clients' children	_	_
·	Assistance with obtaining social services	19	
Employment counseling or training for clients 14 51.9	Employment counseling or training for clients	14	51.9

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	16	59.3
Domestic violence services	13	48.1
Early intervention for HIV	15	55.6
HIV or AIDS education, counseling, or support	21	77.8
Hepatitis education, counseling, or support	16	59.3
Health education other than HIV/AIDS or hepatitis	21	77.8
Substance abuse education	24	88.9
Transportation assistance to treatment	15	55.6
Mental health services	19	70.4
Acupuncture	2	7.4
Residential beds for clients' children	1	3.7
Self-help groups	11	40.7
Smoking/tobacco cessation counseling	12	44.4
No services offered	_	_
Other services		
Treatment for gambling disorder	5	18.5
Treatment for Internet use disorder	3	11.1
Treatment for other addiction disorder	5	18.5
No services offered	21	77.8

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Fac	ilities		
	No.	%		
Substance abuse counseling	27	100.0		
Relapse prevention	26	96.3		
Cognitive behavioral therapy	24	88.9		
Motivational interviewing	22	81.5		
Anger management	23	85.2		
Brief intervention	23	85.2		
Trauma-related counseling	22	81.5		
12-step facilitation	19	70.4		
Contingency management/motivational incentives	14	51.9		
Dialectical behavior therapy	12	44.4		
Rational emotive behavioral therapy	10	37.0		
Matrix model	14	51.9		
Computerized substance abuse treatment	2	7.4		
Community reinforcement plus vouchers	4	14.8		
Other treatment approaches	2	7.4		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	8	_			
Number of clients ²	437	_			
Number of designated beds	482	_			
Utilization rate ³	90.7	_			
Average number of designated beds per facility	60	_			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	252
Methadone	250
Buprenorphine	2
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	11	40.7
Any language other than English	13	48.1
Non-English language provided by		
Staff counselor only	4	30.8
On-call interpreter only	5	38.5
Both staff counselor and on-call interpreter	4	30.8
Languages provided by staff counselor ¹		
Spanish	8	100.0
American Indian/Alaskan Native		
languages	_	_
Other	1	12.5

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	24	88.9
Adult women	15	55.6
Clients with co-occurring disorders	15	55.6
Adult men	17	63.0
Clients who have experienced trauma	9	33.3
Criminal justice clients	11	40.7
DUI/DWI clients	6	22.2
Young adults	8	29.6
Adolescents	3	11.1
Clients who have experienced domestic violence	7	25.9
Clients who have experienced sexual		
abuse	6	22.2
Pregnant or postpartum women	1	3.7
Seniors or older adults	6	22.2
LGBT ¹	8	29.6
Veterans	6	22.2
Clients living with HIV/AIDS	11	40.7
Members of military families	1	3.7
Active duty military	2	7.4
Other	_	_
No program or group offered	3	11.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; *n/a* Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Florida National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Florida, 668 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 62,427 clients in substance abuse treatment on March 31, 2017. The survey response rate in Florida was 89.5 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	282	42.2	27,700	44.4	3,273	89.4
Private for-profit	352	52.7	30,323	48.6	358	9.8
Local, county, or community government	17	2.5	1,909	3.1	29	8.0
State government	3	0.4	278	0.4	_	
Federal government	13	1.9	2,197	3.5	_	
Tribal government	1	0.1	20	*	_	_
Total	668	100.0	62,427	100.0	3,660	100.0

Substance abuse problem treated, by number and percent					
			Clients i	n treatmer	nt on March 31, 2017
	Faciliti	es¹	Clients	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	586	92.9	23,295	37.3	129
Clients with drug abuse only	550	87.2	31,155	49.9	176
Clients with alcohol abuse only	515	81.6	7,977	12.8	45
Total			62,427	100.0	350

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	559	83.7	55,212	88.4	324	35	3,152	86.1
Regular	514	76.9	26,764	42.9	34	25		
Intensive	287	43.0	4,257	6.8	11	10		
Day treatment/partial hospitalization	164	24.6	2,125	3.4	20	13		
Detoxification	78	11.7	1,546	2.5	9	10		
Methadone maintenance	145	21.7	20,520	32.9	354	10		
Residential (non-hospital)	195	29.2	5,656	9.1	30	21	508	13.9
Short term (<30 days)	113	16.9	1,604	2.6	10	12		
Long term (30+ days)	139	20.8	3,266	5.2	15	22		
Detoxification	73	10.9	786	1.3	11	10		
Hospital inpatient	48	7.2	1,559	2.5	20	13	_	_
Treatment	36	5.4	769	1.2	7	18		
Detoxification	46	6.9	790	1.3	14	10		
Total	668		62,427	100.0	243	36	3,660	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	67	5.1
Olionto in facilities with OTDs?		
Clients in facilities with OTPs ²		
Any MAT	19,548	4.7
Methadone	18,300	4.8
Buprenorphine	1,123	4.1
Naltrexone	125	3.7
Clients in facilities without OTPs ²		
Any MAT	3,893	3.7
Buprenorphine	2,497	3.0
Naltrexone	1,396	7.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

No. % Cash or self-payment 631 94.5 Private health insurance 463 69.3 Medicare 154 23.1 Medicaid 254 38.0 State-financed health insurance 202 30.2 192 28.7 Federal military insurance No payment accepted 10 1.5 Access to Recovery (ATR) vouchers2 29 4.3 IHS/Tribal/Urban (ITU) funds 4.9 33 Other payments 1 0.1

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	640	95.8
State substance abuse agency	548	82.0
State mental health department	187	28.0
State department of health	282	42.2
Hospital licensing authority	34	5.1
The Joint Commission	203	30.4
Commission on Accreditation of Rehabilitation Facilities	241	36.1
National Committee for Quality Assurance	15	2.2
Council on Accreditation	29	4.3
Healthcare Facilities Accreditation Program	6	0.9
Other state/local agency/organization	39	5.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent			
	Facil	ities	
	No.	%	
Receives federal, state, county, or local government funds for substance abuse treatment programs	278	41.6	

Treatment at no charge for clients who can't pay

Sliding fee scale

63.3

37.0

423

247

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy by manuser and personic	Faci	lities
	No.	%
Assessment and pre-treatment services		7.0
Screening for substance abuse	646	96.7
Screening for mental health disorders	524	78.4
Comprehensive substance abuse assessment or diagnosis	629	94.2
Comprehensive mental health assessment or diagnosis	392	58.7
Screening for tobacco use	388	58.1
Outreach to persons in the community who may need treatment	377	56.4
Interim services for clients when immediate admission is not possible	319	47.8
No services offered	3	0.4
Testing		
Breathalyzer or other blood alcohol testing	477	71.4
Drug or alcohol urine screening	619	92.7
Screening for hepatitis B	207	31.0
Screening for hepatitis C	230	34.4
HIV testing	308	46.1
STD testing	217	32.5
TB screening	302	45.2
No services offered	39	5.8
Counseling		
Individual counseling	658	98.5
Group counseling	631	94.5
Family counseling	565	84.6
Marital/couples counseling	476	71.3
Transitional services		
Discharge planning	644	96.4
Aftercare/continuing care	530	79.3
No services offered	8	1.2
Pharmacotherapies		
Disulfiram (Antabuse®)	134	20.1
Naltrexone (oral)	206	30.8
Extended-release, injectable naltrexone/Vivitrol®	212	31.7
Acamprosate (Campral®)	145	21.7
Nicotine replacement	234	35.0
Non-nicotine smoking/tobacco cessation medications	162	24.3
Medications for psychiatric disorders	340	50.9
Methadone	50	7.5
Buprenorphine with naloxone (Suboxone®)	196	29.3
Buprenorphine without naloxone	150	22.5
Buprenorphine subdermal implant (Probuphine®)	11	1.6
No services offered	241	36.1
Ancillary services		
Case management services	537	80.4
Social skills development	502	75.1
Mentoring/peer support	371	55.5
Child care for clients' children	23	3.4
Assistance with obtaining social services	333	49.9
Employment counseling or training for clients	260	38.9

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	332	49.7
Domestic violence services	309	46.3
Early intervention for HIV	230	34.4
HIV or AIDS education, counseling, or support	487	72.9
Hepatitis education, counseling, or support	327	49.0
Health education other than HIV/AIDS or hepatitis	363	54.3
Substance abuse education	649	97.2
Transportation assistance to treatment	263	39.4
Mental health services	512	76.6
Acupuncture	76	11.4
Residential beds for clients' children	16	2.4
Self-help groups	354	53.0
Smoking/tobacco cessation counseling	311	46.6
No services offered	4	0.6
Other services		
Treatment for gambling disorder	169	25.3
Treatment for Internet use disorder	137	20.5
Treatment for other addiction disorder	268	40.1
No services offered	386	57.8

	Faci	lities
	No.	%
Substance abuse counseling	657	98.4
Relapse prevention	640	95.8
Cognitive behavioral therapy	630	94.3
Motivational interviewing	595	89.1
Anger management	589	88.2
Brief intervention	546	81.7
Trauma-related counseling	555	83.1
12-step facilitation	512	76.6
Contingency management/motivational incentives	428	64.1
Dialectical behavior therapy	375	56.1
Rational emotive behavioral therapy	366	54.8
Matrix model	253	37.9
Computerized substance abuse treatment	127	19.0
Community reinforcement plus vouchers	90	13.5
Other treatment approaches	80	12.0

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	174	35		
Number of clients ²	5,263	1,369		
Number of designated beds	6,110	1,040		
Utilization rate ³	86.1	131.6		
Average number of designated beds per facility	35	30		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	93
Methadone	87
Buprenorphine	5
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

Facili	ties
No.	%
273	40.9
388	58.1
147	37.9
108	27.8
133	34.3
274	97.9
2	0.7
73	26.1
	273 388 147 108 133 274

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	539	80.7
Adult women	310	46.4
Clients with co-occurring disorders	358	53.6
Adult men	295	44.2
Clients who have experienced trauma	287	43.0
Criminal justice clients	246	36.8
DUI/DWI clients	139	20.8
Young adults	195	29.2
Adolescents	135	20.2
Clients who have experienced domestic violence	201	30.1
Clients who have experienced sexual		
abuse	219	32.8
Pregnant or postpartum women	166	24.9
Seniors or older adults	156	23.4
LGBT ¹	150	22.5
Veterans	173	25.9
Clients living with HIV/AIDS	158	23.7
Members of military families	110	16.5
Active duty military	101	15.1
Other	20	3.0
No program or group offered	129	19.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Georgia National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Georgia, 292 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 25,466 clients in substance abuse treatment on March 31, 2017. The survey response rate in Georgia was 82.9 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	76	26.0	3,228	12.7	331	51.3
Private for-profit	156	53.4	17,887	70.2	203	31.5
Local, county, or community government	15	5.1	822	3.2	38	5.9
State government	38	13.0	2,610	10.2	73	11.3
Federal government	7	2.4	919	3.6	_	_
Tribal government	_	_	_	_	_	_
Total	292	100.0	25,466	100.0	645	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 100			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	223	81.7	7,708	30.3	93	
Clients with drug abuse only	233	85.3	15,030	59.0	188	
Clients with alcohol abuse only	185	67.8	2,728	10.7	33	
Total			25,466	100.0	314	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients age < 18	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	246	84.2	23,162	91.0	170	30	493	76.4
Regular	226	77.4	7,155	28.1	244	21		
Intensive	102	34.9	2,009	7.9	_	15		
Day treatment/partial hospitalization	47	16.1	924	3.6	_	14		
Detoxification	53	18.2	328	1.3	6	5		
Methadone maintenance	74	25.3	12,746	50.1	170	15		
Residential (non-hospital)	62	21.2	1,826	7.2	73	24	104	16.1
Short term (<30 days)	26	8.9	476	1.9	_	20		
Long term (30+ days)	51	17.5	1,125	4.4	73	20		
Detoxification	15	5.1	225	0.9	_	9		
Hospital inpatient	20	6.8	478	1.9	_	27	48	7.4
Treatment	16	5.5	252	1.0	_	20		
Detoxification	20	6.8	226	0.9	<u> </u>	10		
Total	292		25,466	100.0	170	30	645	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	54	4.1
Clients in facilities with OTPs ²		
Any MAT	12,177	2.9
Methadone	11,628	3.0
Buprenorphine	535	1.9
Naltrexone	14	0.4
Clients in facilities without OTPs ²		
Any MAT	489	0.5
Buprenorphine	334	0.4
Naltrexone	155	8.0

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	262	89.7
Private health insurance	154	52.7
Medicare	96	32.9
Medicaid	145	49.7
State-financed health insurance	115	39.4
Federal military insurance	104	35.6
No payment accepted	13	4.5
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	6	2.1
Other payments	6	2.1
Sliding fee scale	147	50.3
Treatment at no charge for clients who can't pay	112	38.4

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	274	93.8
State substance abuse agency	209	71.6
State mental health department	116	39.7
State department of health	123	42.1
Hospital licensing authority	17	5.8
The Joint Commission	59	20.2
Commission on Accreditation of Rehabilitation Facilities	169	57.9
National Committee for Quality Assurance	11	3.8
Council on Accreditation	21	7.2
Healthcare Facilities Accreditation Program	11	3.8
Other state/local agency/organization	14	4.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 102 34.9

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Residence of the control of	Types of services offered, by number and percent		
Assessment and pre-treatment services 8 Screening for substance abuse 282 96.6 Screening for mental health disorders 215 73.6 Comprehensive substance abuse assessment or diagnosis 265 90.8 Comprehensive mental health assessment or diagnosis 158 54.1 Screening for tobacco use 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interim services for clients when immediate admission is not possible 112 38.4 No services offered 4 1.4 Testablayzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis C 120 41.1 HIV testing 144 49.3 STD testing 175 59.9 No services offered 27 95.5 Cocunseling 287 98.3 Group counseling 287 98.3 Group counseling 273 93.5 Family counseling 28	Types of contract entropy manners with percent.	Faci	lities
Screening for substance abuse 282 96.6 Screening for mental health disorders 215 73.6 Comprehensive substance abuse assessment or diagnosis 265 90.8 Comprehensive mental health assessment or diagnosis 158 54.1 Screening for tobacco use 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interim services for clients when immediate admission is not possible 112 38.4 No services offered 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis 170 48.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis 102 34.9 Screening for hepatitis 103 37.7 TB screening 175 59.9 No services offered 11 3.8 Counseling 110 37.7 TB screening 273 93.5 Group counseling 287 98.3 Family counseling 285 87.3 No services offered 2 0.7 Pharmacotherapies 175 59.9 Thank (Indianos protess 176 18.8 Matriaticouples counseling 175 59.9 No services offered 2 0.7 Pharmacotherapies 175 59.9 Disulfram (Antabuse*) 18.8 Metications for psychiatric disorders 18.8 Metications			
Screening for substance abuse 282 96.6 Screening for mental health disorders 215 73.6 Comprehensive substance abuse assessment or diagnosis 265 90.8 Comprehensive substance abuse assessment or diagnosis 158 54.1 Screening for tobacco use 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interin services for clients when immediate admission is not possible 112 38.4 No services offered 4 1.4 Test stream of the blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis C 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 110 37.7 B screening for hepatitis C 120 44.9 STO testing 110 37.7 B screening for hepatitis C 120 44.1 HIV testing 175 59.9 No services offered 27 98.3 Grou	Assessment and pre-treatment services		
Comprehensive substance abuse assessment or diagnosis 265 90.8 Comprehensive mental health assessment or diagnosis 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interim services for clients when immediate admission is not possible 4 1.4 No services offered 4 1.4 Testinalyzer or other blood alcohol testing 170 S.2 Breathalyzer or other blood alcohol testing 170 S.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 41.1 Screening for hepatitis C 120 41.1 HIV testing 110 37.7 STD testing 110 37.7 B screening for hepatitis C 120 41.1 HIV testing 144 49.3 STD testing 110 37.7 B screening for hepatitis C 120 41.1 HIV testing 175 59.9 To Screening for hepatitis C 120 41.1 HIV testing	Screening for substance abuse	282	96.6
Comprehensive mental health assessment or diagnosis 158 54.1 Screening for tobacco use 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interin services for clients when immediate admission is not possible 112 38.4 No services offered 170 68.2 Breathalyzer or other blood alcohol testing 170 68.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis B 102 41.1 Screening for hepatitis B 120 41.1 Screening for hepatitis B 27 41.1 Screening for hepatitis B 28 42 Screening for h		215	73.6
Comprehensive mental health assessment or diagnosis 158 54.1 Screening for tobaccouse 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interim services for clients when immediate admission is not possible 112 38.4 No services offered 4 14.2 Testing 170 58.2 Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis B 102 34.9 Screening for hepatitis B 102 34.9 Screening for hepatitis B 102 34.1 Screening for hepatitis B 122 37.8 Screening for hepatitis B 282 38.3 Screening for hepatitis B	•	265	90.8
Screening for tobacco use 142 48.6 Outreach to persons in the community who may need treatment 190 65.1 Interim services offered 4 1.4 No services offered swhen immediate admission is not possible 4 1.4 Testing 170 58.2 Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 41.1 HIV testing 140 37.7 STD testing 110 37.7 B screening for hepatitis B 120 41.1 HIV testing 144 49.3 STD testing 176 59.9 No services offered 27 98.3 Courseling 287 98.3 Group counseling 287 98.3 Family counseling 282 96.6 Aftercare/continuing care 282 96.6 Aftercare/continuing care 25 87.3 No services offered 2 <	·	158	54.1
Outreach to persons in the community who may need treatment 190 65.1 Interin services for clients when immediate admission is not possible 112 38.4 No services offered 4 1.4 Testing Testing 170 58.2 Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 110 37.7 TB screening 110 37.7 TB screening 175 59.9 No services offered 11 3.8 Counciling 287 98.3 Group counseling 287 98.3 Group counseling 287 98.3 Family counseling 282 96.8 Marital/couples counseling 282 96.8 Marital/couples counseling 282 96.8 Acarpic pelanning 282 96.8 Aftercare/continuing ca	·	142	48.6
Interim services for clients when immediate admission is not possible 112 38.4 No services offered 4 1.4 Testing Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol untine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 144 49.3 STD testing 110 37.7 B Screening for hepatitis B 110 37.7 No services offered 11 38.0 No services offered 287 98.3 No services offered 287 98.3 Group counseling 287 98.3 Agaily Counseling 282 98.6 Aftercare/continuing care 282 96.6 Aftercare/continuing care 282 96.6 No services offered 25 87.3 No services offered 52 17.8 Natificam (Antabuse®) 52 17.8	•	190	65.1
No services offered 4 1.4 Testins Testins Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.1 HIV testing 114 49.3 STD testing 110 37.7 TB screening 110 37.7 TB screening 110 37.7 TB screening 110 37.7 TB screening 110 37.7 No services offered 11 3.8 Counseling 287 98.3 Group counseling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 287 98.3 Family counseling 287 98.3 Family counseling 282 96.6 Actional counseling 283 98.6 Actio		112	38.4
Breathalyzer or other blood alcohol testing 170 58.2 Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 114 49.3 STD testing 115 59.9 No services offered 11 38 Counseling 287 98.3 Individual counseling 287 98.3 Group counseling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 28 96.8 Marital/couples counseling 23 97 Transitional services Bamily counseling 28 96.8 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Ibsulfiran (Antabuse*) 5 17.8	·	4	1.4
Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 114 49.3 STD testing 110 37.7 TB screening 115 59.9 No services offered 11 3.8 Counciling 287 98.3 Group counselling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 273 93.5 Family counseling 282 96.6 Astericare/continuing care 25 87.3 No services offered 25 9.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 <td>Testing</td> <td></td> <td></td>	Testing		
Drug or alcohol urine screening 279 95.5 Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 114 49.3 STD testing 110 37.7 TB screening 115 59.9 No services offered 11 3.8 Counciling 287 98.3 Group counselling 273 93.5 Family counseling 273 93.5 Family counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 273 93.5 Family counseling 282 96.6 Astericare/continuing care 25 87.3 No services offered 25 9.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 <td></td> <td>170</td> <td>58.2</td>		170	58.2
Screening for hepatitis B 102 34.9 Screening for hepatitis C 120 41.1 HIV testing 144 49.3 STD testing 110 37.7 TB screening 175 59.9 No services offered 11 3.8 Counseling 287 98.3 Group counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse*) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol** 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders <	•	279	95.5
Screening for hepatitis C 120 41.1 HIV testing 144 49.3 STD testing 110 37.7 TB screening 175 59.9 No services offered 11 3.8 Counseling Individual counseling 287 98.3 Group counseling 273 93.5 Family counseling 286 80.8 Marital/couples counseling 175 59.9 Transitions services 22 96.6 Aftercare/continuing care 25 87.3 No services offered 25 96.6 Aftercare/continuing care 25 97.7 Pharmacotherapies 25 17.8 No services offered 28 96.6 Natitive on (rail) 48 16.4 Exte		102	34.9
HIV testing 144 49.3 STD testing 110 37.7 TB screening 175 59.9 No services offered 11 3.8 Courseling 287 98.3 Group counseling 273 93.5 Family counseling 236 80.8 Martal/couples counseling 236 80.8 Martal/couples counseling 282 86.6 Aftercare/continuing care 255 87.3 No services offered 25 87.3 No services offered 36 12.3 Nathrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Me			
STD testing 110 37.7 TB screening 175 59.9 No services offered 11 3.8 Courseling 287 98.3 Group counseling 287 98.3 Group counseling 273 93.5 Family counseling 273 93.5 Family counseling 175 59.9 Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Non-nicotine smoking/fobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 55 18.8 Buprenorphine without naloxone 47			
TB screening 175 59.9 No services offered 11 3.8 Counseling 18 8.3 Individual counseling 287 98.3 Group counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Use of services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacothered 25 87.3 No services offered 2 0.7 Pharmacothered 25 87.3 Naltercane (oral) 48 16.4 Extended-release, injectable nattrexone/Vivitrol® 36 12.3 Nacamprosate (Campral®) 36 12.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Medications for psychiatric disorde			
No services offered 11 3.8 Counseling 87 98.3 Individual counseling 273 93.5 Family counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Usustrational services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 25 87.3 Very pharmacotherapies 2 0.7 Pharmacotherapies Disulfiram (Antabuse*) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol* 36 12.3 Acamprosate (Campral*) 36 12.3 Nonicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone*) 50	•		
Counseling 287 98.3 Group counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine with unaloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3			
Individual counseling 287 98.3 Group counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Userbarge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse*) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol* 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone*) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine without plant (Probuphine*) 31 0.3 No services offered 268 91.8			
Group counseling 273 93.5 Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine with naloxone (Suboxone®) 1 0.3 No services offered 81 27.7 Accillary services 268 91.8 Social skills development 250 85.6 <		287	98.3
Family counseling 236 80.8 Marital/couples counseling 175 59.9 Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Subxone®) 50 17.1 Buprenorphine with naloxone (Subxone®) 1 0.3 No services offered 81 27.7 Accillary services 26 91.8 Social skills development 25 85.6			
Marital/couples counseling 175 59.9 Transitional services Transitional services Discharge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Accillary services 268 91.8 Social skills development	· · · · · · · · · · · · · · · · · · ·		
Transitional services Bischarge planning 282 96.6 Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Accillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child ca	· · · · · · · · · · · · · · · · · · ·		
Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social se	·		
Aftercare/continuing care 255 87.3 No services offered 2 0.7 Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 26 91.8 Accillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social se	Discharge planning	282	96.6
Pharmacotherapies Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone (Suboxone®) 10 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2		255	87.3
Disulfiram (Antabuse®) 52 17.8 Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Accillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	No services offered	2	0.7
Naltrexone (oral) 48 16.4 Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 36 12.3 Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Disulfiram (Antabuse®)	52	17.8
Acamprosate (Campral®) 36 12.3 Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Naltrexone (oral)	48	16.4
Nicotine replacement 65 22.3 Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Extended-release, injectable naltrexone/Vivitrol®	36	12.3
Non-nicotine smoking/tobacco cessation medications 55 18.8 Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Acamprosate (Campral®)	36	12.3
Medications for psychiatric disorders 147 50.3 Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Nicotine replacement	65	22.3
Methadone 54 18.5 Buprenorphine with naloxone (Suboxone®) 50 17.1 Buprenorphine without naloxone 47 16.1 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 81 27.7 Ancillary services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Non-nicotine smoking/tobacco cessation medications	55	18.8
Buprenorphine with naloxone (Suboxone®)5017.1Buprenorphine without naloxone4716.1Buprenorphine subdermal implant (Probuphine®)10.3No services offered8127.7Ancillary servicesCase management services26891.8Social skills development25085.6Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	Medications for psychiatric disorders	147	50.3
Buprenorphine without naloxone4716.1Buprenorphine subdermal implant (Probuphine®)10.3No services offered8127.7Ancillary servicesCase management services26891.8Social skills development25085.6Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	Methadone	54	18.5
Buprenorphine subdermal implant (Probuphine®) No services offered 81 27.7 Ancillary services Case management services Social skills development Social skills development Child care for clients' children Assistance with obtaining social services 10 0.3 81 27.7 82.7 17.8 18.9 18.9 18.9 19.8 19.8 19.8 19.8 19.8 10.8	Buprenorphine with naloxone (Suboxone®)	50	17.1
No services offered 81 27.7 Ancillary services 268 91.8 Case management services 268 91.8 Social skills development 250 85.6 Mentoring/peer support 174 59.6 Child care for clients' children 11 3.8 Assistance with obtaining social services 170 58.2	Buprenorphine without naloxone	47	16.1
Ancillary servicesCase management services26891.8Social skills development25085.6Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	Buprenorphine subdermal implant (Probuphine®)	1	0.3
Case management services26891.8Social skills development25085.6Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	No services offered	81	27.7
Social skills development25085.6Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	Ancillary services		
Mentoring/peer support17459.6Child care for clients' children113.8Assistance with obtaining social services17058.2	Case management services	268	91.8
Child care for clients' children113.8Assistance with obtaining social services17058.2	Social skills development	250	85.6
Assistance with obtaining social services 170 58.2	Mentoring/peer support	174	59.6
	Child care for clients' children	11	3.8
Frankright and the same first and the same frankright and the same frankright and the same same same same same same same sam	Assistance with obtaining social services	170	58.2
Employment counseling or training for clients 144 49.3	Employment counseling or training for clients	144	49.3

Types of services offered, by number and percent (continued)		
	Fac	cilities
	No.	%
Assistance in locating housing for clients	170	58.2
Domestic violence services	126	43.2
Early intervention for HIV	98	33.6
HIV or AIDS education, counseling, or support	196	67.1
Hepatitis education, counseling, or support	150	51.4
Health education other than HIV/AIDS or hepatitis	183	62.7
Substance abuse education	285	97.6
Transportation assistance to treatment	103	35.3
Mental health services	198	67.8
Acupuncture	5	1.7
Residential beds for clients' children	13	4.5
Self-help groups	134	45.9
Smoking/tobacco cessation counseling	107	36.6
No services offered	<u> </u>	_
Other services		
Treatment for gambling disorder	50	17.1
Treatment for Internet use disorder	37	12.7
Treatment for other addiction disorder	95	32.5
No services offered	191	65.4

	Faci	lities
	No.	%
Substance abuse counseling	287	98.3
Relapse prevention	281	96.2
Cognitive behavioral therapy	273	93.5
Motivational interviewing	259	88.7
Anger management	251	86.0
Brief intervention	246	84.2
Trauma-related counseling	232	79.5
12-step facilitation	217	74.3
Contingency management/motivational incentives	179	61.3
Dialectical behavior therapy	158	54.1
Rational emotive behavioral therapy	141	48.3
Matrix model	158	54.1
Computerized substance abuse treatment	62	21.2
Community reinforcement plus vouchers	39	13.4
Other treatment approaches	17	5.8

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	49	13				
Number of clients ²	1,523	401				
Number of designated beds	1,612	350				
Utilization rate ³	94.5	114.6				
Average number of designated beds per facility	33	27				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	117
Methadone	111
Buprenorphine	5
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	89	30.5
Any language other than English	116	39.7
Non-English language provided by		
Staff counselor only	25	21.6
On-call interpreter only	65	56.0
Both staff counselor and on-call interpreter	26	22.4
Languages provided by staff counselor ¹		
Spanish	50	98.0
American Indian/Alaskan Native		
languages	_	_
Other	5	9.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	217	74.3
Adult women	143	49.0
Clients with co-occurring disorders	144	49.3
Adult men	130	44.5
Clients who have experienced trauma	107	36.6
Criminal justice clients	93	31.8
DUI/DWI clients	50	17.1
Young adults	96	32.9
Adolescents	68	23.3
Clients who have experienced domestic violence	89	30.5
Clients who have experienced sexual		
abuse	87	29.8
Pregnant or postpartum women	75	25.7
Seniors or older adults	70	24.0
LGBT ¹	64	21.9
Veterans	77	26.4
Clients living with HIV/AIDS	59	20.2
Members of military families	53	18.2
Active duty military	45	15.4
Other	9	3.1
No program or group offered	75	25.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Hawaii National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Hawaii, 168 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 4,922 clients in substance abuse treatment on March 31, 2017. The survey response rate in Hawaii was 93.9 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients under age 18	
	No.	%	No.	%	No.	%
Private non-profit	138	82.1	3,673	74.6	1,306	97.7
Private for-profit	23	13.7	877	17.8	31	2.3
Local, county, or community government	_	_	_	_	_	_
State government	2	1.2	89	1.8	_	
Federal government	5	3.0	283	5.7	_	
Tribal government	_	_	_	_	_	_
Total	168	100.0	4,922	100.0	1,337	100.0

Substance abuse problem treated, by number and percent					
Clients in treatment on March 31, 2017					
	Facilities ¹		Clients ²		Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	148	94.9	2,878	58.5	175
Clients with drug abuse only	100	64.1	1,511	30.7	109
Clients with alcohol abuse only	92	59.0	534	10.8	36
Total			4,922	100.0	320

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20 ⁻	17	
_	Facil	ities¹		All clients CI				age < 18
_					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	157	93.5	4,490	91.2	184	14	1,318	98.6
Regular	157	93.5	2,004	40.7	20	12		
Intensive	53	31.5	1,313	26.7	33	15		
Day treatment/partial hospitalization	16	9.5	252	5.1	_	8		
Detoxification	6	3.6	23	0.5	_	2		
Methadone maintenance	11	6.5	898	18.2	184	20		
Residential (non-hospital)	16	9.5	432	8.8	_	16	19	1.4
Short term (<30 days)	6	3.6	144	2.9	_	16		
Long term (30+ days)	16	9.5	262	5.3	_	10		
Detoxification	5	3.0	26	0.5	_	5		
Hospital inpatient	_	_	_	_	_	_	_	_
Treatment	_	_	_	_		_		
Detoxification	_	_	_	_	_	_		
Total	168		4,922	100.0	184	14	1,337	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	5	0.4
Clients in facilities with OTPs ²		
Cheffic in facilities with OTPS		
Any MAT	859	0.2
Methadone	733	0.2
Buprenorphine	126	0.5
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	118	0.1
Buprenorphine	89	0.1
Naltrexone	29	0.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	. -	
	No.	%
Cash or self-payment	62	36.9
Private health insurance	55	32.7
Medicare	24	14.3
Medicaid	47	28.0
State-financed health insurance	47	28.0
Federal military insurance	23	13.7
No payment accepted	79	47.0
Access to Recovery (ATR) vouchers ²	10	6.0
IHS/Tribal/Urban (ITU) funds	4	2.4
Other payments	_	_
Sliding fee scale	19	11.3
Treatment at no charge for clients who can't pay	123	73.2

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	133	79.2
State substance abuse agency	81	48.2
State mental health department	16	9.5
State department of health	77	45.8
Hospital licensing authority	5	3.0
The Joint Commission	7	4.2
Commission on Accreditation of Rehabilitation Facilities	105	62.5
National Committee for Quality Assurance	_	_
Council on Accreditation	9	5.4
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	2	1.2

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 147 87.5

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services effered, by flumber and percent	Faci	lities
	No.	%
Assessment and pre-treatment services	140.	70
Screening for substance abuse	162	96.4
Screening for mental health disorders	58	34.5
Comprehensive substance abuse assessment or diagnosis	157	93.5
Comprehensive mental health assessment or diagnosis	34	20.2
Screening for tobacco use	139	82.7
Outreach to persons in the community who may need treatment	101	60.1
Interim services for clients when immediate admission is not possible	79	47.0
No services offered	3	1.8
Testing		1.0
Breathalyzer or other blood alcohol testing	49	29.2
Drug or alcohol urine screening	67	39.9
Screening for hepatitis B	12	7.1
Screening for hepatitis C	15	8.9
HIV testing	14	8.3
STD testing	9	5.4
TB screening	22	13.1
No services offered	98	58.3
Counseling	90	30.3
Individual counseling	168	100.0
Group counseling	164	97.6
Family counseling	119	70.8
Marital/couples counseling	60	35.7
Transitional services	00	33.7
Discharge planning	164	97.6
Aftercare/continuing care	99	58.9
No services offered	1	0.6
Pharmacotherapies	•	0.0
Disulfiram (Antabuse®)	6	3.6
Naltrexone (oral)	8	4.8
Extended-release, injectable naltrexone/Vivitrol®	5	3.0
Acamprosate (Campral®)	7	4.2
Nicotine replacement	13	7.7
Non-nicotine smoking/tobacco cessation medications	10	6.0
Medications for psychiatric disorders	21	12.5
Methadone	4	2.4
Buprenorphine with naloxone (Suboxone®)	12	7.1
Buprenorphine with naloxone	6	3.6
Buprenorphine subdermal implant (Probuphine®)	<u> </u>	—
No services offered	139	82.7
Ancillary services	100	02.1
Case management services	142	84.5
Social skills development	150	89.3
Mentoring/peer support	131	78.0
Child care for clients' children	31	18.5
Assistance with obtaining social services	43	25.6
Employment counseling or training for clients	84	50.0
	5 ,	00.0

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	41	24.4
Domestic violence services	29	17.3
Early intervention for HIV	12	7.1
HIV or AIDS education, counseling, or support	68	40.5
Hepatitis education, counseling, or support	37	22.0
Health education other than HIV/AIDS or hepatitis	59	35.1
Substance abuse education	165	98.2
Transportation assistance to treatment	87	51.8
Mental health services	46	27.4
Acupuncture	6	3.6
Residential beds for clients' children	3	1.8
Self-help groups	38	22.6
Smoking/tobacco cessation counseling	118	70.2
No services offered	1	0.6
Other services		
Treatment for gambling disorder	17	10.1
Treatment for Internet use disorder	12	7.1
Treatment for other addiction disorder	19	11.3
No services offered	145	86.3

	Faci	Facilities	
	No.	%	
Substance abuse counseling	166	98.8	
Relapse prevention	162	96.4	
Cognitive behavioral therapy	135	80.4	
Motivational interviewing	162	96.4	
Anger management	149	88.7	
Brief intervention	119	70.8	
Trauma-related counseling	117	69.6	
12-step facilitation	75	44.6	
Contingency management/motivational incentives	85	50.6	
Dialectical behavior therapy	42	25.0	
Rational emotive behavioral therapy	28	16.7	
Matrix model	48	28.6	
Computerized substance abuse treatment	11	6.5	
Community reinforcement plus vouchers	14	8.3	
Other treatment approaches	5	3.0	

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	14	_				
Number of clients ²	382	_				
Number of designated beds	409	—				
Utilization rate ³	93.4	_				
Average number of designated beds per facility	29	_				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	60
Methadone	51
Buprenorphine	9
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facil	ities
	No.	%
Sign language	42	25.0
Any language other than English	49	29.2
Non-English language provided by		
Staff counselor only	3	6.1
On-call interpreter only	42	85.7
Both staff counselor and on-call interpreter	4	8.2
Languages provided by staff counselor ¹		
Spanish	1	14.3
American Indian/Alaskan Native		
languages	_	_
Other	7	100.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	156	92.9
Adult women	37	22.0
Clients with co-occurring disorders	31	18.5
Adult men	36	21.4
Clients who have experienced trauma	27	16.1
Criminal justice clients	37	22.0
DUI/DWI clients	14	8.3
Young adults	24	14.3
Adolescents	113	67.3
Clients who have experienced domestic violence	22	13.1
Clients who have experienced sexual		
abuse	15	8.9
Pregnant or postpartum women	21	12.5
Seniors or older adults	19	11.3
LGBT ¹	19	11.3
Veterans	21	12.5
Clients living with HIV/AIDS	15	8.9
Members of military families	14	8.3
Active duty military	16	9.5
Other	2	1.2
No program or group offered	12	7.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/




U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities







https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Idaho National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Idaho, 124 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 7,026 clients in substance abuse treatment on March 31, 2017. The survey response rate in Idaho was 90.3 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	12	9.7	437	6.2	61	9.8
Private for-profit	99	79.8	5,628	80.1	481	77.0
Local, county, or community government	8	6.5	772	11.0	77	12.3
State government	_	_	_	_	_	_
Federal government	2	1.6	119	1.7	_	_
Tribal government	3	2.4	70	1.0	6	1.0
Total	124	100.0	7,026	100.0	625	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on Marc						
	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	102	95.3	3,488	52.3	247	
Clients with drug abuse only	89	83.2	1,951	29.3	142	
Clients with alcohol abuse only	86	80.4	1,230	18.4	86	
Total			6,669	100.0	475	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	-		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	<u>%</u>
Outpatient	119	96.0	6,827	97.2	3	39	579	92.6
Regular	119	96.0	3,696	52.6	2	25		
Intensive	108	87.1	2,047	29.1	_	15		
Day treatment/partial hospitalization	11	8.9	243	3.5	_	31		
Detoxification	9	7.3	30	0.4	17	4		
Methadone maintenance	16	12.9	811	11.5	1	9		
Residential (non-hospital)	11	8.9	156	2.2	_	13	44	7.0
Short term (<30 days)	5	4.0	55	8.0	_	10		
Long term (30+ days)	8	6.5	92	1.3	_	9		
Detoxification	5	4.0	9	0.1	_	1		
Hospital inpatient	3	2.4	43	0.6	_	11	2	0.3
Treatment	3	2.4	28	0.4	_	14		
Detoxification	2	1.6	15	0.2	<u>—</u>	8		
Total	124		7,026	100.0	3	38	625	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	3	0.2
Clients in facilities with OTPs ²		
Any MAT	435	0.1
Methadone	364	0.1
Buprenorphine	70	0.3
Naltrexone	1	*
Clients in facilities without OTPs ²		
Any MAT	76	0.1
Buprenorphine	47	0.1
Naltrexone	29	0.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	117	94.4
Private health insurance	92	74.2
Medicare	53	42.7
Medicaid	106	85.5
State-financed health insurance	80	64.5
Federal military insurance	65	52.4
No payment accepted	1	0.8
Access to Recovery (ATR) vouchers ²	86	69.4
IHS/Tribal/Urban (ITU) funds	24	19.4
Other payments	4	3.2
Sliding fee scale	84	67.7
Treatment at no charge for clients who can't pay	59	47.6
4 = 1111		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	117	94.4
State substance abuse agency	108	87.1
State mental health department	72	58.1
State department of health	53	42.7
Hospital licensing authority	2	1.6
The Joint Commission	8	6.5
Commission on Accreditation of Rehabilitation Facilities	14	11.3
National Committee for Quality Assurance	1	0.8
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	1	0.8
Other state/local agency/organization	4	3.2

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 58 46.8

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Assessment and pre-treatment services No. No. Screening for substance abuse 119 96.0 Screening for reubstance abuse assessment or diagnosis 121 97.6 Comprehensive substance abuse assessment or diagnosis 44 67.7 Comprehensive mental health assessment or diagnosis 44 67.7 Comprehensive mental health sassessment or diagnosis 44 67.7 Comprehensive mental health sassessment or diagnosis 44 67.7 Comprehensive mental health assessment or diagnosis 44 67.7 Correcting for hobaco use 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interim services for clients when immediate admission is not possible 62 80.0 No services offered 1 0.8 Properties of release when immediate admission is not possible 82 79.0 Researching or hepatitis B 41 10.6 Properties or Properties B 79.0 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis B 12 12<	Types of services offered, by number and percent		
No.	Types of services effects, by flumber and percent	Faci	litios
Screening for substance abuse 119 96.0 87.1 97.6 108 87.1 97.6 108 87.1 97.6 108 87.1 97.6 108 87.1 97.6 108 87.1 97.6 108 1			
Screening for substance abuse 119 86.0 Screening for mental health disorders 108 87.1 Comprehensive substance abuse assessment or diagnosis 121 97.6 Comprehensive mental health assessment or diagnosis 84 67.7 Screening for tobacco use 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interin services for clients when immediate admission is not possible 62 50.0 No services offered 1 0.8 Test of the possible of the	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 108 87.1 Comprehensive substance abuse assessment or diagnosis 121 97.6 Comprehensive mental health assessment or diagnosis 84 67.7 Screening for tobacco use 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interim services for clients when immediate admission is not possible 62 50.0 No services offered 1 0.8 Testing 8 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV Lesting 18 4.5 STD testing 15 12.1 TB screening 15 12.1 TB screening 12 39.2 Tous envices offered 23 18.5 Tous envices offered 23 18.5 Testing 12 28.4 Group counseling 120 98.8 Family counse		119	96.0
Comprehensive substance abuse assessment or diagnosis 121 97.6 Comprehensive mental health assessment or diagnosis 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interim services for clients when immediate admission is not possible 62 50.0 No services offered 1 0.8 Testing 64 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 18 14.5 Brough counseling 19 96.0 Group counseling 123 99.2 Group counseling 120 98.8 Martial couples counseling 122 98.4 Aftercare/continuing care 13 91.1 <	~		
Comprehensive mental health assessment or diagnosis 84 67.7 Screening for tobacco use 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interim services for clients when immediate admission is not possible 62 50.0 No services offered 7 7 Testing 8 79.0 Breathalyzer or other blood alcohol testing 64 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis B 16 12.9 IVI V testing 18 14.5 STD testing 15 12.1 TB screening for hepatitis B 16 12.9 Screening for hepatitis B 16 12.9 Screening for hepatitis B 16 12.9 Screening for hepatitis B 18 14.5 STD testing 15 12.1 TB screening for hepatitis B 12 12 Streening for hepatitis B 12 12 <tr< td=""><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td></tr<>	· · · · · · · · · · · · · · · · · · ·		
Screening for tobacco use 59 47.6 Outreach to persons in the community who may need treatment 80 64.5 Interim services for clients when immediate admission is not possible 1 0.8 No services offered 1 0.8 Testalny 8 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis B 16 12.9 HIV testing 18 14.5 STD testing 16 12.9 HIV testing 18 14.5 TS screening for hepatitis B 16 12.9 HIV testing 18 14.5 TS streening for hepatitis B 16 12.9 HIV testing 18 14.5 TS To testing 18 14.5 TS Testing 18 14.5 TS To testing 18 14.5 TS To testing 18 18.2 Individual counselling 123 98.2 Fami	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 80 64.5 Interin services for clients when immediate admission is not possible 62 50.0 No services offered 1 0.8 Testing Breathalyzer or other blood alcohol testing 64 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 15 12.1 TB screening 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Counseling 12 99.2 Group counseling 12 96.8 Family counseling 12 96.8 Family counseling 12 98.4 Aftercare/continuing care 11 0.8 Paramitoral pelanting 12 98.4 Aftercare/continuing care 15 12.1 No services offered 1 0.8 <	·		
Interim services for clients when immediate admission is not possible 62 50.0 No services offered 1 0.8 Testing Breathalyzer or other blood alcohol testing 64 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening of fred 23 18.5 TD testing 17 13.7 No services offered 23 18.5 Counseling 12 98.2 Group counseling 120 96.8 Family counseling 120 96.8 Bramily counseling 120 96.8 Bramily counseling 120 96.8 Transitional services 10 86.3 Transitional services 12 98.4 Aftercare/continuing care 11 0.8	· · · · · · · · · · · · · · · · · · ·		
No services offered 1 0.8 Testiny Testiny Breathalyzer or other blood alcohol testing 64 51.6 Drug or alcohol urine screening 88 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening 15 12.1 No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 120 96.8 Bramily co			
Testing 84 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 19 96.0 Martal/couples counseling 19 96.0 Martal/couples counseling 19 96.0 Martal/couples counseling 10 78 Transitional services 11 9.6 Pamily counseling 12 98.4 Aftercare/continuing care 13 9.1 No services offered 13 9.1 No services offered 13 9.1 No services offered 15 12.1 Nalltexance (camptall') 16	·		
Breathalyzer or other blood alcohol testing 64 51.6 Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 17 13.7 No services offered 23 18.5 Counseling 17 13.7 Individual counseling 123 99.2 Group counseling 120 96.8 Family counseling 120 96.8 Family counseling 107 86.3 Transitional services 107 86.3 Transitional services Discharge planning 12 98.4 Aftercare/continuing care 11 0.8 Pharmacotherapies Dischfirent (hatabuse*) 15 12.1 Not (rational care) 15 12.1 Naitrexone (oral) 19 15.3 Extended-release, injectable naltrexone/vivitrol** 16			
Drug or alcohol urine screening 98 79.0 Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Council Individual counseling 123 99.2 Group counseling 120 96.8 Family counseling 120 96.8 Family counseling 19 96.0 Marital/couples counseling 10 96.3 Family counseling 122 98.4 Aftercare/continuing care 11 0.8 Discharge planning 122 98.4 Aftercare/continuing care 11 0.8 No services offered 1 0.8 Parametherajes Disulfiram (Antabuse*) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol**		64	51.6
Screening for hepatitis B 13 10.5 Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 19 96.0 Marital/couples counseling 107 86.3 Transitional services 19 96.0 Discharge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies 15 12.1 Disulfiram (Antabuse*) 15 12.1 Natirexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol** 16 12.9 Acamprosate (Campral**) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessatio	·		
Screening for hepatitis C 16 12.9 HIV testing 18 14.5 STD testing 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Counseling 123 99.2 Individual counseling 123 99.2 Group counseling 120 96.8 Family counseling 107 86.3 Transitions services 107 86.3 Transitional services 107 86.3 Transitional services 113 91.1 Disulfarge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 15 12.1 No services offered 15 12.1 Nations are continuitions of planting and planting and planting and planting			
HIV testing			
STD testing 15 12.1 TB screening 17 13.7 No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 120 96.0 Marital/couples counseling 107 86.3 Transitional services Discharge planning 122 98.4 Aftercare/continuing care 11 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Non-nicotine smoking/lobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 3 2.4 Buprenorphine without naloxone 14 11.3 Buprenorphine without naloxone			
TB screening 17 13.7 No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 119 96.0 Marital/couples counseling 107 86.3 Transitional services Usicharge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Pharmacotherapies Usiulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 2.5 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17	· · · · · · · · · · · · · · · · · · ·		
No services offered 23 18.5 Counseling 123 99.2 Group counseling 120 96.8 Family counseling 119 96.0 Marital/couples counseling 107 86.3 Transitional services Usignature planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse**) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol** 16 12.9 Acamprosate (Campral**) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 3 2.4 Buprenorphine with naloxone (Suboxone*) 17 13.7 Buprenorphine without naloxone 4 11.3 Buprenorphine without naloxone 85 68.5			
Counseling 123 99.2 Group counseling 120 96.8 Family counseling 119 96.0 Marital/couples counseling 107 86.3 Transitional services Discharge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine with unaloxone 35 6.5 Ancillary services 16 93.5 Case management service	· · · · · · · · · · · · · · · · · · ·		
Individual counseling 123 99.2 Group counseling 120 96.8 Family counseling 119 96.0 Marital/couples counseling 107 36.3 Transitional services Userbarge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse*) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol* 16 12.9 Acamprosate (Campral*) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 3 2.4 Buprenorphine with naloxone (Suboxone*) 17 13.7 Buprenorphine with naloxone (Suboxone*) 17 13.7 Buprenorphine without naloxone 85 68.5 Arcallary services <			10.0
Group counseling 120 96.8 Family counseling 119 96.0 Marital/couples counseling 107 86.3 Transitional services Use planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine with naloxone (Suboxone®) 16 1.3 No services offered 85 68.5 Accillary services 16 93.5 <		123	99.2
Family counseling 119 96.0 Marital/couples counseling 107 86.3 Transitional services Transitional services Discharge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine with naloxone (Suboxone®) 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Accillary services 16	·		
Marital/couples counseling 107 86.3 Transitional services Use planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Ruprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7	, -		
Transitional services 122 98.4 Discharge planning 122 98.4 Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Actiliary services 116 93.5 Case management services 116 93.5 Social skills development 105	· · · · · · · · · · · · · · · · · · ·		
Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies 3 15 12.1 Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 <			
Aftercare/continuing care 113 91.1 No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services	Discharge planning	122	98.4
No services offered 1 0.8 Pharmacotherapies Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80			
Disulfiram (Antabuse®) 15 12.1 Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5			0.8
Naltrexone (oral) 19 15.3 Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 16 12.9 Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Disulfiram (Antabuse®)	15	12.1
Acamprosate (Campral®) 15 12.1 Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Naltrexone (oral)	19	15.3
Nicotine replacement 11 8.9 Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Extended-release, injectable naltrexone/Vivitrol®	16	12.9
Non-nicotine smoking/tobacco cessation medications 15 12.1 Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Acamprosate (Campral®)	15	12.1
Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Nicotine replacement	11	8.9
Medications for psychiatric disorders 32 25.8 Methadone 3 2.4 Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5	Non-nicotine smoking/tobacco cessation medications	15	12.1
Buprenorphine with naloxone (Suboxone®) 17 13.7 Buprenorphine without naloxone 14 11.3 Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services 80 64.5		32	25.8
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) 1 0.8 No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support 88 71.0 Child care for clients' children 3 2.4 Assistance with obtaining social services	Methadone	3	2.4
Buprenorphine subdermal implant (Probuphine®) No services offered 85 68.5 Ancillary services Case management services 116 93.5 Social skills development 105 84.7 Mentoring/peer support Child care for clients' children Assistance with obtaining social services 80 64.5	Buprenorphine with naloxone (Suboxone®)	17	13.7
No services offered 85 68.5 Ancillary services	Buprenorphine without naloxone	14	11.3
Ancillary servicesCase management services11693.5Social skills development10584.7Mentoring/peer support8871.0Child care for clients' children32.4Assistance with obtaining social services8064.5	Buprenorphine subdermal implant (Probuphine®)	1	0.8
Case management services11693.5Social skills development10584.7Mentoring/peer support8871.0Child care for clients' children32.4Assistance with obtaining social services8064.5	No services offered	85	68.5
Social skills development10584.7Mentoring/peer support8871.0Child care for clients' children32.4Assistance with obtaining social services8064.5	Ancillary services		
Mentoring/peer support8871.0Child care for clients' children32.4Assistance with obtaining social services8064.5	Case management services	116	93.5
Child care for clients' children32.4Assistance with obtaining social services8064.5	Social skills development	105	84.7
Assistance with obtaining social services 80 64.5	Mentoring/peer support	88	71.0
	Child care for clients' children	3	2.4
Employment counseling or training for clients 42 33.9	Assistance with obtaining social services	80	64.5
	Employment counseling or training for clients	42	33.9

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	87	70.2
Domestic violence services	55	44.4
Early intervention for HIV	15	12.1
HIV or AIDS education, counseling, or support	33	26.6
Hepatitis education, counseling, or support	33	26.6
Health education other than HIV/AIDS or hepatitis	35	28.2
Substance abuse education	119	96.0
Transportation assistance to treatment	50	40.3
Mental health services	112	90.3
Acupuncture	2	1.6
Residential beds for clients' children	_	_
Self-help groups	41	33.1
Smoking/tobacco cessation counseling	41	33.1
No services offered	1	0.8
Other services		
Treatment for gambling disorder	31	25.0
Treatment for Internet use disorder	29	23.4
Treatment for other addiction disorder	53	42.7
No services offered	70	56.5

	Faci	Facilities	
	No.	%	
Substance abuse counseling	121	97.6	
Relapse prevention	119	96.0	
Cognitive behavioral therapy	121	97.6	
Motivational interviewing	118	95.2	
Anger management	108	87.1	
Brief intervention	104	83.9	
Trauma-related counseling	115	92.7	
12-step facilitation	77	62.1	
Contingency management/motivational incentives	85	68.5	
Dialectical behavior therapy	99	79.8	
Rational emotive behavioral therapy	62	50.0	
Matrix model	98	79.0	
Computerized substance abuse treatment	18	14.5	
Community reinforcement plus vouchers	17	13.7	
Other treatment approaches	10	8.1	

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	10	3			
Number of clients ²	156	43			
Number of designated beds	191	68			
Utilization rate ³	81.7	63.2			
Average number of designated beds per facility	19	23			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	25
Methadone	21
Buprenorphine	4
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	25	20.2
Any language other than English	46	37.1
Non-English language provided by		
Staff counselor only	14	30.4
On-call interpreter only	20	43.5
Both staff counselor and on-call interpreter	12	26.1
Languages provided by staff counselor ¹		
Spanish	25	96.2
American Indian/Alaskan Native		
languages	_	_
Other	1	3.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities		
	No.	%	
Any program or group	115	92.7	
Adult women	87	70.2	
Clients with co-occurring disorders	88	71.0	
Adult men	82	66.1	
Clients who have experienced trauma	65	52.4	
Criminal justice clients	73	58.9	
DUI/DWI clients	52	41.9	
Young adults	54	43.5	
Adolescents	65	52.4	
Clients who have experienced domestic violence	41	33.1	
Clients who have experienced sexual abuse	46	37.1	
Pregnant or postpartum women	34	27.4	
Seniors or older adults	35	28.2	
LGBT ¹	27	21.8	
Veterans	30	24.2	
Clients living with HIV/AIDS	18	14.5	
Members of military families	23	18.5	
Active duty military	21	16.9	
Other	2	1.6	
No program or group offered	9	7.3	

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Illinois National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Illinois, 633 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 44,265 clients in substance abuse treatment on March 31, 2017. The survey response rate in Illinois was 93.3 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	344	54.3	26,232	59.3	1,510	77.6
Private for-profit	263	41.5	16,278	36.8	416	21.4
Local, county, or community government	14	2.2	630	1.4	14	0.7
State government	8	1.3	689	1.6	5	0.3
Federal government	4	0.6	436	1.0	_	_
Tribal government	_	_	_	_	_	_
Total	633	100.0	44,265	100.0	1,945	100.0

Substance abuse problem treated, by number and percent							
Clients in treatment on March 31, 2017							
	Faciliti	es¹	Clients ² Clients ² per 100,000				
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	544	93.0	15,811	35.7	150		
Clients with drug abuse only	489	83.6	20,013	45.2	197		
Clients with alcohol abuse only	500	85.5	8,441	19.1	81		
Total			44,265	100.0	427		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹	All clients Clients				Clients	age < 18
_					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	585	92.4	41,152	93.0	230	28	1,711	88.0
Regular	576	91.0	17,863	40.4	25	20		
Intensive	416	65.7	6,144	13.9	14	10		
Day treatment/partial hospitalization	90	14.2	663	1.5	_	10		
Detoxification	58	9.2	562	1.3	5	7		
Methadone maintenance	136	21.5	15,920	36.0	210	15		
Residential (non-hospital)	89	14.1	2,894	6.5	20	16	221	11.4
Short term (<30 days)	56	8.8	1,753	4.0	16	16		
Long term (30+ days)	59	9.3	989	2.2	6	15		
Detoxification	23	3.6	152	0.3	13	8		
Hospital inpatient	24	3.8	219	0.5	12	10	13	0.7
Treatment	13	2.1	94	0.2	22	5		
Detoxification	23	3.6	125	0.3	5	6		
Total	633		44,265	100.0	211	26	1,945	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	68	5.2
Clients in facilities with OTPs ²		
Any MAT	14,596	3.5
Methadone	13,732	3.6
Buprenorphine	753	2.7
Naltrexone	111	3.3
Clients in facilities without OTPs ²		
Any MAT	2,388	2.3
Buprenorphine	2,062	2.4
Naltrexone	326	1.7

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. domey payment opinions, by manual and	po	
	No.	%
Cash or self-payment	605	95.6
Private health insurance	415	65.6
Medicare	154	24.3
Medicaid	330	52.1
State-financed health insurance	248	39.2
Federal military insurance	146	23.1
No payment accepted	6	0.9
Access to Recovery (ATR) vouchers ²	51	8.1
IHS/Tribal/Urban (ITU) funds	6	0.9
Other payments	2	0.3
Sliding fee scale	431	68.1
Treatment at no charge for clients who can't pay	270	42.7
1 = -104		

Facility licensing, certification, or accreditation, by number and percent

Facil	ities¹
No.	%
615	97.2
583	92.1
172	27.2
151	23.9
35	5.5
149	23.5
163	25.8
11	1.7
39	6.2
8	1.3
6	0.9
	No. 615 583 172 151 35 149 163 11 39 8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 313 49.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Assessment and pro-treatment services Formation of the substance abuse 67 9.75 Screening for substance abuse 617 9.75 Comprehensive substance abuse assessment or diagnosis 594 9.8 Comprehensive substance abuse assessment or diagnosis 270 42.7 Comprehensive substance abuse assessment or diagnosis 303 53.4 Comprehensive mental health assessment or diagnosis 303 53.4 Correcting for blobaccouse 303 53.4 Forther and the community who may need treatment 358 56.6 Interim services for clients when immediate admission is not possible 315 49.8 No services offered 450 71.1 19.0 Properties of clients when immediate admission is not possible 315 49.8 No services offered 450 71.1 Properties of the blood alcohol testing 450 71.1 Properties of the blood alcohol testing 450 71.1 Properties of the blood alcohol testing 450 71.2 Properties of the blood alcohol testing 450 71.2 <	Types of services offered, by number and percent		
Assessment and pro-treatment services Kerber (17 month) % Screening for substance abuse 617 97.5 Screening for mental health disorders 436 68.9 Comprehensive mental health assessment or diagnosis 594 49.8 Comprehensive mental health assessment or diagnosis 270 42.7 Screening for tobacco use 338 53.4 Outreach to persons in the community who may need treatment 358 56.6 Interim services for clients when immediate admission is not possible 315 49.8 No services offered 8 1.3 Testing 450 71.1 Drug or alcohol urine screening 450 71.1 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 133 33.6 Screening for hepatitis B 121 19.1 HIV testing 410 22.1 STD testing 65 15.0 Creening	Types of services energy, by number and percent	Faci	litios
Assessment and pre-treatment services 617 97.5 Screening for substance abuse 618 68.9 Comprehensive substance abuse assessment or diagnosis 594 93.8 Comprehensive mental health assessment or diagnosis 270 42.7 Screening for tobacco use 338 53.4 Outreach to persons in the community who may need treatment 38 53.4 Interim services for clients when immediate admission is not possible 315 49.8 No services offered 8 1.3 17.1 Testing 450 71.1 1.1 Drug or alcohol urine screening 454 85.9 9.5 Screening for hepatitis B 113 17.9 17.1 Drug or alcohol urine screening 454 85.9 9.5 Screening for hepatitis B 113 17.9 17.1 Brassiting 49 71.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 17.1 <			
Screening for substance abuse 617 97.5 Screening for mental health disorders 436 68.9 Comprehensive substance abuse assessment or diagnosis 554 93.8 Comprehensive substance abuse assessment or diagnosis 270 42.7 Screening for tobacco use 338 53.4 Outreach to persons in the community who may need treatment 358 56.6 Interin services for clients when immediate admission is not possible 315 49.8 No services offered 8 1.3 Testing 45 1.1 Drug or alcohol urine screening 54 85.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening for hepatitis C 121 19.1 HIV testing 95 15.0 STD testing 95 15.0 TB screening for hepatitis C 121 19.1 HIV testing 213 33.6 STD testing 26 27 99.1<	Assessment and pre-treatment services		
Screening for mental health disorders 436 86.9 Comprehensive substance abuse assessment or diagnosis 594 93.8 Comprehensive mental health assessment or diagnosis 270 42.7 Screening for tobacco use 338 55.6 Outreach to persons in the community who may need treatment 358 55.6 Interim services for clients when immediate admission is not possible 315 49.8 No services offered 31 49.8 No services offered 450 71.1 Tresting 544 85.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 Screening for hepatitis C 121 19.1 HIV testing 95 15.0 TB screening 140 22.1 SD testing 95 15.0 TB screening for hepatitis C 121 33.6 Storesming for hepatitis C 121 33.6 ST besting 18 9.2 Bus certainig 616 62 <td< td=""><td>·</td><td>617</td><td>97.5</td></td<>	·	617	97.5
Comprehensive mental health assessment or diagnosis 270 42.7 Screening for tobacco use 338 53.6 Outreach to persons in the community who may need treatment 358 56.6 Interim services for clients when immediate admission is not possible 315 49.8 No services offered 315 49.8 No services offered 450 71.1 Breathalyzer or other blood alcohol testing 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 121 19.1 HIV I testing 140 22.1 STD testing 95 15.0 TB screening for hepatitis B 61 21 Screening for hepatitis B 121 19.1 Screening for hepatitis C 121 19.1 Screening for hepatitis C 121 19.1 Screening for hepatitis C 121 19.1 Streening for hepatitis C 121 19.1 Streening for hepatitis C 121 <td>Screening for mental health disorders</td> <td>436</td> <td>68.9</td>	Screening for mental health disorders	436	68.9
Comprehensive mental health assessment or diagnosis 270 42.7 Screening for tobacco use 338 55.4 Outreach to persons in the community who may need treatment 358 49.8 Interin services for clients when immediate admission is not possible 315 49.8 No services offered 8 1.3 Testing 450 71.1 Breathalyzer or other blood alcohol testing 546 85.9 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 121 19.1 HIV I testing 140 22.1 STD testing 95 15.0 TB screening for hepatitis B 121 19.1 No services offered 213 33.8 No services offered 5 9.2 Counciling 627 99.1 Individual counseling 627 99.1 Individual counseling 627 99.1 Marital/Loughes counseling 619 9.2		594	93.8
Screening for tobacco use 338 53.4 Outreach to persons in the community who may need treatment 315 49.8 No services offered 8 1.3 Testing 8 1.3 Testing 8 71.1 Breathalyzer or other blood alcohol testing 450 71.1 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 113 17.9 Screening for hepatitis B 161 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening for hepatitis B 160 213 33.6 No services offered 213 33.6 15.0 TB screening for hepatitis B 627 99.1 15.0 TB screening for hepatitis C 121 19.1 19.1 HIV testing 66 267 99.1 15.0 TB screening for hepatitis B 67 99.1 15.0 15.0 15.0	,	270	42.7
Outreach to persons in the community who may need treatment 358 56.6 Interin services for clients when immediate admission is not possible 315 49.8 No services offered 8 1.3 Testing Breathalyzer or other blood alcohol testing 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis C 121 19.1 HIV testing 95 15.0 TB Screening 95 15.0 TB Screening 213 33.6 No services offered 58 9.2 Counseling Individual counseling 627 99.1 Group counseling 68 97.6 Family counseling 618 97.6 Group counseling 619 97.8 Marital-Coupling counseling 619	,	338	53.4
Interim services for clients when immediate admission is not possible 8		358	56.6
No services offered 8 1.3 Testing Testing Breathalyzer or other blood alcohol testing 450 71.1 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 95 15.0 TB screening 68 9.2 Counseling 627 99.1 Group counseling 618 97.6 Group counseling 618 97.6 Family counseling 618 97.6 Family counseling 618 97.6 Family counseling 618 97.8 After are locational services 9.0 9.1 Tesmididual counseling 619 9.8 After care/continuing care 601 94.8 As a feer care/continuing care 601 94.8 No services offered 5 <t< td=""><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td>49.8</td></t<>	· · · · · · · · · · · · · · · · · · ·		49.8
Breathalyzer or other blood alcohol testing 450 71.1 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 1113 17.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 58 9.2 Counseling 627 99.1 Group counseling 618 97.6 Group counseling 618 97.6 Family counseling 618 97.6 Bramity counseling 618 97.6 Aremity counseling 619 97.8 Marital/couples counseling 60.3 20.3 Transitional services Bischarge planning 619 97.8 Aftercare/continuing care 60.1 94.9 No services offered 5 0.8 Plantial/couples for feed 85 13.4 Nality and the plantial feed of the plantial feed of	·	8	1.3
Breathalyzer or other blood alcohol testing 450 71.1 Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 1113 17.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 58 9.2 Counseling 627 99.1 Group counseling 618 97.6 Group counseling 618 97.6 Family counseling 618 97.6 Bramity counseling 618 97.6 Aremity counseling 619 97.8 Marital/couples counseling 60.3 20.3 Transitional services Bischarge planning 619 97.8 Aftercare/continuing care 60.1 94.9 No services offered 5 0.8 Plantial/couples for feed 85 13.4 Nality and the plantial feed of the plantial feed of	Testing		
Drug or alcohol urine screening 544 85.9 Screening for hepatitis B 113 17.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 58 9.2 Consetting Individual counseling 618 97.6 Group counseling 618 97.6 Family counseling 618 97.6 Group counseling 618 97.8 Family counseling 619 97.8 Asiant al/couples counseling 619 97.8 Asiant al/couples counseling 619 97.8 Asiant al/couples counseling 619 97.8 Asterosare/continuing care 60.3 94.9 Discharge planning 619 97.8 Aftercare/continuing care 5 0.8 No services offered 5 0.8 National all all all all all all all all all		450	71.1
Screening for hepatitis B 113 17.9 Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 82 20 Counseling 627 99.1 Group counseling 627 99.1 Group counseling 498 78.7 Barnity counseling 498 78.7 Marital/couples counseling 603 90.3 Tarsitional services Use of great 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse*) 85 13.4 Nallrexone (oral) 104 16.4 Extended-release, injectable nattrexone/Vivitrol** 110 16.7 No-n-icotine replacement 106 16.7 Nor-nicotine smoking/lobacco cessation medications 92 <td>·</td> <td>544</td> <td>85.9</td>	·	544	85.9
Screening for hepatitis C 121 19.1 HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 58 9.2 Courseling Individual counseling 627 99.1 Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 498 78.7 Marital/couples counseling 619 97.8 Marital/couples counseling 619 97.8 Marital/couples counseling 619 97.8 Family counseling 619 97.8 Marital/couples counseling 619 97.8 Aftercare/continuing care 619 97.8 Aftercare/continuing care		113	17.9
HIV testing 140 22.1 STD testing 95 15.0 TB screening 213 33.6 No services offered 58 9.2 Courseling Individual counseling 618 97.6 Group counseling 618 97.6 Family counseling 498 78.7 Martal/couples counseling 498 78.7 Martal/couples counseling 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10	· · · · · · · · · · · · · · · · · · ·	121	19.1
STD lesting 95 15.0 TB screening 213 33.6 No services offered 28 9.2 Counseling Group counseling 627 99.1 Group counseling 627 99.1 Group counseling 498 78.7 Bamily couples counseling 362 60.3 Family counseling 498 78.7 Martal/couples counseling 362 60.3 Tassitional services Bamily counseling 619 78.8 Martal/couples counseling 362 60.3 Tassitional services 619 78.8 Martal/couples counseling 360 97.8 Assitional services offered 619 97.8 No services offered 619 97.8 No services offered 5 0.8 Disulfiram (Antabuse*) 85 13.4 National coloresting 113 17.9 Extended-release, injectable naltrexone/Vivitrol* 113 17.9			
TB screening 213 33.6 No services offered 58 9.2 Counseling 627 99.1 Individual counseling 627 99.1 Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 498 78.7 Aftercare/continuing care 601 94.9 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherere 85 13.4 Aller care of cifered 85 13.4 Nall trexone (oral) 104 16.4 Extended-release, injectable naltrexone/vivitrol** 13 17.9	-	95	15.0
No services offered 58 9.2 Courseling 627 99.1 Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 498 78.7 Marital/couples counseling 498 78.7 Marital/couples counseling 498 78.7 Transitional services Use offered 601 94.9 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Use offered 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with nal		213	
Counseling 627 99.1 Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 382 60.3 Transitional services Discharge planning 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse*) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol* 113 17.9 Acamprosate (Campral*) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone*) 128 20.2 Buprenorphine with unaloxone 66 10.4 No services offered 36 5.0 No services of	· · · · · · · · · · · · · · · · · · ·		
Individual counseling 627 99.1 Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 382 60.3 Transitional services User an individual counseling Discharge planning 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacothered Pharmacotherapics Use of fired 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 5 <	Counseling		
Group counseling 618 97.6 Family counseling 498 78.7 Marital/couples counseling 382 60.3 Transitional services Ususcharge planning 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine with naloxone 7 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0	•	627	99.1
Family counseling 498 78.7 Marital/couples counseling 382 60.3 Transitional services Transitional services Transitional services Discharge planning 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine without naloxone 5 0.8 No services offered 361 57.0 Arcillary s	•		
Marital/couples counselling 382 60.3 Transitional services Feature (april 19 ming) 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Accillary services 534 84.4 Social skills development 435 68.7	, and the second		
Transitional services Bischarge planning 619 97.8 Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Accillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Chi	· · · · · · · · · · · · · · · · · · ·		
Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies S 13.4 Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 287 45.3			
Aftercare/continuing care 601 94.9 No services offered 5 0.8 Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 287 45.3	Discharge planning	619	97.8
Pharmacotherapies Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone (Suboxone®) 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3		601	94.9
Disulfiram (Antabuse®) 85 13.4 Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Accillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	No services offered	5	0.8
Naltrexone (oral) 104 16.4 Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Accillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 113 17.9 Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services Case management services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Disulfiram (Antabuse®)	85	13.4
Acamprosate (Campral®) 93 14.7 Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services Case management services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Naltrexone (oral)	104	16.4
Nicotine replacement 106 16.7 Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services Case management services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Extended-release, injectable naltrexone/Vivitrol®	113	17.9
Non-nicotine smoking/tobacco cessation medications 92 14.5 Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Acamprosate (Campral®)	93	14.7
Medications for psychiatric disorders 201 31.8 Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Nicotine replacement	106	16.7
Methadone 66 10.4 Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Non-nicotine smoking/tobacco cessation medications	92	14.5
Buprenorphine with naloxone (Suboxone®) 128 20.2 Buprenorphine without naloxone 77 12.2 Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Medications for psychiatric disorders	201	31.8
Buprenorphine without naloxone7712.2Buprenorphine subdermal implant (Probuphine®)50.8No services offered36157.0Ancillary servicesCase management services53484.4Social skills development43568.7Mentoring/peer support30347.9Child care for clients' children233.6Assistance with obtaining social services28745.3	Methadone	66	10.4
Buprenorphine subdermal implant (Probuphine®) 5 0.8 No services offered 361 57.0 Ancillary services Case management services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Buprenorphine with naloxone (Suboxone®)	128	20.2
No services offered 361 57.0 Ancillary services 534 84.4 Case management services 534 84.4 Social skills development 435 68.7 Mentoring/peer support 303 47.9 Child care for clients' children 23 3.6 Assistance with obtaining social services 287 45.3	Buprenorphine without naloxone	77	12.2
Ancillary servicesCase management services53484.4Social skills development43568.7Mentoring/peer support30347.9Child care for clients' children233.6Assistance with obtaining social services28745.3	Buprenorphine subdermal implant (Probuphine®)	5	0.8
Case management services53484.4Social skills development43568.7Mentoring/peer support30347.9Child care for clients' children233.6Assistance with obtaining social services28745.3	No services offered	361	57.0
Social skills development43568.7Mentoring/peer support30347.9Child care for clients' children233.6Assistance with obtaining social services28745.3	Ancillary services		
Mentoring/peer support30347.9Child care for clients' children233.6Assistance with obtaining social services28745.3	Case management services	534	84.4
Child care for clients' children233.6Assistance with obtaining social services28745.3	Social skills development	435	68.7
Assistance with obtaining social services 287 45.3	Mentoring/peer support	303	47.9
	Child care for clients' children	23	3.6
Employment counseling or training for clients 167 26.4	Assistance with obtaining social services	287	45.3
	Employment counseling or training for clients	167	26.4

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	229	36.2
Domestic violence services	213	33.6
Early intervention for HIV	151	23.9
HIV or AIDS education, counseling, or support	393	62.1
Hepatitis education, counseling, or support	292	46.1
Health education other than HIV/AIDS or hepatitis	302	47.7
Substance abuse education	624	98.6
Transportation assistance to treatment	179	28.3
Mental health services	372	58.8
Acupuncture	16	2.5
Residential beds for clients' children	10	1.6
Self-help groups	230	36.3
Smoking/tobacco cessation counseling	183	28.9
No services offered	2	0.3
Other services		
Treatment for gambling disorder	127	20.1
Treatment for Internet use disorder	65	10.3
Treatment for other addiction disorder	161	25.4
No services offered	421	66.5

	Faci	lities
	No.	%
Substance abuse counseling	626	98.9
Relapse prevention	608	96.1
Cognitive behavioral therapy	592	93.5
Motivational interviewing	579	91.5
Anger management	526	83.1
Brief intervention	517	81.7
Trauma-related counseling	433	68.4
12-step facilitation	482	76.1
Contingency management/motivational incentives	318	50.2
Dialectical behavior therapy	329	52.0
Rational emotive behavioral therapy	293	46.3
Matrix model	292	46.1
Computerized substance abuse treatment	78	12.3
Community reinforcement plus vouchers	59	9.3
Other treatment approaches	42	6.6

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	81	17			
Number of clients ²	2,779	189			
Number of designated beds	2,785	356			
Utilization rate ³	99.8	53.1			
Average number of designated beds per facility	34	21			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	114
Methadone	107
Buprenorphine	6
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	131	20.7
Any language other than English	325	51.3
Non-English language provided by		
Staff counselor only	140	43.1
On-call interpreter only	119	36.6
Both staff counselor and on-call interpreter	66	20.3
Languages provided by staff counselor ¹		
Spanish	181	87.9
American Indian/Alaskan Native languages	_	_
Other	65	31.6

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	553	87.4
Adult women	249	39.3
Clients with co-occurring disorders	233	36.8
Adult men	260	41.1
Clients who have experienced trauma	161	25.4
Criminal justice clients	205	32.4
DUI/DWI clients	336	53.1
Young adults	173	27.3
Adolescents	168	26.5
Clients who have experienced domestic violence	118	18.6
Clients who have experienced sexual		
abuse	104	16.4
Pregnant or postpartum women	81	12.8
Seniors or older adults	99	15.6
LGBT ¹	98	15.5
Veterans	97	15.3
Clients living with HIV/AIDS	98	15.5
Members of military families	68	10.7
Active duty military	49	7.7
Other	20	3.2
No program or group offered	80	12.6

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HINNA VAJA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Indiana National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Indiana, 305 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 33,301 clients in substance abuse treatment on March 31, 2017. The survey response rate in Indiana was 89.6 percent.

Facility operation, by number and percent							
	Clients in treatment on March 31, 2017					2017	
	Faciliti	es	All clie	nts	Clients und	der age 18	
	No.	%	No.	%	No.	%	
Private non-profit	179	58.7	19,176	57.6	1,395	78.6	
Private for-profit	115	37.7	12,465	37.4	350	19.7	
Local, county, or community government	6	2.0	1,096	3.3	5	0.3	
State government	1	0.3	58	0.2	_	_	
Federal government	4	1.3	506	1.5	25	1.4	
Tribal government	_	_	_	_	_	_	
Total	305	100.0	33,301	100.0	1,775	100.0	

Substance abuse problem treated, by number and percent							
			Clients i	n treatmer	it on March 31, 2017		
_	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	236	92.2	10,170	30.5	189		
Clients with drug abuse only	230	89.8	17,307	52.0	322		
Clients with alcohol abuse only	211	82.4	5,824	17.5	108		
Total			33,301	100.0	619		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	280	91.8	31,808	95.5	488	47	1,717	96.7
Regular	263	86.2	18,865	56.6	21	44		
Intensive	138	45.2	3,156	9.5	65	17		
Day treatment/partial hospitalization	39	12.8	561	1.7	_	20		
Detoxification	31	10.2	122	0.4	29	10		
Methadone maintenance	74	24.3	9,104	27.3	466	14		
Residential (non-hospital)	31	10.2	978	2.9	_	18	48	2.7
Short term (<30 days)	18	5.9	269	0.8	_	17		
Long term (30+ days)	26	8.5	582	1.7	_	12		
Detoxification	11	3.6	127	0.4	_	6		
Hospital inpatient	26	8.5	515	1.5	_	12	10	0.6
Treatment	21	6.9	323	1.0	_	7		
Detoxification	23	7.5	192	0.6	_	6		
Total	305		33,301	100.0	488	45	1,775	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	12	0.9
Clients in facilities with OTPs ²		
Any MAT	7,433	1.8
Methadone	6,673	1.7
Buprenorphine	748	2.7
Naltrexone	12	0.4
Clients in facilities without OTPs ²		
Any MAT	2,816	2.7
Buprenorphine	1,668	2.0
Naltrexone	1,148	5.8

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r arms, payment options, by manner and		
	No.	%
Cash or self-payment	294	96.4
Private health insurance	232	76.1
Medicare	172	56.4
Medicaid	184	60.3
State-financed health insurance	167	54.8
Federal military insurance	160	52.5
No payment accepted	4	1.3
Access to Recovery (ATR) vouchers ²	25	8.2
IHS/Tribal/Urban (ITU) funds	2	0.7
Other payments	8	2.6
Sliding fee scale	216	70.8
Treatment at no charge for clients who can't pay	97	31.8
1 = -114		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	284	93.1
State substance abuse agency	229	75.1
State mental health department	244	80.0
State department of health	100	32.8
Hospital licensing authority	45	14.8
The Joint Commission	98	32.1
Commission on Accreditation of Rehabilitation Facilities	84	27.5
National Committee for Quality Assurance	6	2.0
Council on Accreditation	11	3.6
Healthcare Facilities Accreditation Program	4	1.3
Other state/local agency/organization	7	2.3

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 187 61.3

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Facility No. No. Assessment and pre-treatment services Screening for substance abuse 292 95.7 Screening for mental health disorders 245 80.3 Comprehensive substance abuse assessment or diagnosis 279 91.5 Comprehensive mental health assessment or diagnosis 189 62.0 Outreach to persons in the community who may need treatment 196 64.3 Intertin services for clients when immediate admission is not possible 18 8.7 No services offered 2 7.0 Testing 2 8.3 Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 68 22.3 Screening for hepatitis C 68 22.3 Screening for hepatitis C 68 22.3 Screening for hepatitis C 28 42.4 B screening for hepatitis C 8 29.4 B screening for hepatitis C 28 48.4	Types of services offered, by number and percent		
No. No.	Types of convices effected, by framiber and persons	Faci	litios
Screening for substance abuse 292 95.7			
Screening for substance abuse 292 95.7 Screening for mental health disorders 245 80.3 Comprehensive substance abuse assessment or diagnosis 279 91.5 Comprehensive substance abuse assessment or diagnosis 189 62.0 Screening for tobacco use 202 66.2 Outreach to persons in the community who may need treatment 196 64.3 Interin services for clients when immediate admission is not possible 118 3.7 No services offered 6 2.0 Testing 8 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis C 68 22.3 Screening for hepatitis C 68 22.3 Screening for hepatitis C 68 22.3 HIV testing 51 16.7 TB screening for hepatitis C 68 22.3 TS Tb esting 51 16.7 TB screening for hepatitis C 68 29.3 TB screening for hepatitis C 68 29.3 TB screening for hepatitis C	Assessment and pre-treatment services	110.	78
Screening for mental health disorders 245 80.3 Comprehensive substance abuse assessment or diagnosis 279 91.5 Comprehensive mental health assessment or diagnosis 189 62.0 Screening for tobacco use 202 66.2 Outreach to persons in the community who may need treatment 186 64.3 Interim services for clients when immediate admission is not possible 118 38.7 No services offered 26 20.0 Testing 183 3.3 Breathalyzer or other blood alcohol testing 183 3.3 Drug or alcohol urine screening 257 64.3 Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening 22 7.2 Testing 22 7.2 Testing 22 7.2 Till dividual counseling 294 96.4 Group counseling 294 96.4 <		292	95.7
Comprehensive substance abuse assessment or diagnosis 279 91.5 Comprehensive mental health assessment or diagnosis 189 60.2 Screening for tobacco use 202 66.2 Outreach to persons in the community who may need treatment 196 64.3 Interim services for clients when immediate admission is not possible 18 38.7 No services offered 8 2.0 Testing Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis B 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening 29 40.3 No services offered 22 7.2 Counseling 294 96.4 Group counseling 294 96.4 Group counseling 294 96.4 Testing and planning 289 94.8 Aftercare/continuing ca			
Comprehensive mental health assessment or diagnosis 189 62.0 Screening for tobacco use 66.2 Outreach to persons in the community who may need treatment 196 64.3 Interin services for clients when immediate admission is not possible 118 38.7 No services offered 6 2.0 Testing Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 68 22.3 Screening for hepatitis B 68 22.3 Screening for hepatitis C 68 22.3 Stropening 51 16.7 TB screening No services offered 22 7.2 Counseling 29 9.4 Individual counseling 294 96.4 Group counseling 294 99.4 Family counseling 274 89.8 Family counseling 294 99.4 Aftercare/continuing care 256 83.9 No services offered			
Screening for tobacco use 202 66.2 Outreach to persons in the community who may need treatment 196 64.3 Interim services for clients when immediate admission is not possible 18 38.7 No services offered 6 2.0 Testing Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis B 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening for hepatitis B 65 20.3 No services offered 28 22.3 TB screening for hepatitis B 29 40.3 No services offered 22 7.2 294 96.4 Group counseling 294 89.8 Family counseling 294 94.8 Family counseling 289 94.8 Family counseling 289 94.8	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 196 64.3 Interim services for clients when immediate admission is not possible 118 38.7 No services offered 6 2.0 Testing Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 16 16.7 TB screening 13 40.3 No services offered 22 7.2 Testing Individual counseling 294 96.4 Group counseling 289 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Afterioracy containing 289 94.8 Afterioracy pelaning 289 94.8 Afterioracy pelaning	· · · · · · · · · · · · · · · · · · ·		
Interim services for clients when immediate admission is not possible 188 38.7 No services offered 6 2.0			
No services offered 6 2.0 TestIns TestIns Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 SCroening for hepatitis C 68 22.3 HIV testing 61 16.7 TB screening 11 16.7 TB screening 12 40.3 No services offered 22 7.2 Counseling 294 96.4 Group counseling 294 96.4 Group counseling 294 96.4 Group counseling 294 94.8 Bramily counseling 294 94.8 Bramily counseling 294 94.8 Bramily counseling 298 94.8 Bramily counseling 299 94.8 Bramily counseling 290 94.8 Bramily counseling 299 94.8	· · · · · · · · · · · · · · · · · · ·		
Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 123 40.3 No services offered 22 72 Counseling 294 96.4 Hollvidual counseling 294 96.4 Group counseling 299 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Family counseling 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Ibsulfiram (Antabuse*) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/vivitrol** 87	·		
Breathalyzer or other blood alcohol testing 193 63.3 Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 123 40.3 No services offered 22 7.2 Counseling 294 96.4 Individual counseling 294 96.4 Group counseling 289 94.8 Family counseling 289 94.8 Marital/couples counseling 289 94.8 Family counseling 289 94.8 Afteroar/countries 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 <td>Testing</td> <td></td> <td></td>	Testing		
Drug or alcohol urine screening 257 84.3 Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening 123 40.3 No services offered 22 7.2 Consuling Individual counseling 289 94.8 Group counseling 289 94.8 Family counseling 289 94.8 Aftercare/con		193	63.3
Screening for hepatitis B 58 19.0 Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening 123 40.3 No services offered 22 7.2 Courseling 294 96.4 Group counseling 299 94.8 Family counseling 274 89.8 Marital/couples counseling 274 89.8 Marital/couples counseling 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies 2 26 83.9 Insulfiram (Antabuse*) 59 19.3 Natire cone (oral) 81 26.6 Extended-release, injectable nattrexone/Vivitrol** 87 25.5 Acamprosate (Campral*) 74 24.3 No-inicotine smoking/tobacco cessation	•		
Screening for hepatitis C 68 22.3 HIV testing 65 21.3 STD testing 51 16.7 TB screening 123 40.3 No services offered 22 7.2 Counseling Individual counseling 294 96.4 Group counseling 289 94.8 Family counseling 27 89.8 Marital/couples counseling 27 89.8 Marital/couples counseling 27 89.8 Marital/couples counseling 289 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Family counseling 289 94.8 Pall 289 94.8 Aftercare/continuing care 289 94.8 Aftercare/continuing care 289 94.8 Aftercare/continuing care 289 94.8 Aftercare/continuing care 289 94.8			
HIV testing			
STD testing 51 16.7 TB screening 123 40.3 No services offered 22 7.2 Counseling 294 96.4 Group counseling 289 94.8 Family counseling 220 72.1 Family counseling 220 72.1 Family counseling 289 94.8 Family counseling 289 94.8 Marital/couples counseling 289 94.8 All 266 83.9 94.8 Aftercare/continuing care 59 94.8 83.9 No services offered 7 2.3 2.5 Pharmacotherapies 9 9.3 9.3 Nallersone (oral) 81 26.6 Extended-release, injectable naltrexone/vivitrol* 87			
TB screening 123 40.3 No services offered 22 7.2 Counseling 294 96.4 Individual counseling 289 94.8 Group counseling 289 94.8 Family counseling 274 89.8 Marital/couples counseling 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Pharmacotherapies Signification (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 <t< td=""><td></td><td></td><td></td></t<>			
No services offered 22 7.2 Counseling 96.4 96.4 Group counseling 289 94.8 Family counseling 274 89.8 Marital/couples counseling 270 72.1 Transitional services Usubrational services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse*) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/vivitrol* 87 28.5 Acamprosate (Campral*) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.3 Buprenorphine with naloxone (Suboxone*) 12 3.3 Buprenorphine without naloxone 42			
Counseling 294 96.4 Group counselling 289 94.8 Family counseling 274 89.8 Marital/couples counseling 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine with naloxone (Suboxone®) 71 23.3 Nos services offered 253 83.0 Nos			
Individual counseling 294 96.4 Group counseling 289 94.8 Family counseling 274 89.8 Marital/couples counseling 220 72.1 Transitional services User an individual counseling Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Usulfiram (Antabuse*) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol* 87 28.5 Acamprosate (Campral*) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone*) 71 23.3 Buprenorphine with naloxone 42 13.8 Buprenorphine wit			
Group counseling 289 94.8 Family counseling 274 89.8 Marital/couples counseling 200 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3		294	96.4
Family counseling 274 89.8 Marital/couples counseling 220 72.1 Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine with naloxone (Suboxone®) 72 - No services offered 12 3.8 Buprenorphine without naloxone 25 83.0 Nos services offered 12 3.8			
Marital/couples counseling 220 72.1 Transitional services Transitional services Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development <t< td=""><td>· · · · · ·</td><td></td><td></td></t<>	· · · · · ·		
Transitional services 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Actillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 289 94.8 Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 12 3.9 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 1			
Aftercare/continuing care 256 83.9 No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 12 3.0 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social servic	Discharge planning	289	94.8
No services offered 7 2.3 Pharmacotherapies Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3			
Disulfiram (Antabuse®) 59 19.3 Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3			
Naltrexone (oral) 81 26.6 Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 87 28.5 Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Disulfiram (Antabuse®)	59	19.3
Acamprosate (Campral®) 74 24.3 Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Naltrexone (oral)	81	26.6
Nicotine replacement 88 28.9 Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Extended-release, injectable naltrexone/Vivitrol®	87	28.5
Non-nicotine smoking/tobacco cessation medications 82 26.9 Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Acamprosate (Campral®)	74	24.3
Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Nicotine replacement	88	28.9
Medications for psychiatric disorders 150 49.2 Methadone 12 3.9 Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — No services offered 129 42.3 Ancillary services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Non-nicotine smoking/tobacco cessation medications	82	26.9
Buprenorphine with naloxone (Suboxone®) 71 23.3 Buprenorphine without naloxone 42 13.8 Buprenorphine subdermal implant (Probuphine®) — — — No services offered 129 42.3 Ancillary services Case management services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3		150	49.2
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) No services offered 129 42.3 Ancillary services Case management services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Methadone	12	3.9
Buprenorphine subdermal implant (Probuphine®) — — — No services offered 129 42.3 Ancillary services Case management services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Buprenorphine with naloxone (Suboxone®)	71	23.3
No services offered 129 42.3 Ancillary services 253 83.0 Case management services 253 83.0 Social skills development 243 79.7 Mentoring/peer support 150 49.2 Child care for clients' children 11 3.6 Assistance with obtaining social services 187 61.3	Buprenorphine without naloxone	42	13.8
Ancillary servicesCase management services25383.0Social skills development24379.7Mentoring/peer support15049.2Child care for clients' children113.6Assistance with obtaining social services18761.3	Buprenorphine subdermal implant (Probuphine®)	_	_
Case management services25383.0Social skills development24379.7Mentoring/peer support15049.2Child care for clients' children113.6Assistance with obtaining social services18761.3	No services offered	129	42.3
Social skills development24379.7Mentoring/peer support15049.2Child care for clients' children113.6Assistance with obtaining social services18761.3	Ancillary services		
Mentoring/peer support15049.2Child care for clients' children113.6Assistance with obtaining social services18761.3	Case management services	253	83.0
Child care for clients' children113.6Assistance with obtaining social services18761.3	Social skills development	243	79.7
Assistance with obtaining social services 187 61.3	Mentoring/peer support	150	49.2
	Child care for clients' children	11	3.6
	Assistance with obtaining social services	187	61.3
Employment counseling or training for clients 132 43.3	Employment counseling or training for clients	132	43.3

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	148	48.5
Domestic violence services	147	48.2
Early intervention for HIV	35	11.5
HIV or AIDS education, counseling, or support	119	39.0
Hepatitis education, counseling, or support	110	36.1
Health education other than HIV/AIDS or hepatitis	105	34.4
Substance abuse education	295	96.7
Transportation assistance to treatment	91	29.8
Mental health services	236	77.4
Acupuncture	7	2.3
Residential beds for clients' children	5	1.6
Self-help groups	101	33.1
Smoking/tobacco cessation counseling	137	44.9
No services offered	2	0.7
Other services		
Treatment for gambling disorder	129	42.3
Treatment for Internet use disorder	61	20.0
Treatment for other addiction disorder	124	40.7
No services offered	140	45.9

	Faci	lities
	No.	%
Substance abuse counseling	300	98.4
Relapse prevention	286	93.8
Cognitive behavioral therapy	290	95.1
Motivational interviewing	286	93.8
Anger management	257	84.3
Brief intervention	249	81.6
Trauma-related counseling	248	81.3
12-step facilitation	239	78.4
Contingency management/motivational incentives	113	37.0
Dialectical behavior therapy	174	57.0
Rational emotive behavioral therapy	119	39.0
Matrix model	183	60.0
Computerized substance abuse treatment	44	14.4
Community reinforcement plus vouchers	18	5.9
Other treatment approaches	34	11.1

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	23	14					
Number of clients ²	777	323					
Number of designated beds	737	424					
Utilization rate ³	105.4	76.2					
Average number of designated beds per facility	32	30					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	111
Methadone	100
Buprenorphine	11
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	136	44.6
Any language other than English	166	54.4
Non-English language provided by		
Staff counselor only	15	9.0
On-call interpreter only	125	75.3
Both staff counselor and on-call interpreter	26	15.7
Languages provided by staff counselor ¹		
Spanish	38	92.7
American Indian/Alaskan Native		
languages	_	_
Other	4	9.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	232	76.1
Adult women	125	41.0
Clients with co-occurring disorders	107	35.1
Adult men	108	35.4
Clients who have experienced trauma	100	32.8
Criminal justice clients	100	32.8
DUI/DWI clients	76	24.9
Young adults	78	25.6
Adolescents	83	27.2
Clients who have experienced domestic violence	64	21.0
Clients who have experienced sexual		
abuse	63	20.7
Pregnant or postpartum women	57	18.7
Seniors or older adults	33	10.8
LGBT ¹	34	11.1
Veterans	36	11.8
Clients living with HIV/AIDS	25	8.2
Members of military families	20	6.6
Active duty military	21	6.9
Other	7	2.3
No program or group offered	73	23.9

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Iowa National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Iowa, 163 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 11,631 clients in substance abuse treatment on March 31, 2017. The survey response rate in Iowa was 97.7 percent.

Facility operation, by number and percer	nt						
	Clients in treatment on March 31, 2017						
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	128	78.5	8,621	74.1	536	77.9	
Private for-profit	27	16.6	2,427	20.9	147	21.4	
Local, county, or community government	2	1.2	105	0.9	5	0.7	
State government	2	1.2	159	1.4	_	_	
Federal government	2	1.2	283	2.4	_	_	
Tribal government	2	1.2	36	0.3	_	_	
Total	163	100.0	11,631	100.0	688	100.0	

Substance abuse problem treated, by number and percent								
Clients in treatment on March 31, 2017								
	Faciliti	es¹	Clients ² Clients ² per 100,000 por					
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	128	96.2	5,420	46.6	208			
Clients with drug abuse only	101	75.9	3,476	29.9	138			
Clients with alcohol abuse only	104	78.2	2,735	23.5	107			
Total			11,631	100.0	453			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	149	91.4	10,894	93.7	116	36	609	88.5
Regular	142	87.1	8,318	71.5	61	35		
Intensive	95	58.3	1,175	10.1	75	8		
Day treatment/partial hospitalization	20	12.3	54	0.5	_	7		
Detoxification	8	4.9	5	*	_	5		
Methadone maintenance	18	11.0	1,342	11.5	87	21		
Residential (non-hospital)	33	20.2	706	6.1	_	14	71	10.3
Short term (<30 days)	29	17.8	347	3.0	_	14		
Long term (30+ days)	27	16.6	356	3.1	_	10		
Detoxification	7	4.3	3	*	_	2		
Hospital inpatient	8	4.9	31	0.3	_	4	8	1.2
Treatment	4	2.5	8	0.1	_	8		
Detoxification	8	4.9	23	0.2	_	4		
Total	163		11,631	100.0	116	36	688	100.0

¹Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	7	0.5
Clients in facilities with OTPs ²		
Any MAT	1,350	0.3
Methadone	1,200	0.3
Buprenorphine	147	0.5
Naltrexone	3	0.1
Clients in facilities without OTPs ²		
Any MAT	224	0.2
Buprenorphine	178	0.2
Naltrexone	46	0.2

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

· domey paymont options, by mamber an	po. o	
	No.	%
Cash or self-payment	158	96.9
Private health insurance	148	90.8
Medicare	38	23.3
Medicaid	145	89.0
State-financed health insurance	121	74.2
Federal military insurance	62	38.0
No payment accepted	2	1.2
Access to Recovery (ATR) vouchers ²	93	57.1
IHS/Tribal/Urban (ITU) funds	4	2.5
Other payments	_	_
Sliding fee scale	114	69.9
Treatment at no charge for clients who can't pay	65	39.9
1 Capilities may assent more than one type of neumant		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	162	99.4
State substance abuse agency	125	76.7
State mental health department	46	28.2
State department of health	126	77.3
Hospital licensing authority	9	5.5
The Joint Commission	15	9.2
Commission on Accreditation of Rehabilitation Facilities	62	38.0
National Committee for Quality Assurance	1	0.6
Council on Accreditation	11	6.7
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	3	1.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 107 65.6

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Typos of convices effects, by frameof and percent	Fac	ilities
	No.	%
Assessment and pre-treatment services	110.	7,0
Screening for substance abuse	157	96.3
Screening for mental health disorders	126	77.3
Comprehensive substance abuse assessment or diagnosis	160	98.2
Comprehensive mental health assessment or diagnosis	64	39.3
Screening for tobacco use	131	80.4
Outreach to persons in the community who may need treatment	105	64.4
Interim services for clients when immediate admission is not possible	99	60.7
No services offered	1	0.6
Testing		
Breathalyzer or other blood alcohol testing	98	60.1
Drug or alcohol urine screening	149	91.4
Screening for hepatitis B	22	13.5
Screening for hepatitis C	23	14.1
HIV testing	21	12.9
STD testing	19	11.7
TB screening	59	36.2
No services offered	12	7.4
Counseling		
Individual counseling	163	100.0
Group counseling	154	94.5
Family counseling	151	92.6
Marital/couples counseling	116	71.2
Transitional services		
Discharge planning	160	98.2
Aftercare/continuing care	155	95.1
No services offered	1	0.6
Pharmacotherapies		
Disulfiram (Antabuse®)	19	11.7
Naltrexone (oral)	30	18.4
Extended-release, injectable naltrexone/Vivitrol®	17	10.4
Acamprosate (Campral®)	29	17.8
Nicotine replacement	45	27.6
Non-nicotine smoking/tobacco cessation medications	28	17.2
Medications for psychiatric disorders	50	30.7
Methadone	7	4.3
Buprenorphine with naloxone (Suboxone®)	21	12.9
Buprenorphine without naloxone	17	10.4
Buprenorphine subdermal implant (Probuphine®)	_	-
No services offered	89	54.6
Ancillary services		
Case management services	130	79.8
Social skills development	111	68.1
Mentoring/peer support	86	52.8
Child care for clients' children	7	4.3
Assistance with obtaining social services	107	65.6
Employment counseling or training for clients	54	33.1

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	81	49.7
Domestic violence services	68	41.7
Early intervention for HIV	29	17.8
HIV or AIDS education, counseling, or support	70	42.9
Hepatitis education, counseling, or support	54	33.1
Health education other than HIV/AIDS or hepatitis	74	45.4
Substance abuse education	160	98.2
Transportation assistance to treatment	72	44.2
Mental health services	86	52.8
Acupuncture	3	1.8
Residential beds for clients' children	7	4.3
Self-help groups	73	44.8
Smoking/tobacco cessation counseling	80	49.1
No services offered	_	_
Other services		
Treatment for gambling disorder	58	35.6
Treatment for Internet use disorder	11	6.7
Treatment for other addiction disorder	40	24.5
No services offered	84	51.5

	Fac	ilities
	No.	%
Substance abuse counseling	163	100.0
Relapse prevention	157	96.3
Cognitive behavioral therapy	156	95.7
Motivational interviewing	157	96.3
Anger management	141	86.5
Brief intervention	135	82.8
Frauma-related counseling	123	75.5
12-step facilitation	134	82.2
Contingency management/motivational incentives	88	54.0
Dialectical behavior therapy	69	42.3
Rational emotive behavioral therapy	79	48.5
Matrix model	107	65.6
Computerized substance abuse treatment	30	18.4
Community reinforcement plus vouchers	23	14.1
Other treatment approaches	12	7.4

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	30	3				
Number of clients ²	651	15				
Number of designated beds	737	34				
Utilization rate ³	88.3	44.1				
Average number of designated beds per facility	25	11				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	43
Methadone	38
Buprenorphine	5
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	37	22.7
Any language other than English	63	38.7
Non-English language provided by		
Staff counselor only	6	9.5
On-call interpreter only	46	73.0
Both staff counselor and on-call interpreter	11	17.5
Languages provided by staff counselor ¹		
Spanish	16	94.1
American Indian/Alaskan Native		
languages	_	_
Other	2	11.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ities
	No.	%
Any program or group	139	85.3
Adult women	82	50.3
Clients with co-occurring disorders	79	48.5
Adult men	72	44.2
Clients who have experienced trauma	51	31.3
Criminal justice clients	44	27.0
DUI/DWI clients	58	35.6
Young adults	48	29.4
Adolescents	77	47.2
Clients who have experienced domestic violence	42	25.8
Clients who have experienced sexual		
abuse	31	19.0
Pregnant or postpartum women	19	11.7
Seniors or older adults	14	8.6
LGBT ¹	14	8.6
Veterans	13	8.0
Clients living with HIV/AIDS	10	6.1
Members of military families	10	6.1
Active duty military	7	4.3
Other	4	2.5
No program or group offered	24	14.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HITTONIA SERVICES. LITTONIA SERV

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Kansas National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Kansas, 182 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 10,710 clients in substance abuse treatment on March 31, 2017. The survey response rate in Kansas was 91.6 percent.

Facility operation, by number and percent							
	Clients in treatment on March 31, 2017						
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	99	54.4	4,269	39.9	301	37.5	
Private for-profit	61	33.5	4,402	41.1	388	48.4	
Local, county, or community government	16	8.8	1,495	14.0	113	14.1	
State government	1	0.5	12	0.1	_	-	
Federal government	4	2.2	490	4.6	_	_	
Tribal government	1	0.5	42	0.4	_	_	
Total	182	100.0	10,710	100.0	802	100.0	

Substance abuse problem treated, by number and percent								
Clients in treatment on March 31, 201								
	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.			
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	152	91.6	4,336	40.5	173			
Clients with drug abuse only	144	86.7	4,414	41.2	194			
Clients with alcohol abuse only	146	88.0	1,960	18.3	83			
Total			10,710	100.0	450			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent										
			Clients in treatment on March 31, 2017							
_	Facil	ities¹	All clients Client					age < 18		
					Median no. of clients per	Median no. of clients per				
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%		
Outpatient	170	93.4	9,985	93.2	325	30	800	99.8		
Regular	167	91.8	6,572	61.4	187	25				
Intensive	88	48.4	1,039	9.7	_	10				
Day treatment/partial hospitalization	6	3.3	20	0.2	_	20				
Detoxification	10	5.5	15	0.1	_	3				
Methadone maintenance	28	15.4	2,339	21.8	225	15				
Residential (non-hospital)	25	13.7	702	6.6	_	30	2	0.2		
Short term (<30 days)	20	11.0	302	2.8	_	21				
Long term (30+ days)	18	9.9	335	3.1	_	14				
Detoxification	14	7.7	65	0.6	_	6				
Hospital inpatient	3	1.6	23	0.2	_	8	_	_		
Treatment	2	1.1	8	0.1	_	8				
Detoxification	2	1.1	15	0.1	_	8				
Total	182		10,710	100.0	325	30	802	100.0		

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	8	0.6
Clients in facilities with OTPs ²		
Any MAT	2,393	0.6
Methadone	2,292	0.6
Buprenorphine	101	0.4
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	213	0.2
Buprenorphine	160	0.2
Naltrexone	53	0.3

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹ No. % Cash or self-payment 173 95.1 Private health insurance 141 77.5 Medicare 52 28.6 Medicaid 131 72.0 State-financed health insurance 89 48.9 36.8 Federal military insurance 67 No payment accepted 0.5 1 Access to Recovery (ATR) vouchers2 n/a n/a IHS/Tribal/Urban (ITU) funds 11 6.0 Other payments 1 0.5 122 67.0 Sliding fee scale 87 47.8 Treatment at no charge for clients who can't pay

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	179	98.4
State substance abuse agency	172	94.5
State mental health department	62	34.1
State department of health	36	19.8
Hospital licensing authority	4	2.2
The Joint Commission	21	11.5
Commission on Accreditation of Rehabilitation Facilities	20	11.0
National Committee for Quality Assurance	6	3.3
Council on Accreditation	9	4.9
Healthcare Facilities Accreditation Program	1	0.5
Other state/local agency/organization	3	1.6

¹ Facilities may be licensed by more than one agency/organization.

acilities	
. %	
4 57.1	

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Assessment and pre-treatment services No. % Screening for substance abuse 179 88.4 Screening for substance abuse assessment or diagnosis 175 62.2 Comprehensive substance abuse assessment or diagnosis 74 40.7 Comprehensive mental health assessment or diagnosis 76 41.8 Outreach to persons in the community who may need treatment 130 71.4 Interim services for clients when immediate admission is not possible 123 67.6 No services offered 9 54.4 Presenting for hepatitis B 9 54.4 Presenting or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis B 25 13.7 Screening for hepatitis B 18 64.8 HIV testing 25 13.7 Screening for hepatitis B 18 14.8 HIV testing 18 18 Screening for hepatitis B 18 19.2 Individual counseling 18 9.2 G	Types of services offered, by number and percent		
No.	Types of services effered, by flumber and percent	Eaci	litios
Screening for substance abuse 179 98.4			
Screening for substance abuse 179 88.4 Screening for mental health disorders 105 57.7 Comprehensive substance abuse assessment or diagnosis 175 96.2 Comprehensive mental health assessment or diagnosis 74 40.7 Screening for tobacco use 76 41.8 Outreach to persons in the community who may need treatment 130 71.4 Interin services for clients when immediate admission is not possible 123 87.6 No services offered — — Testing — — Breathalyzer or other blood alcohol testing 99 54.4 Drug or alcohol urine screening 118 54.8 Screening for hepatitis B 25 13.7 Screening for hepatitis B 25 13.7 Screening for hepatitis B 26 14.3 Streening for hepatitis B 26 14.3 Streening for hepatitis B 25 13.7 TB screening for hepatitis B 26 14.3 STD testing 26 14.3 STD testing	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 105 57.7 Comprehensive substance abuse assessment or diagnosis 76 26.2 Comprehensive mental health assessment or diagnosis 76 41.8 Outreach to persons in the community who may need treatment 130 71.4 Interim services for clients when immediate admission is not possible 123 67.6 No services offered — — Testing — — Breathalyzer or other blood alcohol testing 99 54.4 Drug or alcohol urine screening 18 64.8 Screening for hepatitis G 25 13.7 Screening for hepatitis C 26 14.3 HIV Lesting 26 14.3 STD testing 25 13.7 TB screening for hepatitis C 25 13.7 Screening for hepatitis C 26 14.3 HIV Lesting 26 14.3 HIV Lesting 26 14.3 But Services 29.7 29.7 Counseling 18 19.2		179	98.4
Comprehensive substance abuse assessment or diagnosis 175 96.2 Comprehensive mental health assessment or diagnosis 74 40.7 Screening for tobacco use 76 41.8 Outreach to persons in the community who may need treatment 130 71.6 Interim services for clients when immediate admission is not possible 123 67.6 No services offered ————————————————————————————————————	~		
Comprehensive mental health assessment or diagnosis	•		
Screening for tobacco use 76 41.8 Outreach to persons in the community who may need treatment 130 77.6 Interim services for clients when immediate admission is not possible 123 67.6 No services offered — — Testing 99 54.4 Drug or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis B 26 14.3 HIV testing 26 14.3 STD testing 25 13.7 TB screening for hepatitis B 25 13.7 Streening for hepatitis B 26 14.3 HIV testing 26 14.3 TB screening for hepatitis B 26 14.3 Streening for hepatitis B 26 14.3 TB screening for hepatitis B 26 14.3 TB screening for hepatitis B 28 19.1 No services offered 181 99.5 Family counseling 181 99.5 Family counseling	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 130 71.4 Interim services for clients when immediate admission is not possible 123 67.6 No services offered — — Testing 99 54.4 Drug or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis C 26 14.3 HIV testing 25 13.7 STD lesting 25 13.7 TB screening or hepatitis B 25 13.7 Streening for hepatitis B 25 14.3 HIV testing 26 14.3 STD lesting 25 13.7 TB screening or hepatitis B 25 13.7 STD lesting 25 13.7 D screening or hepatitis B 25 13.7 Testing 25 13.7 D screening or hepatitis B 29.1 13.7 O services offered 181 99.5 Group counseling 181 99.5	·		
Interim services for clients when immediate admission is not possible 123 67.6 No services offered 7 7 7 7 7 7 7 7 7	~		
No services offered — — Testiny Set 4 Breathalyzer or other blood alcohol testing 99 54.4 Drug or alcohol urine screening 118 64.8 Screening for hepatitis C 26 11.3 Screening for hepatitis C 26 14.3 HIV testing 26 14.3 STD testing 25 13.7 TB screening 53 29.1 No services offered 54 29.7 Counseling 181 99.5 Group counseling 181 99.5 Group counseling 180 92.9 Bramily counseling 181 99.5 Group counseling 181 99.5 Group counseling 181 99.5 Bramily counseling 181 99.5 Group counseling 181 99.5 Group counseling 181 99.5 Group counseling 181 99.5 Group counseling 181 99.5 <t< td=""><td></td><td></td><td></td></t<>			
Intention 99 54.4 Drug or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis C 26 14.3 HIV testing 25 13.7 STD testing 25 13.7 TB screening for hepatitis C 53 29.1 No services offered 54 29.7 TB screening S 53 29.1 No services offered 54 29.7 Counseling 181 99.5 Group counseling 180 99.5 Group counseling 169 99.5 Family counseling 150 82.4 Marital/couples counseling 181 99.5 Family counseling 181 99.5 Aftercare/continuing care 167	·	_	_
Breathalyzer or other blood alcohol testing 99 54.4 Drug or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis C 26 14.3 HIV testing 26 14.3 STD lesting 53 29.1 TB screening 53 29.1 No services offered 54 29.7 Counseling 181 99.5 Individual counseling 181 99.5 Group counseling 169 92.9 Family counseling 181 99.5 Group counseling 181 99.5 Family counseling 181 <t< td=""><td></td><td></td><td></td></t<>			
Drug or alcohol urine screening 118 64.8 Screening for hepatitis B 25 13.7 Screening for hepatitis C 26 14.3 HIV testing 26 14.3 STD testing 25 13.7 TB screening 53 29.1 No services offered 54 29.7 Consuling Individual counseling 181 99.5 Group counseling 169 92.9 Family counseling 169 92.9 Family counseling 160 82.4 Marital/couples counseling 160 82.4 Marital/couples counseling 160 82.4 Marital/couples counseling 181 99.5 Family counseling 181 99.5 Marital/couples counseling 181 99.5 Family counseling 181 99.5 Family counseling 181 99.5 Aftercare/continuing care 181 99.5 Aftercare/continuing care 18 11.		99	54.4
Screening for hepatitis B 25 13.7 Screening for hepatitis C 26 14.3 HIV testing 26 14.3 STD testing 25 13.7 TB screening 53 29.1 No services offered 429.7 Counseling 181 99.5 Group counseling 181 99.5 Group counseling 150 82.4 Marital/couples counseling 18 19.5 Discharge planning 181 9.5 Aftercare/continuing care </td <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Screening for hepatitis C 26 14.3 HIV testing 26 14.3 STD testing 25 13.7 TB screening 53 29.1 No services offered 54 29.7 Courseling Individual counseling 181 99.5 Group counseling 169 92.9 Family counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse*) 21 11.5 Naltrexone (oral) 28 15.4 Naltrexone (oral) 28 15.4 Non-nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medication			
HIV testing 26 14.3 STD testing 25 13.7 TB screening 53 29.1 No services offered 54 29.7 Counseling 81 99.5 Individual counseling 169 92.9 Family counseling 169 92.9 Family counseling 150 82.4 Martal/couples counseling 123 67.6 Transitional services 123 67.6 Transitional services 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies 21 11.5 Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications			
STD testing 25 13.7 TB screening 53 29.1 No services offered 54 29.7 Counseling 181 99.5 Group counseling 169 92.9 Family counseling 169 92.9 Family counseling 169 92.9 Family counseling 123 67.6 Transitional services 123 67.6 Discharge planning 181 99.5 Aftercare/continuing care 181 99.5 No services offered 1 0.5 Pharmacotherapies 1 0.5 Pharmacotherapies 2 11.5 Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 36 19.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 30.2 Methadone <			
TB screening 53 29.1 No services offered 54 29.7 Counseling 181 99.5 Group counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 160 82.4 Marital/couples counseling 181 99.5 Aftercare/continuing care 167 91.8 Aftercare/continuing care 167 91.8 Aftercare/continuing care 167 91.8 Aftercare/continuing care 167 91.8 Aftercare/continuing care 16 8.8 Astendary 21 11.5 <tr< td=""><td></td><td></td><td></td></tr<>			
No services offered 54 29.7 Counseling 181 99.5 Group counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Using planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse*) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol** 16 8.8 Acamprosate (Campral**) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone*) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorph	· · · · · · · · · · · · · · · · · · ·		
Counseling 181 99.5 Group counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine with unaloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 <t< td=""><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td></t<>	· · · · · · · · · · · · · · · · · · ·		
Individual counseling 181 99.5 Group counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Userpane planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse*) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol* 16 8.8 Acamprosate (Campral*) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone*) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine without naloxone 12 6.6		01	20.1
Group counseling 169 92.9 Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Transitional services Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campra®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine without naloxone 12 6.1 Social skills development 13 73.1		181	99.5
Family counseling 150 82.4 Marital/couples counseling 123 67.6 Transitional services Transitional services Discharge planning care 167 91.8 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered	·		
Marital/couples counseling 123 67.6 Transitional services Transitional services Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Transitional Matchabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Accil skills development 12 6.6 Buprenorphine subdermal implant (Probuphine®)	· · · · · · · · · · · · · · · · · · ·		
Transitional services Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Accillary services 118 64.8 Social skills development 133 73.1 Child care for clients' children 4 2.2 <	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 181 99.5 Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 11 64.8 Ancillary services 118 64.8 Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93		120	01.0
Aftercare/continuing care 167 91.8 No services offered 1 0.5 Pharmacotherapies 3 11.5 Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance w		181	99.5
No services offered 1 0.5 Pharmacotherapies Usulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2			
Pharmacotherapies Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2			
Disulfiram (Antabuse®) 21 11.5 Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2	Pharmacotherapies		
Naltrexone (oral) 28 15.4 Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2		21	11.5
Extended-release, injectable naltrexone/Vivitrol® 16 8.8 Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2	·	28	15.4
Acamprosate (Campral®) 36 19.8 Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2		16	8.8
Nicotine replacement 28 15.4 Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2	·	36	19.8
Non-nicotine smoking/tobacco cessation medications 25 13.7 Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2		28	15.4
Medications for psychiatric disorders 55 30.2 Methadone 8 4.4 Buprenorphine with naloxone (Suboxone®) 26 14.3 Buprenorphine without naloxone 12 6.6 Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2		25	13.7
Buprenorphine with naloxone (Suboxone®) Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) No services offered 112 61.5 Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 14.3 12 6.6 11.1 12 61.5 13 73.1 42 22 43 53 54 64 75 75 76 76 76 76 77 78 78 78 78 78		55	30.2
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) 2 1.1 No services offered 112 61.5 Ancillary services Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2	Methadone	8	4.4
Buprenorphine subdermal implant (Probuphine®) No services offered Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 1.1 61.5 118 64.8 50.1 64.8 51.1 64.8 50.1 64.8 6	Buprenorphine with naloxone (Suboxone®)	26	14.3
No services offered 112 61.5 Ancillary services 8 64.8 Case management services 118 64.8 Social skills development 133 73.1 Mentoring/peer support 93 51.1 Child care for clients' children 4 2.2 Assistance with obtaining social services 106 58.2	Buprenorphine without naloxone	12	6.6
Ancillary servicesCase management services11864.8Social skills development13373.1Mentoring/peer support9351.1Child care for clients' children42.2Assistance with obtaining social services10658.2	Buprenorphine subdermal implant (Probuphine®)	2	1.1
Case management services11864.8Social skills development13373.1Mentoring/peer support9351.1Child care for clients' children42.2Assistance with obtaining social services10658.2	No services offered	112	61.5
Social skills development13373.1Mentoring/peer support9351.1Child care for clients' children42.2Assistance with obtaining social services10658.2	Ancillary services		
Mentoring/peer support9351.1Child care for clients' children42.2Assistance with obtaining social services10658.2	Case management services	118	64.8
Child care for clients' children42.2Assistance with obtaining social services10658.2	Social skills development	133	73.1
Assistance with obtaining social services 106 58.2	Mentoring/peer support	93	51.1
	Child care for clients' children	4	2.2
Employment counseling or training for clients 74 40.7	Assistance with obtaining social services	106	58.2
	Employment counseling or training for clients	74	40.7

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	92	50.5
Domestic violence services	70	38.5
Early intervention for HIV	25	13.7
HIV or AIDS education, counseling, or support	106	58.2
Hepatitis education, counseling, or support	96	52.7
Health education other than HIV/AIDS or hepatitis	89	48.9
Substance abuse education	174	95.6
Transportation assistance to treatment	53	29.1
Mental health services	100	54.9
Acupuncture	1	0.5
Residential beds for clients' children	6	3.3
Self-help groups	69	37.9
Smoking/tobacco cessation counseling	63	34.6
No services offered	2	1.1
Other services		
Treatment for gambling disorder	32	17.6
Treatment for Internet use disorder	15	8.2
Treatment for other addiction disorder	39	21.4
No services offered	125	68.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Faci	lities		
	No.	%		
Substance abuse counseling	181	99.5		
Relapse prevention	174	95.6		
Cognitive behavioral therapy	178	97.8		
Motivational interviewing	159	87.4		
Anger management	136	74.7		
Brief intervention	142	78.0		
Trauma-related counseling	118	64.8		
12-step facilitation	119	65.4		
Contingency management/motivational incentives	82	45.1		
Dialectical behavior therapy	72	39.6		
Rational emotive behavioral therapy	92	50.5		
Matrix model	88	48.4		
Computerized substance abuse treatment	33	18.1		
Community reinforcement plus vouchers	10	5.5		
Other treatment approaches	6	3.3		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	19	2			
Number of clients ²	542	18			
Number of designated beds	725	20			
Utilization rate ³	74.8	90.0			
Average number of designated beds per facility	38	10			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	82
Methadone	79
Buprenorphine	3
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	42	23.1
Any language other than English	65	35.7
Non-English language provided by		
Staff counselor only	7	10.8
On-call interpreter only	45	69.2
Both staff counselor and on-call interpreter	13	20.0
Languages provided by staff counselor ¹		
Spanish	19	95.0
American Indian/Alaskan Native		
languages	_	
Other	2	10.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	132	72.5
Adult women	69	37.9
Clients with co-occurring disorders	62	34.1
Adult men	61	33.5
Clients who have experienced trauma	50	27.5
Criminal justice clients	73	40.1
DUI/DWI clients	64	35.2
Young adults	45	24.7
Adolescents	63	34.6
Clients who have experienced domestic violence	37	20.3
Clients who have experienced sexual		
abuse	35	19.2
Pregnant or postpartum women	36	19.8
Seniors or older adults	35	19.2
LGBT ¹	30	16.5
Veterans	28	15.4
Clients living with HIV/AIDS	29	15.9
Members of military families	25	13.7
Active duty military	20	11.0
Other	7	3.8
No program or group offered	50	27.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

PHILAM SERVICES OF THE PHILAM SERVICES OF THE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



2017 State Profile — Kentucky National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Kentucky, 359 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 29,228 clients in substance abuse treatment on March 31, 2017. The survey response rate in Kentucky was 86.8 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	186	51.8	13,397	45.8	2,046	84.7
Private for-profit	167	46.5	14,868	50.9	370	15.3
Local, county, or community government	1	0.3	160	0.5	_	_
State government	1	0.3	20	0.1	_	_
Federal government	4	1.1	783	2.7	_	_
Tribal government	_	_	_	_	_	_
Total	359	100.0	29,228	100.0	2,416	100.0

Substance abuse problem treated, by number and percent						
			Clients i	n treatmer	nt on March 31, 2017	
_	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	289	91.7	10,559	36.7	270	
Clients with drug abuse only	257	81.6	14,202	49.4	391	
Clients with alcohol abuse only	233	74.0	3,975	13.8	104	
Total			28,737	100.0	764	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	318	88.6	26,069	89.2	267	31	2,315	95.8
Regular	307	85.5	16,029	54.8	2	28		
Intensive	132	36.8	2,075	7.1	_	14		
Day treatment/partial hospitalization	34	9.5	131	0.4	_	12		
Detoxification	24	6.7	155	0.5	9	5		
Methadone maintenance	63	17.5	7,679	26.3	267	50		
Residential (non-hospital)	55	15.3	2,841	9.7	_	20	45	1.9
Short term (<30 days)	31	8.6	545	1.9	_	16		
Long term (30+ days)	40	11.1	2,087	7.1	_	29		
Detoxification	20	5.6	209	0.7	_	8		
Hospital inpatient	16	4.5	318	1.1	_	18	56	2.3
Treatment	12	3.3	112	0.4	_	7		
Detoxification	16	4.5	206	0.7	_	10		
Total	359		29,228	100.0	267	33	2,416	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs),
by number and percent

,		
	No.	%
Facilities with OTPs ¹	15	1.1
Olionto in facilities with OTDs2		
Clients in facilities with OTPs ²		
Any MAT	5,226	1.3
Methadone	4,896	1.3
Buprenorphine	330	1.2
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	4,640	4.5
Buprenorphine	4,397	5.2
Naltrexone	243	1.2
AB A CHOTECHNIA AND A CA		

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	•	
	No.	%
Cash or self-payment	342	95.3
Private health insurance	232	64.6
Medicare	141	39.3
Medicaid	232	64.6
State-financed health insurance	171	47.6
Federal military insurance	152	42.3
No payment accepted	7	1.9
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	10	2.8
Other payments	5	1.4
Sliding fee scale	211	58.8
Treatment at no charge for clients who ca	ın't pay 136	37.9

Facility licensing, certification, or accreditation, by number and percent

Facilities ¹	
No.	%
334	93.0
295	82.2
186	51.8
93	25.9
18	5.0
75	20.9
85	23.7
9	2.5
25	7.0
3	0.8
6	1.7
	No. 334 295 186 93 18 75 85 9 25

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 152 42.3

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Facility Image: Image	Types of services offered, by number and percent		
Assessment and pre-treatment services No. % Screening for substance abuse 353 98.3 Screening for mental health disorders 272 75.8 Comprehensive mental health disorders 336 93.6 Comprehensive mental health assessment or diagnosis 199 55.4 Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 61.0 Interim services for clients when immediate admission is not possible 149 41.5 No services offered 29 77.1 3.3 Festing 68 47.1 3.3 Festing 69 47.1 4.1 Screening for hepatitis B 60 16.7 6.6 18.4 HIV testing 63 17.5 5.7 6.6 18.4 HIV testing for hepatitis C 66 18.4 4.7 13.1 5.2 5.7 1.6 5.2 5.7 1.6 5.2 5.7 1.6 5.2 5.2 5.7 1.6 5.2 </th <th>Types of Services offered, by flumber and percent</th> <th>Faci</th> <th>1:4:</th>	Types of Services offered, by flumber and percent	Faci	1:4:
Assessment and pre-treatment services \$353 \$9.3 \$0.3 \$0.5 \$0			
Screening for substance abuse 353 98.3 Screening for mental health disorders 272 75.8 Comprehensive substance abuse assessment or diagnosis 336 93.6 Comprehensive mental health assessment or diagnosis 199 55.4 Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 61.0 Interim services for clients when immediate admission is not possible 149 41.5 No services offered 1 0.3 Testing Interim services offered Drug or alcohal urine screening 257 71.6 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 Screening for hepatitis C 66 18.4 HIV testing 47 13.1 Storeening for hepatitis C 66 18.4 HIV testing 37 21.4 Storeening for hepatitis C 66 18.4 HIV testing 37 21.4 Storeening for	Assessment and pre-treatment services	NO.	
Screening for mental health disorders 272 75.8 Comprehensive substance abuse assessment or diagnosis 336 936 Comprehensive webstance abuse assessment or diagnosis 199 55.4 Comprehensive webstance abuse assessment or diagnosis 199 55.7 Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 41.5 Intering services for clients when immediate admission is not possible 149 41.5 No services offered 1 10.3 17.7 Testing 169 47.1 1 Drug or alcohol urine screening 257 71.6 5 Screening for hepatitis B 60 16.7 16.5 Screening for hepatitis C 66 18.4 11.1 15.5 15.1 15.2 15.1 15.2 <t< td=""><td>·</td><td>353</td><td>98.3</td></t<>	·	353	98.3
Comprehensive substance abuse assessment or diagnosis 336 93.6 Comprehensive mental health assessment or diagnosis 199 55.4 Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 61.0 Interim services for clients when immediate admission is not possible 149 41.5 No services offered 1 0.3 Testing Testing 66 47.1 Drug or alcohol urine screening 257 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 47 13.1 S Screening for hepatitis C 66 18.4 No services offered 37 22.4 Courseling 47 13.1 B screening for hepatitis C 66 18.4 IV testing 37 22.4 Courseling 47 21.4 B screening for hepatitis C 68 7.7 Counseling 37			
Comprehensive mental health assessment or diagnosis 199 55.4 Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 61.0 Interim services for clients when immediate admission is not possible 149 41.5 No services offered 10 0.3 Testing 169 47.1 Breathalyzer or other blood alcohol testing 169 47.1 Drug or alcohol urine screening 267 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis B 60 18.4 Screening for hepatitis B 66 18.4 Screening for hepatitis B 47 13.1 Screening for hepatitis B 66 18.4 Streening for hepatitis B 66 18.4 Screening for hepatitis B 77 21.4 Streening for hepatitis B 77 21.4 Screening for hepatitis B 30 18.7 STD testing 37 21.2 STD testing 38 22 <td>•</td> <td></td> <td></td>	•		
Screening for tobacco use 206 57.4 Outreach to persons in the community who may need treatment 219 61.0 Interin services of clients when immediate admission is not possible 1 0.3 Testing 8 1 0.3 Testing 8 7.1 0.3 Testing 86 18.4 1.6 0.6 18.4 Breathalyzer or other blood alcohol testing 60 18.7 1.6 0.6 18.4 1.6 0.6 18.4 1.6 0.6 18.4 1.6 0.6 18.4 1.7 1.6 0.6 18.4 1.7 1.6 0.6 18.4 1.7 1.5 0.6 18.4 1.7 1.5 0.6 18.4 1.7 1.5 0.6 18.4 1.7 1.3 1.7 5 0.7 1.2 4.2 1.4 0.8 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 219 61.0 Interin services for clents when immediate admission is not possible 149 41.5 No services offered 1 0.3 Testing 8 169 47.1 Breathalyzer or other blood alcohol testing 169 47.1 Drug or alcohol urine screening 257 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 47 13.1 STD testing 47 13.1 T8 screening Green 87 24.2 Council 87	·		
Interim services offered 149 41.5 No services offered 1 0.3 Testing 1 0.3 Testing 1 0.7 Breathalyzer or other blood alcohol testing 169 47.1 Drug or alcohol urine screening 257 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 67 21.4 No services offered 87 24.2 Counseling 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Group counseling 351 97.8 Bamily counseling 351 97.8 Bramity countering 36 2.2 <t< td=""><td>· · · · · · ·</td><td></td><td></td></t<>	· · · · · · ·		
No services offered 1 0.3 Testins 1 47.1 Drug or alcohol urine screening 47.1 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 47 13.1 TB screening for hepatitis C 87 24.2 STD testing 47 13.1 No services offered 87 24.2 Counseling 351 9.7 8 Group counseling 351 9.7 8 Group counseling 36 74.7 Amity counseling 36 74.7 Family counseling 30 94.7 Family counseling 33 94.4 Marital/couples counseling 28 74.7 Family counseling 339 94.4 Tearnitional services 339 94.4 Tearnity counseling 339 94.2 Tearnity counseling 339 94.2 <td></td> <td></td> <td></td>			
Breathalyzer or other blood alcohol testing 169 47.1 Drug or alcohol urine screening 257 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Individual counseling 351 97.8 Family counseling 340 94.7 Family counseling 248 74.7 Family counseling 340 94.7 Family counseling 38 74.7 Family counseling 38 94.2 Family counseling 38 74.7 Family counseling 38 74			
Breathalyzer or other blood alcohol testing 47.1 Drug or alcohol urine screening 257 71.6 Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 33 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Group counseling 340 94.7 Family counseling 340 94.7 Family counseling 340 94.7 Barital-Couples counseling 340 94.7 Family counseling 39 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Paramacotherapies 32 90.0 Ibuilfriam (Antabuse*) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitol* 64 17.8 Acamprosate (Campral*)		'	0.5
Drug or alcohol urine screening 257 71.6 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Individual counseling 351 97.8 Group counseling 340 94.7 Family counseling 268 74.7 Marital/couples counseling 268 74.7 Transitional services 339 94.4 Aftercare/continuing care 339 94.4 Aftercare/continuing care 323 90.0 No services offered 3 2.2 Pharmacotherapies 3 9.2 Disulfiram (Antabuse*) 30 8.4 No services offered 64 17.8 Acamprosate (Campral*) 4 17.8 Acamprosate (Campral*) 42 11.7 Non-nicotine eplacement 53		160	47.1
Screening for hepatitis B 60 16.7 Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 361 97.8 Group counseling 351 97.8 Group counseling 364 94.7 Family counseling 268 74.7 Marital/couples counseling 268 74.7 Family counseling 30 94.4 Aftercare/continuing care 323 90.0 Ischarge planning 33 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies 3 2.2 Distilifiam (Antabuse®) 30 8.4 Natirexone (oral) 54 15.0 Extended-release, injectable nattrexone/Vivitrol® 42 17.7 Nicotine replacement			
Screening for hepatitis C 66 18.4 HIV testing 63 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling Individual counseling 351 9.8 Group counseling 340 94.7 Family counseling 268 74.7 Marital/couples counseling 268 74.7 Marital/couples counseling 339 94.4 Aftercare/continuing care 32 90.0 No services offered 33 90.0 No services offered 32 90.0 No services offered 30 8.4 Natifexnone (crail) 30 8.4 Natifexnone (crail) 30 8.4 Natifexnone (crail of crail c			
HIV testing 63 17.5 STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Group counseling 360 94.7 Family counseling 268 74.7 Marital/couples counseling 268 74.7 Marital/couples counseling 224 62.4 Tensitional services 224 62.4 Tensitional services 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies 32 90.0 No services offered 8 2.2 Pharmacotherapies 30 8.4 Nalitrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 5 14.8 Non-nicotine explacement 15 <td>-</td> <td></td> <td></td>	-		
STD testing 47 13.1 TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Group counseling 351 97.8 Group counseling 351 97.8 Group counseling 360 74.7 Barnital/couples counseling 224 62.4 Tarniticouples counseling 239 94.4 Aftercare/continuing care 339 94.4 Aftercare/continuing care 339 94.4 Aftercare/continuing care 30 8.4 Agentage 30 8.4 Acter care/continuing care 30 8.4 Set tranitical/counte			
TB screening 77 21.4 No services offered 87 24.2 Counseling 351 97.8 Individual counseling 361 97.8 Group counseling 340 94.7 Family counseling 268 74.7 Martial/couples counseling 268 74.7 Martial/couples counseling 224 62.4 Transitional services 2 74.7 Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies 30 8.4 Nattrexone (oral) 54 15.0 Extended-release, injectable naltrexone/vivitrol® 30 8.4 Nattrexone (oral) 54 15.0 Extended-release, injectable naltrexone/vivitrol® 64 17.8 Acamprosate (Campral®) 30 8.4 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143			
No services offered 87 24.2 Counseling 351 97.8 Group counseling 340 94.7 Family counseling 268 74.7 Family counseling 268 74.7 Marital/couples counseling 224 62.4 Transitional services Using planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 15 4.2 Buprenorphine without			
Counseling 351 97.8 Group counseling 340 94.7 Family counseling 268 74.7 Marital/couples counseling 224 62.4 Marital/couples counseling 224 62.4 Transitional services Transitional services Transitional services Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies 30 8.4 Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without n			
Individual counseling 351 97.8 Group counseling 340 94.7 Family counseling 268 74.7 Marital/couples counseling 224 62.4 Transitional services Transitional services Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Pharmacotherapies Disulfiram (Antabuse*) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol* 64 17.8 Acamprosate (Campral**) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone*) 58 16.2 Buprenorphine without naloxone 16 4.5		87	24.2
Group counseling 340 94.7 Family counseling 268 74.7 Marital/couples counseling 224 62.4 Transitional services 8 224 Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse*) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol* 64 17.8 Acamprosate (Campral*) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone*) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine*) 1 0.3 No services offered 167 46.5 Acaillary services 310 86.4 </td <td></td> <td>0.54</td> <td>27.0</td>		0.54	27.0
Family counseling 268 74.7 Marital/couples counseling 224 62.4 Transitional services Transitional services Discharge planning care 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 15 4.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 16 46.5 Ancillary services 31	~		
Marital/couples counseling 224 62.4 Transitional services Image: Counting Care Services offered Services Organical Services Services offered Services Services offered Services Services offered Services Servi	· · · · · · · · · · · · · · · · · · ·		
Transitional services 339 94.4 Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Usisifiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support <			
Discharge planning 339 94.4 Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buy sorvices offered 42 11.7 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 1	<u> </u>	224	62.4
Aftercare/continuing care 323 90.0 No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 42 11.7 Nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 No services offered 42 11.7 Ancillary services 31 0.3 Ancillary services 31 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
No services offered 8 2.2 Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Pharmacotherapies Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4	· · · · · · · · · · · · · · · · · · ·		
Disulfiram (Antabuse®) 30 8.4 Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4		8	2.2
Naltrexone (oral) 54 15.0 Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4	·		
Extended-release, injectable naltrexone/Vivitrol® 64 17.8 Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Acamprosate (Campral®) 42 11.7 Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Nicotine replacement 53 14.8 Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4	·		
Non-nicotine smoking/tobacco cessation medications 39 10.9 Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Medications for psychiatric disorders 143 39.8 Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Methadone 15 4.2 Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4	•		
Buprenorphine with naloxone (Suboxone®) 58 16.2 Buprenorphine without naloxone 42 11.7 Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services Case management services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children Assistance with obtaining social services 181 50.4			
Buprenorphine subdermal implant (Probuphine®) 1 0.3 No services offered 167 46.5 Ancillary services Case management services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
No services offered 167 46.5 Ancillary services 310 86.4 Case management services 310 86.4 Social skills development 267 74.4 Mentoring/peer support 216 60.2 Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4			
Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 310 86.4 74.4 60.2 60.2 16 4.5 17 4.5 18 50.4			
Case management services31086.4Social skills development26774.4Mentoring/peer support21660.2Child care for clients' children164.5Assistance with obtaining social services18150.4		167	46.5
Social skills development26774.4Mentoring/peer support21660.2Child care for clients' children164.5Assistance with obtaining social services18150.4	Ancillary services		
Mentoring/peer support21660.2Child care for clients' children164.5Assistance with obtaining social services18150.4			
Child care for clients' children 16 4.5 Assistance with obtaining social services 181 50.4	·		
Assistance with obtaining social services 181 50.4	Mentoring/peer support		
Employment counseling or training for clients 144 40.1	~		
	Employment counseling or training for clients	144	40.1

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	173	48.2
Domestic violence services	186	51.8
Early intervention for HIV	79	22.0
HIV or AIDS education, counseling, or support	154	42.9
Hepatitis education, counseling, or support	138	38.4
Health education other than HIV/AIDS or hepatitis	145	40.4
Substance abuse education	338	94.2
Transportation assistance to treatment	90	25.1
Mental health services	249	69.4
Acupuncture	1	0.3
Residential beds for clients' children	7	1.9
Self-help groups	115	32.0
Smoking/tobacco cessation counseling	101	28.1
No services offered	1	0.3
Other services		
Treatment for gambling disorder	82	22.8
Treatment for Internet use disorder	59	16.4
Treatment for other addiction disorder	117	32.6
No services offered	228	63.5

	Faci	Facilities	
	No.	%	
Substance abuse counseling	357	99.4	
Relapse prevention	343	95.5	
Cognitive behavioral therapy	333	92.8	
Motivational interviewing	321	89.4	
Anger management	299	83.3	
Brief intervention	275	76.6	
Trauma-related counseling	261	72.7	
12-step facilitation	255	71.0	
Contingency management/motivational incentives	171	47.6	
Dialectical behavior therapy	177	49.3	
Rational emotive behavioral therapy	197	54.9	
Matrix model	140	39.0	
Computerized substance abuse treatment	87	24.2	
Community reinforcement plus vouchers	37	10.3	
Other treatment approaches	21	5.8	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	46	12		
Number of clients ²	2,710	299		
Number of designated beds	2,228	427		
Utilization rate ³	121.6	70.0		
Average number of designated beds per facility	48	36		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	117
Methadone	110
Buprenorphine	7
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	178	49.6
Any language other than English	205	57.1
Non-English language provided by		
Staff counselor only	17	8.3
On-call interpreter only	175	85.4
Both staff counselor and on-call interpreter	13	6.3
Languages provided by staff counselor ¹		
Spanish	28	93.3
American Indian/Alaskan Native		
languages	_	_
Other	2	6.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	310	86.4
Adult women	155	43.2
Clients with co-occurring disorders	133	37.0
Adult men	143	39.8
Clients who have experienced trauma	94	26.2
Criminal justice clients	147	40.9
DUI/DWI clients	165	46.0
Young adults	93	25.9
Adolescents	89	24.8
Clients who have experienced domestic violence	81	22.6
Clients who have experienced sexual	75	00.0
abuse	75	20.9
Pregnant or postpartum women	102	28.4
Seniors or older adults	64	17.8
LGBT ¹	53	14.8
Veterans	64	17.8
Clients living with HIV/AIDS	55	15.3
Members of military families	52	14.5
Active duty military	43	12.0
Other	9	2.5
No program or group offered	49	13.6

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

Structure Services log

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



2017 State Profile — Louisiana National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Louisiana, 136 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 10,066 clients in substance abuse treatment on March 31, 2017. The survey response rate in Louisiana was 88.5 percent.

Facility operation, by number and percent						
	Clients in treatmer			n treatmen	t on March 31,	2017
	Facilities		ilities All clients Clients und		ler age 18	
	No.	%	No.	%	No.	%
Private non-profit	41	30.1	1,648	16.4	72	41.4
Private for-profit	53	39.0	6,020	59.8	53	30.5
Local, county, or community government	12	8.8	573	5.7	11	6.3
State government	21	15.4	1,303	12.9	35	20.1
Federal government	7	5.1	496	4.9	_	_
Tribal government	2	1.5	26	0.3	3	1.7
Total	136	100.0	10,066	100.0	174	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients	Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	120	93.0	2,901	28.8	78	
Clients with drug abuse only	115	89.1	6,095	60.5	169	
Clients with alcohol abuse only	98	76.0	1,070	10.6	30	
Total			10,066	100.0	277	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent								
				Clients in treatment on March 31, 2017					
_	Facili	ities¹			All clients		Clients	Clients age < 18	
					Median no. of clients per	Median no. of clients per			
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%	
Outpatient	103	75.7	8,473	84.2	396	33	121	69.5	
Regular	87	64.0	2,281	22.7	2	19			
Intensive	69	50.7	1,518	15.1	_	20			
Day treatment/partial hospitalization	16	11.8	49	0.5	_	8			
Detoxification	19	14.0	83	8.0	_	9			
Methadone maintenance	33	24.3	4,542	45.1	396	12			
Residential (non-hospital)	40	29.4	1,352	13.4	_	25	53	30.5	
Short term (<30 days)	21	15.4	545	5.4	_	25			
Long term (30+ days)	30	22.1	740	7.4	_	20			
Detoxification	13	9.6	67	0.7	_	5			
Hospital inpatient	15	11.0	241	2.4	_	19	_	_	
Treatment	13	9.6	124	1.2	_	15			
Detoxification	15	11.0	117	1.2	_	7			
Total	136		10,066	100.0	396	36	174	100.0	

¹ Facilities may provide more than one type of care.

,		
	No.	%
Facilities with OTPs ¹	10	0.8
Ollanda to facilities with OTD-2		
Clients in facilities with OTPs ²		
Any MAT	3,644	0.9
Methadone	3,422	0.9
Buprenorphine	222	0.8
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	1,209	1.2
Buprenorphine	1,143	1.4
Naltrexone	66	0.3
1D 1 1 1 1 OTD 1 1111 1 1 1 1 0 2 D 1 1 1 1 1		

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	114	83.8
Private health insurance	91	66.9
Medicare	39	28.7
Medicaid	85	62.5
State-financed health insurance	41	30.1
Federal military insurance	40	29.4
No payment accepted	6	4.4
Access to Recovery (ATR) vouchers ²	12	8.8
IHS/Tribal/Urban (ITU) funds	3	2.2
Other payments	_	_
Sliding fee scale	57	41.9
Treatment at no charge for clients who can't pay	72	52.9

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	125	91.9
State substance abuse agency	96	70.6
State mental health department	47	34.6
State department of health	104	76.5
Hospital licensing authority	25	18.4
The Joint Commission	20	14.7
Commission on Accreditation of Rehabilitation Facilities	67	49.3
National Committee for Quality Assurance	3	2.2
Council on Accreditation	10	7.4
Healthcare Facilities Accreditation Program	1	0.7
Other state/local agency/organization	3	2.2

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 75 55.1

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Faci	lities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	133	97.8
Screening for mental health disorders	94	69.1
Comprehensive substance abuse assessment or diagnosis	128	94.1
Comprehensive mental health assessment or diagnosis	60	44.1
Screening for tobacco use	100	73.5
Outreach to persons in the community who may need treatment	104	76.5
Interim services for clients when immediate admission is not possible	68	50.0
No services offered	1	0.7
esting		
Breathalyzer or other blood alcohol testing	87	64.0
Drug or alcohol urine screening	133	97.8
Screening for hepatitis B	46	33.8
Screening for hepatitis C	53	39.0
HIV testing	68	50.0
STD testing	56	41.2
TB screening	81	59.6
No services offered	3	2.2
Counseling		
ndividual counseling	135	99.3
Group counseling	130	95.6
Family counseling	120	88.2
Marital/couples counseling	98	72.1
ransitional services		
Discharge planning	135	99.3
Aftercare/continuing care	123	90.4
No services offered	1	0.7
Pharmacotherapies		
Disulfiram (Antabuse®)	32	23.5
Naltrexone (oral)	43	31.6
Extended-release, injectable naltrexone/Vivitrol®	36	26.5
Acamprosate (Campral®)	44	32.4
Nicotine replacement	68	50.0
Non-nicotine smoking/tobacco cessation medications	50	36.8
Medications for psychiatric disorders	78	57.4
Methadone	10	7.4
Buprenorphine with naloxone (Suboxone®)	34	25.0
Buprenorphine without naloxone	28	20.6
Buprenorphine subdermal implant (Probuphine®)	2	1.5
No services offered	39	28.7
Ancillary services		
Case management services	119	87.5
Social skills development	104	76.5
Mentoring/peer support	90	66.2
Child care for clients' children	6	4.4
Assistance with obtaining social services	87	64.0
Employment counseling or training for clients	47	34.6

Types of services offered, by number and percent (continued)		
	Fa	cilities
	No.	%
Assistance in locating housing for clients	80	58.8
Domestic violence services	45	33.1
Early intervention for HIV	44	32.4
HIV or AIDS education, counseling, or support	85	62.5
Hepatitis education, counseling, or support	71	52.2
Health education other than HIV/AIDS or hepatitis	83	61.0
Substance abuse education	136	100.0
Transportation assistance to treatment	58	42.6
Mental health services	83	61.0
Acupuncture	3	2.2
Residential beds for clients' children	6	4.4
Self-help groups	77	56.6
Smoking/tobacco cessation counseling	80	58.8
No services offered	<u> </u>	-
Other services		
Treatment for gambling disorder	54	39.7
Treatment for Internet use disorder	18	13.2
Treatment for other addiction disorder	42	30.9
No services offered	73	53.7

	Faci	lities
	No.	%
Substance abuse counseling	133	97.8
Relapse prevention	132	97.1
Cognitive behavioral therapy	123	90.4
Motivational interviewing	120	88.2
Anger management	108	79.4
Brief intervention	115	84.6
Trauma-related counseling	91	66.9
12-step facilitation	109	80.1
Contingency management/motivational incentives	73	53.7
Dialectical behavior therapy	62	45.6
Rational emotive behavioral therapy	73	53.7
Matrix model	67	49.3
Computerized substance abuse treatment	31	22.8
Community reinforcement plus vouchers	11	8.1
Other treatment approaches	10	7.4

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	38	11			
Number of clients ²	1,300	192			
Number of designated beds	1,551	374			
Utilization rate ³	83.8	51.3			
Average number of designated beds per facility	41	34			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	78
Methadone	73
Buprenorphine	5
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	38	27.9
Any language other than English	40	29.4
Non-English language provided by		
Staff counselor only	5	12.5
On-call interpreter only	31	77.5
Both staff counselor and on-call interpreter	4	10.0
Languages provided by staff counselor ¹		
Spanish	9	100.0
American Indian/Alaskan Native languages		
Other		11 1
Other	ı	11.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	110	80.9
Adult women	65	47.8
Clients with co-occurring disorders	64	47.1
Adult men	55	40.4
Clients who have experienced trauma	39	28.7
Criminal justice clients	40	29.4
DUI/DWI clients	23	16.9
Young adults	28	20.6
Adolescents	30	22.1
Clients who have experienced domestic violence	22	16.2
Clients who have experienced sexual		
abuse	23	16.9
Pregnant or postpartum women	27	19.9
Seniors or older adults	23	16.9
LGBT ¹	19	14.0
Veterans	28	20.6
Clients living with HIV/AIDS	22	16.2
Members of military families	16	11.8
Active duty military	18	13.2
Other	4	2.9
No program or group offered	26	19.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; *n/a* Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Maine National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Maine, 199 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 11,801 clients in substance abuse treatment on March 31, 2017. The survey response rate in Maine was 88.2 percent.

Facility operation, by number and percei	nt					
			Clients	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	89	44.7	4,370	37.0	275	61.1
Private for-profit	104	52.3	7,196	61.0	169	37.6
Local, county, or community government	1	0.5	93	0.8	3	0.7
State government	_	_	_	_	_	_
Federal government	2	1.0	25	0.2	_	_
Tribal government	3	1.5	117	1.0	3	0.7
Total	199	100.0	11,801	100.0	450	100.0

Substance abuse problem treated, by number and percent						
			Clients i	n treatmer	nt on March 31, 2017	
_	Faciliti	es¹	Clients ² Clients ² per 100,00			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	159	90.3	3,451	29.2	298	
Clients with drug abuse only	146	83.0	7,017	59.5	635	
Clients with alcohol abuse only	140	79.5	1,333	11.3	114	
Total			11,801	100.0	1,048	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	177	88.9	11,482	97.3	398	20	416	92.4
Regular	172	86.4	4,974	42.1	50	18		
Intensive	44	22.1	527	4.5	10	13		
Day treatment/partial hospitalization	7	3.5	39	0.3	_	20		
Detoxification	9	4.5	30	0.3	_	15		
Methadone maintenance	47	23.6	5,912	50.1	398	33		
Residential (non-hospital)	21	10.6	257	2.2	_	12	34	7.6
Short term (<30 days)	5	2.5	39	0.3	_	11		
Long term (30+ days)	19	9.5	215	1.8	_	12		
Detoxification	_	_	3	*	_	3		
Hospital inpatient	5	2.5	62	0.5	_	14	_	_
Treatment	3	1.5	18	0.2	_	9		
Detoxification	5	2.5	44	0.4	<u> </u>	12		
Total	199		11,801	100.0	398	18	450	100.0

¹ Facilities may provide more than one type of care.

· ·		
	No.	%
Facilities with OTPs ¹	10	0.8
Clients in facilities with OTPs ²		
Any MAT	4,286	1.0
Methadone	3,928	1.0
Buprenorphine	358	1.3
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	2,188	2.1
Buprenorphine	2,143	2.5
Naltrexone	45	0.2

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r demay payment options, by names and		
	No.	%
Cash or self-payment	193	97.0
Private health insurance	165	82.9
Medicare	102	51.3
Medicaid	163	81.9
State-financed health insurance	107	53.8
Federal military insurance	108	54.3
No payment accepted	1	0.5
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	27	13.6
Other payments	_	_
Sliding fee scale	133	66.8
Treatment at no charge for clients who can't pay	80	40.2
1 = -1141		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	175	87.9
State substance abuse agency	164	82.4
State mental health department	120	60.3
State department of health	55	27.6
Hospital licensing authority	8	4.0
The Joint Commission	11	5.5
Commission on Accreditation of Rehabilitation Facilities	19	9.5
National Committee for Quality Assurance	8	4.0
Council on Accreditation	10	5.0
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	12	6.0

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 81 40.7

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy by manuscraina personic	Faci	lities
	No.	%
Assessment and pre-treatment services		76
Screening for substance abuse	195	98.0
Screening for mental health disorders	162	81.4
Comprehensive substance abuse assessment or diagnosis	188	94.5
Comprehensive mental health assessment or diagnosis	112	56.3
Screening for tobacco use	149	74.9
Outreach to persons in the community who may need treatment	89	44.7
Interim services for clients when immediate admission is not possible	68	34.2
No services offered	1	0.5
Testing		
Breathalyzer or other blood alcohol testing	67	33.7
Drug or alcohol urine screening	129	64.8
Screening for hepatitis B	31	15.6
Screening for hepatitis C	32	16.1
HIV testing	27	13.6
STD testing	22	11.1
TB screening	42	21.1
No services offered	62	31.2
Counseling		
Individual counseling	195	98.0
Group counseling	144	72.4
Family counseling	157	78.9
Marital/couples counseling	125	62.8
Transitional services		
Discharge planning	185	93.0
Aftercare/continuing care	166	83.4
No services offered	4	2.0
Pharmacotherapies		
Disulfiram (Antabuse®)	29	14.6
Naltrexone (oral)	42	21.1
Extended-release, injectable naltrexone/Vivitrol®	29	14.6
Acamprosate (Campral®)	35	17.6
Nicotine replacement	44	22.1
Non-nicotine smoking/tobacco cessation medications	32	16.1
Medications for psychiatric disorders	60	30.2
Methadone	10	5.0
Buprenorphine with naloxone (Suboxone®)	53	26.6
Buprenorphine without naloxone	35	17.6
Buprenorphine subdermal implant (Probuphine®)	1	0.5
No services offered	119	59.8
Ancillary services		
Case management services	104	52.3
Social skills development	130	65.3
Mentoring/peer support	79	39.7
Child care for clients' children	3	1.5
Assistance with obtaining social services	104	52.3
Employment counseling or training for clients	43	21.6

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	92	46.2
Domestic violence services	67	33.7
Early intervention for HIV	21	10.6
HIV or AIDS education, counseling, or support	59	29.6
Hepatitis education, counseling, or support	58	29.1
Health education other than HIV/AIDS or hepatitis	76	38.2
Substance abuse education	182	91.5
Transportation assistance to treatment	49	24.6
Mental health services	147	73.9
Acupuncture	5	2.5
Residential beds for clients' children	2	1.0
Self-help groups	59	29.6
Smoking/tobacco cessation counseling	104	52.3
No services offered	2	1.0
Other services		
Treatment for gambling disorder	55	27.6
Treatment for Internet use disorder	38	19.1
Treatment for other addiction disorder	84	42.2
No services offered	107	53.8

	Faci	lities
	No.	%
Substance abuse counseling	198	99.5
Relapse prevention	191	96.0
Cognitive behavioral therapy	185	93.0
Motivational interviewing	184	92.5
Anger management	153	76.9
Brief intervention	164	82.4
Trauma-related counseling	163	81.9
12-step facilitation	122	61.3
Contingency management/motivational incentives	84	42.2
Dialectical behavior therapy	106	53.3
Rational emotive behavioral therapy	67	33.7
Matrix model	60	30.2
Computerized substance abuse treatment	26	13.1
Community reinforcement plus vouchers	15	7.5
Other treatment approaches	15	7.5

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	17	3		
Number of clients ²	213	39		
Number of designated beds	216	52		
Utilization rate ³	98.6	75.0		
Average number of designated beds per facility	13	17		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	321
Methadone	294
Buprenorphine	27
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	79	39.7
Any language other than English	86	43.2
Non-English language provided by		
Staff counselor only	4	4.7
On-call interpreter only	76	88.4
Both staff counselor and on-call interpreter	6	7.0
Languages provided by staff counselor ¹		
Spanish	4	40.0
American Indian/Alaskan Native languages	_	_
Other	6	60.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	153	76.9
Adult women	70	35.2
Clients with co-occurring disorders	87	43.7
Adult men	66	33.2
Clients who have experienced trauma	62	31.2
Criminal justice clients	50	25.1
DUI/DWI clients	65	32.7
Young adults	45	22.6
Adolescents	30	15.1
Clients who have experienced domestic violence	42	21.1
Clients who have experienced sexual	40	0.1.1
abuse	42	21.1
Pregnant or postpartum women	39	19.6
Seniors or older adults	35	17.6
LGBT ¹	32	16.1
Veterans	34	17.1
Clients living with HIV/AIDS	23	11.6
Members of military families	26	13.1
Active duty military	23	11.6
Other	4	2.0
No program or group offered	46	23.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Maryland National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Maryland, 387 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 48,654 clients in substance abuse treatment on March 31, 2017. The survey response rate in Maryland was 85.7 percent.

Facility operation, by number and perce	nt					
			Clients i	n treatmen	t on March 31,	2017
	Facilities All clients Clients u			Clients und	ınder age 18	
	No.	%	No.	%	No.	%
Private non-profit	138	35.7	14,547	29.9	304	32.9
Private for-profit	203	52.5	28,653	58.9	369	39.9
Local, county, or community government	17	4.4	1,969	4.0	121	13.1
State government	21	5.4	2,650	5.4	131	14.2
Federal government	8	2.1	835	1.7	_	_
Tribal government	_	_	_	_	_	_
Total	387	100.0	48,654	100.0	925	100.0

Substance abuse problem treated, by number and percent								
Clients in treatment on March 31, 2017								
_	Faciliti	es¹	Clients	Clients ² Clients ² per 100,000 pop.				
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	316	90.0	14,146	29.1	292			
Clients with drug abuse only	293	83.5	29,244	60.1	615			
Clients with alcohol abuse only	249	70.9	5,263	10.8	108			
Total			48,654	100.0	1,015			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹		All clients			Clients age < 18	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	339	87.6	46,815	96.2	337	41	888	96.0
Regular	319	82.4	14,332	29.5	27	30		
Intensive	214	55.3	3,831	7.9	17	15		
Day treatment/partial hospitalization	39	10.1	465	1.0	_	14		
Detoxification	68	17.6	435	0.9	8	16		
Methadone maintenance	151	39.0	27,752	57.0	333	20		
Residential (non-hospital)	68	17.6	1,702	3.5	40	16	26	2.8
Short term (<30 days)	24	6.2	393	0.8	_	18		
Long term (30+ days)	59	15.2	1,205	2.5	40	12		
Detoxification	14	3.6	104	0.2	_	9		
Hospital inpatient	10	2.6	137	0.3	_	13	11	1.2
Treatment	6	1.6	100	0.2	_	24		
Detoxification	10	2.6	37	0.1	<u> </u>	4		
Total	387		48,654	100.0	337	39	925	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	70	5.3
Clients in facilities with OTPs ²		
Any MAT	27,571	6.7
Methadone	25,026	6.5
Buprenorphine	2,340	8.5
Naltrexone	205	6.0
Clients in facilities without OTPs ²		
Any MAT	3,578	3.4
Buprenorphine	3,103	3.7
Naltrexone	475	2.4

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	349	90.2
Private health insurance	229	59.2
Medicare	120	31.0
Medicaid	292	75.5
State-financed health insurance	167	43.2
Federal military insurance	92	23.8
No payment accepted	12	3.1
Access to Recovery (ATR) vouchers ²	59	15.2
IHS/Tribal/Urban (ITU) funds	13	3.4
Other payments	1	0.3
Sliding fee scale	208	53.7
Treatment at no charge for clients who can't pay	126	32.6
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facil	lities¹
	No.	%
Any listed agency/organization	365	94.3
State substance abuse agency	336	86.8
State mental health department	186	48.1
State department of health	257	66.4
Hospital licensing authority	13	3.4
The Joint Commission	69	17.8
Commission on Accreditation of Rehabilitation Facilities	126	32.6
National Committee for Quality Assurance	15	3.9
Council on Accreditation	8	2.1
Healthcare Facilities Accreditation Program	8	2.1
Other state/local agency/organization	13	3.4

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Facili	14100
	Faci No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	380	98.2
Screening for mental health disorders	289	74.7
Comprehensive substance abuse assessment or diagnosis	367	94.8
Comprehensive mental health assessment or diagnosis	191	49.4
Screening for tobacco use	287	74.2
Outreach to persons in the community who may need treatment	233	60.2
Interim services for clients when immediate admission is not possible	162	41.9
No services offered	5	1.3
	J	1.3
Testing Prostholyzer or other blood clockel testing	324	83.7
Breathalyzer or other blood alcohol testing		
Drug or alcohol urine screening	366	94.6
Screening for hepatitis B	114	29.5
Screening for hepatitis C	129 122	33.3 31.5
HIV testing		
STD testing	90	23.3
TB screening	173	44.7
No services offered	16	4.1
Counseling	070	00.4
Individual counseling	373	96.4
Group counseling	367	94.8
Family counseling	309	79.8
Marital/couples counseling	240	62.0
Transitional services		
Discharge planning	371	95.9
Aftercare/continuing care	324	83.7
No services offered	7	1.8
Pharmacotherapies 22 16 16 16 16 16 16 16 16 16 16 16 16 16	2.4	0.1.0
Disulfiram (Antabuse®)	94	24.3
Naltrexone (oral)	104	26.9
Extended-release, injectable naltrexone/Vivitrol®	102	26.4
Acamprosate (Campral®)	72	18.6
Nicotine replacement	89	23.0
Non-nicotine smoking/tobacco cessation medications	62	16.0
Medications for psychiatric disorders	136	35.1
Methadone	67	17.3
Buprenorphine with naloxone (Suboxone®)	157	40.6
Buprenorphine without naloxone	110	28.4
Buprenorphine subdermal implant (Probuphine®)	14	3.6
No services offered	157	40.6
Ancillary services		
Case management services	316	81.7
Social skills development	265	68.5
Mentoring/peer support	210	54.3
Child care for clients' children	21	5.4
Assistance with obtaining social services Employment counseling or training for clients	241 145	62.3 37.5

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	199	51.4		
Domestic violence services	129	33.3		
Early intervention for HIV	105	27.1		
HIV or AIDS education, counseling, or support	245	63.3		
Hepatitis education, counseling, or support	225	58.1		
Health education other than HIV/AIDS or hepatitis	223	57.6		
Substance abuse education	368	95.1		
Transportation assistance to treatment	163	42.1		
Mental health services	244	63.0		
Acupuncture	40	10.3		
Residential beds for clients' children	10	2.6		
Self-help groups	173	44.7		
Smoking/tobacco cessation counseling	186	48.1		
No services offered	1	0.3		
Other services				
Treatment for gambling disorder	134	34.6		
Treatment for Internet use disorder	44	11.4		
Treatment for other addiction disorder	98	25.3		
No services offered	220	56.8		

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Facil	lities		
	No.	%		
Substance abuse counseling	381	98.4		
Relapse prevention	367	94.8		
Cognitive behavioral therapy	357	92.2		
Motivational interviewing	350	90.4		
Anger management	303	78.3		
Brief intervention	307	79.3		
Trauma-related counseling	275	71.1		
12-step facilitation	302	78.0		
Contingency management/motivational incentives	235	60.7		
Dialectical behavior therapy	172	44.4		
Rational emotive behavioral therapy	180	46.5		
Matrix model	145	37.5		
Computerized substance abuse treatment	60	15.5		
Community reinforcement plus vouchers	53	13.7		
Other treatment approaches	26	6.7		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	46	6			
Number of clients ²	1,303	131			
Number of designated beds	1,660	189			
Utilization rate ³	78.5	69.3			
Average number of designated beds per facility	36	32			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	456
Methadone	414
Buprenorphine	39
Naltrexone	3

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	90	23.3
Any language other than English	123	31.8
Non-English language provided by		
Staff counselor only	32	26.0
On-call interpreter only	64	52.0
Both staff counselor and on-call interpreter	27	22.0
Languages provided by staff counselor ¹		
Spanish	53	89.8
American Indian/Alaskan Native languages	_	_
Other	18	30.5

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	345	89.1
Adult women	218	56.3
Clients with co-occurring disorders	202	52.2
Adult men	212	54.8
Clients who have experienced trauma	143	37.0
Criminal justice clients	150	38.8
DUI/DWI clients	172	44.4
Young adults	151	39.0
Adolescents	95	24.5
Clients who have experienced domestic violence	99	25.6
Clients who have experienced sexual		
abuse	104	26.9
Pregnant or postpartum women	100	25.8
Seniors or older adults	102	26.4
LGBT ¹	87	22.5
Veterans	80	20.7
Clients living with HIV/AIDS	99	25.6
Members of military families	54	14.0
Active duty military	49	12.7
Other	11	2.8
No program or group offered	42	10.9

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

S CHANGE VASA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Massachusetts National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Massachusetts, 351 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 58,280 clients in substance abuse treatment on March 31, 2017. The survey response rate in Massachusetts was 91 percent.

Facility operation, by number and percent						
	Clients in treatment on Mai				t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	257	73.2	27,069	46.4	1,064	72.4
Private for-profit	85	24.2	29,729	51.0	406	27.6
Local, county, or community government	3	0.9	408	0.7	_	-
State government	4	1.1	519	0.9	_	-
Federal government	2	0.6	555	1.0	_	_
Tribal government	_	_	_	_	_	_
Total	351	100.0	58,280	100.0	1,470	100.0

Substance abuse problem treated, by number and percent							
	it on March 31, 2017						
_	Facilities ¹ Clients ²				Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	301	94.1	19,257	33.1	336		
Clients with drug abuse only	266	83.1	33,315	57.2	600		
Clients with alcohol abuse only	237	74.1	5,666	9.7	99		
Total			58,238	100.0	1,034		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clients in treatment on March 31, 201				
_	Facil	ities¹			All clients		Clients age < 18	
				Median no. Median no. of				
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	222	63.2	53,719	92.2	402	83	1,382	94.0
Regular	193	55.0	18,454	31.7	20	66		
Intensive	69	19.7	1,842	3.2	28	23		
Day treatment/partial hospitalization	32	9.1	872	1.5	34	21		
Detoxification	42	12.0	286	0.5	12	5		
Methadone maintenance	122	34.8	32,265	55.4	409	57		
Residential (non-hospital)	119	33.9	3,291	5.6	22	24	45	3.1
Short term (<30 days)	35	10.0	754	1.3	22	25		
Long term (30+ days)	91	25.9	2,386	4.1	1	24		
Detoxification	8	2.3	151	0.3	20	31		
Hospital inpatient	36	10.3	1,270	2.2	32	16	43	2.9
Treatment	25	7.1	566	1.0	42	13		
Detoxification	34	9.7	704	1.2	29	7		
Total	351		58,280	100.0	330	35	1,470	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	67	5.1
Clients in facilities with OTPs ²		
Any MAT	22,249	5.4
Methadone	21,739	5.7
Buprenorphine	406	1.5
Naltrexone	104	3.1
Clients in facilities without OTPs ²		
Any MAT	11,628	11.2
Buprenorphine	10,299	12.2
Naltrexone	1,329	6.8

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	296	84.3
Private health insurance	253	72.1
Medicare	203	57.8
Medicaid	263	74.9
State-financed health insurance	250	71.2
Federal military insurance	135	38.5
No payment accepted	19	5.4
Access to Recovery (ATR) vouchers ²	37	10.5
IHS/Tribal/Urban (ITU) funds	7	2.0
Other payments	_	_
Sliding fee scale	188	53.6
Treatment at no charge for clients who can't pay	196	55.8
45 99		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	341	97.2
State substance abuse agency	313	89.2
State mental health department	83	23.6
State department of health	291	82.9
Hospital licensing authority	35	10.0
The Joint Commission	99	28.2
Commission on Accreditation of Rehabilitation Facilities	119	33.9
National Committee for Quality Assurance	18	5.1
Council on Accreditation	15	4.3
Healthcare Facilities Accreditation Program	1	0.3
Other state/local agency/organization	8	2.3

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 231 65.8

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by fidiliber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	334	95.2
Screening for mental health disorders	255	72.6
Comprehensive substance abuse assessment or diagnosis	320	91.2
Comprehensive mental health assessment or diagnosis	175	49.9
Screening for tobacco use	308	87.7
Outreach to persons in the community who may need treatment	164	46.7
Interim services for clients when immediate admission is not possible	95	27.1
No services offered	2	0.6
Testing		0.0
Breathalyzer or other blood alcohol testing	220	62.7
Drug or alcohol urine screening	291	82.9
	127	36.2
Screening for hepatitis B Screening for hepatitis C	147	36.2 41.9
HIV testing	147	41.9
	120	34.2
STD testing		54.2 52.7
TB screening	185	
No services offered	40	11.4
Counseling	224	05.0
Individual counseling	334	95.2
Group counseling	314	89.5
Family counseling	295	84.0
Marital/couples counseling	226	64.4
Transitional services	000	0.4.0
Discharge planning	332	94.6
Aftercare/continuing care	308	87.7
No services offered	10	2.8
Pharmacotherapies Distribute (Anthorne)	0.5	07.4
Disulfiram (Antabuse®)	95	27.1
Naltrexone (oral)	146	41.6
Extended-release, injectable naltrexone/Vivitrol®	122	34.8
Acamprosate (Campral®)	107	30.5
Nicotine replacement	133	37.9
Non-nicotine smoking/tobacco cessation medications	104	29.6
Medications for psychiatric disorders	194	55.3
Methadone	64	18.2
Buprenorphine with naloxone (Suboxone®)	149	42.5
Buprenorphine without naloxone	104	29.6
Buprenorphine subdermal implant (Probuphine®)	15	4.3
No services offered	86	24.5
Ancillary services		
Case management services	305	86.9
Social skills development	268	76.4
Mentoring/peer support	195	55.6
Child care for clients' children	18	5.1
Assistance with obtaining social services	237	67.5
Employment counseling or training for clients	103	29.3

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	196	55.8
Domestic violence services	142	40.5
Early intervention for HIV	117	33.3
HIV or AIDS education, counseling, or support	269	76.6
Hepatitis education, counseling, or support	257	73.2
Health education other than HIV/AIDS or hepatitis	250	71.2
Substance abuse education	343	97.7
Transportation assistance to treatment	166	47.3
Mental health services	228	65.0
Acupuncture	9	2.6
Residential beds for clients' children	14	4.0
Self-help groups	179	51.0
Smoking/tobacco cessation counseling	280	79.8
No services offered	_	_
Other services		
Treatment for gambling disorder	121	34.5
Treatment for Internet use disorder	43	12.3
Treatment for other addiction disorder	107	30.5
No services offered	192	54.7

	Faci	lities
	No.	%
Substance abuse counseling	349	99.4
Relapse prevention	344	98.0
Cognitive behavioral therapy	339	96.6
Motivational interviewing	345	98.3
Anger management	299	85.2
Brief intervention	289	82.3
Trauma-related counseling	319	90.9
12-step facilitation	247	70.4
Contingency management/motivational incentives	201	57.3
Dialectical behavior therapy	208	59.3
Rational emotive behavioral therapy	111	31.6
Matrix model	86	24.5
Computerized substance abuse treatment	34	9.7
Community reinforcement plus vouchers	37	10.5
Other treatment approaches	21	6.0

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	113	26			
Number of clients ²	3,235	1,069			
Number of designated beds	3,348	1,037			
Utilization rate ³	96.6	103.1			
Average number of designated beds per facility	30	40			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	324
Methadone	317
Buprenorphine	6
Naltrexone	2

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

_	Facili	ties
	No.	%
Sign language	162	46.2
Any language other than English	237	67.5
Non-English language provided by		
Staff counselor only	61	25.7
On-call interpreter only	63	26.6
Both staff counselor and on-call interpreter	113	47.7
Languages provided by staff counselor ¹		
Spanish	159	91.4
American Indian/Alaskan Native languages	_	_
Other	68	39.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	291	82.9
Adult women	186	53.0
Clients with co-occurring disorders	204	58.1
Adult men	185	52.7
Clients who have experienced trauma	174	49.6
Criminal justice clients	92	26.2
DUI/DWI clients	53	15.1
Young adults	115	32.8
Adolescents	52	14.8
Clients who have experienced domestic violence	109	31.1
Clients who have experienced sexual		
abuse	114	32.5
Pregnant or postpartum women	114	32.5
Seniors or older adults	82	23.4
LGBT ¹	91	25.9
Veterans	70	19.9
Clients living with HIV/AIDS	99	28.2
Members of military families	41	11.7
Active duty military	29	8.3
Other	18	5.1
No program or group offered	60	17.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HILINA SERVICES. CO.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Michigan National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Michigan, 456 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 54,064 clients in substance abuse treatment on March 31, 2017. The survey response rate in Michigan was 90.7 percent.

Facility operation, by number and percent							
	Clients in treatment on March 31, 2017						
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	240	52.6	31,314	57.9	1,779	71.4	
Private for-profit	162	35.5	18,253	33.8	417	16.7	
Local, county, or community government	29	6.4	2,534	4.7	176	7.1	
State government	3	0.7	291	0.5	14	0.6	
Federal government	6	1.3	567	1.0	_	_	
Tribal government	16	3.5	1,105	2.0	105	4.2	
Total	456	100.0	54,064	100.0	2,491	100.0	

Substance abuse problem treated, by number and percent							
Clients in treatment on March 31, 201							
_	Faciliti	Facilities ¹		Clients ² Clients ² per 100,00			
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	389	94.4	23,692	43.8	291		
Clients with drug abuse only	360	87.4	17,767	32.9	217		
Clients with alcohol abuse only	351	85.2	12,605	23.3	154		
Total			54,064	100.0	662		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	403	88.4	51,159	94.6	199	47	2,385	95.7
Regular	395	86.6	36,480	67.5	10	45		
Intensive	168	36.8	2,495	4.6	17	15		
Day treatment/partial hospitalization	38	8.3	349	0.6	_	15		
Detoxification	40	8.8	373	0.7	4	10		
Methadone maintenance	82	18.0	11,462	21.2	219	15		
Residential (non-hospital)	83	18.2	2,790	5.2	_	23	106	4.3
Short term (<30 days)	65	14.3	933	1.7	_	12		
Long term (30+ days)	68	14.9	1,535	2.8	_	19		
Detoxification	35	7.7	322	0.6	_	9		
Hospital inpatient	10	2.2	115	0.2	_	5	_	_
Treatment	7	1.5	63	0.1	_	6		
Detoxification	8	1.8	52	0.1	<u> </u>	5		
Total	456		54,064	100.0	199	38	2,491	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	37	2.8
Clients in facilities with OTPs ²		
Any MAT	10,529	2.5
Methadone	10,237	2.7
Buprenorphine	275	1.0
Naltrexone	17	0.5
Clients in facilities without OTPs ²		
Any MAT	1,947	1.9
Buprenorphine	1,450	1.7
Naltrexone	497	2.5

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

i domey paymont options, by named a		
	No.	%
Cash or self-payment	423	92.8
Private health insurance	366	80.3
Medicare	270	59.2
Medicaid	321	70.4
State-financed health insurance	255	55.9
Federal military insurance	198	43.4
No payment accepted	4	0.9
Access to Recovery (ATR) vouchers ²	58	12.7
IHS/Tribal/Urban (ITU) funds	32	7.0
Other payments	_	_
Sliding fee scale	267	58.6
Treatment at no charge for clients who can't pa	y 166	36.4
1 Facilities may assent more than one time of narment		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹		
	No.	%	
Any listed agency/organization	449	98.5	
State substance abuse agency	409	89.7	
State mental health department	161	35.3	
State department of health	196	43.0	
Hospital licensing authority	20	4.4	
The Joint Commission	91	20.0	
Commission on Accreditation of Rehabilitation Facilities	250	54.8	
National Committee for Quality Assurance	9	2.0	
Council on Accreditation	54	11.8	
Healthcare Facilities Accreditation Program	4	0.9	
Other state/local agency/organization	14	3.1	

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 254 55.7

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	447	98.0
Screening for mental health disorders	367	80.5
Comprehensive substance abuse assessment or diagnosis	431	94.5
Comprehensive mental health assessment or diagnosis	263	57.7
Screening for tobacco use	272	59.6
Outreach to persons in the community who may need treatment	254	55.7
Interim services for clients when immediate admission is not possible	194	42.5
No services offered	194	42.5
Testing Prosthet was an other blood slockel testing	056	FC 4
Breathalyzer or other blood alcohol testing	256	56.1
Drug or alcohol urine screening	337	73.9
Screening for hepatitis B	87	19.1
Screening for hepatitis C	95	20.8
HIV testing	76	16.7
STD testing	64	14.0
TB screening	121	26.5
No services offered	110	24.1
Counseling		
Individual counseling	452	99.1
Group counseling	393	86.2
Family counseling	388	85.1
Marital/couples counseling	336	73.7
Transitional services		
Discharge planning	439	96.3
Aftercare/continuing care	402	88.2
No services offered	7	1.5
Pharmacotherapies		
Disulfiram (Antabuse®)	93	20.4
Naltrexone (oral)	63	13.8
Extended-release, injectable naltrexone/Vivitrol®	73	16.0
Acamprosate (Campral®)	70	15.4
Nicotine replacement	92	20.2
Non-nicotine smoking/tobacco cessation medications	72	15.8
Medications for psychiatric disorders	206	45.2
Methadone	37	8.1
Buprenorphine with naloxone (Suboxone®)	91	20.0
Buprenorphine without naloxone	39	8.6
Buprenorphine subdermal implant (Probuphine®)	2	0.4
No services offered	192	42.1
Ancillary services		
Case management services	325	71.3
Social skills development	325	71.3
Mentoring/peer support	258	56.6
Child care for clients' children	30	6.6
Assistance with obtaining social services	248	54.4
Employment counseling or training for clients	142	31.1
Continued		

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	218	47.8
Domestic violence services	223	48.9
Early intervention for HIV	81	17.8
HIV or AIDS education, counseling, or support	183	40.1
Hepatitis education, counseling, or support	151	33.1
Health education other than HIV/AIDS or hepatitis	185	40.6
Substance abuse education	430	94.3
Transportation assistance to treatment	201	44.1
Mental health services	359	78.7
Acupuncture	64	14.0
Residential beds for clients' children	13	2.9
Self-help groups	188	41.2
Smoking/tobacco cessation counseling	184	40.4
No services offered	1	0.2
Other services		
Treatment for gambling disorder	152	33.3
Treatment for Internet use disorder	108	23.7
Treatment for other addiction disorder	193	42.3
No services offered	235	51.5

	Faci	lities
	No.	%
Substance abuse counseling	451	98.9
Relapse prevention	437	95.8
Cognitive behavioral therapy	438	96.1
Motivational interviewing	415	91.0
Anger management	392	86.0
Brief intervention	388	85.1
Trauma-related counseling	402	88.2
12-step facilitation	336	73.7
Contingency management/motivational incentives	228	50.0
Dialectical behavior therapy	278	61.0
Rational emotive behavioral therapy	194	42.5
Matrix model	115	25.2
Computerized substance abuse treatment	70	15.4
Community reinforcement plus vouchers	54	11.8
Other treatment approaches	19	4.2

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	75	6					
Number of clients ²	2,455	59					
Number of designated beds	3,111	109					
Utilization rate ³	78.9	54.1					
Average number of designated beds per facility	41	18					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	106
Methadone	103
Buprenorphine	3
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	197	43.2
Any language other than English	217	47.6
Non-English language provided by		
Staff counselor only	12	5.5
On-call interpreter only	164	75.6
Both staff counselor and on-call interpreter	41	18.9
Languages provided by staff counselor ¹		
Spanish	35	66.0
American Indian/Alaskan Native		
languages	2	3.8
Other	23	43.4

Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities		
	No.	%	
Any program or group	347	76.1	
Adult women	212	46.5	
Clients with co-occurring disorders	225	49.3	
Adult men	209	45.8	
Clients who have experienced trauma	178	39.0	
Criminal justice clients	163	35.7	
DUI/DWI clients	126	27.6	
Young adults	125	27.4	
Adolescents	100	21.9	
Clients who have experienced domestic violence	109	23.9	
Clients who have experienced sexual			
abuse	112	24.6	
Pregnant or postpartum women	97	21.3	
Seniors or older adults	100	21.9	
LGBT ¹	76	16.7	
Veterans	91	20.0	
Clients living with HIV/AIDS	64	14.0	
Members of military families	48	10.5	
Active duty military	47	10.3	
Other	21	4.6	
No program or group offered	109	23.9	

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Minnesota National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Minnesota, 356 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 25,993 clients in substance abuse treatment on March 31, 2017. The survey response rate in Minnesota was 94 percent.

Facility operation, by number and percent						
	Clients in treatment on N					2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	151	42.4	7,414	28.5	356	44.4
Private for-profit	162	45.5	11,488	44.2	301	37.6
Local, county, or community government	5	1.4	5,643	21.7	_	_
State government	7	2.0	132	0.5	29	3.6
Federal government	3	8.0	149	0.6	_	_
Tribal government	28	7.9	1,167	4.5	115	14.4
Total	356	100.0	25,993	100.0	801	100.0

Substance abuse problem treated, by number and percent								
Clients in treatment on March 31, 2017								
_	Faciliti	es¹	Clients ² Clients ² per 100,000					
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	319	92.5	9,365	36.0	205			
Clients with drug abuse only	252	73.0	10,685	41.1	247			
Clients with alcohol abuse only	253	73.3	5,943	22.9	137			
Total			25,993	100.0	589			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹		All clients Clients a				age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	268	75.3	17,210	66.2	229	26	605	75.5
Regular	241	67.7	4,275	16.4	30	14		
Intensive	215	60.4	5,115	19.7	16	20		
Day treatment/partial hospitalization	45	12.6	779	3.0	_	18		
Detoxification	7	2.0	201	8.0	_	50		
Methadone maintenance	44	12.4	6,840	26.3	246	30		
Residential (non-hospital)	130	36.5	8,707	33.5	33	17	196	24.5
Short term (<30 days)	69	19.4	3,809	14.7	15	20		
Long term (30+ days)	104	29.2	1,659	6.4	_	15		
Detoxification	21	5.9	3,239	12.5	18	9		
Hospital inpatient	4	1.1	76	0.3	32	18	_	_
Treatment	3	0.8	41	0.2	27	7		
Detoxification	3	0.8	35	0.1	5	15		
Total	356		25,993	100.0	229	25	801	100.0

¹ Facilities may provide more than one type of care.

· ·		
	No.	%
Facilities with OTPs ¹	18	1.4
Clients in facilities with OTPs ²		
Any MAT	6,440	1.6
Methadone	6,033	1.6
Buprenorphine	404	1.5
Naltrexone	3	0.1
Clients in facilities without OTPs ²		
Any MAT	901	0.9
Buprenorphine	720	0.9
Naltrexone	181	0.9

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

i demi, payment epitette, by manner and		
	No.	%
Cash or self-payment	332	93.3
Private health insurance	331	93.0
Medicare	109	30.6
Medicaid	187	52.5
State-financed health insurance	321	90.2
Federal military insurance	108	30.3
No payment accepted	2	0.6
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	104	29.2
Other payments	_	_
Sliding fee scale	96	27.0
Treatment at no charge for clients who can't pay	99	27.8
1 = -:::::::::::::::::::::::::::::::::::		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	338	94.9
State substance abuse agency	292	82.0
State mental health department	84	23.6
State department of health	243	68.3
Hospital licensing authority	16	4.5
The Joint Commission	55	15.4
Commission on Accreditation of Rehabilitation Facilities	36	10.1
National Committee for Quality Assurance	6	1.7
Council on Accreditation	6	1.7
Healthcare Facilities Accreditation Program	2	0.6
Other state/local agency/organization	19	5.3

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 161 45.2

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Facility No. No. Assessment and pre-freatment services Value of the presenting for substance abuse 329 92.4 Screening for substance abuse 239 67.1 Comprehensive substance abuse assessment or diagnosis 343 60.3 Comprehensive mental health assessment or diagnosis 143 60.3 Correling for tobacco use 212 59.6 Outreach to persons in the community who may need treatment 201 65.6 Interin services for clients when immediate admission is not possible 111 31.2 No services offered 284 74.2 Programment 349 74.2 Streathalyzer or other blood alcohol testing 284 74.2 Drug or alcohol urine screening 37 47.7 Screening for hepatitis C 50 14.0 Hill Vesting 48 13.5 STD testing 48 13.5 STD testing 36 8.3 Bis screening for hepatitis C 30 8.3 Hill Vesting	Types of services offered, by number and percent		
No. No.	Types of services effered, by flumber and percent	Eaci	litios
Screening for substance abuse 329 92.4			
Screening for substance abuse 329 92.4 Screening for mental health disorders 239 67.1 Comprehensive substance abuse assessment or diagnosis 159 44.7 Comprehensive mental health assessment or diagnosis 159 44.7 Screening for tobacco use 1212 59.6 Outreach to persons in the community who may need treatment 201 56.5 Interin services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing 84 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis B 40 11.2 Screening for hepatitis B 48 13.5 Streening for hepatitis B 48 13.5 Streening for hepatitis B 40 11.2 Screening for hepatitis B 48 13.5 St B screening for hepatitis B 40 11.2 Streening for hepatitis B 49 4 St D screeni	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 239 67.1 Comprehensive substance abuse assessment or diagnosis 159 44.7 Screening for tobacco use 212 59.6 Outreach to persons in the community who may need treatment 201 56.5 Interim services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing 284 74.2 Breathalyzer or other blood alcohol testing 264 74.2 Drug or alcohol urine screening 337 4.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV Lesting 48 13.5 STD testing 48 13.5 TB screening 35 49 No services offered 12 3.4 Counseling 35 9.3 Group counseling 35 9.3 Group counseling 35 9.8 Bramily counseling 36 8.3 Family counseling<		329	92.4
Comprehensive substance abuse assessment or diagnosis 343 96.3 Comprehensive mental health assessment or diagnosis 159 44.7 Screening for tobacco use 212 59.6 Outreach to persons in the community who may need treatment 201 56.5 Interim services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing 337 94.7 Breathalyzer or other blood alcohol testing 264 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 35 99.4 Group counseling 354 99.4 Group counseling 354 99.4 Group counseling 351 98.6 Aftercare/continuing care 338 94.9 <td></td> <td></td> <td></td>			
Comprehensive mental health assessment or diagnosis 159 44.7 Screening for tobacco use 212 59.6 Outreach to persons in the community who may need treatment 201 56.5 Interim services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing 264 74.2 Breathalyzer or other blood alcohol testing 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening for hepatitis B 40 12.2 Stock processor 96 27.0 Use streening for hepatitis B 41 13.5 STD testing 48<			
Screening for tobacco use 212 59.6 Outreach to persons in the community who may need treatment 201 56.5 Interim services for clients when immediate admission is not possible 6 1.7 No services offered 6 1.7 Testing 337 94.7 Breathalyzer or other blood alcohol testing 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis B 48 13.5 Screening for hepatitis B 48 13.5 TS Streening 48 13.5 TB screening of hepatitis B 48 13.5 TB screening for hepatitis B 56 17.	·		
Outreach to persons in the community who may need treatment 201 56.5 Interim services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing 8 74.2 Breathalyzer or other blood alcohol testing 264 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TS screening 96 27.0 No services offered 12 3.4 Counciling 354 99.4 Group counseling 350 98.3 Family counseling 350 98.3 Family counseling 351 98.6 Group counseling 351 98.6 Group counseling 351 98.6 Againstale counting 351 98.6 Afteriorace/continuing care 38 94.9 <td>·</td> <td></td> <td></td>	·		
Interim services for clients when immediate admission is not possible 111 31.2 No services offered 6 1.7 Testing	•		
No services offered 6 1.7 Testins Testins Breathalyzer or other blood alcohol testing 264 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 48 13.5 TB screening 48 13.5 TB screening 48 13.5 TB screening 48 13.5 No services offered 12 3.4 Counseling 354 99.4 Group counseling 350 98.3 Family counseling 351 98.3 Family counseling 351 98.6 Bramitional services 351 98.6 Bramity counseling 351 98.6 Bramity counseling 351 98.6 Bramity counseling 351 98.6 Bramity counseling 351 98.6 Bramity			
Testing 264 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 12 3.4 Counseling 354 99.4 Group counseling 350 98.3 Family counseling 350 98.3 Family counseling 350 98.3 Family counseling 350 98.3 Family counseling 351 98.6 Stages of group counseling 351 98.6 Aftercare/continuing care 358 94.9 No services offered	·		
Breathalyzer or other blood alcohol testing 264 74.2 Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 12 34 Counseling 354 99.4 Individual counseling 350 98.3 Family counseling 350 98.3 Family counseling 351 98.6 Aftercare/Continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Ibsulfiram (Antabuse*) 54 15.2 No services offered 1 0.3 Pharmacotherapies 5 15.7 Potation (ratabuse*) 54 15.2 Nalitexone (oral) 66 18.5 Extended-release, injectable naltrexone/vivitrol* 56			
Drug or alcohol urine screening 337 94.7 Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 12 34 Courseling Individual counseling 354 99.4 Group counseling 350 98.3 Family counseling 351 99.8 Bard 350 98.3 Family counseling 351 98.6 Aftercare/continuing care </td <td></td> <td>264</td> <td>74.2</td>		264	74.2
Screening for hepatitis B 40 11.2 Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 12 3.4 Counseling 354 99.4 Group counseling 350 98.3 Family counseling 298 83.7 Family counseling 191 53.7 Transitional services 298 83.7 Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies 1 0.3 Disulfiram (Antabuse*) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol** 56 15.7 Nicotine replacement 80 22.5 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medication	·		
Screening for hepatitis C 50 14.0 HIV testing 48 13.5 STD testing 48 13.5 TB screening 96 27.0 No services offered 12 3.4 Courseling Individual counseling 354 99.4 Group counseling 350 98.3 Family counseling 350 98.3 Family counseling 350 98.3 Family counseling 351 98.6 Marital/couples counseling 351 98.6 Family counseling 351 98.6 Marital/couples counseling 351 98.6 Marital/couples counseling 351 98.6 Marital/couples counseling 351 98.6 Marital/couples counseling 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotheraples 1 0.3 Disulfiram (Antabuse*) 54 15.2			
HIV testing			
STD testing 48 13.5 TB screening 96 27.0 No services offered 12 3.4 Counseling 354 99.4 Group counseling 350 98.3 Family counseling 350 98.3 Family counseling 351 98.6 Ashardeal counseling 351 98.6 Ashardea services 358 94.9 Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies 54 15.2 Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine			
TB screening 96 27.0 No services offered 12 3.4 Counseling 354 99.4 Individual counseling 350 98.3 Family counseling 298 33.7 Marital/couples counseling 191 53.7 Transitional services 351 98.6 Services offered 351 98.6 Aftercare/continuing care 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Pharmacotherapies 54 15.2 No services offered 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 3.1 Buprenorp	· · · · · · · · · · · · · · · · · · ·		
No services offered 12 3.4 Counseling 354 99.4 Group counseling 350 98.3 Family counseling 298 83.7 Marital/couples counseling 191 53.7 Marital/couples counseling 191 53.7 Transitional services Usus planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse*) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol* 56 15.7 Acamprosate (Campral*) 56 15.7 Acamprosate (Campral*) 56 15.7 No-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone*) 59 16.6 Buprenorphin	•		
Counseling 354 99.4 Group counseling 350 98.3 Family counseling 298 83.7 Marital/couples counseling 191 53.7 Transitional services Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine with utalcoxone 59 16.6 Reup contraction of fired to subdermal implant (Probuphine®) 4 1.1			
Individual counseling 354 99.4 Group counseling 350 98.3 Family counseling 298 83.7 Marital/couples counseling 191 53.7 Transitional services Userpan="2">Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse*) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol* 56 15.7 Acamprosate (Campral*) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone*) 59 16.6 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine*) 4 <			
Group counseling 350 98.3 Family counseling 298 83.7 Marital/couples counseling 191 53.7 Transitional services Transitional services Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine without naloxone 21 59.6 Ancillary services 288 80.9		354	99.4
Family counseling 298 83.7 Marital/couples counseling 191 53.7 Transitional services Transitional services Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered			
Marital/couples counseling 191 53.7 Transitional services Userbarge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services Case management services 288 80.9 Social skills developmen	· · · · · · · · · · · · · · · · · · ·		
Transitional services 351 98.6 Discharge planning 351 98.6 Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Actility services 288 80.9 Case management services 288 80.9 Social skills development 284 <td></td> <td></td> <td></td>			
Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children			
Aftercare/continuing care 338 94.9 No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children	Discharge planning	351	98.6
No services offered 1 0.3 Pharmacotherapies Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206			
Disulfiram (Antabuse®) 54 15.2 Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	· · · · · · · · · · · · · · · · · · ·		0.3
Naltrexone (oral) 66 18.5 Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 56 15.7 Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Disulfiram (Antabuse®)	54	15.2
Acamprosate (Campral®) 56 15.7 Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Naltrexone (oral)	66	18.5
Nicotine replacement 80 22.5 Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Extended-release, injectable naltrexone/Vivitrol®	56	15.7
Non-nicotine smoking/tobacco cessation medications 53 14.9 Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Acamprosate (Campral®)	56	15.7
Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Nicotine replacement	80	22.5
Medications for psychiatric disorders 107 30.1 Methadone 17 4.8 Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Non-nicotine smoking/tobacco cessation medications	53	14.9
Buprenorphine with naloxone (Suboxone®) 78 21.9 Buprenorphine without naloxone 59 16.6 Buprenorphine subdermal implant (Probuphine®) 4 1.1 No services offered 212 59.6 Ancillary services Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9		107	30.1
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) No services offered 212 59.6 Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 290 16.6 80.9 80.9 80.9 64.6 64.6 65.3 65.3	Methadone	17	4.8
Buprenorphine subdermal implant (Probuphine®) No services offered 212 59.6 Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 24 1.1 212 59.6 80.9 80.9 64.6 64.6 65.3 65.3	Buprenorphine with naloxone (Suboxone®)	78	21.9
No services offered 212 59.6 Ancillary services 80.9 Case management services 288 80.9 Social skills development 284 79.8 Mentoring/peer support 230 64.6 Child care for clients' children 19 5.3 Assistance with obtaining social services 206 57.9	Buprenorphine without naloxone	59	16.6
Ancillary servicesCase management services28880.9Social skills development28479.8Mentoring/peer support23064.6Child care for clients' children195.3Assistance with obtaining social services20657.9	Buprenorphine subdermal implant (Probuphine®)	4	1.1
Case management services28880.9Social skills development28479.8Mentoring/peer support23064.6Child care for clients' children195.3Assistance with obtaining social services20657.9	No services offered	212	59.6
Social skills development28479.8Mentoring/peer support23064.6Child care for clients' children195.3Assistance with obtaining social services20657.9	Ancillary services		
Mentoring/peer support23064.6Child care for clients' children195.3Assistance with obtaining social services20657.9	Case management services	288	80.9
Child care for clients' children195.3Assistance with obtaining social services20657.9	Social skills development	284	79.8
Assistance with obtaining social services 206 57.9	Mentoring/peer support	230	64.6
	Child care for clients' children	19	5.3
Employment counseling or training for clients 115 32.3	Assistance with obtaining social services	206	57.9
Employment downsoling of training for oliono	Employment counseling or training for clients	115	32.3

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	205	57.6
Domestic violence services	107	30.1
Early intervention for HIV	56	15.7
HIV or AIDS education, counseling, or support	250	70.2
Hepatitis education, counseling, or support	220	61.8
Health education other than HIV/AIDS or hepatitis	235	66.0
Substance abuse education	348	97.8
Transportation assistance to treatment	166	46.6
Mental health services	211	59.3
Acupuncture	16	4.5
Residential beds for clients' children	8	2.2
Self-help groups	228	64.0
Smoking/tobacco cessation counseling	125	35.1
No services offered	<u> </u>	_
Other services		
Treatment for gambling disorder	31	8.7
Treatment for Internet use disorder	17	4.8
Treatment for other addiction disorder	53	14.9
No services offered	291	81.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent					
	Facil	lities			
	No.	%			
Substance abuse counseling	352	98.9			
Relapse prevention	346	97.2			
Cognitive behavioral therapy	331	93.0			
Motivational interviewing	346	97.2			
Anger management	256	71.9			
Brief intervention	263	73.9			
Trauma-related counseling	258	72.5			
12-step facilitation	295	82.9			
Contingency management/motivational incentives	220	61.8			
Dialectical behavior therapy	210	59.0			
Rational emotive behavioral therapy	179	50.3			
Matrix model	208	58.4			
Computerized substance abuse treatment	43	12.1			
Community reinforcement plus vouchers	43	12.1			
Other treatment approaches	35	9.8			

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	122	3					
Number of clients ²	3,660	56					
Number of designated beds	3,482	63					
Utilization rate ³	105.1	88.9					
Average number of designated beds per facility	29	21					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	115
Methadone	108
Buprenorphine	7
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

_	Facilities		
	No.	%	
Sign language	64	18.0	
Any language other than English	84	23.6	
Non-English language provided by			
Staff counselor only	16	19.0	
On-call interpreter only	59	70.2	
Both staff counselor and on-call interpreter	9	10.7	
Languages provided by staff counselor ¹			
Spanish	11	44.0	
American Indian/Alaskan Native languages	4	16.0	
Other	12	48.0	

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	295	82.9
Adult women	150	42.1
Clients with co-occurring disorders	182	51.1
Adult men	149	41.9
Clients who have experienced trauma	104	29.2
Criminal justice clients	84	23.6
DUI/DWI clients	72	20.2
Young adults	67	18.8
Adolescents	74	20.8
Clients who have experienced domestic violence	75	21.1
Clients who have experienced sexual		
abuse	74	20.8
Pregnant or postpartum women	61	17.1
Seniors or older adults	49	13.8
LGBT ¹	53	14.9
Veterans	39	11.0
Clients living with HIV/AIDS	37	10.4
Members of military families	19	5.3
Active duty military	23	6.5
Other	19	5.3
No program or group offered	61	17.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Mississippi National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Mississippi, 89 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 4,164 clients in substance abuse treatment on March 31, 2017. The survey response rate in Mississippi was 91.8 percent.

Facility operation, by number and percent						
	Clients in treatment on March 31, 2017					
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	51	57.3	2,232	53.6	397	61.6
Private for-profit	16	18.0	652	15.7	64	9.9
Local, county, or community government	14	15.7	785	18.9	26	4.0
State government	6	6.7	93	2.2	7	1.1
Federal government	1	1.1	2	*	_	_
Tribal government	1	1.1	400	9.6	150	23.3
Total	89	100.0	4,164	100.0	644	100.0

Substance abuse problem treated, by number and percent							
Clients in treatment on March 31, 20							
	Faciliti	Facilities ¹ Clients ² Clients ² per 1					
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	75	94.9	2,016	48.4	75		
Clients with drug abuse only	69	87.3	1,304	31.3	52		
Clients with alcohol abuse only	66	83.5	844	20.3	28		
Total			4,164	100.0	155		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	<u>%</u>	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	64	71.9	3,355	80.6	169	18	565	87.7
Regular	57	64.0	2,733	65.6	_	15		
Intensive	29	32.6	343	8.2	_	11		
Day treatment/partial hospitalization	17	19.1	104	2.5	_	16		
Detoxification	2	2.2	_	_	_	_		
Methadone maintenance	4	4.5	175	4.2	169	_		
Residential (non-hospital)	26	29.2	617	14.8	_	25	32	5.0
Short term (<30 days)	19	21.3	300	7.2	_	11		
Long term (30+ days)	22	24.7	288	6.9	_	16		
Detoxification	8	9.0	29	0.7	_	5		
Hospital inpatient	13	14.6	192	4.6	_	11	47	7.3
Treatment	12	13.5	138	3.3	_	12		
Detoxification	12	13.5	54	1.3	_	7		
Total	89		4,164	100.0	169	22	644	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	1	0.1
Clients in facilities with OTPs ²		
Any MAT	169	*
Methadone	169	*
Buprenorphine	_	_
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	80	0.1
Buprenorphine	57	0.1
Naltrexone	23	0.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent No. %

	No.	%
Cash or self-payment	86	96.6
Private health insurance	66	74.2
Medicare	45	50.6
Medicaid	59	66.3
State-financed health insurance	44	49.4
Federal military insurance	48	53.9
No payment accepted	1	1.1
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	4	4.5
Other payments	_	_
Sliding fee scale	64	71.9
Treatment at no charge for clients who can't pay	52	58.4

Facility licensing, certification, or accreditation, by number and percent

	Fac	Facilities ¹	
	No.	%	
Any listed agency/organization	86	96.6	
State substance abuse agency	44	49.4	
State mental health department	73	82.0	
State department of health	33	37.1	
Hospital licensing authority	12	13.5	
The Joint Commission	14	15.7	
Commission on Accreditation of Rehabilitation Facilities	14	15.7	
National Committee for Quality Assurance	3	3.4	
Council on Accreditation	4	4.5	
Healthcare Facilities Accreditation Program	1	1.1	
Other state/local agency/organization	_	<u> </u>	

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 60 67.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

No.	acilities
No.	
Screening for substance abuse 89 Screening for mental health disorders 76 Comprehensive substance abuse assessment or diagnosis 79 Comprehensive mental health assessment or diagnosis 79 Comprehensive mental health assessment or diagnosis 62 Screening for tobacco use 40 Dutreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered —— ***esting** Sreathalyzer or other blood alcohol testing 71 Correcting for hepatitis B 21 Correcting for hepatitis B 21 HU testing 33 STD testing 16 Els creening for hepatitis C 25 HIV testing 33 STD testing 41 No services offered 41 **No services offered 41 **No services offered 41 **No services offered 42 **Intervices offered 43 **Intervices offered 44 **Intervices offered 45 **Intervices offered 45 **Intervices offered 45 **Intervices offered 46 **Intervices offered 47 **Intervices offered 48 **I	%
Screening for substance abuse 89 Screening for mental health disorders 76 Comprehensive substance abuse assessment or diagnosis 62 Comprehensive mental health assessment or diagnosis 62 Screening for tobacco use 40 Outreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — esting 31 Breathalyzer or other blood alcohol testing 31 Orrug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 STD testing 16 IB screening 41 No services offered 11 Voservices offered 11 Voservices offered 11 Voservices offered 11 Voservices offered 12 Voservices offered 12 Voservices offered 12 Voservices offered 12 Vose	
Comprehensive substance abuse assessment or diagnosis 79 Comprehensive mental health assessment or diagnosis 62 Screening for tobacco use 40 Dutreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — sesting 31 Breathalyzer or other blood alcohol testing 31 Drug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HV testing 33 STD testing 16 IB screening 41 No services offered 11 douseling 89 Group counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Aftercare/continuing care 82 No services offered 1 Discharge planning 85 Aftercare/continuing care 82 No services offere	100.0
Comprehensive substance abuse assessment or diagnosis 79 Comprehensive mental health assessment or diagnosis 62 Screening for tobacco use 40 Dutreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — sesting 31 Breathalyzer or other blood alcohol testing 31 Drug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HV testing 33 STD testing 16 IB screening 41 No services offered 11 douseling 89 Group counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Aftercare/continuing care 82 No services offered 1 Discharge planning 85 Aftercare/continuing care 82 No services offere	85.4
Comprehensive mental health assessment or diagnosis 62 Screening for tobacco use 40 Outreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — esting 31 Breathalyzer or other blood alcohol testing 31 Orung or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 STD testing 16 ITB screening 16 No services offered 11 Counseling 89 Group counseling 89 Group counseling 87 Family counseling 87 Marital/couples counseling 87 Family counseling 85 Aftercare/continuing care 82	88.8
Screening for tobacco use 40 Dutreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — esting — Breathalyzer or other blood alcohol testing 31 Drug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 STD testing 16 IB screening 41 No services offered 11 No services offered 11 No services offered 89 Group counseling 89 Group counseling 89 Group counseling 87 Variatial/couples counseling 67 Variatial/couples counseling 87 Variatial services 21 Discharge planning 85 After care/continuing care 82 No services offered 1 Valatrawone (oral) 14 Acamp	69.7
Cutreach to persons in the community who may need treatment 71 Interim services for clients when immediate admission is not possible 50 No services offered — esting 31 Breathalyzer or other blood alcohol testing 31 Drug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 Screening for hepatitis C 25 IV string 33 STD testing 16 IB screening 41 No services offered 11 Vounseling 89 Group counseling 89 Group counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Aftercare/continuing care 82 No services offered 1 Valuations of fired 1 Valuations (Antabuse*) 9 Natiferam (Antabuse*) 9 Natiferam (Antabuse*) 11 Accomprosate	44.9
Services offered Services of	79.8
No services offered — Sesting 31 Breathalyzer or other blood alcohol testing 31 Orug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 STD testing 16 IB screening 41 No services offered 11 Counseling 89 Group counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Aftercare/continuing care 82 No services offered 1 Observices offered 1 Aftercare/continuing care 82 No services offered 1 Aftercare/continuing care 82 No services offered 1 Acamproset (Fred) 1 Acamproset (Campral**) 14 Accomprosate (Campral**) 14 Accomprosate (Campral**) 14 Nicotine repl	56.2
Breathalyzer or other blood alcohol testing 31 Drug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 Screening for hepatitis C 33 STD testing 16 IB screening 41 No services offered 11 Scounseling 81 Moival counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Transitional services 82 Discharge planning 85 Aftercare/continuing care 82 No services offered 1 Plantamacotherapies 9 Valitrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72	_
Orug or alcohol urine screening 71 Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 SETD testing 16 TB screening 41 No services offered 11 Scourseling 41 Individual counseling 89 Group counseling 87 Marital/couples counseling 67 Fransitional services 87 Marital/couples counseling 85 Aftercare/continuing care 82 No services offered 1 Vibrarmacotherapies 1 Disulfiram (Antabuse*) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol* 11 Acamprosate (Campral*) 14 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone*) 14 Buprenorphine without naloxone 10	
Screening for hepatitis B 21 Screening for hepatitis C 25 HIV testing 33 SETD testing 16 FB screening 41 No services offered 11 Vounseling 89 Group counseling 89 Group counseling 87 Marital/couples counseling 87 Marital/couples counseling 67 Aftercare/continuing care 82 No services offered 1 Answerd (continuing care 82 No services offered 1 Inamacotherapies 1 Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	34.8
Gereening for hepatitis C 25 HIV testing 33 STD testing 16 TB screening 41 No services offered 11 Courseling 31 Individual counseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 87 Marital/couples counseling 87 Inscharge planning 85 Aftercare/continuing care 82 No services offered 1 Intermacotherapies 1 Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	79.8
HIV testing 33 33 33 33 33 33 33	23.6
STD testing 16 Its screening 41 No services offered 11 Counseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 67 Variational services 82 Discharge planning 85 Aftercare/continuing care 82 No services offered 1 Inharmacotherapies 1 Disulfiram (Antabuse*) 9 Nattrexone (oral) 14 Accamprosate (Campral*) 11 Accamprosate (Campral*) 14 Victotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone*) 14 Buprenorphine without naloxone 10	28.1
STD testing 16 Its screening 41 No services offered 11 Sounseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 67 Variational services 82 Discharge planning 85 Aftercare/continuing care 82 No services offered 1 Variational services 9 Natheracotherapies 1 Variational services 1 Variational services 9 Natercare/continuing care 82 No services offered 1 Valence offered 1 Valence offered 1 Valence (oral) 9 Nattrexone (oral) 14 Acamprosate (Campral®) 11 Nation-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	37.1
FB screening 41 No services offered 11 Sounseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 67 ransitional services 82 Discharge planning care 82 Aftercare/continuing care 82 No services offered 1 Inharmacotherapies 9 Nattrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	18.0
counseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 67 Marital/couples counseling 67 ransitional services Discharge planning 85 Aftercare/continuing care 82 No services offered 1 harmacotherapies Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Vicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	46.1
Individual counseling 89 Group counseling 83 Family counseling 87 Marital/couples counseling 67 Fansitional services Discharge planning 85 Aftercare/continuing care 82 No services offered 1 Indiamacotherapies Disulfiram (Antabuse®) 9 Valtrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Vicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 10 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	12.4
Group counseling 83 Family counseling 87 Marital/couples counseling 67 ransitional services Discharge planning 85 Aftercare/continuing care 82 No services offered 1 harmacotherapies Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Suprenorphine with naloxone (Suboxone®) 14 Suprenorphine without naloxone 10	
Family counseling 87 Marital/couples counseling 67 Fansitional services Discharge planning 85 Aftercare/continuing care 82 All services offered 1 Inharmacotherapies Disulfiram (Antabuse®) 9 Valtrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Vicotine replacement 25 Vion-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Suprenorphine with naloxone (Suboxone®) 14 Burenorphine without naloxone 10	100.0
Marital/couples counseling 67 ransitional services Discharge planning 85 Aftercare/continuing care 82 No services offered 1 harmacotherapies Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 16 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	93.3
Discharge planning 85 Aftercare/continuing care 82 No services offered 1 harmacotherapies Disulfiram (Antabuse®) 9 Naltrexone (oral) 14 Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 10 Suprenorphine with naloxone (Suboxone®) 14 Suprenorphine without naloxone 10	97.8
Discharge planning Aftercare/continuing care Aftercare/continuing care As services offered Answer an	75.3
Aftercare/continuing care No services offered 1 harmacotherapies Disulfiram (Antabuse®) Naltrexone (oral) Extended-release, injectable naltrexone/Vivitrol® Acamprosate (Campral®) Nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Suprenorphine with naloxone (Suboxone®) 10 11 12 13 14 15 15 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	
No services offered Intermacotherapies Disulfiram (Antabuse®) Naltrexone (oral) Extended-release, injectable naltrexone/Vivitrol® Acamprosate (Campral®) Nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Buprenorphine with naloxone (Suboxone®) 10	95.5
Charmacotherapies Disulfiram (Antabuse®) Naltrexone (oral) Extended-release, injectable naltrexone/Vivitrol® Acamprosate (Campral®) Nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Buprenorphine with naloxone (Suboxone®) Buprenorphine without naloxone 10	92.1
Disulfiram (Antabuse®) Naltrexone (oral) Extended-release, injectable naltrexone/Vivitrol® Acamprosate (Campral®) Nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Buprenorphine with naloxone (Suboxone®) 10	1.1
Naltrexone (oral) Extended-release, injectable naltrexone/Vivitrol® Acamprosate (Campral®) Non-nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Nethadone Suprenorphine with naloxone (Suboxone®) 10	
Extended-release, injectable naltrexone/Vivitrol® 11 Acamprosate (Campral®) 14 Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	10.1
Acamprosate (Campral®) Nicotine replacement Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	15.7
Nicotine replacement 25 Non-nicotine smoking/tobacco cessation medications 17 Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	12.4
Non-nicotine smoking/tobacco cessation medications Medications for psychiatric disorders Methadone Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	15.7
Medications for psychiatric disorders 72 Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	28.1
Methadone 1 Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	19.1
Buprenorphine with naloxone (Suboxone®) 14 Buprenorphine without naloxone 10	80.9
Buprenorphine without naloxone 10	1.1
	15.7
Buprenorphine subdermal implant (Probuphine®)	11.2
	1.1
No services offered 13	14.6
ncillary services	
Case management services 71	79.8
Social skills development 76	85.4
Mentoring/peer support 59	66.3
Child care for clients' children 4	4.5
Assistance with obtaining social services 60	07.4
Employment counseling or training for clients 33	67.4 37.1

Types of services offered, by number and percent (continued)		
	Fac	ilities
	No.	%
Assistance in locating housing for clients	49	55.1
Domestic violence services	47	52.8
Early intervention for HIV	37	41.6
HIV or AIDS education, counseling, or support	74	83.1
Hepatitis education, counseling, or support	57	64.0
Health education other than HIV/AIDS or hepatitis	52	58.4
Substance abuse education	88	98.9
Transportation assistance to treatment	37	41.6
Mental health services	80	89.9
Acupuncture	-	_
Residential beds for clients' children	4	4.5
Self-help groups	47	52.8
Smoking/tobacco cessation counseling	38	42.7
No services offered	<u> </u>	_
Other services		
Treatment for gambling disorder	29	32.6
Treatment for Internet use disorder	18	20.2
Treatment for other addiction disorder	37	41.6
No services offered	48	53.9

	Fac	Facilities	
	No.	%	
Substance abuse counseling	89	100.0	
Relapse prevention	86	96.6	
Cognitive behavioral therapy	88	98.9	
Motivational interviewing	78	87.6	
Anger management	83	93.3	
Brief intervention	74	83.1	
Trauma-related counseling	77	86.5	
12-step facilitation	71	79.8	
Contingency management/motivational incentives	49	55.1	
Dialectical behavior therapy	47	52.8	
Rational emotive behavioral therapy	59	66.3	
Matrix model	32	36.0	
Computerized substance abuse treatment	9	10.1	
Community reinforcement plus vouchers	7	7.9	
Other treatment approaches	4	4.5	

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	19	10			
Number of clients ²	498	184			
Number of designated beds	791	162			
Utilization rate ³	63.0	113.6			
Average number of designated beds per facility	42	16			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted the	rapy 6
Methadone	6
Buprenorphine	_
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	40	44.9
Any language other than English	38	42.7
Non-English language provided by		
Staff counselor only	1	2.6
On-call interpreter only	33	86.8
Both staff counselor and on-call interpreter	4	10.5
Languages provided by staff counselor ¹		
Spanish	3	60.0
American Indian/Alaskan Native		
languages	1	20.0
Other	1	20.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	74	83.1
Adult women	42	47.2
Clients with co-occurring disorders	45	50.6
Adult men	38	42.7
Clients who have experienced trauma	35	39.3
Criminal justice clients	24	27.0
DUI/DWI clients	29	32.6
Young adults	23	25.8
Adolescents	26	29.2
Clients who have experienced domestic violence	21	23.6
Clients who have experienced sexual		
abuse	23	25.8
Pregnant or postpartum women	21	23.6
Seniors or older adults	22	24.7
LGBT ¹	16	18.0
Veterans	20	22.5
Clients living with HIV/AIDS	18	20.2
Members of military families	10	11.2
Active duty military	12	13.5
Other	1	1.1
No program or group offered	15	16.9

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Missouri National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Missouri, 257 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 21,914 clients in substance abuse treatment on March 31, 2017. The survey response rate in Missouri was 91.5 percent.

Facility operation, by number and percent							
	Clients			s in treatment on March 31, 2017			
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	185	72.0	15,625	71.3	1,170	95.6	
Private for-profit	61	23.7	5,173	23.6	54	4.4	
Local, county, or community government	_	_	_	_	_	-	
State government	3	1.2	311	1.4	_	_	
Federal government	8	3.1	805	3.7	_	_	
Tribal government	_	_	_	_	_	_	
Total	257	100.0	21,914	100.0	1,224	100.0	

Substance abuse problem treated, by number and percent									
Clients in treatment of					nt on March 31, 2017				
_	Facilities ¹ Clients ² Clients ² per 100,				Facilities ¹ Clients ² Clie		Facilities ¹		Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older				
Clients with both alcohol and drug abuse	231	95.1	9,822	44.8	195				
Clients with drug abuse only	216	88.9	8,704	39.7	174				
Clients with alcohol abuse only	205	84.4	3,388	15.5	68				
Total			21,914	100.0	437				

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	240	93.4	20,328	92.8	204	50	949	77.5
Regular	228	88.7	8,342	38.1	5	27		
Intensive	173	67.3	6,010	27.4	5	27		
Day treatment/partial hospitalization	84	32.7	1,038	4.7	2	10		
Detoxification	28	10.9	155	0.7	5	8		
Methadone maintenance	96	37.4	4,783	21.8	197	15		
Residential (non-hospital)	55	21.4	1,238	5.6	_	17	240	19.6
Short term (<30 days)	48	18.7	802	3.7	_	16		
Long term (30+ days)	28	10.9	355	1.6	_	15		
Detoxification	20	7.8	81	0.4	_	4		
Hospital inpatient	11	4.3	348	1.6	_	23	35	2.9
Treatment	8	3.1	215	1.0	_	31		
Detoxification	8	3.1	133	0.6	<u> </u>	3		
Total	257		21,914	100.0	204	50	1,224	100.0

¹ Facilities may provide more than one type of care.

Opioid treatmen	t programs (OTPs),
by number and p	percent

	No.	%
Facilities with OTPs ¹	14	1.1
Clients in facilities with OTPs ²		
Any MAT	4,100	1.0
Methadone	3,699	1.0
Buprenorphine	393	1.4
Naltrexone	8	0.2
Clients in facilities without OTPs ²		
Any MAT	1,478	1.4
Buprenorphine	882	1.0
Naltrexone	596	3.0

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	•	
	No.	%
Cash or self-payment	235	91.4
Private health insurance	183	71.2
Medicare	85	33.1
Medicaid	174	67.7
State-financed health insurance	98	38.1
Federal military insurance	133	51.8
No payment accepted	7	2.7
Access to Recovery (ATR) vouchers ²	38	14.8
IHS/Tribal/Urban (ITU) funds	6	2.3
Other payments	1	0.4
Sliding fee scale	198	77.0
Treatment at no charge for clients who can't pay	168	65.4

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	250	97.3
State substance abuse agency	212	82.5
State mental health department	200	77.8
State department of health	49	19.1
Hospital licensing authority	8	3.1
The Joint Commission	36	14.0
Commission on Accreditation of Rehabilitation Facilities	166	64.6
National Committee for Quality Assurance	6	2.3
Council on Accreditation	10	3.9
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	5	1.9

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 203 79.0

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services effered, by flumber and percent	Facilities	
	No.	%
Assessment and pre-treatment services	110.	70
Screening for substance abuse	250	97.3
Screening for mental health disorders	198	77.0
Comprehensive substance abuse assessment or diagnosis	234	91.1
Comprehensive mental health assessment or diagnosis	127	49.4
Screening for tobacco use	181	70.4
Outreach to persons in the community who may need treatment	132	51.4
Interim services for clients when immediate admission is not possible	123	47.9
No services offered	4	1.6
Testing		
Breathalyzer or other blood alcohol testing	189	73.5
Drug or alcohol urine screening	225	87.5
Screening for hepatitis B	49	19.1
Screening for hepatitis C	55	21.4
HIV testing	53	20.6
STD testing	49	19.1
TB screening	69	26.8
No services offered	24	9.3
Counseling	2 1	0.0
Individual counseling	252	98.1
Group counseling	251	97.7
Family counseling	219	85.2
Marital/couples counseling	181	70.4
Transitional services	101	70.1
Discharge planning	254	98.8
Aftercare/continuing care	240	93.4
No services offered	2	0.8
Pharmacotherapies		
Disulfiram (Antabuse®)	49	19.1
Naltrexone (oral)	98	38.1
Extended-release, injectable naltrexone/Vivitrol®	97	37.7
Acamprosate (Campral®)	66	25.7
Nicotine replacement	70	27.2
Non-nicotine smoking/tobacco cessation medications	59	23.0
Medications for psychiatric disorders	119	46.3
Methadone	14	5.4
Buprenorphine with naloxone (Suboxone®)	74	28.8
Buprenorphine without naloxone	34	13.2
Buprenorphine subdermal implant (Probuphine®)	2	0.8
No services offered	116	45.1
Ancillary services		
Case management services	221	86.0
Social skills development	202	78.6
Mentoring/peer support	153	59.5
Child care for clients' children	20	7.8
Assistance with obtaining social services	180	70.0
Employment counseling or training for clients	139	54.1

Types of services offered, by number and percent (continued)			
	Facilities		
	No.	%	
Assistance in locating housing for clients	156	60.7	
Domestic violence services	83	32.3	
Early intervention for HIV	37	14.4	
HIV or AIDS education, counseling, or support	130	50.6	
Hepatitis education, counseling, or support	129	50.2	
Health education other than HIV/AIDS or hepatitis	165	64.2	
Substance abuse education	251	97.7	
Transportation assistance to treatment	120	46.7	
Mental health services	180	70.0	
Acupuncture	6	2.3	
Residential beds for clients' children	11	4.3	
Self-help groups	123	47.9	
Smoking/tobacco cessation counseling	128	49.8	
No services offered	1	0.4	
Other services			
Treatment for gambling disorder	42	16.3	
Treatment for Internet use disorder	16	6.2	
Treatment for other addiction disorder	45	17.5	
No services offered	187	72.8	

	Faci	Facilities	
	No.	%	
Substance abuse counseling	252	98.1	
Relapse prevention	247	96.1	
Cognitive behavioral therapy	240	93.4	
Motivational interviewing	241	93.8	
Anger management	229	89.1	
Brief intervention	222	86.4	
Trauma-related counseling	220	85.6	
12-step facilitation	209	81.3	
Contingency management/motivational incentives	149	58.0	
Dialectical behavior therapy	141	54.9	
Rational emotive behavioral therapy	115	44.7	
Matrix model	177	68.9	
Computerized substance abuse treatment	89	34.6	
Community reinforcement plus vouchers	28	10.9	
Other treatment approaches	15	5.8	

Facility capacity and utilization rate ¹			
	Residential	Hospital inpatient	
Number of facilities	51	4	
Number of clients ²	1,212	195	
Number of designated beds	1,222	116	
Utilization rate ³	99.2	168.1	
Average number of designated beds per facility	24	29	

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	67
Methadone	61
Buprenorphine	6
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	161	62.6
Any language other than English	142	55.3
Non-English language provided by		
Staff counselor only	3	2.1
On-call interpreter only	137	96.5
Both staff counselor and on-call interpreter	2	1.4
Languages provided by staff counselor ¹		
Spanish	5	100.0
American Indian/Alaskan Native		
languages	_	_
Other	1	20.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	212	82.5
Adult women	102	39.7
Clients with co-occurring disorders	113	44.0
Adult men	88	34.2
Clients who have experienced trauma	83	32.3
Criminal justice clients	78	30.4
DUI/DWI clients	90	35.0
Young adults	44	17.1
Adolescents	51	19.8
Clients who have experienced domestic violence	45	17.5
Clients who have experienced sexual		
abuse	44	17.1
Pregnant or postpartum women	38	14.8
Seniors or older adults	27	10.5
LGBT ¹	24	9.3
Veterans	34	13.2
Clients living with HIV/AIDS	27	10.5
Members of military families	22	8.6
Active duty military	20	7.8
Other	1	0.4
No program or group offered	45	17.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Montana National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Montana, 70 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 5,762 clients in substance abuse treatment on March 31, 2017. The survey response rate in Montana was 95.9 percent.

Facility operation, by number and percer	nt					
	Clients in trea				t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	41	58.6	2,316	40.2	140	61.4
Private for-profit	13	18.6	2,296	39.8	31	13.6
Local, county, or community government	_	_	_	_	_	_
State government	2	2.9	111	1.9	6	2.6
Federal government	7	10.0	190	3.3	_	_
Tribal government	7	10.0	849	14.7	51	22.4
Total	70	100.0	5,762	100.0	228	100.0

Substance abuse problem treated, by number and percent						
	Clients in treatment on March 31, 2017					
	Faciliti	es¹	Clients ² Clients ² per 100,000			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	59	95.2	2,893	66.8	331	
Clients with drug abuse only	48	77.4	762	17.6	89	
Clients with alcohol abuse only	49	79.0	679	15.7	80	
Total			4,334	100.0	500	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility		No.	%
Outpatient	61	87.1	5,429	94.2	199	46	199	87.3
Regular	61	87.1	2,253	39.1	_	42		
Intensive	37	52.9	990	17.2	_	19		
Day treatment/partial hospitalization	7	10.0	43	0.7	_	8		
Detoxification	11	15.7	23	0.4	6	12		
Methadone maintenance	16	22.9	2,120	36.8	189	5		
Residential (non-hospital)	14	20.0	241	4.2	_	15	29	12.7
Short term (<30 days)	10	14.3	166	2.9	_	22		
Long term (30+ days)	10	14.3	67	1.2	_	7		
Detoxification	4	5.7	8	0.1	_	4		
Hospital inpatient	7	10.0	92	1.6	_	17	_	_
Treatment	6	8.6	73	1.3	_	22		
Detoxification	7	10.0	19	0.3	_	4		
Total	70		5,762	100.0	199	45	228	100.0

¹ Facilities may provide more than one type of care.

· ·		
	No.	%
Facilities with OTPs ¹	3	0.2
Clients in facilities with OTPs ²		
Any MAT	600	0.1
Methadone	483	0.1
Buprenorphine	115	0.4
Naltrexone	2	0.1
Clients in facilities without OTPs ²		
Any MAT	139	0.1
Buprenorphine	78	0.1
Naltrexone	61	0.3

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r demay payment options, by named and		
	No.	%
Cash or self-payment	63	90.0
Private health insurance	61	87.1
Medicare	28	40.0
Medicaid	57	81.4
State-financed health insurance	45	64.3
Federal military insurance	42	60.0
No payment accepted	1	1.4
Access to Recovery (ATR) vouchers ²	21	30.0
IHS/Tribal/Urban (ITU) funds	23	32.9
Other payments	_	_
Sliding fee scale	46	65.7
Treatment at no charge for clients who can't pay	38	54.3
1 = -1141		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	62	88.6
State substance abuse agency	56	80.0
State mental health department	25	35.7
State department of health	22	31.4
Hospital licensing authority	3	4.3
The Joint Commission	6	8.6
Commission on Accreditation of Rehabilitation Facilities	14	20.0
National Committee for Quality Assurance	4	5.7
Council on Accreditation	2	2.9
Healthcare Facilities Accreditation Program	2	2.9
Other state/local agency/organization	2	2.9

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 50 71.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Page Page	Types of services offered, by number and percent		
No. %	Types of services offered, by flumber and percent	Faci	litios
Screening for substance abuse 67 95.7			
Screening for mental health disorders 54 77.1 Comprehensive substance abuse assessment or diagnosis 68 97.1 Comprehensive wental health assessment or diagnosis 36 97.1 Comprehensive wental health assessment or diagnosis 36 51.4 Comprehensive wental health assessment or diagnosis 36 51.4 Comprehensive wental health assessment or diagnosis 41 58.6 Comprehensive wental health assessment or diagnosis 51 72.9 Utterach to persons in the community who may need treatment 54 77.1 Intering for the persons in the community who may need treatment 54 77.1 Intering for the control of control of the community who may need treatment 54 77.1 Setting 41 58.6 58.6 Orus of alcohol urine screening 59 84.3 32.2 45.7 If Vesting 28 40.0 32.2 45.7 If Vesting 28 40.0 32.2 45.7 If Vesting 28 40.0 40.0 40.0 It Vesting 2	Assessment and pre-treatment services		
Comprehensive substance abuse assessment or diagnosis 68 97.1 Comprehensive mental health assessment or diagnosis 36 51.4 Comprehensive mental health assessment or diagnosis 36 51.4 Correcening for tobacco use 41 58.6 Dureach to persons in the community who may need treatment 51 77.2 No services offered — — esting — — esting or closhol urine screening 59 84.8 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 35.7 Ill Vesting 25 35.7 B screening 31 44.3 No services offered 8 97.1 dous ervices offered 6 65.7 dous ervices offered 6 65.7 dous ervices of	Screening for substance abuse	67	95.7
Comprehensive substance abuse assessment or diagnosis 68 97.1 Comprehensive mental health assessment or diagnosis 36 51.4 Comprehensive mental health assessment or diagnosis 36 51.4 Correcening for tobacco use 41 58.6 Dureach to persons in the community who may need treatment 51 77.2 No services offered — — esting — — esting or closhol urine screening 59 84.8 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 35.7 Ill Vesting 25 35.7 B screening 31 44.3 No services offered 8 97.1 dous ervices offered 6 65.7 dous ervices offered 6 65.7 dous ervices of	Screening for mental health disorders	54	77.1
Comprehensive mental health assessment or diagnosis 36 51.4		68	97.1
Screening for tobacco use 41 58.6 Dutreach to persons in the community who may need treatment 54 77.1 Interim services for Cilents when immediate admission is not possible 51 72.9 do services offered — — setting — — setting — — streethalyzer or other blood alcohol testing 41 58.6 Drug or alcohol urine screening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 28 40.0 If U testing 28 40.0 B screening 31 44.3 40 services offered 8 11.4 bosering 70 100.0 Group counseling 70 100.0 Group counseling 68 97.1 Marital/couples counseling 70 100.0 Acrampilo counseling 67 95.7 Micreare/continuing care 67 95.7 Micreare/continuing care 67 95.7 <td>·</td> <td>36</td> <td>51.4</td>	·	36	51.4
Dutreach to persons in the community who may need treatment 54 77.1 Interim services for clients when immediate admission is not possible to services fored 51 72.9 Interim services for clients when immediate admission is not possible to services fored 51 72.9 Interim services for clients when immediate admission is not possible to services fored 58 68 Interim services 41 58.6 Interim services 41 58.6 Interim services 32 45.7 Interim for hepatitis C 32 45.7 If Vesting 28 40.0 If Vesting 25 35.7 B screening for hepatitis C 31 44.3 If Vesting 25 35.7 B screening for hepatitis C 31 44.3 If Vesting 25 35.7 B screening for hepatitis C 31 44.3 Os pervises offered 67 10.0 Oscaptions offered 67 95.7 Interim services 67 95.7 Interimption (Services offered	•	41	58.6
Interim services for clients when immediate admission is not possible to services offered 51 72.9 Ios services offered — — Seritabilityzer or other blood alcohol testing 41 58.6 Drug or alcohol urine sercening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 45.7 HIV testing 25 35.7 BS screening 31 44.3 Ios services offered 31 44.3 Ios services offered 31 44.3 Ios services offered 68 97.1 Group counseling 60 65.7 Group counseling 67 95.7 Jamily counseling 67 95.7 Jamily counseling 67 95.7 Joservices offered 67 95.7 Joservices offered 67 95.7 Joservices offered 71 15.7 Justificam (Antabuse**) 11 15.7 Vealing (Carparal**) 12 30.0 </td <td></td> <td>54</td> <td>77.1</td>		54	77.1
do services offered — pesting reachtalyzer or other blood alcohol testing 41 58.6 Grug or alcohol urine screening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 28 40.0 STD testing 28 40.0 STD testing 25 35.7 Bs screening 31 44.3 do services offered 8 11.4 conseling dividual counseling 70 100.0 Group counseling 68 97.1 amily counseling 68 97.1 amily counseling 67 85.7 darital/couples counseling 68 97.1 varietional services 67 95.7 remistional services 67 95.7 do services offered 67 95.7 do services offered 67 95.7 do services offered 21 30.0 Sisulfiram (Antabuse ⁸) 11<		51	72.9
Breathalyzer or other blood alcohol testing 41 58.6 Drug or alcohol urine screening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 45.7 HV testing 28 40.0 B screening 31 44.3 40 services offered 8 11.4 40 services offered 8 11.4 50 services offered 8 97.1 60 services offered 68 97.1 61 strill younseling 70 100.0 62 carrielly counseling 68 97.1 63 carrielly counseling 68 97.1 64 carrielly counseling 67 95.7 65 carrielly counseling 67 95.7 65 carrielly counseling 67 95.7 66 carrielly counseling 67 95.7 67 carrielly counseling 67 95.7 68 carrielly counseling 67 95.7 68 carrielly counseling 67 95.7 <	No services offered	_	_
Drug or alcohol urine screening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 45.7 All V testing 28 40.0 STD testing 25 35.7 BB screening 31 44.3 40 services offered 8 11.4 ourseling 70 100.0 Group counseling 68 97.1 Family counseling 68 97.1 Family counseling 61 87.1 Apartal/couples counseling 67 95.7 Family counseling 67 95.7 Apartal/couples counsel	Testing		
Drug or alcohol urine screening 59 84.3 Screening for hepatitis B 24 34.3 Screening for hepatitis C 32 45.7 All V testing 28 40.0 STD testing 25 35.7 BB screening 31 44.3 40 services offered 8 11.4 ourseling 70 100.0 Group counseling 68 97.1 Family counseling 68 97.1 Family counseling 61 87.1 Apartal/couples counseling 67 95.7 Family counseling 67 95.7 Apartal/couples counsel	Breathalyzer or other blood alcohol testing	41	58.6
Screening for hepatitis C 32 45.7 HIV testing 28 40.0 ITD testing 25 35.7 IB screening 31 44.3 No services offered 8 11.4 ounseling 70 100.0 dividual counseling 68 97.1 darnital/couples counseling 61 87.1 darital/couples counseling 67 95.7 darital/couples counseling 67 95.7 Aratital/couples counseling 67 95.7 Adartal/couples counseling 67 95.7 Abarital/couples counseling 67 95.7 Active processed fered 65 95.7 Active processed fered 6 65.7 Active processed fered 7 9.5 Active processed fered 11 15.7 Active processed fered 21 30.0 Active processed (Campral®) 11 15.7 Active processed (Campral®) 13 18.6 Active processed	Drug or alcohol urine screening	59	84.3
Screening for hepatitis C 32 45.7 HV testing 28 40.0 HV testing 25 35.7 B screening 31 44.3 40 services offered 8 11.4 ounseling 70 100.0 Group counseling 68 97.1 darital couples counseling 68 97.1 darital couples counseling 67 65.7 Anarital couples counseling 67 95.7 Ararital couples counseling 67 95.7 Anarital couples counseling 67 95.7 Anarital couples counseling 67 95.7 Anarital couples counseling 67 95.7 Antital couples counseling 67 95.7 Aftercard/continuing care 67 95.7 Aftercard/continuing care 67 95.7 Ac	Screening for hepatitis B	24	34.3
HIV testing 28 40.0 STD testing 25 35.7 BB screening 31 44.3 to services offered 8 11.4 ourseling mid vourseling 68 97.1 Group counseling 61 87.1 Arrital/couples counseling 61 87.1 Arrital/couples counseling 61 65.7 Arrital/couples counseling 61 87.1 Arrital/couples counseling 61 87.1 Arrital/couples counseling 61 87.7 Arrital/couples counseling 61 65.7 Arrital/couples counseling 61 65.7 Arrital/couples counseling 61 65.7 Arrital/couples counseling 61 65.7 Arrital/couples counseling 67 95.7 Obscharge planning 67 95.7 Aftercare/continuing care 67 95.7 All tercare/continuing care 67 95.7 Valution and care 11 <	Screening for hepatitis C	32	45.7
B screening 31 44.3 do services offered 8 11.4 ounseling 70 100.0 Group counseling 68 97.1 amily counseling 61 87.1 derival/couples counseling 61 87.1 derival/couples counseling 61 87.1 derival/couples counseling 67 95.7 derival/couples counseling 67 95.7 stansitional services 7 95.7 detercare/continuing care 67 95.7 do services offered 6 95.7 descrices offered 6 95.7 harmacotherapies 11 15.7 delatierxone (oral) 21 30.0 Extended-release, injectable nattrexone/Vivitrol® 18 25.7 decidenting for pasce (Campral®) 19 27.1 dictione replacement 24 34.3 decidations for psychiatric disorders 26 37.1 decidations for psychiatric disorders 26 37.1	HIV testing	28	40.0
do services offered 8 11.4 ounseling 70 10.0 Group counseling 68 97.1 Family counseling 61 87.1 Marital/couples counseling 46 65.7 Araital/couples counseling 46 65.7 Consistional services 8 95.7 Obscharge planning 67 95.7 Obscharge planning 67 95.7 Observices offered - - As services offered - - Interpretation 21 30.0 Eatterwone (oral) 21 30.0 Eatterwone (oral) 21 30.0 Eatterwone (Campral®) 19 27.1 Accomprosate (Campral®) 19 27.1 Accomprosate (Campral®) 19 27.1 Accomprosate (Campral®) 19 27.1 Accomprosate (Campral®) 13 18.6 Medications for psychiatric disorders 26 37.1 Buprenorphine with naloxone (Suboxone®)	STD testing	25	35.7
courseling 70 100.0 Group counseling 68 97.1 Agaily counseling 61 87.1 Agaital/couples counseling 46 65.7 Agaital/couples counseling 67 95.7 Agaital/couples counseling 11 15.7 Agaital/couples counseling 11 15.7 Agaital/couples counseling 12 30.0 Extended-release, injectable naftrexone/vivitrol* 18 25.7 Accomprosate (Campral*) 19 27.1 Accomprosate (Campral*) 1	TB screening	31	44.3
Individual counseling 70 100.0 Group counseling 68 97.1 Family counseling 61 87.1 Againal (couples counseling) 66 65.7 Againal (couples counseling) 67 95.7 Again (couples counseling) 67 95.7 Intercare (continuing care) 67 95.7 Again (couple) 67 95.7 As a convices offered 6 95.7 Internactherapies 11 15.7 Josephilam (Antabuse®) 11 15.7 Julifram (Antabuse®) 12 30.0 Julifram (Antabuse®)	No services offered	8	11.4
Group counseling 68 97.1 Family counseling 61 87.1 Aarital/couples counseling 46 65.7 Arasitional services 87 95.7 Obscharge planning care 67 95.7 As services offered	Counseling		
Family counseling 61 87.1 Marital/couples counseling 46 65.7 Agrital/couples counseling 46 65.7 Agrital/couples counseling 87.7 87.7 Discharge planning care 67 95.7 95.7 Agreement Continuing care 67 95.7 95.7 Agramacotherapies 8 8 8 8 8 9.7 9.0	Individual counseling	70	100.0
Marital/couples counseling 46 65.7 rensitional services Prensitional services Discharge planning care 67 95.7 As tercare/continuing care 67 95.7 As os services offered — — As altrexone (oral) 11 15.7 As altrexone (oral) 21 30.0 Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Ascamprosate (Campral®) 19 27.1 Ascamprosate (Campral®) 13 18.6 Ascamprosate (Campral®) 13 18.6 Ascamprosate (Campral®) 13 18.6 Ascamprosate (Campral®) 26 <th< td=""><td>Group counseling</td><td>68</td><td>97.1</td></th<>	Group counseling	68	97.1
Parasitional services Feature (a continuing care) 67 95.7 All services offered — — — As services offered — — — harmacotherapies — — — — Disulfiram (Antabuse®) 11 15.7 All trexone (oral) 21 30.0 — All trexone (oral) 18 25.7 All trexone (oral) 18 25.7 Accamprosate (Campral®) 19 27.1 Accamprosate (Campral®) 18 25.7 Accamprosate (Campral®) 18 25.7 Accamprosate (Campral®) 18 25.7 Accamprosate (Campral®) 18 26.8 37.1 Accamprosate (Campral®) 18 26.8 37.	Family counseling	61	87.1
Discharge planning 67 95.7 Aftercare/continuing care 67 95.7 No services offered — — Intermacotherapies — — Disulfiram (Antabuse®) 11 15.7 Valtrexone (oral) 21 30.0 Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Acamprosate (Campral®) 19 27.1 Accamprosate (Campral®) 13 18.6 Accamprosate (Campral®) 13 18.6 Accamprosate (Campral®) 13 18.6 Accidentine replacement 26 37.1 Actinations for psychiatric disorders 26 37.1 Actinations for psychiatric disorders 3 <td< td=""><td>Marital/couples counseling</td><td>46</td><td>65.7</td></td<>	Marital/couples counseling	46	65.7
Aftercare/continuing care 67 95.7 As services offered — — Intermacotherapies — — Disulfiram (Antabuse®) 11 15.7 Alattrexone (oral) 21 30.0 Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Accamprosate (Campral®) 19 27.1 Accamprosate (Campral®) 13 18.6 Accamprosate (Campral®) 13 18.6 Action-nicotine smoking/tobacco cessation medications 13 4.3 Bupernorphine with naloxone (Suboxone®)	Fransitional services		
No services offered	Discharge planning	67	95.7
Intermediate Probability of Martin (Antabuse®) 11 15.7 Valid (Color (Coral)) 21 30.0 Valid (Comprosite) 18 25.7 Vaccionary (Comprosite) 19 27.1 Vaccionary (Comprosite) 24 34.3 Vaccionary (Comprosite) 13 18.6 Vaccionary (Comprosite) 13 18.6 Vaccionary (Comprosite) 26 37.1 Vaccionary (Comprosite) 3 4.3 Vaccionary (Comprosite) 15 21.4 Valuations for psychiatric disorders 26 37.1 Vaccionary (Comprosite) 3 4.3 Valuations for psychiatric disorders 3 4.3	Aftercare/continuing care	67	95.7
Disulfiram (Antabuse®) 11 15.7 Altrexone (oral) 21 30.0 Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Acamprosate (Campral®) 19 27.1 Alcon-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 Also services offered 33 47.1 Incillary services 55 78.6 Cocial skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	No services offered	_	_
Valid texone (oral) 21 30.0 Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Acamprosate (Campral®) 19 27.1 Valicotine replacement 24 34.3 Valor-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 Valores offered 33 47.1 Incillary services 55 78.6 Case management services 55 78.6 Cocial skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 18 25.7 Acamprosate (Campral®) 19 27.1 Nicotine replacement 24 34.3 Non-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Disulfiram (Antabuse®)	11	15.7
Acamprosate (Campral®) 19 27.1 Nicotine replacement 24 34.3 Non-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Naltrexone (oral)	21	30.0
Alicotine replacement 24 34.3 Non-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Extended-release, injectable naltrexone/Vivitrol®	18	25.7
Non-nicotine smoking/tobacco cessation medications 13 18.6 Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Acamprosate (Campral®)	19	27.1
Medications for psychiatric disorders 26 37.1 Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Nicotine replacement	24	34.3
Methadone 3 4.3 Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Non-nicotine smoking/tobacco cessation medications	13	18.6
Buprenorphine with naloxone (Suboxone®) 15 21.4 Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services 55 78.6 Case management services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Medications for psychiatric disorders	26	
Buprenorphine without naloxone 12 17.1 Buprenorphine subdermal implant (Probuphine®) 3 4.3 No services offered 33 47.1 Incillary services Case management services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Methadone	3	4.3
Buprenorphine subdermal implant (Probuphine®) So services offered Case management services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4	Buprenorphine with naloxone (Suboxone®)	15	21.4
No services offered 33 47.1 Incillary services 55 78.6 Case management services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Buprenorphine without naloxone	12	17.1
Case management services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Buprenorphine subdermal implant (Probuphine®)	3	4.3
Case management services 55 78.6 Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	No services offered	33	47.1
Social skills development 48 68.6 Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Ancillary services		
Mentoring/peer support 31 44.3 Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Case management services		
Child care for clients' children 2 2.9 Assistance with obtaining social services 45 64.3	Social skills development		
Assistance with obtaining social services 45 64.3	Mentoring/peer support		
	Child care for clients' children		
Employment counseling or training for clients 17 24.3	Assistance with obtaining social services		
	Employment counseling or training for clients	17	24.3

Types of services offered, by number and percent (continued)		
	Fac	ilities
	No.	%
Assistance in locating housing for clients	40	57.1
Domestic violence services	26	37.1
Early intervention for HIV	15	21.4
HIV or AIDS education, counseling, or support	36	51.4
Hepatitis education, counseling, or support	36	51.4
Health education other than HIV/AIDS or hepatitis	36	51.4
Substance abuse education	70	100.0
Transportation assistance to treatment	29	41.4
Mental health services	44	62.9
Acupuncture	1	1.4
Residential beds for clients' children	1	1.4
Self-help groups	24	34.3
Smoking/tobacco cessation counseling	36	51.4
No services offered	_	_
Other services		
Treatment for gambling disorder	37	52.9
Treatment for Internet use disorder	6	8.6
Treatment for other addiction disorder	18	25.7
No services offered	27	38.6

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Fac	ilities		
	No.	%		
Substance abuse counseling	70	100.0		
Relapse prevention	63	90.0		
Cognitive behavioral therapy	64	91.4		
Motivational interviewing	66	94.3		
Anger management	50	71.4		
Brief intervention	55	78.6		
Trauma-related counseling	55	78.6		
12-step facilitation	52	74.3		
Contingency management/motivational incentives	34	48.6		
Dialectical behavior therapy	47	67.1		
Rational emotive behavioral therapy	36	51.4		
Matrix model	40	57.1		
Computerized substance abuse treatment	15	21.4		
Community reinforcement plus vouchers	10	14.3		
Other treatment approaches	10	14.3		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	13	4			
Number of clients ²	241	88			
Number of designated beds	231	114			
Utilization rate ³	104.3	77.2			
Average number of designated beds per facility	18	29			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	57
Methadone	46
Buprenorphine	11
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	22	31.4
Any language other than English	21	30.0
Non-English language provided by		
Staff counselor only	3	14.3
On-call interpreter only	18	85.7
Both staff counselor and on-call interpreter	_	_
Languages provided by staff counselor ¹		
Spanish	1	33.3
American Indian/Alaskan Native		
languages	1	33.3
Other	1	33.3

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	59	84.3
Adult women	31	44.3
Clients with co-occurring disorders	26	37.1
Adult men	29	41.4
Clients who have experienced trauma	25	35.7
Criminal justice clients	17	24.3
DUI/DWI clients	35	50.0
Young adults	20	28.6
Adolescents	25	35.7
Clients who have experienced domestic violence	15	21.4
Clients who have experienced sexual		
abuse	17	24.3
Pregnant or postpartum women	9	12.9
Seniors or older adults	10	14.3
LGBT ¹	8	11.4
Veterans	14	20.0
Clients living with HIV/AIDS	9	12.9
Members of military families	7	10.0
Active duty military	10	14.3
Other	2	2.9
No program or group offered	11	15.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HITTON SERVICES ITEM

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Nebraska National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Nebraska, 125 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 6,461 clients in substance abuse treatment on March 31, 2017. The survey response rate in Nebraska was 89.3 percent.

Facility operation, by number and percent						
Clients in treatment on March 31, 2017					2017	
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	79	63.2	3,424	53.0	191	35.6
Private for-profit	24	19.2	1,151	17.8	175	32.6
Local, county, or community government	5	4.0	1,398	21.6	136	25.3
State government	2	1.6	25	0.4	25	4.7
Federal government	7	5.6	311	4.8	_	_
Tribal government	8	6.4	152	2.4	10	1.9
Total	125	100.0	6,461	100.0	537	100.0

Substance abuse problem treated, by number and percent					
Clients in treatment on March 31, 20					
	Facilities ¹		Clients ² Clients ² per 100,00		
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	111	94.9	2,792	43.2	175
Clients with drug abuse only	87	74.4	2,233	34.6	144
Clients with alcohol abuse only	92	78.6	1,436	22.2	90
Total			6,461	100.0	410

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients age < 18	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	101	80.8	5,604	86.7	304	18	486	90.5
Regular	101	80.8	4,385	67.9	300	15		
Intensive	40	32.0	606	9.4	70	12		
Day treatment/partial hospitalization	4	3.2	13	0.2	_	7		
Detoxification	4	3.2	65	1.0	18	30		
Methadone maintenance	10	8.0	535	8.3	123	5		
Residential (non-hospital)	37	29.6	828	12.8	_	17	50	9.3
Short term (<30 days)	18	14.4	321	5.0	_	17		
Long term (30+ days)	27	21.6	488	7.6	_	17		
Detoxification	8	6.4	19	0.3	_	8		
Hospital inpatient	3	2.4	29	0.4	_	13	1	0.2
Treatment	3	2.4	12	0.2	_	4		
Detoxification	3	2.4	17	0.3	<u> </u>	7		
Total	125		6,461	100.0	304	20	537	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	3	0.2
Clients in facilities with OTPs ²		
Any MAT	560	0.1
Methadone	427	0.1
Buprenorphine	120	0.4
Naltrexone	13	0.4
Clients in facilities without OTPs ²		
Any MAT	55	0.1
Buprenorphine	34	*
Naltrexone	21	0.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	108	86.4
Private health insurance	97	77.6
Medicare	51	40.8
Medicaid	103	82.4
State-financed health insurance	68	54.4
Federal military insurance	65	52.0
No payment accepted	2	1.6
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	23	18.4
Other payments	1	0.8
Sliding fee scale	80	64.0
Treatment at no charge for clients who can't pay	58	46.4
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	106	84.8
State substance abuse agency	86	68.8
State mental health department	43	34.4
State department of health	64	51.2
Hospital licensing authority	12	9.6
The Joint Commission	34	27.2
Commission on Accreditation of Rehabilitation Facilities	52	41.6
National Committee for Quality Assurance	1	0.8
Council on Accreditation	11	8.8
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	2	1.6

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 88 70.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Faci	1141
	No.	lities %
Assessment and pre-treatment services	NO.	/6
Screening for substance abuse	113	90.4
Screening for mental health disorders	100	80.0
Comprehensive substance abuse assessment or diagnosis	108	86.4
Comprehensive mental health assessment or diagnosis	65	52.0
Screening for tobacco use	82	65.6
Outreach to persons in the community who may need treatment	67	53.6
Interim services for clients when immediate admission is not possible	82	65.6
No services offered	6	4.8
	0	4.0
Testing Droothal year or other blood clockel testing	62	FO 4
Breathalyzer or other blood alcohol testing	63	50.4
Drug or alcohol urine screening	85	68.0
Screening for hepatitis B	39	31.2
Screening for hepatitis C	39	31.2
HIV testing	31	24.8
STD testing	29	23.2
TB screening	46	36.8
No services offered	32	25.6
Counseling		
Individual counseling	123	98.4
Group counseling	104	83.2
Family counseling	113	90.4
Marital/couples counseling	96	76.8
Transitional services		
Discharge planning	120	96.0
Aftercare/continuing care	110	88.0
No services offered	2	1.6
Pharmacotherapies		
Disulfiram (Antabuse®)	13	10.4
Naltrexone (oral)	23	18.4
Extended-release, injectable naltrexone/Vivitrol®	15	12.0
Acamprosate (Campral®)	17	13.6
Nicotine replacement	38	30.4
Non-nicotine smoking/tobacco cessation medications	32	25.6
Medications for psychiatric disorders	54	43.2
Methadone	3	2.4
Buprenorphine with naloxone (Suboxone®)	14	11.2
Buprenorphine without naloxone	11	8.8
Buprenorphine subdermal implant (Probuphine®)	1	0.8
No services offered	64	51.2
Ancillary services		
Case management services	96	76.8
Social skills development	94	75.2
Mentoring/peer support	62	49.6
Child care for clients' children	4	3.2
Assistance with obtaining social services	58	46.4
Employment counseling or training for clients	33	26.4
Continued		

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	49	39.2
Domestic violence services	54	43.2
Early intervention for HIV	14	11.2
HIV or AIDS education, counseling, or support	47	37.6
Hepatitis education, counseling, or support	42	33.6
Health education other than HIV/AIDS or hepatitis	60	48.0
Substance abuse education	118	94.4
Transportation assistance to treatment	44	35.2
Mental health services	103	82.4
Acupuncture	2	1.6
Residential beds for clients' children	2	1.6
Self-help groups	64	51.2
Smoking/tobacco cessation counseling	63	50.4
No services offered	1	0.8
Other services		
Treatment for gambling disorder	25	20.0
Treatment for Internet use disorder	19	15.2
Treatment for other addiction disorder	53	42.4
No services offered	68	54.4

	Faci	lities
	No.	%
Substance abuse counseling	119	95.2
Relapse prevention	119	95.2
Cognitive behavioral therapy	122	97.6
Motivational interviewing	118	94.4
Anger management	105	84.0
Brief intervention	109	87.2
Trauma-related counseling	113	90.4
12-step facilitation	96	76.8
Contingency management/motivational incentives	70	56.0
Dialectical behavior therapy	87	69.6
Rational emotive behavioral therapy	70	56.0
Matrix model	53	42.4
Computerized substance abuse treatment	26	20.8
Community reinforcement plus vouchers	24	19.2
Other treatment approaches	8	6.4

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	33	1		
Number of clients ²	795	2		
Number of designated beds	816	29		
Utilization rate ³	97.4	7		
Average number of designated beds per facility	25	29		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	29
Methadone	22
Buprenorphine	6
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	36	28.8
Any language other than English	59	47.2
Non-English language provided by		
Staff counselor only	2	3.4
On-call interpreter only	43	72.9
Both staff counselor and on-call interpreter	14	23.7
Languages provided by staff counselor ¹		
Spanish	15	93.8
American Indian/Alaskan Native languages	_	_
Other	3	18.8

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	83	66.4
Adult women	50	40.0
Clients with co-occurring disorders	51	40.8
Adult men	42	33.6
Clients who have experienced trauma	47	37.6
Criminal justice clients	27	21.6
DUI/DWI clients	11	8.8
Young adults	25	20.0
Adolescents	26	20.8
Clients who have experienced domestic violence	22	17.6
Clients who have experienced sexual		
abuse	23	18.4
Pregnant or postpartum women	22	17.6
Seniors or older adults	21	16.8
LGBT ¹	15	12.0
Veterans	14	11.2
Clients living with HIV/AIDS	12	9.6
Members of military families	10	8.0
Active duty military	9	7.2
Other	3	2.4
No program or group offered	42	33.6

¹ Lesbian, gay, bisexual, or transgender clients.

Location of treatment facilities

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

2017 State Profile — Nevada National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Nevada, 77 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 5,903 clients in substance abuse treatment on March 31, 2017. The survey response rate in Nevada was 82.5 percent.

Facility operation, by number and percent						
	Clients in treatment of			t on March 31,	2017	
	Faciliti	es	All clier	nts	Clients under age 1	
	No.	%	No.	%	No.	%
Private non-profit	41	53.2	3,440	58.3	177	87.6
Private for-profit	25	32.5	1,596	27.0	3	1.5
Local, county, or community government	_	_	<u> </u>	_	_	-
State government	1	1.3	200	3.4	_	_
Federal government	4	5.2	419	7.1	_	_
Tribal government	6	7.8	248	4.2	22	10.9
Total	77	100.0	5,903	100.0	202	100.0

Substance abuse problem treated, by number and percent					
Clients in treatment on March 31, 2017					
	Facilities ¹		Facilities ¹ Clients ²		Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	64	94.1	1,912	32.4	78
Clients with drug abuse only	57	83.8	2,877	48.7	123
Clients with alcohol abuse only	57	83.8	1,114	18.9	46
Total			5,903	100.0	247

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clients in treatment on March 31, 20				
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	-	No.	%
Outpatient	68	88.3	5,203	88.1	100	30	201	99.5
Regular	64	83.1	2,462	41.7	2	21		
Intensive	42	54.5	732	12.4	9	11		
Day treatment/partial hospitalization	12	15.6	144	2.4	6	16		
Detoxification	13	16.9	16	0.3	_	4		
Methadone maintenance	15	19.5	1,849	31.3	191	11		
Residential (non-hospital)	23	29.9	597	10.1	6	22	1	0.5
Short term (<30 days)	11	14.3	245	4.2	<u> </u>	21		
Long term (30+ days)	22	28.6	296	5.0	6	8		
Detoxification	8	10.4	56	0.9		4		
Hospital inpatient	8	10.4	103	1.7	14	14	_	_
Treatment	6	7.8	35	0.6	5	6		
Detoxification	8	10.4	68	1.2	9	8		
Total	77		5,903	100.0	27	44	202	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	11	0.8
Clients in facilities with OTPs ²		
Any MAT	1,734	0.4
Methadone	1,670	0.4
Buprenorphine	62	0.2
Naltrexone	2	0.1
Clients in facilities without OTPs ²		
Any MAT	176	0.2
Buprenorphine	171	0.2
Naltrexone	5	*

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	64	83.1
Private health insurance	58	75.3
Medicare	14	18.2
Medicaid	59	76.6
State-financed health insurance	35	45.5
Federal military insurance	25	32.5
No payment accepted	4	5.2
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	12	15.6
Other payments	_	_
Sliding fee scale	39	50.6
Treatment at no charge for clients who can't pay	43	55.8
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	65	84.4
State substance abuse agency	56	72.7
State mental health department	20	26.0
State department of health	37	48.1
Hospital licensing authority	8	10.4
The Joint Commission	13	16.9
Commission on Accreditation of Rehabilitation Facilities	18	23.4
National Committee for Quality Assurance	_	_
Council on Accreditation	3	3.9
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	3	3.9

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 44 57.1

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Fac	ilities
-	No.	%
Assessment and pre-treatment services	140.	70
Screening for substance abuse	75	97.4
Screening for mental health disorders	58	75.3
Comprehensive substance abuse assessment or diagnosis	68	88.3
Comprehensive mental health assessment or diagnosis	40	51.9
Screening for tobacco use	48	62.3
Outreach to persons in the community who may need treatment	58	75.3
Interim services for clients when immediate admission is not possible	48	62.3
No services offered	1	1.3
Testing		
Breathalyzer or other blood alcohol testing	64	83.1
Drug or alcohol urine screening	70	90.9
Screening for hepatitis B	33	42.9
Screening for hepatitis C	33	42.9
HIV testing	45	58.4
STD testing	32	41.6
TB screening	45	58.4
No services offered	3	3.9
Counseling		0.0
Individual counseling	75	97.4
Group counseling	71	92.2
Family counseling	57	74.0
Marital/couples counseling	47	61.0
Transitional services		
Discharge planning	75	97.4
Aftercare/continuing care	73	94.8
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	20	26.0
Naltrexone (oral)	21	27.3
Extended-release, injectable naltrexone/Vivitrol®	14	18.2
Acamprosate (Campral®)	15	19.5
Nicotine replacement	25	32.5
Non-nicotine smoking/tobacco cessation medications	20	26.0
Medications for psychiatric disorders	28	36.4
Methadone	11	14.3
Buprenorphine with naloxone (Suboxone®)	20	26.0
Buprenorphine without naloxone	15	19.5
Buprenorphine subdermal implant (Probuphine®)	1	1.3
No services offered	38	49.4
Ancillary services		
Case management services	70	90.9
Social skills development	61	79.2
Mentoring/peer support	56	72.7
Child care for clients' children	5	6.5
Assistance with obtaining social services	55	71.4
Employment counseling or training for clients	34	44.2

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	45	58.4
Domestic violence services	33	42.9
Early intervention for HIV	21	27.3
HIV or AIDS education, counseling, or support	39	50.6
Hepatitis education, counseling, or support	29	37.7
Health education other than HIV/AIDS or hepatitis	42	54.5
Substance abuse education	74	96.1
Transportation assistance to treatment	37	48.1
Mental health services	51	66.2
Acupuncture	2	2.6
Residential beds for clients' children	1	1.3
Self-help groups	52	67.5
Smoking/tobacco cessation counseling	41	53.2
No services offered		
Other services		
Treatment for gambling disorder	22	28.6
Treatment for Internet use disorder	12	15.6
Treatment for other addiction disorder	21	27.3
No services offered	46	59.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent			
	Faci	lities	
	No.	%	
Substance abuse counseling	74	96.1	
Relapse prevention	70	90.9	
Cognitive behavioral therapy	68	88.3	
Motivational interviewing	67	87.0	
Anger management	57	74.0	
Brief intervention	63	81.8	
Trauma-related counseling	59	76.6	
12-step facilitation	57	74.0	
Contingency management/motivational incentives	46	59.7	
Dialectical behavior therapy	41	53.2	
Rational emotive behavioral therapy	30	39.0	
Matrix model	38	49.4	
Computerized substance abuse treatment	21	27.3	
Community reinforcement plus vouchers	9	11.7	
Other treatment approaches	6	7.8	

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	19	7				
Number of clients ²	497	103				
Number of designated beds	615	184				
Utilization rate ³	80.8	56.0				
Average number of designated beds per facility	32	26				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	58
Methadone	56
Buprenorphine	2
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	11	14.3
Any language other than English	37	48.1
Non-English language provided by		
Staff counselor only	17	45.9
On-call interpreter only	8	21.6
Both staff counselor and on-call interpreter	12	32.4
Languages provided by staff counselor ¹		
Spanish	28	96.6
American Indian/Alaskan Native		
languages	_	_
Other	5	17.2

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	60	77.9
Adult women	40	51.9
Clients with co-occurring disorders	47	61.0
Adult men	36	46.8
Clients who have experienced trauma	31	40.3
Criminal justice clients	34	44.2
DUI/DWI clients	15	19.5
Young adults	28	36.4
Adolescents	18	23.4
Clients who have experienced domestic violence	27	35.1
Clients who have experienced sexual		
abuse	29	37.7
Pregnant or postpartum women	23	29.9
Seniors or older adults	25	32.5
LGBT ¹	28	36.4
Veterans	26	33.8
Clients living with HIV/AIDS	21	27.3
Members of military families	12	15.6
Active duty military	13	16.9
Other	4	5.2
No program or group offered	17	22.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

CHIMINA SERVICES. SIGN

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — New Hampshire National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In New Hampshire, 67 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 8,631 clients in substance abuse treatment on March 31, 2017. The survey response rate in New Hampshire was 93.2 percent.

Facility operation, by number and percer	nt					
			Clients	in treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	31	46.3	1,728	20.0	49	81.7
Private for-profit	36	53.7	6,903	80.0	11	18.3
Local, county, or community government	_	_	_	_	_	_
State government	_	_	_	_	_	_
Federal government	_	_	_	_	_	_
Tribal government	_	_	_	_	_	_
Total	67	100.0	8,631	100.0	60	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients	Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	53	89.8	1,455	16.9	132	
Clients with drug abuse only	52	88.1	6,477	75.0	595	
Clients with alcohol abuse only	46	78.0	699	8.1	63	
Total			8,631	100.0	791	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clients in treatment on March 31, 2017				
_	Facili	ities¹			All clients		Clients age < 18	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	58	86.6	8,235	95.4	432	52	60	100.0
Regular	56	83.6	1,398	16.2	28	29		
Intensive	15	22.4	197	2.3	_	10		
Day treatment/partial hospitalization	4	6.0	142	1.6	_	2		
Detoxification	11	16.4	49	0.6	8	5		
Methadone maintenance	34	50.7	6,449	74.7	428	77		
Residential (non-hospital)	16	23.9	366	4.2	_	18	_	_
Short term (<30 days)	12	17.9	275	3.2	_	13		
Long term (30+ days)	10	14.9	83	1.0	_	8		
Detoxification	5	7.5	8	0.1	_	4		
Hospital inpatient	2	3.0	30	0.3	_	10	_	_
Treatment	2	3.0	_	_	_	_		
Detoxification	1	1.5	30	0.3	_	10		
Total	67		8,631	100.0	432	45	60	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	8	0.6
Clients in facilities with OTPs ²		
Cheffis in facilities with OTPS		
Any MAT	3,469	8.0
Methadone	3,377	0.9
Buprenorphine	92	0.3
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	3,497	3.4
Buprenorphine	3,355	4.0
Naltrexone	142	0.7
1 Percentage of all OTP facilities in the LLS 2 Percentage of all	mothadone hunr	onorphino

Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	67	100.0
Private health insurance	62	92.5
Medicare	29	43.3
Medicaid	53	79.1
State-financed health insurance	35	52.2
Federal military insurance	34	50.7
No payment accepted	_	_
Access to Recovery (ATR) vouchers ²	7	10.4
IHS/Tribal/Urban (ITU) funds	_	_
Other payments	_	_
Sliding fee scale	30	44.8
Treatment at no charge for clients who can't pay	25	37.3

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	42	62.7
State substance abuse agency	34	50.7
State mental health department	14	20.9
State department of health	25	37.3
Hospital licensing authority	2	3.0
The Joint Commission	2	3.0
Commission on Accreditation of Rehabilitation Facilities	16	23.9
National Committee for Quality Assurance	_	_
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	<u> </u>	_

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 29 43.3

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Image: Im	Types of services offered, by number and percent		
sessesment and pre-treatment services 5 Screening for substance abuse 65 97.0 Screening for mental health disorders 51 76.1 Comprehensive mental health disorders 65 97.0 Comprehensive mental health disorders 57 85.1 Screening for tobacco use 57 85.1 Dutreach to persons in the community who may need treatment 39 58.2 Interim services for clients when immediate admission is not possible 31 46.3 No services offered 1 1.5 setting 1 16.3 Screening for rother blood alcohol testing 45 67.2 Toug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Microbia Screening for hepatitis C	Types of corvious charact, by nambor and percent	Faci	ilities
Screening for substance abuse			
Screening for mental health disorders 51 76.1 Comprehensive substance abuse assessment or diagnosis 65 97.0 Comprehensive mental health assessment or diagnosis 24 35.8 Screening for tobacco use 57 85.1 Outreach to persons in the community who may need treatment 39 58.2 Interim services for clients when immediate admission is not possible 31 46.3 No services offered 31 46.3 Streathalyzer or other blood alcohol testing 45 67.2 Orag alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Screening for hepatitis C 11 16.4 HIV testing 11 16.4 STD testing 10 14.9 Viscorriotes offered 8 19.2 Viscorriotes offered 8 19.2 Os services offered 6 76.1 Outseling 67 100.0 Touck services offered 76.1 10.0 Touck services offered 9	Assessment and pre-treatment services		
Comprehensive substance abuse assessment or diagnosis 65 97.0 Comprehensive mental health assessment or diagnosis 24 35.8 Screening for tobacco use 57 85.1 Dutreach to persons in the community who may need treatment 39 58.2 Interim services for clients when immediate admission is not possible 31 46.3 No services offered 1 1.5 setting 31 46.3 Sireathalyzer or other blood alcohol testing 86.6 86.6 Screening for hepatitis B 11 16.4 Screening for hepatitis B 11 16.4 Screening for hepatitis B 11 16.4 HV testing 11 16.4 HV testing 11 16.4 HV testing 11 16.4 HV testing 10 14.9 B screening for hepatitis C 11 16.4 HV testing 11 16.4 HV testing 15 76.7 B screening for hepatitis B 6 80.6 Middle	Screening for substance abuse	65	97.0
Comprehensive mental health assessment or diagnosis 24 35.8 Screening for tobacco use 57 85.1 Dutreach to persons in the community who may need treatment 39 58.2 Unbrach to persons in the community who may need treatment 31 46.3 No services offered 31 45.3 No services offered 41 15.8 Bertallyzer or other blood alcohol testing 45 67.2 Drug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Hilv Besting 11 16.4 Hilv Besting 11 16.4 STD testing 10 14.9 BS screening for hepatitis C 11 16.4 Hilv Besting 10 14.9 BS STD testing 10 14.9 BS creening for hepatitis C 11 16.4 Vol services offered 3 11.9 Bs screening 6 80.6 Vol services offered 6 80.6 Family counseling	Screening for mental health disorders	51	76.1
Screening for tobacco use 57 85.1 Dutreach to persons in the community who may need treatment 39 58.2 Dutreach to persons in the community who may need treatment 39 58.2 No services offered 1 1.5 esting	Comprehensive substance abuse assessment or diagnosis	65	97.0
Dutreach to persons in the community who may need treatment 39 58.2 16.5 16.	Comprehensive mental health assessment or diagnosis	24	35.8
Interim services for clients when immediate admission is not possible 31 46.3 No services offered 1 1.5 sesting 31 1.5 Breathalyzer or other blood alcohol testing 45 67.2 Drug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Screening for hepatitis C 11 16.4 HIV testing 11 16.4 STD testing 13 19.4 IB screening or hepatitis B 13 19.4 Visit String 13 19.4 Vo services offered 8 11.9 Visit String 6 19.6 String Counseling 67 100.0 Group counseling 67 100.0 Group counseling 67 100.0 Againly Couples counseling 67 100.0 Screaming For support 6 89.6 Altercare/continuing care 6 89.6 Notervices offered 1 1.5 <t< td=""><td>Screening for tobacco use</td><td>57</td><td>85.1</td></t<>	Screening for tobacco use	57	85.1
No services offered 1 1.5 esting sesting Greathalyzer or other blood alcohol testing 45 67.2 Gray alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 HIV testing 11 16.4 STD testing 10 14.9 EB screening 10 14.9 No services offered 8 11.9 Stouseling 67 100.0 Group counseling 60 89.6 Family counseling 61 10.0 Group counseling 60 89.6 Family counseling 60 89.6 Family counseling 60 89.6 Paramity counseling 64 95.5 Family counseling 64 95.5 Ale many counseling 64 95.5 Alte	Outreach to persons in the community who may need treatment	39	58.2
Sesting 45 67.2 Greathalyzer or other blood alcohol testing 45 67.2 Orug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Screening for hepatitis C 11 16.4 IVI Vesting 11 16.4 STD testing 10 14.9 IB screening 13 19.4 Vo services offered 8 11.9 Vo services offered 8 11.9 Vous counseling 67 100.0 Group counseling 67 100.0 <td>Interim services for clients when immediate admission is not possible</td> <td>31</td> <td>46.3</td>	Interim services for clients when immediate admission is not possible	31	46.3
Breathaltyzer or other blood alcohol testing 45 67.2 Drug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 HIV testing 11 16.4 HIV testing 11 16.4 HIV testing 11 16.4 HIV testing 11 18.4 HIV testing 11 18.4 HIV testing 11 18.4 HIV testing 11 18.4 HIV testing 11 19.4 HIV testing 11 18.4 HIV testing 11 18.4 HIV testing 11 18.4 HIV testing 11 19.4 HIV testing 11 19.4 HIV testing 11 19.4 HIV testing 18 19.0 HIV testing 18 19.0 HIV testing 18 19.0 HIV testing 18 19.0 HIV testing 18 19.0 <td>No services offered</td> <td>1</td> <td>1.5</td>	No services offered	1	1.5
Drug or alcohol urine screening 58 86.6 Screening for hepatitis B 11 16.4 Screening for hepatitis C 11 16.4 HIV testing 10 14.9 EB screening 10 14.9 IB screening 13 19.4 No services offered 8 11.9 Sourseling 67 100.0 Group counseling 67 100.0 Group counseling 60 89.6 Family counseling 60 89.6 Family counseling 61 76.1 Marital/couples counseling 51 76.1 Marital/couples counseling 60 89.6 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Aftercare/continuing care 60 89.6 No services offered 2 32.8 Valuracyon (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Accamprosate (Campral®)	Testing Testing		
Screening for hepatitis B 11 16.4 Screening for hepatitis C 11 16.4 HIV testing 11 16.4 STD testing 10 14.9 IB screening 13 19.4 Vo services offered 8 11.9 Vourseling 67 100.0 Group counseling 67 100.0 Group counseling 60 89.6 Family counseling 61 76.1 Marital/couples counseling 64 95.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Handlerwane (oral) 25 37.3 Extended-release, injectable nattrexone/Vivitrol® 25 37.3 Extended-release, injectable nattrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Vicotine replacement 22 32.8 Non-nicotine	Breathalyzer or other blood alcohol testing	45	67.2
Becening for hepatitis C 11 16.4 HIV testing 11 16.4 HIV testing 11 16.4 FIB screening 13 14.9 No services offered 8 11.9 No services offered 8 11.9 No services offered 6 10.0 Group counseling 60 89.6 amily counseling 61 76.1 Marital/couples counseling 6 89.6 Avaital/couples counseling 6 89.6 Valuration Services 2 2 Valuration Services offered 1 1.5 Aftercare/continuing care 6 89.6 No services offered 1 1.5 harmacotherapies 2 3.2 Natitrexone (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 25 37.3 Accamprosate (Campral®) 23 34.3 Avicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation	Drug or alcohol urine screening	58	86.6
HIV testing 11 16.4 STD testing 10 14.9 IB screening 13 19.4 No services offered 8 11.9 Courseling 67 100.0 Group counseling 67 100.0 Group counseling 60 89.6 Family counseling 51 76.1 Marital/couples counseling 30 44.8 Family counseling 60 89.6 Marital/couples counseling 60 89.6 Affectare/continuing care 60 89.6 No services offered 1 1.5 Harmacotheraples 2 32.8 Validerona (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Accomprosate (Campral®) 23 34.3 Microtine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methado	Screening for hepatitis B	11	16.4
STD testing 10 14.9 IB screening 13 19.4 No services offered 8 11.9 Is consening 67 100.0 Group counseling 67 100.0 Group counseling 60 89.6 Family counseling 60 89.6 Family counseling 64 95.5 Aftercare/continuing care 60 89.6 Os services offered 6 89.6 No services offered 22 32.8 Valtrexone (oral) 25 37.3 Extended-release, injectable nattrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Valcotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 23 34.3 Medications for psychiatric disorders 23 34.3 Suprenorphine with natoxone (Suboxone®) 33 49.3 Suprenorphine with natoxone (Suboxone®) 33	Screening for hepatitis C	11	16.4
EB screening 13 19.4 No services offered 8 11.9 Sciounseling 67 100.0 Group counseling 60 89.6 Family counseling 51 76.1 Marital/couples counseling 30 44.8 Marital/couples counseling 64 95.5 Marital/couples counseling 64 95.5 Aftercare/continuing care 60 89.6 As services offered 1 1.5 Aftercare/continuing care 60 89.6 As services offered 1 1.5 Inhamacotherapies 22 32.8 Sualitrexone (oral) 25 37.3 Extended-release, injectable naltrexone/vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Accomprosate (Campral®) 23 34.3 Medications for psychiatric disorders 26 38.8 Medications for psychiatric disorders 26 38.8 Buprenorphine with naloxone (Suboxone®) 3 49.3	HIV testing	11	16.4
FB screening 13 19.4 No services offered 8 11.9 Sciouseling 67 100.0 Group counseling 60 89.6 Family counseling 60 89.6 Family counseling 51 76.1 Marital/couples counseling 30 44.8 Validational services 8 75.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Valenamootherapies 22 32.8 Usualfram (Antabuse®) 22 32.8 Naltrexone (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Accamprosate (Campral®) 23 34.3 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Medications for psychiatric disorders 26 38.8 Suprenorphine with naloxone (Suboxone®) 33 49.3 Suprenorphine with naloxone (Suboxone®)	STD testing	10	14.9
Courseling 67 100.0 Group counseling 60 89.6 Family counseling 51 76.1 Adarital/couples counseling 30 44.8 Variantitional services Variantitional services Discharge planning 64 95.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Intermacotherapies 22 32.8 Vallexone (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Vaciotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Successor effered 26 77.6 Coscale skills development 48 <t< td=""><td>TB screening</td><td>13</td><td>19.4</td></t<>	TB screening	13	19.4
Individual counseling 67 100.0 Group counseling 60 89.6 Family counseling 51 76.1 Marital/couples counseling 30 44.8 Marital/couples counseling 44.8 Instance Institute of the country of the	No services offered	8	11.9
Group counseling 60 89.6 Family counseling 51 76.1 Marital/couples counseling 30 44.8 Family counseling 60 89.5 After care/continuing care 60 89.6 Abservices offered 1 1.5 Charmacotherapies 22 32.8 Valleracyon (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Acamprosate (Campral®) 23 34.3 Value (Campral®) 23 34.3 Value (Champral®) 23 34.3 Value (Champral®) 3 49.3 Value (Champral®) 3	Counseling		
Family counseling 51 76.1 Marital/couples counseling 30 44.8 Pransitional services Standard planning 64 95.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Intermacotherapies 32 32.8 Valid properties (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Accamprosate (Campral®) 23 34.3 Mon-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Suprenorphine with naloxone (Suboxone®) 33 49.3 Suprenorphine without naloxone 23 34.3 Vol services offered 20 29.9 Inciliary services 52 77.6 Social skills development 48 71.6 Accial skills development 48 71.6 Accial skills development 48 71.6	ndividual counseling	67	100.0
Marital/couples counseling 30 44.8 rensitional services rensitional services Discharge planning 64 95.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Intermacotherapies 32 32.8 Validrexone (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Victine replacement 22 32.8 Von-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Suprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No. services offered 20 29.9 Incidiary services 5 7.5 Case management services 52 77.6 Case management	Group counseling	60	89.6
Pransitional services Content of the polar p	Family counseling	51	76.1
Discharge planning 64 95.5 Aftercare/continuing care 60 89.6 No services offered 1 1.5 Intermacotherapies Usulfiram (Antabuse®) 22 32.8 Naltrexone (oral) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Case management services 52 7.6 Cascial skills development 48 71.6 Mentoring/peer support 42 62.7 <td>Marital/couples counseling</td> <td>30</td> <td>44.8</td>	Marital/couples counseling	30	44.8
Aftercare/continuing care 60 89.6 No services offered 1 1.5 Harmacotherapies 22 32.8 Disulfiram (Antabuse®) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Accamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Cocial skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with	ransitional services		
No services offered 1 1.5 Intermacotherapies 22 32.8 Disulfiram (Antabuse®) 25 37.3 Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 No services offered 20 29.9 No services offered 20 29.9 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Discharge planning	64	95.5
Inharmacotherapies 22 32.8 Disulfiram (Antabuse®) 25 37.3 Statended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Viciotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Aftercare/continuing care	60	89.6
Disulfiram (Antabuse®) 22 32.8 Nattrexone (oral) 25 37.3 Extended-release, injectable nattrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	No services offered	1	1.5
Natitrexone (oral) 25 37.3 Extended-release, injectable natitrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Gocial skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 21 31.3 Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Gocial skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Disulfiram (Antabuse®)	22	32.8
Acamprosate (Campral®) 23 34.3 Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Naltrexone (oral)	25	37.3
Nicotine replacement 22 32.8 Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Extended-release, injectable naltrexone/Vivitrol®	21	31.3
Non-nicotine smoking/tobacco cessation medications 23 34.3 Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Acamprosate (Campral®)	23	34.3
Medications for psychiatric disorders 26 38.8 Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Nicotine replacement	22	32.8
Methadone 8 11.9 Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Non-nicotine smoking/tobacco cessation medications	23	34.3
Buprenorphine with naloxone (Suboxone®) 33 49.3 Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Medications for psychiatric disorders	26	38.8
Buprenorphine without naloxone 23 34.3 Buprenorphine subdermal implant (Probuphine®) 1 1.5 No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Methadone	8	11.9
1	Buprenorphine with naloxone (Suboxone®)	33	49.3
No services offered 20 29.9 Incillary services 52 77.6 Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Buprenorphine without naloxone	23	34.3
Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Buprenorphine subdermal implant (Probuphine®)	1	1.5
Case management services 52 77.6 Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	No services offered	20	29.9
Social skills development 48 71.6 Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Ancillary services		
Mentoring/peer support 42 62.7 Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Case management services	52	77.6
Child care for clients' children 5 7.5 Assistance with obtaining social services 31 46.3	Social skills development	48	71.6
Assistance with obtaining social services 31 46.3	Mentoring/peer support	42	62.7
	Child care for clients' children	5	7.5
Employment counseling or training for clients 16 23.9	Assistance with obtaining social services	31	46.3
	Employment counseling or training for clients	16	23.9

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	25	37.3
Domestic violence services	21	31.3
Early intervention for HIV	15	22.4
HIV or AIDS education, counseling, or support	38	56.7
Hepatitis education, counseling, or support	34	50.7
Health education other than HIV/AIDS or hepatitis	30	44.8
Substance abuse education	65	97.0
Transportation assistance to treatment	15	22.4
Mental health services	36	53.7
Acupuncture	5	7.5
Residential beds for clients' children	1	1.5
Self-help groups	38	56.7
Smoking/tobacco cessation counseling	37	55.2
No services offered	_	_
Other services		
Treatment for gambling disorder	15	22.4
Treatment for Internet use disorder	10	14.9
Treatment for other addiction disorder	19	28.4
No services offered	48	71.6

	Faci	lities
	No.	%
Substance abuse counseling	66	98.5
Relapse prevention	65	97.0
Cognitive behavioral therapy	58	86.6
Motivational interviewing	61	91.0
Anger management	53	79.1
Brief intervention	50	74.6
Trauma-related counseling	44	65.7
12-step facilitation	48	71.6
Contingency management/motivational incentives	37	55.2
Dialectical behavior therapy	44	65.7
Rational emotive behavioral therapy	23	34.3
Matrix model	29	43.3
Computerized substance abuse treatment	18	26.9
Community reinforcement plus vouchers	7	10.4
Other treatment approaches	9	13.4

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	13	1			
Number of clients ²	277	10			
Number of designated beds	278	15			
Utilization rate ³	99.6	66.7			
Average number of designated beds per facility	21	15			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	258
Methadone	251
Buprenorphine	7
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	20	29.9
Any language other than English	30	44.8
Non-English language provided by		
Staff counselor only	5	16.7
On-call interpreter only	17	56.7
Both staff counselor and on-call interpreter	8	26.7
Languages provided by staff counselor ¹		
Spanish	10	76.9
American Indian/Alaskan Native		
languages	_	_
Other	3	23.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	46	68.7
Adult women	32	47.8
Clients with co-occurring disorders	22	32.8
Adult men	30	44.8
Clients who have experienced trauma	13	19.4
Criminal justice clients	14	20.9
DUI/DWI clients	12	17.9
Young adults	16	23.9
Adolescents	6	9.0
Clients who have experienced domestic violence	9	13.4
Clients who have experienced sexual abuse	8	11.9
Pregnant or postpartum women	17	25.4
Seniors or older adults	4	6.0
LGBT ¹	3	4.5
Veterans	9	13.4
Clients living with HIV/AIDS	5	7.5
Members of military families	4	6.0
Active duty military	6	9.0
Other	1	1.5
No program or group offered	21	31.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HIMIN VAJA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — New Jersey National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In New Jersey, 344 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 35,659 clients in substance abuse treatment on March 31, 2017. The survey response rate in New Jersey was 87.1 percent.

Facility operation, by number and percei	nt					
	Clients in treatment on March 31, 2017				2017	
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	175	50.9	18,994	53.3	614	59.3
Private for-profit	153	44.5	15,139	42.5	356	34.4
Local, county, or community government	10	2.9	782	2.2	65	6.3
State government	4	1.2	473	1.3	1	0.1
Federal government	2	0.6	271	8.0	_	_
Tribal government	_	_	_	_	_	_
Total	344	100.0	35,659	100.0	1,036	100.0

Substance abuse problem treated, by number and percent					
Clients in treatment on March 31, 2017					
	Faciliti	es¹	Clients ² Clients ² per 100,0		
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	311	94.8	14,215	39.9	195
Clients with drug abuse only	266	81.1	17,370	48.8	243
Clients with alcohol abuse only	269	82.0	4,024	11.3	54
Total			35,609	100.0	492

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facili	ities¹	All clients				Clients age < 18	
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	308	89.5	32,662	91.6	432	45	907	87.5
Regular	294	85.5	10,268	28.8	16	25		
Intensive	225	65.4	5,975	16.8	28	20		
Day treatment/partial hospitalization	79	23.0	2,017	5.7	20	19		
Detoxification	25	7.3	159	0.4	30	11		
Methadone maintenance	94	27.3	14,243	39.9	438	8		
Residential (non-hospital)	46	13.4	2,364	6.6	55	39	129	12.5
Short term (<30 days)	16	4.7	801	2.2	32	36		
Long term (30+ days)	38	11.0	1,355	3.8	80	32		
Detoxification	14	4.1	208	0.6	3	19		
Hospital inpatient	12	3.5	633	1.8	77	37	_	_
Treatment	11	3.2	369	1.0	34	25		
Detoxification	11	3.2	264	0.7	44	19		
Total	344		35,659	100.0	400	45	1,036	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs),
by number and percent

	No.	%
Facilities with OTPs ¹	33	2.5
Clients in facilities with OTPs ²		
Any MAT	14,396	3.5
Methadone	14,040	3.7
Buprenorphine	332	1.2
Naltrexone	24	0.7
Clients in facilities without OTPs ²		
Any MAT	1,866	1.8
Buprenorphine	1,164	1.4
Naltrexone	702	3.6

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

317 Cash or self-payment 92.2 Private health insurance 222 64.5 Medicare 89 25.9 Medicaid 209 60.8 State-financed health insurance 124 36.0 88 25.6 Federal military insurance 12 No payment accepted 3.5

Treatment at no charge for clients who can't pay

Access to Recovery (ATR) vouchers2

IHS/Tribal/Urban (ITU) funds

Other payments

Sliding fee scale

No.

6

1

253

171

%

1.7

0.3

73.5

49.7

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	297	86.3
State substance abuse agency	277	80.5
State mental health department	150	43.6
State department of health	134	39.0
Hospital licensing authority	24	7.0
The Joint Commission	66	19.2
Commission on Accreditation of Rehabilitation Facilities	79	23.0
National Committee for Quality Assurance	4	1.2
Council on Accreditation	16	4.7
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	12	3.5

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent				
	Facilities			
	No.	%		
Receives federal, state, county, or local government funds for substance abuse				
treatment programs	180	52.3		

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

N-SSATS Profile — New Jersey 2017

Residence of the control of	Types of services offered, by number and percent		
No. No.	Types of convices energy, by number and personic	Faci	litios
Screening for substance abuse 330 95.9			
Screening for substance abuse 330 \$5,9 Screening for mental health disorders 279 81.1 Comprehensive substance abuse assessment or diagnosis 333 96.8 Comprehensive substance abuse assessment or diagnosis 230 66.9 Screening for tobacco use 255 68.3 Outreach to persons in the community who may need treatment 195 56.7 Interin services for clients when immediate admission is not possible 14 430 No services offered 1 0.3 Testing Breathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 91 26.5 No services offered 39 98.5	Assessment and pre-treatment services	1101	7,0
Screening for mental health disorders 279 81.1 Comprehensive substance abuse assessment or diagnosis 333 96.8 Comprehensive mental health assessment or diagnosis 230 66.9 Screening for tobacco use 235 68.3 Outreach to persons in the community who may need treatment 195 56.7 Interim services for clients when immediate admission is not possible 148 43.0 No services offered 1 0.3 Testing 194 66.4 Drug or alcohol urine screening 321 33.3 Screening for hepatitis G 74 21.5 Flil Vi testing 63 18.3 Screening for hepatitis G 74 21.5 Fli Vi testing 66 19.2 STD testing 66 19.2 TB screening 33 39 8.5 No services offered 17 4.9 Counseling 33 9.5 1 Group counseling 33 9.2 7.0 Family counseling		330	95.9
Comprehensive substance abuse assessment or diagnosis 333 96.8 Comprehensive mental health assessment or diagnosis 235 68.3 Outreach to persons in the community who may need treatment 195 56.7 Interim services for clients when immediate admission is not possible 148 43.0 No services offered 1 0.3 Testing Interim services of clients when immediate admission is not possible 194 56.4 No services offered 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 B screening for hepatitis P 91 26.5 No services offered 74 21.5 HIV testing 93 27.0 TD screening for hepatitis P 91 26.5 TD screening for hepatitis P 339 98.5 Group courseling 339 <			
Comprehensive mental health assessment or diagnosis 230 66.9 Screening for tobacco use 235 68.3 Outreach to persons in the community who may need treatment 195 56.7 Interim services for clients when immediate admission is not possible 148 43.0 No services offered 1 148 43.0 No services offered 1 66 19.2 Breathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis B 74 21.5 HIV testing 93 2.7 STD testing 66 19.2 TB screening for hepatitis B 33 20.5 STD testing 66 19.2 TB screening for hepatitis C 74 21.5 No services offered 37 95.1 TB screening for hepatitis C 33 98.5 TB screening for hepatitis C 33 339 98.5 TB scr			
Screening for tobacco use 235 68.3 Outreach to persons in the community who may need treatment 195 56.7 Interim services for clients when immediate admission is not possible 148 43.0 No services offered 1 0.3 Tereathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis B 63 27.0 HIV testing 93 27.0 TB screening for hepatitis B 66 19.2 TIV testing 93 27.0 TB screening for hepatitis B 66 19.2 TB screening for hepatitis B 93 27.0 TW testing 93 27.0 TB screening for hepatitis B 329 98.5 TB screening for hepatitis B 339	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 195 56.7 Interin services for clients when immediate admission is not possible 148 43.0 No services offered 1 0.3 Testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 31 4.9 Use the screening 33 98.5 Group counseling 33 98.5 Group counseling 33 98.5 Group counseling 33 98.5 Family counseling 33 98.5 Family counseling 33 98.8 Group counseling 33 98.8 Family counseling 33 98.8 Family counseling 33 98.8 Famil	·		
Interim services for clients when immediate admission is not possible 148 43.0 No services offered 1 0.3 1 1 1 1 1 1 1 1 1			
No services offered 1 0.3 Testins 194 56.4 Breathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis C 74 21.5 HIV testing 33 27.0 Storeening for hepatitis C 74 21.5 HIV testing 66 19.2 TB screening 66 19.2 TB screening 66 19.2 TB screening 31 26.5 No services offered 71 4.9 Counseling 339 98.5 Group counseling 339 98.5 Group counseling 327 95.1 Family counseling 338 92.4 Marital/couples counseling 339 96.8 Family counseling 339 96.8 Bramily counseling 339 96.8 Bramily counseling 339 96.8 Bramily counseling 339 96.8	· · · · · · · · · · · · · · · · · · ·		
Breathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 17 4.9 Counseling Individual counseling 339 98.5 Group counseling 327 95.1 Family counseling 327 95.1 Family counseling 338 98.5 Group counseling 327 95.1 Family counseling 338 98.5 Family counseling 338 98.8 Aforeur 258 75.0 Tarsitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 9.2 Plustifieral Autha	·		
Breathalyzer or other blood alcohol testing 194 56.4 Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 17 4.9 Counseling Individual counseling 339 98.5 Group counseling 327 95.1 Family counseling 327 95.1 Family counseling 338 98.5 Group counseling 327 95.1 Family counseling 338 98.5 Family counseling 338 98.8 Aforeur 258 75.0 Tarsitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 9.2 Plustifieral Autha	Testing		
Drug or alcohol urine screening 321 93.3 Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 17 4.9 Counciling Individual counseling 339 98.5 Group counseling 327 96.1 Family counseling 318 92.4 Marital/couples counseling 33 96.8 Aftercare/continuing care 31 90.1 No services offered 3 9.9 Transitional services 3 9.9 Disculfiram (Antabuse*) 43 12.5 No services offered 3 9.9 Pharmacotherapies 93 2.7.0 Disulfiram (Antabuse*) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol** 93 <td< td=""><td></td><td>194</td><td>56.4</td></td<>		194	56.4
Screening for hepatitis B 63 18.3 Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 74.9 Courseling 339 98.5 Group counseling 37 95.1 Family counseling 318 92.4 Marital/couples counseling 258 75.0 Transitional services 33 96.8 Discharge planning 33 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies 310 90.1 Disulfiram (Antabuse*) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol** 93 27.0 Acamprosate (Campral*) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications	,		
Screening for hepatitis C 74 21.5 HIV testing 93 27.0 STD testing 66 19.2 TB screening 91 26.5 No services offered 17 4.9 Counseling Individual counseling 339 98.5 Group counseling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 328 75.0 Family counseling 333 96.8 Aftercare/continuing care 310 90.1 No services offered 31 90.1 No services offered 31 9.9 Pharmacotherapies 107 31.1 Disulfiram (Antabuse*) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrof* 93 27.0 Acamprosate (Campral*) 70 19.5 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders			
HIV testing			
STD testing 66 19.2 TB screening 91 26.5 No services offered 17 4.9 Counseling 339 98.5 Group counseling 339 98.5 Group counseling 327 95.1 Family counseling 38 92.4 Marital/couples counseling 258 75.0 Transitional services Discharge planning 33 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 1.25 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3			
TB screening 91 26.5 No services offered 17 4.9 Courseling 339 98.5 Group counseling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 318 92.4 Transitional services 310 90.1 Sibcharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 310 90.1 Pharmacotherapies 43 12.5 Naltream (artal countries and planning and planni			
No services offered 17 4.9 Counseling 339 98.5 Group counseling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 318 92.4 Aftercare/continuing care 310 90.1 No services offered 310 90.1 Pharmacothereal 310 90.1 Nalifer (crease, injectable naltrexone/vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications			
Counseling 339 98.5 Group counselling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 258 75.0 Transitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine with naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6			
Individual counseling 339 98.5 Group counseling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 258 75.0 Transitional services Userpan="2">Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse*) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol* 93 27.0 Acamprosate (Campral*) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone*) 92 26.7 Buprenorphine with naloxone 11 34.0 Arcillary services Case managemen			
Group counseling 327 95.1 Family counseling 318 92.4 Marital/couples counseling 258 75.0 Transitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine with naloxone (Suboxone®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1		339	98.5
Family counseling 318 92.4 Marital/couples counseling 258 75.0 Transitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies ************************************	~		
Marital/couples counseling 258 75.0 Transitional services Transitional services Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies ************************************	,		
Transitional services 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Actillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 333 96.8 Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164<			
Aftercare/continuing care 310 90.1 No services offered 3 0.9 Pharmacotherapies Services Services Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7	Discharge planning	333	96.8
No services offered 3 0.9 Pharmacotherapies Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0			
Disulfiram (Antabuse®) 43 12.5 Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 20 64.0			0.9
Naltrexone (oral) 107 31.1 Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 93 27.0 Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Disulfiram (Antabuse®)	43	12.5
Acamprosate (Campral®) 67 19.5 Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Naltrexone (oral)	107	31.1
Nicotine replacement 79 23.0 Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Extended-release, injectable naltrexone/Vivitrol®	93	27.0
Non-nicotine smoking/tobacco cessation medications 56 16.3 Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Acamprosate (Campral®)	67	19.5
Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Nicotine replacement	79	23.0
Medications for psychiatric disorders 191 55.5 Methadone 32 9.3 Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Non-nicotine smoking/tobacco cessation medications	56	16.3
Buprenorphine with naloxone (Suboxone®) 92 26.7 Buprenorphine without naloxone 51 14.8 Buprenorphine subdermal implant (Probuphine®) 2 0.6 No services offered 117 34.0 Ancillary services 303 88.1 Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0		191	55.5
Buprenorphine without naloxone5114.8Buprenorphine subdermal implant (Probuphine®)20.6No services offered11734.0Ancillary servicesCase management services30388.1Social skills development27680.2Mentoring/peer support16447.7Child care for clients' children236.7Assistance with obtaining social services22064.0	Methadone	32	9.3
Buprenorphine subdermal implant (Probuphine®) No services offered Ancillary services Case management services Social skills development Mentoring/peer support Child care for clients' children Assistance with obtaining social services 2 0.6 34.0 88.1 80.2 47.7 6.7 6.7 6.7	Buprenorphine with naloxone (Suboxone®)	92	26.7
No services offered 117 34.0 Ancillary services 303 88.1 Case management services 303 88.1 Social skills development 276 80.2 Mentoring/peer support 164 47.7 Child care for clients' children 23 6.7 Assistance with obtaining social services 220 64.0	Buprenorphine without naloxone	51	14.8
Ancillary servicesCase management services30388.1Social skills development27680.2Mentoring/peer support16447.7Child care for clients' children236.7Assistance with obtaining social services22064.0	Buprenorphine subdermal implant (Probuphine®)	2	0.6
Case management services30388.1Social skills development27680.2Mentoring/peer support16447.7Child care for clients' children236.7Assistance with obtaining social services22064.0	No services offered	117	34.0
Social skills development27680.2Mentoring/peer support16447.7Child care for clients' children236.7Assistance with obtaining social services22064.0	Ancillary services		
Mentoring/peer support16447.7Child care for clients' children236.7Assistance with obtaining social services22064.0	Case management services	303	88.1
Child care for clients' children236.7Assistance with obtaining social services22064.0	Social skills development	276	80.2
Assistance with obtaining social services 220 64.0	Mentoring/peer support	164	47.7
	Child care for clients' children	23	6.7
	Assistance with obtaining social services	220	64.0
Employment counseling or training for clients 148 43.0	Employment counseling or training for clients	148	43.0

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	159	46.2
Domestic violence services	159	46.2
Early intervention for HIV	93	27.0
HIV or AIDS education, counseling, or support	193	56.1
Hepatitis education, counseling, or support	171	49.7
Health education other than HIV/AIDS or hepatitis	196	57.0
Substance abuse education	334	97.1
Transportation assistance to treatment	163	47.4
Mental health services	282	82.0
Acupuncture	9	2.6
Residential beds for clients' children	3	0.9
Self-help groups	158	45.9
Smoking/tobacco cessation counseling	191	55.5
No services offered	_	_
Other services		
Treatment for gambling disorder	118	34.3
Treatment for Internet use disorder	59	17.2
Treatment for other addiction disorder	130	37.8
No services offered	179	52.0

	Faci	lities
	No.	%
Substance abuse counseling	341	99.1
Relapse prevention	336	97.7
Cognitive behavioral therapy	335	97.4
Motivational interviewing	324	94.2
Anger management	302	87.8
Brief intervention	292	84.9
Trauma-related counseling	275	79.9
12-step facilitation	305	88.7
Contingency management/motivational incentives	212	61.6
Dialectical behavior therapy	208	60.5
Rational emotive behavioral therapy	213	61.9
Matrix model	150	43.6
Computerized substance abuse treatment	40	11.6
Community reinforcement plus vouchers	30	8.7
Other treatment approaches	16	4.7

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	44	10					
Number of clients ²	2,032	445					
Number of designated beds	2,324	494					
Utilization rate ³	87.4	90.1					
Average number of designated beds per facility	53	49					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	160
Methadone	156
Buprenorphine	4
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	47	13.7
Any language other than English	146	42.4
Non-English language provided by		
Staff counselor only	85	58.2
On-call interpreter only	32	21.9
Both staff counselor and on-call interpreter	29	19.9
Languages provided by staff counselor ¹		
Spanish	106	93.0
American Indian/Alaskan Native languages	_	_
Other	36	31.6
Outo	00	01.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	302	87.8
Adult women	213	61.9
Clients with co-occurring disorders	214	62.2
Adult men	195	56.7
Clients who have experienced trauma	159	46.2
Criminal justice clients	146	42.4
DUI/DWI clients	133	38.7
Young adults	149	43.3
Adolescents	117	34.0
Clients who have experienced domestic violence	116	33.7
Clients who have experienced sexual		
abuse	119	34.6
Pregnant or postpartum women	103	29.9
Seniors or older adults	100	29.1
LGBT ¹	96	27.9
Veterans	90	26.2
Clients living with HIV/AIDS	91	26.5
Members of military families	59	17.2
Active duty military	48	14.0
Other	14	4.1
No program or group offered	42	12.2

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — New Mexico National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In New Mexico, 136 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 18,808 clients in substance abuse treatment on March 31, 2017. The survey response rate in New Mexico was 83.7 percent.

Facility operation, by number and percent								
			Clients i	n treatmen	t on March 31,	2017		
	Faciliti	es	All clie	nts	Clients und	der age 18		
	No.	%	No.	%	No.	%		
Private non-profit	60	44.1	6,588	35.0	672	56.0		
Private for-profit	44	32.4	9,220	49.0	177	14.8		
Local, county, or community government	3	2.2	829	4.4	28	2.3		
State government	5	3.7	382	2.0	80	6.7		
Federal government	4	2.9	208	1.1	80	6.7		
Tribal government	20	14.7	1,581	8.4	162	13.5		
Total	136	100.0	18,808	100.0	1,199	100.0		

Substance abuse problem treated, by number and percent								
	nt on March 31, 2017							
_	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.			
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	116	90.6	7,603	40.4	434			
Clients with drug abuse only	107	83.6	7,739	41.2	472			
Clients with alcohol abuse only	107	83.6	3,464	18.4	195			
Total			18,806	100.0	1,100			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report substance abuse problem treated in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent									
				Clients in treatment on March 31, 20					
_	Facil	ities¹			All clients		Clients	age < 18	
					Median no.	Median no. of			
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%	
Outpatient	123	90.4	18,141	96.5	390	53	1,085	90.5	
Regular	113	83.1	10,076	53.6	180	49			
Intensive	53	39.0	1,155	6.1	_	19			
Day treatment/partial hospitalization	8	5.9	50	0.3	_	12			
Detoxification	16	11.8	843	4.5	260	5			
Methadone maintenance	30	22.1	6,017	32.0	379	33			
Residential (non-hospital)	20	14.7	605	3.2	_	16	114	9.5	
Short term (<30 days)	11	8.1	54	0.3	_	10			
Long term (30+ days)	14	10.3	251	1.3	_	16			
Detoxification	8	5.9	300	1.6	_	8			
Hospital inpatient	5	3.7	62	0.3	_	14	_	_	
Treatment	3	2.2	34	0.2	_	10			
Detoxification	5	3.7	28	0.1	<u> </u>	6			
Total	136		18,808	100.0	390	50	1,199	100.0	

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	14	1.1
Clients in facilities with OTPs ²		
Any MAT	5,478	1.3
Methadone	5,184	1.4
Buprenorphine	291	1.1
Naltrexone	3	0.1
Clients in facilities without OTPs ²		
Any MAT	852	8.0
Buprenorphine	773	0.9
Naltrexone	79	0.4

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. activity paryment options, by manner and	. po. oo	
	No.	%
Cash or self-payment	105	77.2
Private health insurance	96	70.6
Medicare	58	42.6
Medicaid	114	83.8
State-financed health insurance	78	57.4
Federal military insurance	55	40.4
No payment accepted	10	7.4
Access to Recovery (ATR) vouchers ²	12	8.8
IHS/Tribal/Urban (ITU) funds	31	22.8
Other payments	_	_
Sliding fee scale	67	49.3
Treatment at no charge for clients who can't pay	76	55.9
1 = -104		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	92	67.6
State substance abuse agency	48	35.3
State mental health department	40	29.4
State department of health	62	45.6
Hospital licensing authority	8	5.9
The Joint Commission	21	15.4
Commission on Accreditation of Rehabilitation Facilities	24	17.6
National Committee for Quality Assurance	7	5.1
Council on Accreditation	5	3.7
Healthcare Facilities Accreditation Program	1	0.7
Other state/local agency/organization	7	5.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent						
	Facilities					
	No.	%				
Receives federal, state, county, or local government funds for substance abuse	•					
treatment programs	91	66.9				

¹ Facilities may accept more than one type of payment. ² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by named and persons	Faci	lities
	No.	%
Assessment and pre-treatment services		7.
Screening for substance abuse	128	94.1
Screening for mental health disorders	112	82.4
Comprehensive substance abuse assessment or diagnosis	120	88.2
Comprehensive mental health assessment or diagnosis	86	63.2
Screening for tobacco use	85	62.5
Outreach to persons in the community who may need treatment	91	66.9
Interim services for clients when immediate admission is not possible	76	55.9
No services offered	1	0.7
Testing		
Breathalyzer or other blood alcohol testing	73	53.7
Drug or alcohol urine screening	90	66.2
Screening for hepatitis B	32	23.5
Screening for hepatitis C	37	27.2
HIV testing	34	25.0
STD testing	30	22.1
TB screening	40	29.4
No services offered	34	25.0
Counseling		
Individual counseling	133	97.8
Group counseling	120	88.2
Family counseling	123	90.4
Marital/couples counseling	102	75.0
Transitional services		
Discharge planning	125	91.9
Aftercare/continuing care	117	86.0
No services offered	5	3.7
Pharmacotherapies		
Disulfiram (Antabuse®)	24	17.6
Naltrexone (oral)	30	22.1
Extended-release, injectable naltrexone/Vivitrol®	24	17.6
Acamprosate (Campral®)	21	15.4
Nicotine replacement	31	22.8
Non-nicotine smoking/tobacco cessation medications	34	25.0
Medications for psychiatric disorders	58	42.6
Methadone	14	10.3
Buprenorphine with naloxone (Suboxone®)	23	16.9
Buprenorphine without naloxone	13	9.6
Buprenorphine subdermal implant (Probuphine®)	1	0.7
No services offered	63	46.3
Ancillary services		
Case management services	111	81.6
Social skills development	112	82.4
Mentoring/peer support	69	50.7
Child care for clients' children	5	3.7
Assistance with obtaining social services	98	72.1
Employment counseling or training for clients	49	36.0

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	83	61.0
Domestic violence services	87	64.0
Early intervention for HIV	22	16.2
HIV or AIDS education, counseling, or support	55	40.4
Hepatitis education, counseling, or support	59	43.4
Health education other than HIV/AIDS or hepatitis	72	52.9
Substance abuse education	128	94.1
Transportation assistance to treatment	53	39.0
Mental health services	102	75.0
Acupuncture	25	18.4
Residential beds for clients' children	2	1.5
Self-help groups	55	40.4
Smoking/tobacco cessation counseling	56	41.2
No services offered	2	1.5
Other services		
Treatment for gambling disorder	52	38.2
Treatment for Internet use disorder	29	21.3
Treatment for other addiction disorder	54	39.7
No services offered	66	48.5

	Faci	lities
	No.	%
Substance abuse counseling	133	97.8
Relapse prevention	128	94.1
Cognitive behavioral therapy	128	94.1
Motivational interviewing	125	91.9
Anger management	121	89.0
Brief intervention	116	85.3
Frauma-related counseling	120	88.2
12-step facilitation	91	66.9
Contingency management/motivational incentives	81	59.6
Dialectical behavior therapy	73	53.7
Rational emotive behavioral therapy	59	43.4
Matrix model	65	47.8
Computerized substance abuse treatment	23	16.9
Community reinforcement plus vouchers	22	16.2
Other treatment approaches	22	16.2

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	17	3					
Number of clients ²	563	28					
Number of designated beds	602	34					
Utilization rate ³	93.5	82.4					
Average number of designated beds per facility	35	11					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	262
Methadone	248
Buprenorphine	14
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	30	22.1
Any language other than English	92	67.6
Non-English language provided by		
Staff counselor only	47	51.1
On-call interpreter only	17	18.5
Both staff counselor and on-call interpreter	28	30.4
Languages provided by staff counselor ¹		
Spanish	57	76.0
American Indian/Alaskan Native		
languages	23	30.7
Other	5	6.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities		
	No.	%	
Any program or group	105	77.2	
Adult women	70	51.5	
Clients with co-occurring disorders	74	54.4	
Adult men	65	47.8	
Clients who have experienced trauma	63	46.3	
Criminal justice clients	56	41.2	
DUI/DWI clients	32	23.5	
Young adults	50	36.8	
Adolescents	42	30.9	
Clients who have experienced domestic violence	53	39.0	
Clients who have experienced sexual abuse	49	36.0	
3,15 3, 5 5	49 34	25.0	
Pregnant or postpartum women Seniors or older adults	35	25.7	
LGBT ¹	39	28.7	
Veterans	36	26.5	
Clients living with HIV/AIDS	26	19.1	
Members of military families	28	20.6	
Active duty military	17	12.5	
Other	9	6.6	
No program or group offered	31	22.8	
	-		

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — New York National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In New York, 842 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 110,078 clients in substance abuse treatment on March 31, 2017. The survey response rate in New York was 93.8 percent.

Facility operation, by number and percent								
	Clients in treatment on March 31, 2017							
	Faciliti	es	All clie	nts	Clients und	ler age 18		
	No.	%	No.	%	No.	%		
Private non-profit	596	70.8	75,423	68.5	1,993	73.6		
Private for-profit	138	16.4	22,099	20.1	448	16.5		
Local, county, or community government	53	6.3	6,766	6.1	192	7.1		
State government	42	5.0	3,949	3.6	25	0.9		
Federal government	8	1.0	1,495	1.4	_	_		
Tribal government	5	0.6	346	0.3	50	1.8		
Total	842	100.0	110,078	100.0	2,708	100.0		

Substance abuse problem treated, by number and percent								
Clients in treatment on March 3								
	Facilities ¹ Clients ² C							
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	756	93.8	46,244	42.0	286			
Clients with drug abuse only	734	91.1	49,433	44.9	310			
Clients with alcohol abuse only	645	80.0	14,341	13.0	88			
Total			110,018	100.0	684			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	lities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	579	68.8	100,629	91.4	359	116	2,479	91.5
Regular	522	62.0	51,694	47.0	63	94		
Intensive	225	26.7	4,565	4.1	19	20		
Day treatment/partial hospitalization	63	7.5	1,801	1.6	10	32		
Detoxification	76	9.0	321	0.3	5	7		
Methadone maintenance	415	49.3	42,248	38.4	355	16		
Residential (non-hospital)	214	25.4	7,507	6.8	60	22	224	8.3
Short term (<30 days)	57	6.8	1,476	1.3	45	22		
Long term (30+ days)	166	19.7	5,552	5.0	49	20		
Detoxification	30	3.6	479	0.4	30	15		
Hospital inpatient	72	8.6	1,942	1.8	17	19	5	0.2
Treatment	56	6.7	930	8.0	16	20		
Detoxification	51	6.1	1,012	0.9	9	12		
Total	842		110,078	100.0	272	72	2,708	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	130	9.9
Clients in facilities with OTPs ²		
Any MAT	36,596	8.8
Methadone	35,540	9.3
Buprenorphine	1,034	3.7
Naltrexone	22	0.6
Clients in facilities without OTPs ²		
Any MAT	9,143	8.8
Buprenorphine	7,198	8.5
Naltrexone	1,945	9.9

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

1 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
	No.	%
Cash or self-payment	789	93.7
Private health insurance	666	79.1
Medicare	382	45.4
Medicaid	737	87.5
State-financed health insurance	527	62.6
Federal military insurance	238	28.3
No payment accepted	8	1.0
Access to Recovery (ATR) vouchers ²	25	3.0
IHS/Tribal/Urban (ITU) funds	31	3.7
Other payments	8	1.0
Sliding fee scale	674	80.0
Treatment at no charge for clients who can't pay	360	42.8
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	827	98.2
State substance abuse agency	797	94.7
State mental health department	143	17.0
State department of health	310	36.8
Hospital licensing authority	108	12.8
The Joint Commission	243	28.9
Commission on Accreditation of Rehabilitation Facilities	89	10.6
National Committee for Quality Assurance	19	2.3
Council on Accreditation	33	3.9
Healthcare Facilities Accreditation Program	7	0.8
Other state/local agency/organization	23	2.7

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 433 51.4

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Facili	114100
	Facil	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	805	95.6
Screening for mental health disorders	683	81.1
Comprehensive substance abuse assessment or diagnosis	804	95.5
Comprehensive mental health assessment or diagnosis	437	51.9
Screening for tobacco use	794	94.3
Outreach to persons in the community who may need treatment	478	56.8
Interim services for clients when immediate admission is not possible	328	39.0
No services offered	5	0.6
	J J	0.0
Testing Prosthely was as other bland clockel testing	748	88.8
Breathalyzer or other blood alcohol testing		
Drug or alcohol urine screening	826	98.1
Screening for hepatitis B	336	39.9
Screening for hepatitis C	375	44.5
HIV testing	328	39.0
STD testing	262	31.1
TB screening	414	49.2
No services offered	9	1.1
Counseling		
Individual counseling	841	99.9
Group counseling	819	97.3
Family counseling	688	81.7
Marital/couples counseling	464	55.1
Transitional services		
Discharge planning	833	98.9
Aftercare/continuing care	691	82.1
No services offered	3	0.4
Pharmacotherapies		
Disulfiram (Antabuse®)	263	31.2
Naltrexone (oral)	435	51.7
Extended-release, injectable naltrexone/Vivitrol®	360	42.8
Acamprosate (Campral®)	354	42.0
Nicotine replacement	507	60.2
Non-nicotine smoking/tobacco cessation medications	345	41.0
Medications for psychiatric disorders	543	64.5
Methadone	125	14.8
Buprenorphine with naloxone (Suboxone®)	516	61.3
Buprenorphine without naloxone	304	36.1
Buprenorphine subdermal implant (Probuphine®)	10	1.2
No services offered	119	14.1
Ancillary services		
Case management services	659	78.3
Social skills development	649	77.1
Mentoring/peer support	413	49.0
Child care for clients' children	44	5.2
Assistance with obtaining social services	659	78.3
Employment counseling or training for clients	440	52.3
Continued		

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	516	61.3
Domestic violence services	336	39.9
Early intervention for HIV	269	31.9
HIV or AIDS education, counseling, or support	600	71.3
Hepatitis education, counseling, or support	596	70.8
Health education other than HIV/AIDS or hepatitis	643	76.4
Substance abuse education	832	98.8
Transportation assistance to treatment	490	58.2
Mental health services	541	64.3
Acupuncture	22	2.6
Residential beds for clients' children	18	2.1
Self-help groups	440	52.3
Smoking/tobacco cessation counseling	729	86.6
No services offered	1	0.1
Other services		
Treatment for gambling disorder	204	24.2
Treatment for Internet use disorder	27	3.2
Treatment for other addiction disorder	122	14.5
No services offered	581	69.0

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Facil	lities		
	No.	%		
Substance abuse counseling	836	99.3		
Relapse prevention	826	98.1		
Cognitive behavioral therapy	797	94.7		
Motivational interviewing	812	96.4		
Anger management	730	86.7		
Brief intervention	752	89.3		
Trauma-related counseling	683	81.1		
12-step facilitation	627	74.5		
Contingency management/motivational incentives	442	52.5		
Dialectical behavior therapy	433	51.4		
Rational emotive behavioral therapy	391	46.4		
Matrix model	271	32.2		
Computerized substance abuse treatment	62	7.4		
Community reinforcement plus vouchers	72	8.6		
Other treatment approaches	42	5.0		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	205	68			
Number of clients ²	7,390	1,894			
Number of designated beds	8,003	1,779			
Utilization rate ³	92.3	106.5			
Average number of designated beds per facility	39	26			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	184
Methadone	179
Buprenorphine	5
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	151	17.9
Any language other than English	447	53.1
Non-English language provided by		
Staff counselor only	219	49.0
On-call interpreter only	102	22.8
Both staff counselor and on-call interpreter	126	28.2
Languages provided by staff counselor ¹		
Spanish	331	95.9
American Indian/Alaskan Native languages	_	_
Other	93	27.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	732	86.9
Adult women	542	64.4
Clients with co-occurring disorders	514	61.0
Adult men	543	64.5
Clients who have experienced trauma	342	40.6
Criminal justice clients	342	40.6
DUI/DWI clients	213	25.3
Young adults	298	35.4
Adolescents	214	25.4
Clients who have experienced domestic violence	228	27.1
Clients who have experienced sexual		
abuse	202	24.0
Pregnant or postpartum women	143	17.0
Seniors or older adults	188	22.3
LGBT ¹	156	18.5
Veterans	146	17.3
Clients living with HIV/AIDS	183	21.7
Members of military families	60	7.1
Active duty military	55	6.5
Other	46	5.5
No program or group offered	110	13.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; *n/a* Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HITTONIAN SERVICES. LITER SERVICES L

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — North Carolina National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In North Carolina, 472 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 49,179 clients in substance abuse treatment on March 31, 2017. The survey response rate in North Carolina was 77.5 percent.

Facility operation, by number and perce	nt					
Clients in treatment on March 31, 2017						2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	184	39.0	19,517	39.7	475	20.4
Private for-profit	252	53.4	26,205	53.3	1,819	78.1
Local, county, or community government	12	2.5	773	1.6	3	0.1
State government	13	2.8	798	1.6	25	1.1
Federal government	9	1.9	1,796	3.7	4	0.2
Tribal government	2	0.4	90	0.2	3	0.1
Total	472	100.0	49,179	100.0	2,329	100.0

Substance abuse problem treated, by number and percent						
			Clients i	n treatmer	nt on March 31, 2017	
_	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	402	91.0	19,822	40.3	235	
Clients with drug abuse only	377	85.3	23,198	47.2	282	
Clients with alcohol abuse only	325	73.5	6,159	12.5	71	
Total			49,179	100.0	588	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent									
			Clients in treatment on March 31, 20				17		
_	Facil	ities¹	All clients				Clients	age < 18	
					Median no.	Median no. of			
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%	
Outpatient	393	83.3	46,460	94.5	338	35	2,260	97.0	
Regular	361	76.5	20,764	42.2	210	25			
Intensive	194	41.1	4,184	8.5	40	16			
Day treatment/partial hospitalization	60	12.7	910	1.9	75	15			
Detoxification	44	9.3	403	8.0	5	13			
Methadone maintenance	121	25.6	20,199	41.1	320	50			
Residential (non-hospital)	76	16.1	2,130	4.3	_	13	69	3.0	
Short term (<30 days)	25	5.3	285	0.6	_	15			
Long term (30+ days)	60	12.7	1,734	3.5	_	10			
Detoxification	15	3.2	111	0.2	_	10			
Hospital inpatient	33	7.0	589	1.2	35	14	_	_	
Treatment	23	4.9	306	0.6	14	15			
Detoxification	31	6.6	283	0.6	21	9			
Total	472		49,179	100.0	332	29	2,329	100.0	

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

· ·		
	No.	%
Facilities with OTPs ¹	49	3.7
Clients in facilities with OTPs ²		
Any MAT	16,793	4.1
Methadone	14,497	3.8
Buprenorphine	2,261	8.2
Naltrexone	35	1.0
Clients in facilities without OTPs ²		
Any MAT	5,988	5.7
Buprenorphine	5,504	6.5
Naltrexone	484	2.5

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	•	
	No.	%
Cash or self-payment	416	88.1
Private health insurance	294	62.3
Medicare	206	43.6
Medicaid	317	67.2
State-financed health insurance	240	50.8
Federal military insurance	186	39.4
No payment accepted	13	2.8
Access to Recovery (ATR) vouchers ²	5	1.1
IHS/Tribal/Urban (ITU) funds	23	4.9
Other payments	2	0.4
Sliding fee scale	224	47.5
Treatment at no charge for clients who can't pay	210	44.5

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	422	89.4
State substance abuse agency	306	64.8
State mental health department	241	51.1
State department of health	210	44.5
Hospital licensing authority	24	5.1
The Joint Commission	63	13.3
Commission on Accreditation of Rehabilitation Facilities	207	43.9
	201	10.0
National Committee for Quality Assurance	18	3.8
Council on Accreditation	37	7.8
Healthcare Facilities Accreditation Program	6	1.3
Other state/local agency/organization	16	3.4

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 191 40.5

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by manuser and percent	Faci	lities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	446	94.5
Screening for mental health disorders	330	69.9
Comprehensive substance abuse assessment or diagnosis	428	90.7
Comprehensive mental health assessment or diagnosis	257	54.4
Screening for tobacco use	292	61.9
Outreach to persons in the community who may need treatment	261	55.3
Interim services for clients when immediate admission is not possible	202	42.8
No services offered	12	2.5
Testing		
Breathalyzer or other blood alcohol testing	306	64.8
Drug or alcohol urine screening	418	88.6
Screening for hepatitis B	92	19.5
Screening for hepatitis C	121	25.6
HIV testing	139	29.4
STD testing	113	23.9
TB screening	141	29.9
No services offered	45	9.5
Counseling		
Individual counseling	461	97.7
Group counseling	427	90.5
Family counseling	348	73.7
Marital/couples counseling	261	55.3
Transitional services		
Discharge planning	439	93.0
Aftercare/continuing care	388	82.2
No services offered	13	2.8
Pharmacotherapies		
Disulfiram (Antabuse®)	86	18.2
Naltrexone (oral)	104	22.0
Extended-release, injectable naltrexone/Vivitrol®	85	18.0
Acamprosate (Campral®)	82	17.4
Nicotine replacement	111	23.5
Non-nicotine smoking/tobacco cessation medications	103	21.8
Medications for psychiatric disorders	227	48.1
Methadone	49	10.4
Buprenorphine with naloxone (Suboxone®)	122	25.8
Buprenorphine without naloxone	105	22.2
Buprenorphine subdermal implant (Probuphine®)	5	1.1
No services offered	194	41.1
Ancillary services		
Case management services	330	69.9
Social skills development	316	66.9
Mentoring/peer support	202	42.8
Child care for clients' children	33	7.0
Assistance with obtaining social services	217	46.0
Employment counseling or training for clients	144	30.5

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	220	46.6
Domestic violence services	168	35.6
Early intervention for HIV	80	16.9
HIV or AIDS education, counseling, or support	218	46.2
Hepatitis education, counseling, or support	190	40.3
Health education other than HIV/AIDS or hepatitis	202	42.8
Substance abuse education	443	93.9
Transportation assistance to treatment	177	37.5
Mental health services	320	67.8
Acupuncture	9	1.9
Residential beds for clients' children	18	3.8
Self-help groups	162	34.3
Smoking/tobacco cessation counseling	213	45.1
No services offered	3	0.6
Other services		
Treatment for gambling disorder	83	17.6
Treatment for Internet use disorder	61	12.9
Treatment for other addiction disorder	139	29.4
No services offered	325	68.9

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent			
	Faci	lities	
	No.	%	
Substance abuse counseling	462	97.9	
Relapse prevention	427	90.5	
Cognitive behavioral therapy	441	93.4	
Motivational interviewing	437	92.6	
Anger management	361	76.5	
Brief intervention	378	80.1	
Trauma-related counseling	328	69.5	
12-step facilitation	328	69.5	
Contingency management/motivational incentives	270	57.2	
Dialectical behavior therapy	257	54.4	
Rational emotive behavioral therapy	199	42.2	
Matrix model	226	47.9	
Computerized substance abuse treatment	80	16.9	
Community reinforcement plus vouchers	61	12.9	
Other treatment approaches	30	6.4	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	70	20		
Number of clients ²	1,990	402		
Number of designated beds	2,042	461		
Utilization rate ³	97.5	87.2		
Average number of designated beds per facility	29	23		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	163
Methadone	141
Buprenorphine	22
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	121	25.6
Any language other than English	185	39.2
Non-English language provided by		
Staff counselor only	32	17.3
On-call interpreter only	118	63.8
Both staff counselor and on-call interpreter	35	18.9
Languages provided by staff counselor ¹		
Spanish	61	91.0
American Indian/Alaskan Native		
languages	1	1.5
Other	7	10.4

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	386	81.8
Adult women	218	46.2
Clients with co-occurring disorders	219	46.4
Adult men	200	42.4
Clients who have experienced trauma	175	37.1
Criminal justice clients	142	30.1
DUI/DWI clients	135	28.6
Young adults	143	30.3
Adolescents	123	26.1
Clients who have experienced domestic violence	122	25.8
Clients who have experienced sexual		
abuse	146	30.9
Pregnant or postpartum women	125	26.5
Seniors or older adults	92	19.5
LGBT ¹	101	21.4
Veterans	101	21.4
Clients living with HIV/AIDS	98	20.8
Members of military families	74	15.7
Active duty military	61	12.9
Other	11	2.3
No program or group offered	86	18.2

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

O HEALTH SELVICES. TO SHOW THE SELVICES TO SHOW THE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



2017 State Profile — North Dakota National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In North Dakota, 71 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 2,781 clients in substance abuse treatment on March 31, 2017. The survey response rate in North Dakota was 92.5 percent.

Facility operation, by number and percer	nt					
			Clients	in treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	22	31.0	675	24.3	28	20.7
Private for-profit	32	45.1	1,105	39.7	48	35.6
Local, county, or community government	1	1.4	6	0.2	_	_
State government	10	14.1	782	28.1	53	39.3
Federal government	2	2.8	118	4.2	3	2.2
Tribal government	4	5.6	95	3.4	3	2.2
Total	71	100.0	2,781	100.0	135	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 100			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	67	97.1	1,348	48.5	219	
Clients with drug abuse only	52	75.4	601	21.6	98	
Clients with alcohol abuse only	60	87.0	831	29.9	139	
Total			2,781	100.0	457	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
			Clients in treatment on March 31, 2017					
_	Facili	ities¹		All clients			Clients age < 18	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	64	90.1	2,340	84.1	147	13	120	88.9
Regular	63	88.7	1,313	47.2	80	10		
Intensive	41	57.7	531	19.1	16	9		
Day treatment/partial hospitalization	22	31.0	292	10.5	20	7		
Detoxification	5	7.0	12	0.4	5	2		
Methadone maintenance	8	11.3	192	6.9	87	9		
Residential (non-hospital)	21	29.6	419	15.1	12	8	13	9.6
Short term (<30 days)	13	18.3	91	3.3	1	7		
Long term (30+ days)	19	26.8	306	11.0	11	7		
Detoxification	9	12.7	22	8.0	_	6		
Hospital inpatient	2	2.8	22	8.0	_	11	2	1.5
Treatment	2	2.8	22	0.8	_	11		
Detoxification	2	2.8	_	_	<u>—</u>	_		
Total	71		2,781	100.0	153	12	135	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	2	0.2
Clients in facilities with OTPs ²		
Any MAT	182	*
Methadone	67	*
Buprenorphine	110	0.4
Naltrexone	5	0.1
Clients in facilities without OTPs ²		
Any MAT	39	*
Buprenorphine	34	*
Naltrexone	5	*

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	65	91.5
Private health insurance	45	63.4
Medicare	22	31.0
Medicaid	30	42.3
State-financed health insurance	32	45.1
Federal military insurance	22	31.0
No payment accepted	2	2.8
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	19	26.8
Other payments	_	_
Sliding fee scale	26	36.6
Treatment at no charge for clients who can't pay	27	38.0
45 000		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	66	93.0
State substance abuse agency	64	90.1
State mental health department	30	42.3
State department of health	14	19.7
Hospital licensing authority	4	5.6
The Joint Commission	7	9.9
Commission on Accreditation of Rehabilitation Facilities	4	5.6
National Committee for Quality Assurance	_	_
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	1	1.4

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 26 36.6

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Faci	lities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	68	95.8
Screening for mental health disorders	41	57.7
Comprehensive substance abuse assessment or diagnosis	65	91.5
Comprehensive mental health assessment or diagnosis	26	36.6
Screening for tobacco use	61	85.9
Outreach to persons in the community who may need treatment	42	59.2
nterim services for clients when immediate admission is not possible	46	64.8
No services offered	1	1.4
esting		
Breathalyzer or other blood alcohol testing	45	63.4
Drug or alcohol urine screening	57	80.3
Screening for hepatitis B	7	9.9
Screening for hepatitis C	7	9.9
HIV testing	5	7.0
STD testing	5	7.0
TB screening	17	23.9
No services offered	8	11.3
Counseling		
ndividual counseling	68	95.8
Group counseling	66	93.0
Family counseling	59	83.1
Marital/couples counseling	41	57.7
ransitional services		
Discharge planning	66	93.0
Aftercare/continuing care	63	88.7
No services offered	4	5.6
harmacotherapies		
Disulfiram (Antabuse®)	13	18.3
Naltrexone (oral)	14	19.7
Extended-release, injectable naltrexone/Vivitrol®	12	16.9
Acamprosate (Campral®)	11	15.5
Nicotine replacement	10	14.1
Non-nicotine smoking/tobacco cessation medications	11	15.5
Medications for psychiatric disorders	19	26.8
Methadone	2	2.8
Buprenorphine with naloxone (Suboxone®)	6	8.5
Buprenorphine without naloxone	5	7.0
Buprenorphine subdermal implant (Probuphine®)	-	_
No services offered	49	69.0
ncillary services		
Case management services	52	73.2
Social skills development	49	69.0
Mentoring/peer support	24	33.8
Child care for clients' children	4	5.6
Assistance with obtaining social services	28	39.4
Employment counseling or training for clients	15	21.1
antinuad		

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	29	40.8
Domestic violence services	24	33.8
Early intervention for HIV	3	4.2
HIV or AIDS education, counseling, or support	12	16.9
Hepatitis education, counseling, or support	14	19.7
Health education other than HIV/AIDS or hepatitis	21	29.6
Substance abuse education	69	97.2
Transportation assistance to treatment	23	32.4
Mental health services	47	66.2
Acupuncture	3	4.2
Residential beds for clients' children	3	4.2
Self-help groups	24	33.8
Smoking/tobacco cessation counseling	31	43.7
No services offered	_	-
Other services		
Treatment for gambling disorder	5	7.0
Treatment for Internet use disorder	6	8.5
Treatment for other addiction disorder	15	21.1
No services offered	55	77.5

	Faci	Facilities	
	No.	%	
Substance abuse counseling	69	97.2	
Relapse prevention	65	91.5	
Cognitive behavioral therapy	60	84.5	
Motivational interviewing	57	80.3	
Anger management	40	56.3	
Brief intervention	51	71.8	
Trauma-related counseling	42	59.2	
12-step facilitation	51	71.8	
Contingency management/motivational incentives	34	47.9	
Dialectical behavior therapy	28	39.4	
Rational emotive behavioral therapy	11	15.5	
Matrix model	20	28.2	
Computerized substance abuse treatment	16	22.5	
Community reinforcement plus vouchers	6	8.5	
Other treatment approaches	5	7.0	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	17	2		
Number of clients ²	380	22		
Number of designated beds	259	118		
Utilization rate ³	146.7	18.6		
Average number of designated beds per facility	15	59		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	24
Methadone	9
Buprenorphine	15
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

%
14.1
18.3
7.7
76.9
15.4
33.3
33.3
66.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	57	80.3
Adult women	21	29.6
Clients with co-occurring disorders	28	39.4
Adult men	22	31.0
Clients who have experienced trauma	21	29.6
Criminal justice clients	20	28.2
DUI/DWI clients	30	42.3
Young adults	21	29.6
Adolescents	23	32.4
Clients who have experienced domestic violence	19	26.8
Clients who have experienced sexual		
abuse	12	16.9
Pregnant or postpartum women	11	15.5
Seniors or older adults	11	15.5
LGBT ¹	7	9.9
Veterans	10	14.1
Clients living with HIV/AIDS	5	7.0
Members of military families	5	7.0
Active duty military	5	7.0
Other	3	4.2
No program or group offered	14	19.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

S CHANGE VASA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Ohio National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Ohio, 409 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 56,197 clients in substance abuse treatment on March 31, 2017. The survey response rate in Ohio was 88.3 percent.

Facility operation, by number and percei	nt					
	Clients in treatment o				t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	316	77.3	43,385	77.2	3,123	92.6
Private for-profit	64	15.6	9,283	16.5	238	7.1
Local, county, or community government	7	1.7	789	1.4	2	0.1
State government	4	1.0	658	1.2	8	0.2
Federal government	18	4.4	2,082	3.7	_	_
Tribal government	_	_	_	_	_	_
Total	409	100.0	56,197	100.0	3,371	100.0

Substance abuse problem treated, by number and percent						
			Clients i	n treatmer	nt on March 31, 2017	
_	Faciliti	es¹	Clients ² Clients ² per 100,000			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	340	91.4	22,571	40.2	227	
Clients with drug abuse only	333	89.5	26,495	47.1	282	
Clients with alcohol abuse only	296	79.6	7,131	12.7	75	
Total			56,197	100.0	583	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	363	88.8	52,395	93.2	513	80	3,218	95.5
Regular	347	84.8	27,962	49.8	50	45		
Intensive	234	57.2	6,604	11.8	27	20		
Day treatment/partial hospitalization	56	13.7	909	1.6	21	12		
Detoxification	49	12.0	572	1.0	20	5		
Methadone maintenance	163	39.9	16,348	29.1	334	30		
Residential (non-hospital)	86	21.0	3,081	5.5	31	15	153	4.5
Short term (<30 days)	37	9.0	498	0.9	34	12		
Long term (30+ days)	71	17.4	2,483	4.4	13	15		
Detoxification	11	2.7	100	0.2	18	11		
Hospital inpatient	23	5.6	721	1.3	12	25	_	_
Treatment	14	3.4	527	0.9	_	36		
Detoxification	21	5.1	194	0.3	12	12		
Total	409		56,197	100.0	527	67	3,371	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	22	1.7
Clients in facilities with OTPs ²		
Any MAT	9,442	2.3
Methadone	6,909	1.8
Buprenorphine	2,237	8.1
Naltrexone	296	8.7
Clients in facilities without OTPs ²		
Any MAT	11,193	10.7
Buprenorphine	8,754	10.4
Naltrexone	2,439	12.4

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

. domey paymont options, by mamber and	P 0. 0 0	
	No.	%
Cash or self-payment	379	92.7
Private health insurance	311	76.0
Medicare	200	48.9
Medicaid	358	87.5
State-financed health insurance	175	42.8
Federal military insurance	173	42.3
No payment accepted	4	1.0
Access to Recovery (ATR) vouchers ²	55	13.4
IHS/Tribal/Urban (ITU) funds	4	1.0
Other payments	1	0.2
Sliding fee scale	294	71.9
Treatment at no charge for clients who can't pay	248	60.6
1 Facilities may assent more than one type of neumant		

Facility licensing, certification, or accreditation, by number and percent

Facil	lities¹
No.	%
394	96.3
355	86.8
270	66.0
68	16.6
21	5.1
101	24.7
216	52.8
5	1.2
38	9.3
10	2.4
16	3.9
	No. 394 355 270 68 21 101 216 5 38 10

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Assessment and pro-treatment services very company of the substance abuse 384 39,3 Screening for substance abuse 384 39,3 Screening for substance abuse assessment or diagnosis 383 38,6 Comprehensive substance abuse assessment or diagnosis 254 62,1 Comprehensive mental health assessment or diagnosis 255 62,3 Correcting for bobacco use 256 62,3 Cutrach to persons in the community who may need treatment 263 64,3 Interim services for clients when immediate admission is not possible 209 51,1 No services offered 7 7,7 Fersenting for hepatitis for persons in the community who may need treatment 63 63,3 No services offered 218 53,3 68,3 Prosenting for hepatitis for persons in the community who may need treatment 10 20 64 Screening for hepatitis for persons in the community who may need treatment 10 25 62,3 Screening for hepatitis for the platitis for th	Types of services offered, by number and percent		
Assessment and pro-treatment services 8 Screening for substance abuse 384 93.9 Screening for mental health disorders 311 76.0 Comprehensive substance abuse assessment or diagnosis 383 33.6 Comprehensive mental health assessment or diagnosis 254 62.1 Screening for tobacco use 255 62.3 Outreach to persons in the community who may need treatment 63 64.3 Interim services for clients when immediate admission is not possible 209 51.1 No services offered 7 7.7 Testing 218 53.3 Drug or alcohal urine screening 353 86.3 Screening for hepatitis E 104 25.4 Screening for hepatitis B 104 25.4 Screening for hepatitis B 107 26.2 STD testing 84 20.5 TB screening for hepatitis B 404 20.5 TB screening for hepatitis B 404 20.5 TB screening for hepatitis B 40 20.5 TB screening for hepatitis	Types of cervices energy, by named and persont	Faci	litios
Screening for substance abuse 384 33.9 Screening for mental health disorders 311 76.0 Comprehensive substance abuse assessment or diagnosis 383 33.6 Comprehensive mental health assessment or diagnosis 254 62.1 Screening for tobacco use 255 62.3 Outreach to persons in the community who may need treatment 263 64.3 Interim services for clients when immediate admission is not possible 209 51.1 No services offered 7 7 7.7 Testing 218 53.3 Drug or alcohol urine screening 353 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis B 104 25.4 Screening for hepatitis B 104 25.4 Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening for hepatitis C 117 28.6 HIV testing 218 23.3 Screening for hepatitis C 117 28.6 HIV testing 309 26.7 No services offered 52 12.7 Counseling 309 26.7 No services offered 52 12.7 Counseling 309 30.1 Group counseling 404 88.8 Group counseling 393 96.1 Family counseling 393 96.1 Family counseling 393 96.1 Family counseling 394 39.3 Aftercare/continuing care 343 33.9 No services offered 9 2.2 Tensting 394 39.5 Tensting 395 51.5 Tensting 396 51.5 Tensting 396 51.5 Tensting 397 39.3 No services offered 39.4 Aftercare/continuing care 34.3 Aftercare/con			
Screening for substance abuse 384 93.9 Screening for mental health disorders 311 76.0 Comprehensive substance abuse assessment or diagnosis 254 62.1 Comprehensive mental health assessment or diagnosis 255 62.3 Outreach to persons in the community who may need treatment 263 64.3 Interin services for clients when immediate admission is not possible 7 7.7 No services offered 7 1.7 Testing 2 83.3 20.0 Drug or alcohol urine screening 533 86.3 86.3 Screening for hepatitis C 101 25.4 25.2 HIV testing 107 28.2 28.5 10.2 26.2 STD testing 84 20.5 10.2 20.2 <th>Assessment and pre-treatment services</th> <th></th> <th></th>	Assessment and pre-treatment services		
Screening for mental health disorders 311 76.0 Comprehensive substance abuse assessment or diagnosis 284 62.1 Comprehensive mental health assessment or diagnosis 254 62.3 Comprehensive mental health assessment or diagnosis 255 62.3 Outreach to persons in the community who may need treatment 283 64.3 Interim services for clients when immediate admission is not possible 209 51.1 No services offered 7 7.1 Testing 218 33.3 Breathalyzer or other blood alcohol testing 353 68.3 Drug or alcohol urine screening 353 68.3 Screening for hepatitis C 117 26.2 HIV testing 107 26.2 STD testing 84 20.5 TB screening for hepatitis C 117 26.2 HIV testing 107 26.2 STD testing 84 20.5 TB screening for hepatitis C 117 26.2 HIV testing 102 26.7 TB screening for hepatitis C <td></td> <td>384</td> <td>93.9</td>		384	93.9
Comprehensive mental health assessment or diagnosis 254 62.1 Screening for tobacco use 255 62.3 Outreach to persons in the community who may need treatment 263 64.3 Interim services for clients when immediate admission is not possible 209 51.1 No services offered 7 7.7 Breathalyzer or other blood alcohol testing 218 53.3 Drug or alcohol urine screening 353 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis B 104 25.4 Screening for hepatitis B 107 28.6 STD testing 84 20.5 TB screening No hepatitis C 117 28.6 STD testing 84 20.5 TB screening No hepatitis C 109 26.7 No services offered 20 20.7 Vossering C 20 20.7 Individual counseling 393 96.1 Group counseling 393 96.1 Family counseling 389 98.2	Screening for mental health disorders	311	76.0
Comprehensive mental health assessment or diagnosis 254 62.1 Screening for tobaccouse 62.3 64.3 Outreach to persons in the community who may need treatment 26.3 64.3 Interin services for clients when immediate admission is not possible 209 51.1 No services offered 7 7.7 Breathalyzer or other blood alcohol testing 218 53.3 Drug or alcohol urine screening 353 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis B 104 25.4 Screening for hepatitis B 107 26.2 Streening for hepatitis B 109 26.7 Screening for hepatitis B 109 26.7 Streening for hepatitis B 404 20.5 Streening for hepatitis B 404 20.5 Streening for		383	93.6
Screening for tobacco use 255 62.3 Outreach to persons in the community who may need treatment 263 64.3 Interim services for clients when immediate admission is not possible 209 51.1 No services offered 7 1.7 Testing Breathalyzer or other blood alcohol testing 218 53.3 Drug or alcohol urine screening 363 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis B 107 28.6 HIV testing 84 20.5 TD testing 84 20.5 TB screening for hepatitis B 109 26.7 No services offered 109 26.7 TB screening 404 29.6 No services offered 404 29.8 Group counseling 39 96.1 Family counseling 39 96.1 Family counseling 389 95.1 Family counseling 389 95.1 Family counseling 389 95.1 </td <td>,</td> <td></td> <td>62.1</td>	,		62.1
Outreach to persons in the community who may need treatment 263 64.3 Interin services for clients when immediate admission is not possible 209 51.1 No services offered 7 1.7 Testing 353 86.3 Breathalyzer or other blood alcohol testing 218 53.3 Screening for hepatitis B 104 25.4 Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 44 20.5 TB screening 109 26.7 No services offered 52 12.7 Touristing 44 98.8 Group counseling 393 96.1 Family counseling 393 96.1 Marital/Couples counseling 393 95.1 Marital/Couples counseling 393 95.1 Tassitional services 9 22 Testing planning 393 95.1 No services offered 9 22 Testing planning 393 95.1	· · · · · · · · · · · · · · · · · · ·	255	62.3
Interim services for clients when immediate admission is not possible 7	-	263	64.3
No services offered 7 1.7 Testing 53.3 Breathalyzer or other blood alcohol testing 218 53.3 Drug or alcohol urine screening 363 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Counseling 404 98.8 Group counseling 39 96.1 Family counseling 39 96.1 Family counseling 39 96.1 Family counseling 39 95.1 Family counseling 39 96.1 Family counseling 39 95.1 Family counseling 39 96.1 Family counseling 39 96.1 Family counseling 39 96.1 Family counseling 39 9.2 <			51.1
Breathalyzer or other blood alcohol testing 53.3 86.3 Drug or alcohol urine screening 35.3 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Counseling Individual counseling 404 98.8 Group counseling 393 96.1 Family counseling 393 96.1 Family counseling 39.0 39.0 Marital/couples counseling 39.0 39.1 Marital/couples counseling 65.0 15.9 Discha	·		1.7
Drug or alcohol urine screening 353 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis C 1117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Consetting Individual counseling 404 98.8 Group counseling 393 96.1 Family counseling 393 96.1 Aftercare/continuing cace 343 83.9 <td< td=""><td>Testing</td><td></td><td></td></td<>	Testing		
Drug or alcohol urine screening 353 86.3 Screening for hepatitis B 104 25.4 Screening for hepatitis C 1117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Consetting Individual counseling 404 98.8 Group counseling 393 96.1 Family counseling 393 96.1 Aftercare/continuing cace 343 83.9 <td< td=""><td>•</td><td>218</td><td>53.3</td></td<>	•	218	53.3
Screening for hepatitis B 104 25.4 Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 20 12.7 Counseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services Use of planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse*) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol* 168 41.1 Acamprosate (Campral*) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 8	·	353	86.3
Screening for hepatitis C 117 28.6 HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Courseling 404 98.8 Group counseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 327 80.0 Marital/couples counseling 389 95.1 Family counseling 389 95.1 Marital/couples counseling 389 95.1 Family counseling 389 95.1 Marital/couples counseling 389 95.1 Family counseling 389 95.1 Marital/couples counseling 389 95.1 Tamsitions services 9 2.2 Pharmacotherance 161 39.4 Aftercare/continuing care 36 15.9 Naltrexone (oral) 161<	· · ·	104	25.4
HIV testing 107 26.2 STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Courseling 32 21.7 Individual counseling 393 96.1 Group counseling 393 96.1 Family counseling 327 80.0 Martal/couples counseling 327 80.0 Martal/couples counseling 389 95.1 Transitional services 343 83.9 Transitional services 343 83.9 Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse*) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol* 168 41.1 Acamprosate (Campral*) 79 19.3 Nicotine replacement 115			
STD testing 84 20.5 TB screening 109 26.7 No services offered 52 12.7 Courseling 404 98.8 Group counseling 404 98.8 Group counseling 393 96.1 Family couples counseling 221 54.0 Brail couples counseling 221 54.0 Transitional services 383 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies 9 2.2 Disulfiram (Antabuse®) 65 15.9 Nalitrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Non-nicotine smoking/kobacco cessation medications 87 21.3 Medications for psychiatric disorders 19 4.6 Buprenorphine with naloxone (Suboxone®) 15 3.7 Buprenorphine without naloxone 112 <			
TB screening 109 26.7 No services offered 52 12.7 Counseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 327 80.0 Marital/couples counseling 327 80.0 Transitional services Transitional services Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Pharmacotherapies 9 2.2 Pharmacotherapies 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable natirexone/Vivitrol® 65 15.9 Naltrexone (oral) 168 41.1 Extended-release, injectable natirexone/Vivitrol® 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87			
No services offered 52 12.7 Courseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services Usicharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Usinfiram (Antabuse*) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol* 168 41.1 Acamprosate (Campral*) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone*) 155 37.9 Buprenorphine without naloxone 112 27.4			
Counseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse*) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol** 168 41.1 Acamprosate (Campral**) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone**) 155 37.9 Buprenorphine with unlexone 12 27.4 Buprenorphine			
Individual counseling 404 98.8 Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services User Transitional services Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacothered 365 15.9 Naltrexone (oral) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 15 1.2			
Group counseling 393 96.1 Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services Ususcharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine with naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 384 93.9		404	98.8
Family counseling 327 80.0 Marital/couples counseling 221 54.0 Transitional services Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine with undermal implant (Probuphine®) 5 1.2 No services offered 33 3.5 Pharmacompline without naloxone 31 3.5 Reparation of the pharmacompline without naloxone	· ·		
Marital/couples counseling 221 54.0 Transitional services Transitional services Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 37 33.5 Ancillary services Case management services 384 93.	· · · · · · · · · · · · · · · · · · ·		
Transitional services Bischarge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 33 3.5 Accillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 389 95.1 Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 33 3.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children			
Aftercare/continuing care 343 83.9 No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining soc	Discharge planning	389	95.1
No services offered 9 2.2 Pharmacotherapies Disulfiram (Antabuse®) 65 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8			
Disulfiram (Antabuse®) 15.9 Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Accillary services 384 93.9 Case management services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8			2.2
Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8	Pharmacotherapies		
Naltrexone (oral) 161 39.4 Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8		65	15.9
Extended-release, injectable naltrexone/Vivitrol® 168 41.1 Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8		161	39.4
Acamprosate (Campral®) 79 19.3 Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8	, ,	168	41.1
Nicotine replacement 115 28.1 Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8	·	79	19.3
Non-nicotine smoking/tobacco cessation medications 87 21.3 Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8		115	28.1
Medications for psychiatric disorders 201 49.1 Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8	·	87	21.3
Methadone 19 4.6 Buprenorphine with naloxone (Suboxone®) 155 37.9 Buprenorphine without naloxone 112 27.4 Buprenorphine subdermal implant (Probuphine®) 5 1.2 No services offered 137 33.5 Ancillary services 384 93.9 Social skills development 320 78.2 Mentoring/peer support 231 56.5 Child care for clients' children 49 12.0 Assistance with obtaining social services 314 76.8		201	49.1
Buprenorphine without naloxone11227.4Buprenorphine subdermal implant (Probuphine®)51.2No services offered13733.5Ancillary servicesCase management services38493.9Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8		19	4.6
Buprenorphine without naloxone11227.4Buprenorphine subdermal implant (Probuphine®)51.2No services offered13733.5Ancillary servicesCase management services38493.9Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8	Buprenorphine with naloxone (Suboxone®)	155	37.9
Buprenorphine subdermal implant (Probuphine®)51.2No services offered13733.5Ancillary servicesCase management services38493.9Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8		112	27.4
Ancillary servicesCase management services38493.9Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8	Buprenorphine subdermal implant (Probuphine®)	5	1.2
Case management services38493.9Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8	No services offered	137	33.5
Social skills development32078.2Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8	Ancillary services		
Mentoring/peer support23156.5Child care for clients' children4912.0Assistance with obtaining social services31476.8	Case management services	384	93.9
Child care for clients' children4912.0Assistance with obtaining social services31476.8	Social skills development	320	78.2
Assistance with obtaining social services 314 76.8	Mentoring/peer support	231	56.5
	Child care for clients' children	49	12.0
Employment counseling or training for clients 174 42.5	Assistance with obtaining social services	314	76.8
	Employment counseling or training for clients	174	42.5

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	285	69.7
Domestic violence services	162	39.6
Early intervention for HIV	53	13.0
HIV or AIDS education, counseling, or support	176	43.0
Hepatitis education, counseling, or support	189	46.2
Health education other than HIV/AIDS or hepatitis	216	52.8
Substance abuse education	387	94.6
Transportation assistance to treatment	233	57.0
Mental health services	303	74.1
Acupuncture	7	1.7
Residential beds for clients' children	15	3.7
Self-help groups	186	45.5
Smoking/tobacco cessation counseling	153	37.4
No services offered	1	0.2
Other services		
Treatment for gambling disorder	149	36.4
Treatment for Internet use disorder	36	8.8
Treatment for other addiction disorder	121	29.6
No services offered	209	51.1

	Faci	lities
	No.	%
Substance abuse counseling	407	99.5
Relapse prevention	395	96.6
Cognitive behavioral therapy	395	96.6
Motivational interviewing	375	91.7
Anger management	355	86.8
Brief intervention	331	80.9
Trauma-related counseling	336	82.2
12-step facilitation	299	73.1
Contingency management/motivational incentives	237	57.9
Dialectical behavior therapy	206	50.4
Rational emotive behavioral therapy	180	44.0
Matrix model	167	40.8
Computerized substance abuse treatment	56	13.7
Community reinforcement plus vouchers	49	12.0
Other treatment approaches	22	5.4

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	77	14		
Number of clients ²	1,863	344		
Number of designated beds	1,992	355		
Utilization rate ³	93.5	96.9		
Average number of designated beds per facility	26	25		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	81
Methadone	59
Buprenorphine	19
Naltrexone	3

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	234	57.2
Any language other than English	232	56.7
Non-English language provided by		
Staff counselor only	9	3.9
On-call interpreter only	188	81.0
Both staff counselor and on-call interpreter	35	15.1
Languages provided by staff counselor ¹		
Spanish	39	88.6
American Indian/Alaskan Native		
languages		_
Other	11	25.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	342	83.6
Adult women	188	46.0
Clients with co-occurring disorders	196	47.9
Adult men	168	41.1
Clients who have experienced trauma	140	34.2
Criminal justice clients	146	35.7
DUI/DWI clients	44	10.8
Young adults	91	22.2
Adolescents	118	28.9
Clients who have experienced domestic violence	64	15.6
Clients who have experienced sexual		
abuse	69	16.9
Pregnant or postpartum women	82	20.0
Seniors or older adults	39	9.5
LGBT ¹	40	9.8
Veterans	48	11.7
Clients living with HIV/AIDS	25	6.1
Members of military families	24	5.9
Active duty military	17	4.2
Other	13	3.2
No program or group offered	67	16.4

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Oklahoma National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Oklahoma, 191 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 14,466 clients in substance abuse treatment on March 31, 2017. The survey response rate in Oklahoma was 92.8 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	97	50.8	7,267	50.2	556	66.7
Private for-profit	47	24.6	5,077	35.1	146	17.5
Local, county, or community government	3	1.6	44	0.3	21	2.5
State government	10	5.2	532	3.7	15	1.8
Federal government	6	3.1	396	2.7	_	_
Tribal government	28	14.7	1,150	7.9	95	11.4
Total	191	100.0	14,466	100.0	833	100.0

Substance abuse problem treated, by number and percent					
Clients in treatment on March 3					nt on March 31, 2017
	Faciliti	es ¹	Clients	S ²	Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	170	93.9	5,419	37.5	166
Clients with drug abuse only	155	85.6	6,673	46.1	216
Clients with alcohol abuse only	148	81.8	2,374	16.4	76
Total			14,466	100.0	459

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	158	82.7	13,250	91.6	128	40	721	86.6
Regular	156	81.7	9,180	63.5	5	40		
Intensive	57	29.8	646	4.5	_	12		
Day treatment/partial hospitalization	8	4.2	23	0.2	_	5		
Detoxification	19	9.9	78	0.5	4	6		
Methadone maintenance	34	17.8	3,323	23.0	140	8		
Residential (non-hospital)	45	23.6	1,074	7.4	_	22	110	13.2
Short term (<30 days)	24	12.6	210	1.5	_	8		
Long term (30+ days)	39	20.4	812	5.6	_	18		
Detoxification	8	4.2	52	0.4	_	5		
Hospital inpatient	9	4.7	142	1.0	_	5	2	0.2
Treatment	4	2.1	76	0.5	_	76		
Detoxification	9	4.7	66	0.5	_	5		
Total	191		14,466	100.0	128	36	833	100.0

¹ Facilities may provide more than one type of care.

No.	%
15	1.1
3,351	8.0
3,197	0.8
142	0.5
12	0.4
305	0.3
207	0.2
98	0.5
	3,351 3,197 142 12 305 207

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	149	78.0
Private health insurance	97	50.8
Medicare	49	25.7
Medicaid	137	71.7
State-financed health insurance	80	41.9
Federal military insurance	58	30.4
No payment accepted	8	4.2
Access to Recovery (ATR) vouchers ²	14	7.3
IHS/Tribal/Urban (ITU) funds	43	22.5
Other payments	1	0.5
Sliding fee scale	96	50.3
Treatment at no charge for clients who can't pay	127	66.5

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	173	90.6
State substance abuse agency	144	75.4
State mental health department	122	63.9
State department of health	46	24.1
Hospital licensing authority	7	3.7
The Joint Commission	27	14.1
Commission on Accreditation of Rehabilitation Facilities	97	50.8
National Committee for Quality Assurance	_	_
Council on Accreditation	5	2.6
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	4	2.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 118 61.8

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent Facilities No. % Assessment and pre-treatment services Screening for substance abuse 189 99.0 Screening for mental health disorders 160 83.8 Comprehensive substance abuse assessment or diagnosis 178 93.2 Comprehensive mental health assessment or diagnosis 94 49.2 Screening for tobacco use 158 82.7 Outreach to persons in the community who may need treatment 163 85.3 Interim services for clients when immediate admission is not possible 136 71.2 No services offered
Assessment and pre-treatment servicesScreening for substance abuse18999.0Screening for mental health disorders16083.8Comprehensive substance abuse assessment or diagnosis17893.2Comprehensive mental health assessment or diagnosis9449.2Screening for tobacco use15882.7Outreach to persons in the community who may need treatment16385.3Interim services for clients when immediate admission is not possible13671.2
Assessment and pre-treatment services Screening for substance abuse 189 99.0 Screening for mental health disorders 160 83.8 Comprehensive substance abuse assessment or diagnosis 178 93.2 Comprehensive mental health assessment or diagnosis 94 49.2 Screening for tobacco use 158 82.7 Outreach to persons in the community who may need treatment 163 85.3 Interim services for clients when immediate admission is not possible 136 71.2
Screening for substance abuse18999.0Screening for mental health disorders16083.8Comprehensive substance abuse assessment or diagnosis17893.2Comprehensive mental health assessment or diagnosis9449.2Screening for tobacco use15882.7Outreach to persons in the community who may need treatment16385.3Interim services for clients when immediate admission is not possible13671.2
Screening for mental health disorders16083.8Comprehensive substance abuse assessment or diagnosis17893.2Comprehensive mental health assessment or diagnosis9449.2Screening for tobacco use15882.7Outreach to persons in the community who may need treatment16385.3Interim services for clients when immediate admission is not possible13671.2
Comprehensive substance abuse assessment or diagnosis17893.2Comprehensive mental health assessment or diagnosis9449.2Screening for tobacco use15882.7Outreach to persons in the community who may need treatment16385.3Interim services for clients when immediate admission is not possible13671.2
Comprehensive mental health assessment or diagnosis 94 49.2 Screening for tobacco use 158 82.7 Outreach to persons in the community who may need treatment 163 85.3 Interim services for clients when immediate admission is not possible 136 71.2
Screening for tobacco use 158 82.7 Outreach to persons in the community who may need treatment 163 85.3 Interim services for clients when immediate admission is not possible 136 71.2
Outreach to persons in the community who may need treatment 163 85.3 Interim services for clients when immediate admission is not possible 136 71.2
Interim services for clients when immediate admission is not possible 136 71.2
'
Testing
Breathalyzer or other blood alcohol testing 72 37.7
Drug or alcohol urine screening 147 77.0
Screening for hepatitis B 32 16.8
Screening for hepatitis C 40 20.9
HIV testing 43 22.5
STD testing 32 16.8
TB screening 56 29.3
No services offered 40 20.9
Counseling
Individual counseling 189 99.0
Group counseling 182 95.3
Family counseling 165 86.4
Marital/couples counseling 144 75.4
Transitional services
Discharge planning 185 96.9
Aftercare/continuing care 169 88.5
No services offered 1 0.5
Pharmacotherapies
Disulfiram (Antabuse®) 19 9.9
Naltrexone (oral) 20 10.5
Extended-release, injectable naltrexone/Vivitrol® 10 5.2
Acamprosate (Campral®) 22 11.5
Nicotine replacement 50 26.2
Non-nicotine smoking/tobacco cessation medications 37 19.4
Medications for psychiatric disorders 69 36.1
Methadone 15 7.9
Buprenorphine with naloxone (Suboxone®) 29 15.2
Buprenorphine without naloxone 16 8.4
Buprenorphine subdermal implant (Probuphine®) — — — —
No services offered 94 49.2
Ancillary services
Case management services 181 94.8
Social skills development 158 82.7
Mentoring/peer support 116 60.7
Child care for clients' children 11 5.8
Assistance with obtaining social services 146 76.4
Employment counseling or training for clients 63 33.0

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	128	67.0
Domestic violence services	94	49.2
Early intervention for HIV	46	24.1
HIV or AIDS education, counseling, or support	132	69.1
Hepatitis education, counseling, or support	114	59.7
Health education other than HIV/AIDS or hepatitis	114	59.7
Substance abuse education	185	96.9
Transportation assistance to treatment	92	48.2
Mental health services	142	74.3
Acupuncture	1	0.5
Residential beds for clients' children	9	4.7
Self-help groups	75	39.3
Smoking/tobacco cessation counseling	139	72.8
No services offered	_	_
Other services		
Treatment for gambling disorder	52	27.2
Treatment for Internet use disorder	22	11.5
Treatment for other addiction disorder	58	30.4
No services offered	107	56.0

	Faci	lities
	No.	%
Substance abuse counseling	188	98.4
Relapse prevention	185	96.9
Cognitive behavioral therapy	187	97.9
Motivational interviewing	173	90.6
Anger management	165	86.4
Brief intervention	156	81.7
Trauma-related counseling	173	90.6
12-step facilitation	112	58.6
Contingency management/motivational incentives	94	49.2
Dialectical behavior therapy	78	40.8
Rational emotive behavioral therapy	101	52.9
Matrix model	96	50.3
Computerized substance abuse treatment	42	22.0
Community reinforcement plus vouchers	15	7.9
Other treatment approaches	7	3.7

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	41	2		
Number of clients ²	1,029	44		
Number of designated beds	1,258	75		
Utilization rate ³	81.8	58.7		
Average number of designated beds per facility	31	38		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	85
Methadone	81
Buprenorphine	4
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	78	40.8
Any language other than English	91	47.6
Non-English language provided by		
Staff counselor only	10	11.0
On-call interpreter only	67	73.6
Both staff counselor and on-call interpreter	14	15.4
Languages provided by staff counselor ¹		
Spanish	19	79.2
American Indian/Alaskan Native		
languages	3	12.5
Other	4	16.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	148	77.5
Adult women	110	57.6
Clients with co-occurring disorders	102	53.4
Adult men	107	56.0
Clients who have experienced trauma	97	50.8
Criminal justice clients	84	44.0
DUI/DWI clients	41	21.5
Young adults	61	31.9
Adolescents	56	29.3
Clients who have experienced domestic violence	64	33.5
Clients who have experienced sexual		
abuse	60	31.4
Pregnant or postpartum women	52	27.2
Seniors or older adults	49	25.7
LGBT ¹	46	24.1
Veterans	50	26.2
Clients living with HIV/AIDS	36	18.8
Members of military families	34	17.8
Active duty military	29	15.2
Other	6	3.1
No program or group offered	43	22.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; *n/a* Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

S CHAMINA SERVICES USA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Oregon National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Oregon, 226 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 24,027 clients in substance abuse treatment on March 31, 2017. The survey response rate in Oregon was 92.7 percent.

Facility operation, by number and percent						
	Clients in treatment on				t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	125	55.3	13,054	54.3	476	48.7
Private for-profit	69	30.5	8,232	34.3	194	19.9
Local, county, or community government	20	8.8	2,106	8.8	168	17.2
State government	1	0.4	16	0.1	_	_
Federal government	5	2.2	213	0.9	100	10.2
Tribal government	6	2.7	406	1.7	39	4.0
Total	226	100.0	24,027	100.0	977	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 100,000 p			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	199	94.3	9,857	41.0	284	
Clients with drug abuse only	175	82.9	9,434	39.3	281	
Clients with alcohol abuse only	174	82.5	4,736	19.7	140	
Total			24,027	100.0	705	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report substance abuse problem treated in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	203	89.8	22,579	94.0	515	58	856	87.6
Regular	194	85.8	12,874	53.6	181	45		
Intensive	144	63.7	3,060	12.7	_	16		
Day treatment/partial hospitalization	34	15.0	301	1.3	_	7		
Detoxification	19	8.4	675	2.8	7	4		
Methadone maintenance	39	17.3	5,669	23.6	633	20		
Residential (non-hospital)	39	17.3	1,400	5.8	_	19	121	12.4
Short term (<30 days)	28	12.4	561	2.3	_	6		
Long term (30+ days)	33	14.6	650	2.7	_	16		
Detoxification	26	11.5	189	8.0	_	4		
Hospital inpatient	3	1.3	48	0.2	_	8	_	_
Treatment	2	0.9	12	*	_	_		
Detoxification	3	1.3	36	0.1	_	8		
Total	226		24,027	100.0	515	49	977	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs),	
by number and percent	

	No.	%
Facilities with OTPs ¹	13	1.0
Clients in facilities with OTPs ²		
Any MAT	5,328	1.3
Methadone	4,657	1.2
Buprenorphine	626	2.3
Naltrexone	45	1.3
Clients in facilities without OTPs ²		
Any MAT	1,678	1.6
Buprenorphine	1,506	1.8
Naltrexone	172	0.9

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

i dominy puryment opinione, by manifest		
	No.	%
Cash or self-payment	214	94.7
Private health insurance	208	92.0
Medicare	78	34.5
Medicaid	191	84.5
State-financed health insurance	136	60.2
Federal military insurance	92	40.7
No payment accepted	1	0.4
Access to Recovery (ATR) vouchers ²	40	17.7
IHS/Tribal/Urban (ITU) funds	43	19.0
Other payments	_	_
Sliding fee scale	172	76.1
Treatment at no charge for clients who can't p	ay 129	57.1
1 =====================================		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	222	98.2
State substance abuse agency	210	92.9
State mental health department	129	57.1
State department of health	63	27.9
Hospital licensing authority	5	2.2
The Joint Commission	16	7.1
Commission on Accreditation of Rehabilitation Facilities	27	11.9
National Committee for Quality Assurance	2	0.9
Council on Accreditation	6	2.7
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	7	3.1

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Eaci	lities
	No.	%
Assessment and pre-treatment services	140.	70
Screening for substance abuse	215	95.1
Screening for mental health disorders	178	78.8
Comprehensive substance abuse assessment or diagnosis	218	96.5
Comprehensive mental health assessment or diagnosis	120	53.1
Screening for tobacco use	201	88.9
Outreach to persons in the community who may need treatment	148	65.5
Interim services for clients when immediate admission is not possible	139	61.5
No services offered	_	_
Testing		
Breathalyzer or other blood alcohol testing	101	44.7
Drug or alcohol urine screening	218	96.5
Screening for hepatitis B	54	23.9
Screening for hepatitis C	52	23.0
HIV testing	42	18.6
STD testing	34	15.0
TB screening	60	26.5
No services offered	6	2.7
Counseling		2.1
Individual counseling	226	100.0
Group counseling	225	99.6
Family counseling	214	94.7
Marital/couples counseling	148	65.5
Transitional services	710	00.0
Discharge planning	224	99.1
Aftercare/continuing care	199	88.1
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	34	15.0
Naltrexone (oral)	39	17.3
Extended-release, injectable naltrexone/Vivitrol®	36	15.9
Acamprosate (Campral®)	21	9.3
Nicotine replacement	54	23.9
Non-nicotine smoking/tobacco cessation medications	39	17.3
Medications for psychiatric disorders	88	38.9
Methadone	13	5.8
Buprenorphine with naloxone (Suboxone®)	49	21.7
Buprenorphine without naloxone	31	13.7
Buprenorphine subdermal implant (Probuphine®)	2	0.9
No services offered	102	45.1
Ancillary services		
Case management services	211	93.4
Social skills development	188	83.2
Mentoring/peer support	157	69.5
Child care for clients' children	24	10.6
Assistance with obtaining social services	160	70.8
Employment counseling or training for clients	101	44.7

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	156	69.0
Domestic violence services	108	47.8
Early intervention for HIV	46	20.4
HIV or AIDS education, counseling, or support	112	49.6
Hepatitis education, counseling, or support	113	50.0
Health education other than HIV/AIDS or hepatitis	128	56.6
Substance abuse education	221	97.8
Transportation assistance to treatment	135	59.7
Mental health services	158	69.9
Acupuncture	20	8.8
Residential beds for clients' children	8	3.5
Self-help groups	114	50.4
Smoking/tobacco cessation counseling	162	71.7
No services offered	_	_
Other services		
Treatment for gambling disorder	78	34.5
Treatment for Internet use disorder	24	10.6
Treatment for other addiction disorder	64	28.3
No services offered	120	53.1

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent			
	Facil	ities	
	No.	%	
Substance abuse counseling	224	99.1	
Relapse prevention	220	97.3	
Cognitive behavioral therapy	220	97.3	
Motivational interviewing	221	97.8	
Anger management	184	81.4	
Brief intervention	181	80.1	
Trauma-related counseling	200	88.5	
12-step facilitation	176	77.9	
Contingency management/motivational incentives	136	60.2	
Dialectical behavior therapy	179	79.2	
Rational emotive behavioral therapy	107	47.3	
Matrix model	124	54.9	
Computerized substance abuse treatment	37	16.4	
Community reinforcement plus vouchers	33	14.6	
Other treatment approaches	22	9.7	

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	34	2			
Number of clients ²	1,297	14			
Number of designated beds	970	17			
Utilization rate ³	133.7	82.4			
Average number of designated beds per facility	29	9			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	129
Methadone	112
Buprenorphine	15
Naltrexone	1

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	108	47.8
Any language other than English	140	61.9
Non-English language provided by		
Staff counselor only	29	20.7
On-call interpreter only	75	53.6
Both staff counselor and on-call interpreter	36	25.7
Languages provided by staff counselor ¹		
Spanish	60	92.3
American Indian/Alaskan Native		
languages	2	3.1
Other	8	12.3

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	203	89.8
Adult women	133	58.8
Clients with co-occurring disorders	117	51.8
Adult men	125	55.3
Clients who have experienced trauma	116	51.3
Criminal justice clients	96	42.5
DUI/DWI clients	124	54.9
Young adults	69	30.5
Adolescents	70	31.0
Clients who have experienced domestic violence	66	29.2
Clients who have experienced sexual		
abuse	59	26.1
Pregnant or postpartum women	45	19.9
Seniors or older adults	36	15.9
LGBT ¹	45	19.9
Veterans	37	16.4
Clients living with HIV/AIDS	25	11.1
Members of military families	17	7.5
Active duty military	16	7.1
Other	19	8.4
No program or group offered	23	10.2

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Pennsylvania National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Pennsylvania, 502 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 64,303 clients in substance abuse treatment on March 31, 2017. The survey response rate in Pennsylvania was 93.3 percent.

Facility operation, by number and percent						
			Clients	in treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	284	56.6	31,509	49.0	1,292	66.5
Private for-profit	211	42.0	31,287	48.7	652	33.5
Local, county, or community government	1	0.2	14	*	_	_
State government	1	0.2	75	0.1	_	_
Federal government	5	1.0	1,418	2.2	_	_
Tribal government	_	_	_	_	_	_
Total	502	100.0	64,303	100.0	1,944	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31						
_	Facilities ¹ Clients ²				Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	448	90.7	22,317	34.7	211	
Clients with drug abuse only	440	89.1	34,072	53.0	330	
Clients with alcohol abuse only	390	78.9	7,914	12.3	74	
Total			64,303	100.0	615	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clients in treatment on March 31, 20				
_	Facil	ities¹		All clients			Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	374	74.5	57,460	89.4	380	79	1,807	93.0
Regular	353	70.3	21,250	33.0	19	51		
Intensive	256	51.0	9,410	14.6	78	25		
Day treatment/partial hospitalization	76	15.1	903	1.4	10	12		
Detoxification	26	5.2	77	0.1	_	10		
Methadone maintenance	159	31.7	25,820	40.2	320	20		
Residential (non-hospital)	143	28.5	6,318	9.8	35	25	137	7.0
Short term (<30 days)	77	15.3	2,885	4.5	44	25		
Long term (30+ days)	114	22.7	2,618	4.1	16	21		
Detoxification	46	9.2	815	1.3	12	15		
Hospital inpatient	22	4.4	525	8.0	29	14	_	_
Treatment	17	3.4	368	0.6	24	14		
Detoxification	20	4.0	157	0.2	19	8		
Total	502		64,303	100.0	303	60	1,944	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	79	6.0
Clients in facilities with OTPs ²		
Any MAT	23,225	5.6
Methadone	22,136	5.8
Buprenorphine	993	3.6
Naltrexone	96	2.8
Clients in facilities without OTPs ²		
Any MAT	5,033	4.8
Buprenorphine	3,666	4.3
Naltrexone	1,367	7.0

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	461	91.8
Private health insurance	350	69.7
Medicare	126	25.1
Medicaid	410	81.7
State-financed health insurance	252	50.2
Federal military insurance	92	18.3
No payment accepted	1	0.2
Access to Recovery (ATR) vouchers ²	21	4.2
IHS/Tribal/Urban (ITU) funds	2	0.4
Other payments	1	0.2
Sliding fee scale	212	42.2
Treatment at no charge for clients who can't pay	172	34.3

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	491	97.8
State substance abuse agency	434	86.5
State mental health department	125	24.9
State department of health	383	76.3
Hospital licensing authority	29	5.8
The Joint Commission	100	19.9
Commission on Accreditation of Rehabilitation Facilities	151	30.1
National Committee for Quality Assurance	10	2.0
Council on Accreditation	21	4.2
Healthcare Facilities Accreditation Program	2	0.4
Other state/local agency/organization	15	3.0

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 261 52.0

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	471	93.8
Screening for mental health disorders	320	63.7
Comprehensive substance abuse assessment or diagnosis	462	92.0
Comprehensive mental health assessment or diagnosis	203	40.4
Screening for tobacco use	303	60.4
Outreach to persons in the community who may need treatment	307	61.2
Interim services for clients when immediate admission is not possible	224	44.6
No services offered	11	2.2
	- 11	۷.۷
Testing Prostholyzer or other blood clockel testing	307	61.2
Breathalyzer or other blood alcohol testing		
Drug or alcohol urine screening	448	89.2
Screening for hepatitis B	132	26.3
Screening for hepatitis C	167	33.3
HIV testing	150	29.9
STD testing	111	22.1
TB screening	225	44.8
No services offered	42	8.4
Counseling		
Individual counseling	500	99.6
Group counseling	477	95.0
Family counseling	458	91.2
Marital/couples counseling	356	70.9
Transitional services		
Discharge planning	495	98.6
Aftercare/continuing care	482	96.0
No services offered	3	0.6
Pharmacotherapies		
Disulfiram (Antabuse®)	75	14.9
Naltrexone (oral)	167	33.3
Extended-release, injectable naltrexone/Vivitrol®	182	36.3
Acamprosate (Campral®)	81	16.1
Nicotine replacement	129	25.7
Non-nicotine smoking/tobacco cessation medications	88	17.5
Medications for psychiatric disorders	235	46.8
Methadone	77	15.3
Buprenorphine with naloxone (Suboxone®)	165	32.9
Buprenorphine without naloxone	90	17.9
Buprenorphine subdermal implant (Probuphine®)	7	1.4
No services offered	156	31.1
Ancillary services		
Case management services	352	70.1
Social skills development	344	68.5
Mentoring/peer support	281	56.0
Child care for clients' children	39	7.8
Assistance with obtaining social services	363	72.3
Employment counseling or training for clients	171	34.1
Continued		

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	287	57.2		
Domestic violence services	171	34.1		
Early intervention for HIV	124	24.7		
HIV or AIDS education, counseling, or support	263	52.4		
Hepatitis education, counseling, or support	242	48.2		
Health education other than HIV/AIDS or hepatitis	260	51.8		
Substance abuse education	493	98.2		
Transportation assistance to treatment	254	50.6		
Mental health services	285	56.8		
Acupuncture	13	2.6		
Residential beds for clients' children	16	3.2		
Self-help groups	265	52.8		
Smoking/tobacco cessation counseling	210	41.8		
No services offered	1	0.2		
Other services				
Treatment for gambling disorder	140	27.9		
Treatment for Internet use disorder	39	7.8		
Treatment for other addiction disorder	102	20.3		
No services offered	316	62.9		

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent			
	Facil	ities	
	No.	%	
Substance abuse counseling	497	99.0	
Relapse prevention	485	96.6	
Cognitive behavioral therapy	483	96.2	
Motivational interviewing	470	93.6	
Anger management	414	82.5	
Brief intervention	415	82.7	
Trauma-related counseling	420	83.7	
12-step facilitation	442	88.0	
Contingency management/motivational incentives	278	55.4	
Dialectical behavior therapy	302	60.2	
Rational emotive behavioral therapy	267	53.2	
Matrix model	148	29.5	
Computerized substance abuse treatment	57	11.4	
Community reinforcement plus vouchers	64	12.7	
Other treatment approaches	29	5.8	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	136	16		
Number of clients ²	6,231	325		
Number of designated beds	6,591	351		
Utilization rate ³	94.5	92.6		
Average number of designated beds per facility	48	22		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	181
Methadone	173
Buprenorphine	8
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	123	24.5
Any language other than English	186	37.1
Non-English language provided by		
Staff counselor only	60	32.3
On-call interpreter only	94	50.5
Both staff counselor and on-call interpreter	32	17.2
Languages provided by staff counselor ¹		
Spanish	79	85.9
American Indian/Alaskan Native languages	_	_
Other	21	22.8
Ottiei	۷ ۱	22.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	421	83.9
Adult women	260	51.8
Clients with co-occurring disorders	255	50.8
Adult men	235	46.8
Clients who have experienced trauma	203	40.4
Criminal justice clients	170	33.9
DUI/DWI clients	101	20.1
Young adults	154	30.7
Adolescents	112	22.3
Clients who have experienced domestic violence	118	23.5
Clients who have experienced sexual		
abuse	123	24.5
Pregnant or postpartum women	119	23.7
Seniors or older adults	93	18.5
LGBT ¹	98	19.5
Veterans	91	18.1
Clients living with HIV/AIDS	88	17.5
Members of military families	44	8.8
Active duty military	33	6.6
Other	15	3.0
No program or group offered	81	16.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:


https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Puerto Rico National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Puerto Rico, 97 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 9,232 clients in substance abuse treatment on March 31, 2017. The survey response rate in Puerto Rico was 68.2 percent.

Facility operation, by number and perce	nt					
	Clients in treatment of				t on March 31,	, 2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	62	63.9	2,187	23.7	946	86.2
Private for-profit	19	19.6	2,692	29.2	142	12.9
Local, county, or community government	_	_	_	_	_	_
State government	15	15.5	4,022	43.6	9	0.8
Federal government	1	1.0	331	3.6	_	_
Tribal government	_	_	_	_	_	_
Total	97	100.0	9,232	100.0	1,097	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 201						
	Faciliti	es¹	Clients ² Clients ² per 100,000 p			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	59	85.5	1,801	19.7	50	
Clients with drug abuse only	54	78.3	6,537	71.6	222	
Clients with alcohol abuse only	35	50.7	795	8.7	28	
Total			9,132	100.0	300	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facili	ties¹			All clients		Clients age < 1	
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	39	40.2	6,051	65.5	460	80	126	11.5
Regular	29	29.9	1,546	16.7	_	53		
Intensive	16	16.5	153	1.7	_	7		
Day treatment/partial hospitalization	14	14.4	124	1.3	_	5		
Detoxification	15	15.5	220	2.4	35	10		
Methadone maintenance	22	22.7	4,008	43.4	460	44		
Residential (non-hospital)	56	57.7	1,632	17.7	_	23	955	87.1
Short term (<30 days)	16	16.5	28	0.3	_	5		
Long term (30+ days)	54	55.7	1,466	15.9	_	20		
Detoxification	16	16.5	138	1.5	_	10		
Hospital inpatient	14	14.4	1,549	16.8	_	19	16	1.5
Treatment	12	12.4	1,274	13.8	_	27		
Detoxification	13	13.4	275	3.0	_	11		
Total	97		9,232	100.0	460	40	1,097	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	6	0.5
Cliente in facilities with OTDs2		
Clients in facilities with OTPs ²		
Any MAT	3,615	0.9
Methadone	3,615	0.9
Buprenorphine	_	_
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	591	0.6
Buprenorphine	586	0.7
Naltrexone	5	*
1 Development of all OTD facilities in the LLC 2 Development of all		

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

Cash or self-payment 44 45.4 Private health insurance 30 30.9 Medicare 20 20.6 Medicaid 17 17.5 State-financed health insurance 27 27.8 23 Federal military insurance 23.7 No payment accepted 50 51.5 Access to Recovery (ATR) vouchers² n/a n/a IHS/Tribal/Urban (ITU) funds 2 2.1

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	93	95.9
State substance abuse agency	88	90.7
State mental health department	76	78.4
State department of health	77	79.4
Hospital licensing authority	17	17.5
The Joint Commission	24	24.7
Commission on Accreditation of Rehabilitation Facilities	15	15.5
National Committee for Quality Assurance	9	9.3
Council on Accreditation	8	8.2
Healthcare Facilities Accreditation Program	10	10.3
Other state/local agency/organization	2	2.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent				
	Facilities			
-	No.	%		
Receives federal, state, county, or local government funds for substance abuse				
treatment programs	66	68.0		

Treatment at no charge for clients who can't pay

Other payments

Sliding fee scale

20.6

78.4

20

76

No.

%

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Facilities	
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	97	100.0
Screening for mental health disorders	63	64.9
Comprehensive substance abuse assessment or diagnosis	84	86.6
Comprehensive mental health assessment or diagnosis	69	71.1
Screening for tobacco use	49	50.5
Outreach to persons in the community who may need treatment	64	66.0
nterim services for clients when immediate admission is not possible	37	38.1
No services offered	_	_
esting		
Breathalyzer or other blood alcohol testing	21	21.6
Drug or alcohol urine screening	92	94.8
Screening for hepatitis B	35	36.1
Screening for hepatitis C	36	37.1
HIV testing	57	58.8
STD testing	42	43.3
TB screening	50	51.5
No services offered	4	4.1
Counseling		
ndividual counseling	95	97.9
Group counseling	94	96.9
Family counseling	90	92.8
Marital/couples counseling	68	70.1
ransitional services		
Discharge planning	90	92.8
Aftercare/continuing care	79	81.4
No services offered	_	
Pharmacotherapies		
Disulfiram (Antabuse®)	11	11.3
Naltrexone (oral)	11	11.3
Extended-release, injectable naltrexone/Vivitrol®	3	3.1
Acamprosate (Campral®)	14	14.4
Nicotine replacement	19	19.6
Non-nicotine smoking/tobacco cessation medications	19	19.6
Medications for psychiatric disorders	29	29.9
Methadone	6	6.2
Buprenorphine with naloxone (Suboxone®)	24	24.7
Buprenorphine without naloxone	7	7.2
Buprenorphine subdermal implant (Probuphine®)	2	2.1
No services offered	49	50.5
Ancillary services		
Case management services	83	85.6
Social skills development	75 	77.3
Mentoring/peer support	47	48.5
Child care for clients' children	10	10.3
Assistance with obtaining social services	74	76.3
Employment counseling or training for clients	46	47.4

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	60	61.9		
Domestic violence services	49	50.5		
Early intervention for HIV	54	55.7		
HIV or AIDS education, counseling, or support	63	64.9		
Hepatitis education, counseling, or support	42	43.3		
Health education other than HIV/AIDS or hepatitis	68	70.1		
Substance abuse education	95	97.9		
Transportation assistance to treatment	63	64.9		
Mental health services	66	68.0		
Acupuncture	9	9.3		
Residential beds for clients' children	5	5.2		
Self-help groups	41	42.3		
Smoking/tobacco cessation counseling	43	44.3		
No services offered	_	_		
Other services				
Treatment for gambling disorder	19	19.6		
Treatment for Internet use disorder	13	13.4		
Treatment for other addiction disorder	23	23.7		
No services offered	67	69.1		

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Faci	lities		
	No.	%		
Substance abuse counseling	90	92.8		
Relapse prevention	82	84.5		
Cognitive behavioral therapy	70	72.2		
Motivational interviewing	71	73.2		
Anger management	77	79.4		
Brief intervention	75	77.3		
Trauma-related counseling	51	52.6		
12-step facilitation	37	38.1		
Contingency management/motivational incentives	46	47.4		
Dialectical behavior therapy	26	26.8		
Rational emotive behavioral therapy	55	56.7		
Matrix model	19	19.6		
Computerized substance abuse treatment	9	9.3		
Community reinforcement plus vouchers	15	15.5		
Other treatment approaches	5	5.2		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	38	7			
Number of clients ²	1,561	395			
Number of designated beds	1,303	170			
Utilization rate ³	119.8	232.4			
Average number of designated beds per facility	34	24			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	108
Methadone	108
Buprenorphine	_
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	16	16.5
Any language other than English	83	85.6
Non-English language provided by		
Staff counselor only	62	74.7
On-call interpreter only	7	8.4
Both staff counselor and on-call interpreter	14	16.9
Languages provided by staff counselor ¹		
Spanish	76	100.0
American Indian/Alaskan Native languages	_	_
Other	_	_

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	61	62.9
Adult women	32	33.0
Clients with co-occurring disorders	41	42.3
Adult men	41	42.3
Clients who have experienced trauma	33	34.0
Criminal justice clients	32	33.0
DUI/DWI clients	8	8.2
Young adults	30	30.9
Adolescents	12	12.4
Clients who have experienced domestic violence	32	33.0
Clients who have experienced sexual abuse	34	35.1
3,10 3, 0 0	3 4 17	35.1 17.5
Pregnant or postpartum women Seniors or older adults	33	34.0
LGBT ¹	33	34.0
Veterans	28	28.9
Clients living with HIV/AIDS	40	41.2
Members of military families	27	27.8
Active duty military	18	18.6
Other	3	3.1
No program or group offered	36	37.1

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at: https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HITTONIAN SERVICES LIGHT

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



2017 State Profile — Rhode Island National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Rhode Island, 48 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 8,001 clients in substance abuse treatment on March 31, 2017. The survey response rate in Rhode Island was 89.1 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31	, 2017
	Faciliti	es	All clie	nts	Clients und	der age 18
	No.	%	No.	%	No.	%
Private non-profit	31	64.6	4,396	54.9	51	100.0
Private for-profit	14	29.2	3,243	40.5	<u> </u>	_
Local, county, or community government	_	_	_	_	<u> </u>	_
State government	_	_	_	_	<u> </u>	_
Federal government	2	4.2	360	4.5	<u> </u>	_
Tribal government	1	2.1	2	*	_	-
Total	48	100.0	8,001	100.0	51	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	44	93.6	3,132	39.1	365	
Clients with drug abuse only	39	83.0	3,869	48.4	453	
Clients with alcohol abuse only	33	70.2	1,000	12.5	115	
Total			8,001	100.0	933	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	41	85.4	7,660	95.7	332	84	51	100.0
Regular	40	83.3	2,369	29.6	24	50		
Intensive	20	41.7	337	4.2	11	21		
Day treatment/partial hospitalization	9	18.8	26	0.3	11	15		
Detoxification	15	31.3	16	0.2	2	_		
Methadone maintenance	25	52.1	4,912	61.4	279	26		
Residential (non-hospital)	11	22.9	269	3.4	35	16	_	_
Short term (<30 days)	8	16.7	123	1.5	11	21		
Long term (30+ days)	10	20.8	126	1.6	28	12		
Detoxification	2	4.2	20	0.2	20	_		
Hospital inpatient	4	8.3	72	0.9	15	_	_	_
Treatment	2	4.2	17	0.2	9	_		
Detoxification	4	8.3	55	0.7	10	-		
Total	48		8,001	100.0	332	57	51	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	18	1.4
Cliente in facilities with OTBs2		
Clients in facilities with OTPs ²		
Any MAT	4,435	1.1
Methadone	4,155	1.1
Buprenorphine	249	0.9
Naltrexone	31	0.9
Clients in facilities without OTPs ²		
Any MAT	659	0.6
Buprenorphine	625	0.7
Naltrexone	34	0.2

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

i domey paymont options, by manifor	u.i.u. po.o.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	No.	%
Cash or self-payment	45	93.8
Private health insurance	43	89.6
Medicare	20	41.7
Medicaid	42	87.5
State-financed health insurance	38	79.2
Federal military insurance	22	45.8
No payment accepted	_	_
Access to Recovery (ATR) vouchers ²	15	31.3
IHS/Tribal/Urban (ITU) funds	1	2.1
Other payments	_	_
Sliding fee scale	16	33.3
Treatment at no charge for clients who can't p	pay 12	25.0
1 Facilities may accept more than one type of nayment		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	46	95.8
State substance abuse agency	40	83.3
State mental health department	34	70.8
State department of health	31	64.6
Hospital licensing authority	8	16.7
The Joint Commission	13	27.1
Commission on Accreditation of Rehabilitation Facilities	26	54.2
National Committee for Quality Assurance	2	4.2
Council on Accreditation	5	10.4
Healthcare Facilities Accreditation Program	1	2.1
Other state/local agency/organization	_	_

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	_	
		ilities
Assessment and any functional analysis	No.	<u>%</u>
Assessment and pre-treatment services	40	05.0
Screening for substance abuse	46	95.8
Screening for mental health disorders	37	77.1
Comprehensive substance abuse assessment or diagnosis	48	100.0
Comprehensive mental health assessment or diagnosis	35	72.9
Screening for tobacco use	39	81.3
Outreach to persons in the community who may need treatment	32	66.7
Interim services for clients when immediate admission is not possible	21	43.8
No services offered		
Testing	40	22.2
Breathalyzer or other blood alcohol testing	40	83.3
Drug or alcohol urine screening	46	95.8
Screening for hepatitis B	13	27.1
Screening for hepatitis C	18	37.5
HIV testing	18	37.5
STD testing	10	20.8
TB screening	21	43.8
No services offered	1	2.1
Counseling		
Individual counseling	47	97.9
Group counseling	44	91.7
Family counseling	43	89.6
Marital/couples counseling	34	70.8
Transitional services		
Discharge planning	48	100.0
Aftercare/continuing care	46	95.8
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	22	45.8
Naltrexone (oral)	24	50.0
Extended-release, injectable naltrexone/Vivitrol®	20	41.7
Acamprosate (Campral®)	20	41.7
Nicotine replacement	21	43.8
Non-nicotine smoking/tobacco cessation medications	15	31.3
Medications for psychiatric disorders	29	60.4
Methadone	18	37.5
Buprenorphine with naloxone (Suboxone®)	31	64.6
Buprenorphine without naloxone	20	41.7
Buprenorphine subdermal implant (Probuphine®)	2	4.2
No services offered	3	6.3
Ancillary services		
Case management services	45	93.8
Social skills development	38	79.2
Mentoring/peer support	32	66.7
Child care for clients' children	3	6.3
Assistance with obtaining social services	35	72.9
Employment counseling or training for clients	17	35.4
Continued		

Types of services offered, by number and percent (continued)					
	Facilities				
	No.	%			
Assistance in locating housing for clients	36	75.0			
Domestic violence services	20	41.7			
Early intervention for HIV	19	39.6			
HIV or AIDS education, counseling, or support	34	70.8			
Hepatitis education, counseling, or support	33	68.8			
Health education other than HIV/AIDS or hepatitis	30	62.5			
Substance abuse education	47	97.9			
Transportation assistance to treatment	29	60.4			
Mental health services	37	77.1			
Acupuncture	7	14.6			
Residential beds for clients' children	1	2.1			
Self-help groups	23	47.9			
Smoking/tobacco cessation counseling	31	64.6			
No services offered	_	_			
Other services					
Treatment for gambling disorder	16	33.3			
Treatment for Internet use disorder	5	10.4			
Treatment for other addiction disorder	10	20.8			
No services offered	30	62.5			

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent					
	Faci	lities			
	No.	%			
Substance abuse counseling	47	97.9			
Relapse prevention	46	95.8			
Cognitive behavioral therapy	46	95.8			
Motivational interviewing	43	89.6			
Anger management	39	81.3			
Brief intervention	39	81.3			
Trauma-related counseling	39	81.3			
12-step facilitation	35	72.9			
Contingency management/motivational incentives	28	58.3			
Dialectical behavior therapy	30	62.5			
Rational emotive behavioral therapy	16	33.3			
Matrix model	12	25.0			
Computerized substance abuse treatment	4	8.3			
Community reinforcement plus vouchers	5	10.4			
Other treatment approaches		_			

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	11	3				
Number of clients ²	269	63				
Number of designated beds	284	58				
Utilization rate ³	94.7	108.6				
Average number of designated beds per facility	26	19				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	419
Methadone	392
Buprenorphine	23
Naltrexone	3

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	10	20.8
Any language other than English	29	60.4
Non-English language provided by		
Staff counselor only	8	27.6
On-call interpreter only	13	44.8
Both staff counselor and on-call interpreter	8	27.6
Languages provided by staff counselor ¹		
Spanish	15	93.8
American Indian/Alaskan Native languages	_	_
Other	4	25.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	41	85.4
Adult women	30	62.5
Clients with co-occurring disorders	30	62.5
Adult men	26	54.2
Clients who have experienced trauma	14	29.2
Criminal justice clients	18	37.5
DUI/DWI clients	11	22.9
Young adults	7	14.6
Adolescents	6	12.5
Clients who have experienced domestic violence	8	16.7
Clients who have experienced sexual abuse	8	16.7
	o 15	31.3
Pregnant or postpartum women Seniors or older adults	12	25.0
LGBT ¹	8	16.7
Veterans	9	18.8
Clients living with HIV/AIDS	6	12.5
Members of military families	5	10.4
Active duty military	6	12.5
Other	2	4.2
No program or group offered	7	14.6

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

THINK SERVICES. LO.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities





https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — South Carolina National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In South Carolina, 108 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 16,844 clients in substance abuse treatment on March 31, 2017. The survey response rate in South Carolina was 94.8 percent.

Facility operation, by number and percent								
			Clients i	n treatmen	t on March 31,	2017		
	Facilities		All clie	nts	Clients und	ler age 18		
	No.	%	No.	%	No.	%		
Private non-profit	38	35.2	5,423	32.2	887	55.6		
Private for-profit	28	25.9	6,221	36.9	49	3.1		
Local, county, or community government	23	21.3	3,109	18.5	403	25.3		
State government	16	14.8	1,667	9.9	255	16.0		
Federal government	3	2.8	424	2.5	_	_		
Tribal government	_	_	_	_	_	_		
Total	108	100.0	16,844	100.0	1,594	100.0		

Substance abuse problem treated, by number and percent									
	nt on March 31, 2017								
	Facilities ¹ Clients ²				Facilities ¹ Clients ² Clie		Facilities ¹ Clients ² Clients ²		Clients ² per 100,000 pop.
	No.	%	No.	%	age 18 or older				
Clients with both alcohol and drug abuse	88	87.1	5,459	32.4	122				
Clients with drug abuse only	89	88.1	8,814	52.3	211				
Clients with alcohol abuse only	78	77.2	2,571	15.3	56				
Total			16,844	100.0	389				

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
				Clients in treatment on March 31, 201				
_	Facil	ities¹			All clients		Clients	age < 18
_					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	90	83.3	16,060	95.3	322	66	1,532	96.1
Regular	81	75.0	8,417	50.0	236	65		
Intensive	47	43.5	1,663	9.9	187	20		
Day treatment/partial hospitalization	11	10.2	38	0.2	_	19		
Detoxification	11	10.2	8	*	_	8		
Methadone maintenance	27	25.0	5,934	35.2	314	20		
Residential (non-hospital)	18	16.7	538	3.2	22	18	16	1.0
Short term (<30 days)	8	7.4	106	0.6	6	9		
Long term (30+ days)	11	10.2	406	2.4	6	23		
Detoxification	2	1.9	26	0.2	10	16		
Hospital inpatient	12	11.1	246	1.5	_	13	46	2.9
Treatment	9	8.3	138	8.0	_	14		
Detoxification	11	10.2	108	0.6	_	7		
Total	108		16,844	100.0	322	55	1,594	100.0

¹ Facilities may provide more than one type of care.

	NI-	0/
	No.	%
Facilities with OTPs ¹	16	1.2
Clients in facilities with OTPs ²		
Any MAT	5,931	1.4
Methadone	5,360	1.4
Buprenorphine	564	2.0
Naltrexone	7	0.2
Clients in facilities without OTPs ²		
Any MAT	436	0.4
Buprenorphine	382	0.5
Naltrexone	54	0.3

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r dome, payment opinione, by manner and		
	No.	%
Cash or self-payment	98	90.7
Private health insurance	74	68.5
Medicare	22	20.4
Medicaid	69	63.9
State-financed health insurance	54	50.0
Federal military insurance	37	34.3
No payment accepted	8	7.4
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	2	1.9
Other payments	_	_
Sliding fee scale	47	43.5
Treatment at no charge for clients who can't pay	66	61.1
1 = -104		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	101	93.5
State substance abuse agency	78	72.2
State mental health department	8	7.4
State department of health	85	78.7
Hospital licensing authority	9	8.3
The Joint Commission	18	16.7
Commission on Accreditation of Rehabilitation Facilities	71	65.7
National Committee for Quality Assurance	7	6.5
Council on Accreditation	3	2.8
Healthcare Facilities Accreditation Program	1	0.9
Other state/local agency/organization	7	6.5

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 61 56.5

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by humber and percent	Fac	ilities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	102	94.4
Screening for mental health disorders	61	56.5
Comprehensive substance abuse assessment or diagnosis	100	92.6
Comprehensive mental health assessment or diagnosis	26	24.1
Screening for tobacco use	74	68.5
Outreach to persons in the community who may need treatment	78	72.2
Interim services for clients when immediate admission is not possible	69	63.9
No services offered	1	0.9
Testing		
Breathalyzer or other blood alcohol testing	73	67.6
Drug or alcohol urine screening	104	96.3
Screening for hepatitis B	30	27.8
Screening for hepatitis C	38	35.2
HIV testing	58	53.7
STD testing	24	22.2
TB screening	62	57.4
No services offered	1	0.9
Counseling		
Individual counseling	108	100.0
Group counseling	100	92.6
Family counseling	94	87.0
Marital/couples counseling	79	73.1
Transitional services		
Discharge planning	107	99.1
Aftercare/continuing care	98	90.7
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	14	13.0
Naltrexone (oral)	15	13.9
Extended-release, injectable naltrexone/Vivitrol®	14	13.0
Acamprosate (Campral®)	12	11.1
Nicotine replacement	20	18.5
Non-nicotine smoking/tobacco cessation medications	15	13.9
Medications for psychiatric disorders	24	22.2
Methadone	16	14.8
Buprenorphine with naloxone (Suboxone®)	29	26.9
Buprenorphine without naloxone	23	21.3
Buprenorphine subdermal implant (Probuphine®)	1	0.9
No services offered	62	57.4
Ancillary services		
Case management services	102	94.4
Social skills development	79	73.1
Mentoring/peer support	50	46.3
Child care for clients' children	7	6.5
Assistance with obtaining social services	56	51.9
Employment counseling or training for clients	30	27.8

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	45	41.7
Domestic violence services	42	38.9
Early intervention for HIV	49	45.4
HIV or AIDS education, counseling, or support	70	64.8
Hepatitis education, counseling, or support	43	39.8
Health education other than HIV/AIDS or hepatitis	45	41.7
Substance abuse education	107	99.1
Transportation assistance to treatment	26	24.1
Mental health services	42	38.9
Acupuncture	4	3.7
Residential beds for clients' children	5	4.6
Self-help groups	57	52.8
Smoking/tobacco cessation counseling	52	48.1
No services offered	_	-
Other services		
Treatment for gambling disorder	57	52.8
Treatment for Internet use disorder	12	11.1
Treatment for other addiction disorder	28	25.9
No services offered	44	40.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Faci	lities		
	No.	%		
Substance abuse counseling	105	97.2		
Relapse prevention	106	98.1		
Cognitive behavioral therapy	99	91.7		
Motivational interviewing	101	93.5		
Anger management	83	76.9		
Brief intervention	91	84.3		
Trauma-related counseling	84	77.8		
12-step facilitation	78	72.2		
Contingency management/motivational incentives	47	43.5		
Dialectical behavior therapy	33	30.6		
Rational emotive behavioral therapy	54	50.0		
Matrix model	53	49.1		
Computerized substance abuse treatment	10	9.3		
Community reinforcement plus vouchers	12	11.1		
Other treatment approaches	2	1.9		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	16	10			
Number of clients ²	521	237			
Number of designated beds	546	182			
Utilization rate ³	95.4	130.2			
Average number of designated beds per facility	34	18			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	118
Methadone	107
Buprenorphine	11
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	54	50.0
Any language other than English	64	59.3
Non-English language provided by		
Staff counselor only	3	4.7
On-call interpreter only	42	65.6
Both staff counselor and on-call interpreter	19	29.7
Languages provided by staff counselor ¹		
Spanish	22	100.0
American Indian/Alaskan Native		
languages	_	_
Other	2	9.1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	91	84.3
Adult women	55	50.9
Clients with co-occurring disorders	43	39.8
Adult men	47	43.5
Clients who have experienced trauma	34	31.5
Criminal justice clients	42	38.9
DUI/DWI clients	52	48.1
Young adults	27	25.0
Adolescents	46	42.6
Clients who have experienced domestic violence	26	24.1
Clients who have experienced sexual		
abuse	25	23.1
Pregnant or postpartum women	33	30.6
Seniors or older adults	15	13.9
LGBT ¹	7	6.5
Veterans	10	9.3
Clients living with HIV/AIDS	16	14.8
Members of military families	6	5.6
Active duty military	8	7.4
Other	4	3.7
No program or group offered	17	15.7

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

HIMIN SERVICES. CO.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — South Dakota National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In South Dakota, 58 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 2,941 clients in substance abuse treatment on March 31, 2017. The survey response rate in South Dakota was 90.6 percent.

Facility operation, by number and percen	nt					
	Clients in treatment on March 31, 2017					
	Facilities		All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	30	51.7	1,552	52.8	140	46.5
Private for-profit	10	17.2	704	23.9	64	21.3
Local, county, or community government	2	3.4	272	9.2	_	_
State government	2	3.4	18	0.6	_	_
Federal government	7	12.1	182	6.2	78	25.9
Tribal government	7	12.1	213	7.2	19	6.3
Total	58	100.0	2,941	100.0	301	100.0

Substance abuse problem treated, by number and percent					
			Clients i	n treatmer	it on March 31, 2017
	Faciliti	es¹	Clients ² Clients ² per 100,000 po		
	No.	%	No.	%	age 18 or older
Clients with both alcohol and drug abuse	52	94.5	1,734	59.0	230
Clients with drug abuse only	41	74.5	466	15.9	68
Clients with alcohol abuse only	45	81.8	741	25.2	106
Total			2,941	100.0	403

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent									
			Clients in treatment on March 31, 2017						
_	Facili	ities¹		All clients				Clients age < 18	
					Median no. of clients per	<u>-</u>			
	No.	<u></u> %	No.	%	OTP facility	non-OTP facility	No.	<u>%</u>	
Outpatient	48	82.8	2,367	80.5	154	27	178	59.1	
Regular	48	82.8	1,706	58.0	_	15			
Intensive	35	60.3	438	14.9	_	15			
Day treatment/partial hospitalization	8	13.8	57	1.9	_	18			
Detoxification	1	1.7	16	0.5	16	_			
Methadone maintenance	5	8.6	150	5.1	138	6			
Residential (non-hospital)	15	25.9	440	15.0	_	19	88	29.2	
Short term (<30 days)	8	13.8	105	3.6	_	11			
Long term (30+ days)	12	20.7	314	10.7	_	21			
Detoxification	1	1.7	21	0.7	_	_			
Hospital inpatient	4	6.9	134	4.6	_	18	35	11.6	
Treatment	3	5.2	119	4.0	_	18			
Detoxification	2	3.4	15	0.5	_	15			
Total	58		2,941	100.0	154	27	301	100.0	

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	1	0.1
OI 4 1 6 1111 111 OTD 2		
Clients in facilities with OTPs ²		
Any MAT	154	*
Methadone	154	*
Buprenorphine	_	_
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	22	*
Buprenorphine	10	*
Naltrexone	12	0.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	•	
	No.	%
Cash or self-payment	47	81.0
Private health insurance	39	67.2
Medicare	15	25.9
Medicaid	34	58.6
State-financed health insurance	32	55.2
Federal military insurance	25	43.1
No payment accepted	3	5.2
Access to Recovery (ATR) vouchers ²	13	22.4
IHS/Tribal/Urban (ITU) funds	24	41.4
Other payments	1	1.7
Sliding fee scale	33	56.9
Treatment at no charge for clients who can't pay	36	62.1

Facility licensing, certification, or accreditation, by number and percent

	Facil	ities¹
	No.	%
Any listed agency/organization	55	94.8
State substance abuse agency	46	79.3
State mental health department	12	20.7
State department of health	29	50.0
Hospital licensing authority	5	8.6
The Joint Commission	7	12.1
Commission on Accreditation of Rehabilitation Facilities	7	12.1
National Committee for Quality Assurance	1	1.7
Council on Accreditation	2	3.4
Healthcare Facilities Accreditation Program	2	3.4
Other state/local agency/organization	8	13.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 48 82.8

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Session of an appeal of the appeal	Types of services offered, by number and percent		
seesament and pre-treatment services No. % creening for substance abuse 56 96.6 creening for mental health disorders 49 94.5 comprehensive mental health disorders 28 48.3 comprehensive mental health assessment or diagnosis 28 48.2 services offered 10 17.2 2 creening for feet patitity 31 22.4 45.9 to services offered	Types of services offered, by flutiliser and percent	Faci	ilitios
Sessment and pre-treatment services 56 96.6			
creening for substance abuse 56 96.6 creening for mental nealth disorders 49 84.5 comprehensive substance abuse assessment or diagnosis 57 98.3 comprehensive mental health assessment or diagnosis 28 48.3 creening for tobacco use 48 82.8 utreach to persons in the community who may need treatment 48 82.8 services offered — — stift — — — stift — — — stug or alcohol urine screening 48 82.8 2.8 creening for hepatitis B 10 17.2 17.2 11 19.0 17.2<	Assessment and pre-treatment services		
omprehensive substance abuse assessment or diagnosis 57 98.3 omprehensive mental health assessment or diagnosis 28 48.3 28.8 cereaing for tobacco use 48 82.8 <td>Screening for substance abuse</td> <td>56</td> <td>96.6</td>	Screening for substance abuse	56	96.6
omprehensive mental health assessment or diagnosis 28 48.3 creening for tobacco use 48 82.8 uttrach to be presons in the community who may need treatment 48 82.8 sterim services for clients when immediate admission is not possible 48 82.8 o services offered — — string — — string — — reathalyzer or other blood alcohol testing 35 60.3 rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 To testing 11 19.0 B screening 34 58.6 o services offered 3 38 usesing 58 100.0 pusseling 58 100.0 autistional counseling 58 100.0 autistical couples courseling 58 100.0 autistical couples courseling 58 <	Screening for mental health disorders	49	84.5
comprehensive mental health assessment or diagnosis 28 48.3 creening for tobacco use 48 82.8 uttreach to persons in the community who may need treatment 48 82.8 terrim services for clients when immediate admission is not possible 48 82.8 o services offered — — sting — — treathalyzer or other blood alcohol testing 35 60.3 rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 11 19.0 IV testing 13 22.4 To testing 11 19.0 B screening 34 58.6 o services offered 5 8.6 o services offered 5 8.8 very cleaning 58 100.0 amily counseling 51 87.9 amily counseling 51 87.9 amily counseling 51 87.9		57	98.3
creening for tobacco use 48 82.8 utreach to persons in the community who may need treatment 48 82.8 terting hervices for clients when immediate admission is not possible	•	28	48.3
utreach to persons in the community who may need treatment 48 32.8 terim services for clients when immediate admission is not possible 48 32.8 o services offered – – – isting — –	Screening for tobacco use	48	82.8
Iterim services for clients when immediate admission is not possible 48 82.8 o services offered — — string — — string — — reathalyzer or other blood alcohol testing 35 60.3 rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 constricting 58 100.0 croup counseling 57 88.3 amily counseling 57 88.3 amily counseling 57 88.3 amily counseling 58 100.0 amily counseling 58 100.0 scharge planning 58 100.0 fischerage planning 58 100.0 fischerage planning 58	Outreach to persons in the community who may need treatment	48	82.8
o services offered — — sting — — eathalyzer or other blood alcohol testing 35 60.3 rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 B screening 34 58.6 o services offered 8 13.8 bunseling 51 8.3 dividual counseling 57 98.3 amily counseling 58 100.0 rought counseling 57 98.3 amily counseling 58 100.0 rought counseling 57 98.3 antity counseling 58 100.0 <th< td=""><td></td><td>48</td><td>82.8</td></th<>		48	82.8
reathalyzer or other blood alcohol testing rug or alcohol urine screening rug or alcohol urine screening reathalyzer or other blood alcohol testing rug or alcohol urine screening reathalyzer or alcohol urine screening reathalyzer or alcohol urine screening reathalyzer or hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 15 19.0 B screening 34 58.6 o services offered 34 58.6 o services offered 38 100.0 roup counseling 39 67.2 amily counseling 57 98.3 amily counseling 57 98.3 amily counseling 57 98.3 amily counseling 58 100.0 roup counseling 59 28.3 amily counseling 59 29.3 arital/couples counseling 59 100.0 fetercare/continuing care 50 services offered 50 services offered 51 100.0 fetercare/continuing care 54 93.1 altrexone (oral) 58 100.0 tetrareac/continuing care 59 15.5 altrexone (oral) 11 19.0 15.5 altrexone (oral) 11 19.0 15.5 altrexone (oral) 11 19.0 15.5 altrexone (oral) 16 19.3 acamprosate (Campralio) 17 22.9 dedications for psychiatric disorders 18 13.8 control-picaement of 22.9 dedications for psychiatric disorders 19 32.8 dedications for psychiatric disorders 10 1.7 uprenorphine with naloxone 10 25.9 as emanagement services 20 38 65.5 as emanagement services 21 47 81.0 22 40 44.8 23 42 40 46.9 24 44.8 25 40 44.8 26 44.8 26 44.8 26 44.8 27 52 55.2	No services offered	_	_
rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 busseling 58 100.0 dividual counseling 57 98.3 amily counseling 57 98.3 amily counseling 51 37.9 antal couples counseling 58 100.0 amily counseling 58 100.0 are parametic screec 51 37.9 satiticouples counseling 58 100.0 latite screec fered 5 93.1 o services offered 5 93.1 o services offered 5 93.1 stellare, countinuing care 54 93.1 o services offered 5 93.1 stellare, countinuing care 5 93.1	esting		
rug or alcohol urine screening 44 75.9 creening for hepatitis B 10 17.2 creening for hepatitis C 11 19.0 IV testing 13 22.4 TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 busseling 58 100.0 dividual counseling 57 98.3 amily counseling 57 98.3 amily counseling 51 37.9 antal couples counseling 58 100.0 amily counseling 58 100.0 are parametic screec 51 37.9 satiticouples counseling 58 100.0 latite screec fered 5 93.1 o services offered 5 93.1 o services offered 5 93.1 stellare, countinuing care 54 93.1 o services offered 5 93.1 stellare, countinuing care 5 93.1	Breathalyzer or other blood alcohol testing	35	60.3
creening for hepatitis C 11 19.0 IV testing 13 22.4 TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 burseling 58 100.0 dividual counseling 57 98.3 amily counseling 57 98.3 amily counseling 51 87.9 amily counseling 51 87.9 antital/couples counseling 59 67.2 amily counseling 51 87.9 antital/couples counseling 58 100.0 fetercare/continuing care 54 93.1 o services offered 5 93.1 o services offered 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/vivitrol® 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorde	Drug or alcohol urine screening	44	75.9
creening for hepatitis C 11 19.0 IV testing 13 22.4 TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 burseling 58 100.0 dividual counseling 57 98.3 amily counseling 57 98.3 amily counseling 51 87.9 amily counseling 51 87.9 antital/couples counseling 59 67.2 amily counseling 51 87.9 antital/couples counseling 58 100.0 fetercare/continuing care 54 93.1 o services offered 5 93.1 o services offered 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/vivitrol® 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorde	Screening for hepatitis B	10	17.2
Vitesting 13 22.4 15 16 17 19.0 18 19.0 18 19.0 18 19.0 18 19.0 18 19.0	Screening for hepatitis C	11	19.0
TD testing 11 19.0 B screening 34 58.6 o services offered 8 13.8 Descriptions of services offered 8 100.0 rouge counseling 57 98.3 amitional services ansitional services sischarge planning 58 100.0 fleercare/continuing care 54 93.1 o services offered - - ansitional Annabase** 9 15.5 altersace (ornal) 11 19.0 kended-release, injectable naltrexone/Vivitrol** 8 13.8 acamprosate (Campral**) 8 13.8 ictotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 dedications for psychiatric disorders 13 22.4 ledications for psychiatric disorders 1 1.7 uprenorphine with naloxone (Suboxone**) 6 1.3 uprenorphine without naloxone 5 6 o services offered <td< td=""><td>HIV testing</td><td>13</td><td>22.4</td></td<>	HIV testing	13	22.4
B screening 34 58.6 o services offered 8 13.8 burseling 58 100.0 troup counseling 57 98.3 amily counseling 51 87.9 larital/couples counseling 39 67.2 larital/couples counseling 58 100.0 flercare/continuing care 54 93.1 o services offered 5 93.1 o services offered 9 15.5 altrexner/continuing care 9 15.5 altrexner/continuing care 9 15.5 saltrexner/continuing care 5 13.8 scotine-replacement 1 13.8 locitie s	STD testing	11	19.0
vounseling 58 100.0 roup counseling 57 98.3 amily counseling 51 87.9 amily counseling 39 67.2 amiltal/couples counseling 39 67.2 amital/couples counseling 39 67.2 amital/couples counseling 58 100.0 feercare/continuing care 54 93.1 o services offered — — amazotherapies 31 10.0 isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 camprosate (practical comprals) 8 13.8 corn-nicotine smoking/tobacco cessation medications 13 22.4 detications for psychiatric disorders 19 32.8 dethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 6 <td>TB screening</td> <td>34</td> <td>58.6</td>	TB screening	34	58.6
dividual counseling 58 100.0 roup counseling 57 98.3 amily counseling 51 87.9 antial/couples counseling 39 67.2 ansitional services Use ansitional services ischarge planning 58 100.0 flercare/continuing care 54 93.1 o services offered	No services offered	8	13.8
group counseling 57 98.3 amily counseling 51 87.9 larital/couples counseling 39 67.2 ansitional services services ischarge planning 58 100.0 ftercare/continuing care 54 93.1 o services offered — — narmacotherapies sulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 stended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Subxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine without naloxone 5 8.6 os services offered 3 65.5 oservices offered	counseling		
amily counseling 51 87.9 darital/couples counseling 39 67.2 ansitional services 39 67.2 step of tercare/continuing care 54 93.1 o services offered — — name cotherapies — — isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 ciotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Subxone®) 6 10.3 uprenorphine without naloxone 5 8.6 po services offered 3 65.5 ncillary services 4 81.0 ocical skills development 48 82.8 lentoring/peer support 26 44.8 <td>ndividual counseling</td> <td>58</td> <td>100.0</td>	ndividual counseling	58	100.0
darital/couples counseling 39 67.2 ansitional services secharge planning 58 100.0 fitercare/continuing care 54 93.1 o services offered — — narmacotherapies — — isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 cording replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 1.7 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 1.3 1.3 1.3 1.3 1.3 1.4 1.5 1.5 1.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <td>Group counseling</td> <td>57</td> <td>98.3</td>	Group counseling	57	98.3
ansitional services 58 100.0 itscharge planning 58 100.0 ftercare/continuing care 54 93.1 o services offered — — narmacotherapies — — isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 <	Family counseling	51	87.9
sischarge planning 58 100.0 ftercare/continuing care 54 93.1 o services offered — — narmacotherapies sulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 elethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 recillary services 3 65.5 ase management services 47 81.0 ocial skills development 48 82.8 tentoring/peer support 4 6.9 sistance with obtaining social services 32 55.2	Marital/couples counseling	39	67.2
ffercare/continuing care 54 93.1 o services offered — — narmacotherapies isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 dedications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lethoring/peer support 46 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social service	ransitional services		
o services offered —	Discharge planning	58	100.0
Instramacotherapies isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 dedications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 38 65.5 ase management services 47 81.0 ocial skills development 48 82.8 tentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Aftercare/continuing care	54	93.1
isulfiram (Antabuse®) 9 15.5 altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 38 65.5 ase management services 47 81.0 ocial skills development 48 82.8 tentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	No services offered	_	
altrexone (oral) 11 19.0 xtended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 rcillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	harmacotherapies		
extended-release, injectable naltrexone/Vivitrol® 8 13.8 camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Disulfiram (Antabuse®)	9	15.5
camprosate (Campral®) 8 13.8 icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Naltrexone (oral)	11	19.0
icotine replacement 15 25.9 on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Extended-release, injectable naltrexone/Vivitrol®	8	13.8
on-nicotine smoking/tobacco cessation medications 13 22.4 ledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Acamprosate (Campral®)	8	13.8
eledications for psychiatric disorders 19 32.8 lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Nicotine replacement	15	25.9
lethadone 1 1.7 uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Non-nicotine smoking/tobacco cessation medications	13	22.4
uprenorphine with naloxone (Suboxone®) 6 10.3 uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 81.0 ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Medications for psychiatric disorders	19	
uprenorphine without naloxone 5 8.6 uprenorphine subdermal implant (Probuphine®) — — o services offered 38 65.5 ncillary services 81.0 ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Methadone	1	1.7
uprenorphine subdermal implant (Probuphine®) o services offered o services ase management services ase management services ocial skills development lentoring/peer support hild care for clients' children ssistance with obtaining social services - — - — - — - — - — - — - — - — - — -	Buprenorphine with naloxone (Suboxone®)	6	
o services offered 38 65.5 ncillary services 81.0 ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Buprenorphine without naloxone	5	8.6
ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Buprenorphine subdermal implant (Probuphine®)	_	_
ase management services 47 81.0 ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	No services offered	38	65.5
ocial skills development 48 82.8 lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	ncillary services		
lentoring/peer support 26 44.8 hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Case management services		
hild care for clients' children 4 6.9 ssistance with obtaining social services 32 55.2	Social skills development		
ssistance with obtaining social services 32 55.2	Mentoring/peer support	26	
	Child care for clients' children		
mployment counseling or training for clients 18 31.0	Assistance with obtaining social services		
	Employment counseling or training for clients	18	31.0

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	31	53.4
Domestic violence services	24	41.4
Early intervention for HIV	7	12.1
HIV or AIDS education, counseling, or support	31	53.4
Hepatitis education, counseling, or support	22	37.9
Health education other than HIV/AIDS or hepatitis	27	46.6
Substance abuse education	57	98.3
Transportation assistance to treatment	32	55.2
Mental health services	41	70.7
Acupuncture	1	1.7
Residential beds for clients' children	2	3.4
Self-help groups	29	50.0
Smoking/tobacco cessation counseling	26	44.8
No services offered	_	_
Other services		
Treatment for gambling disorder	23	39.7
Treatment for Internet use disorder	8	13.8
Treatment for other addiction disorder	22	37.9
No services offered	23	39.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent			
	Faci	lities	
	No.	%	
Substance abuse counseling	56	96.6	
Relapse prevention	56	96.6	
Cognitive behavioral therapy	54	93.1	
Motivational interviewing	55	94.8	
Anger management	44	75.9	
Brief intervention	51	87.9	
Trauma-related counseling	43	74.1	
12-step facilitation	48	82.8	
Contingency management/motivational incentives	37	63.8	
Dialectical behavior therapy	28	48.3	
Rational emotive behavioral therapy	22	37.9	
Matrix model	33	56.9	
Computerized substance abuse treatment	4	6.9	
Community reinforcement plus vouchers	9	15.5	
Other treatment approaches	4	6.9	

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	10	3		
Number of clients ²	312	134		
Number of designated beds	285	169		
Utilization rate ³	109.5	79.3		
Average number of designated beds per facility	29	56		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	18
Methadone	18
Buprenorphine	_
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

Facilities	
No.	%
22	37.9
27	46.6
2	7.4
20	74.1
5	18.5
1	14.3
5	71.4
1	14.3
	No. 22 27 2 20 5 1

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	54	93.1
Adult women	21	36.2
Clients with co-occurring disorders	32	55.2
Adult men	20	34.5
Clients who have experienced trauma	22	37.9
Criminal justice clients	30	51.7
DUI/DWI clients	30	51.7
Young adults	17	29.3
Adolescents	25	43.1
Clients who have experienced domestic violence	14	24.1
Clients who have experienced sexual		
abuse	17	29.3
Pregnant or postpartum women	13	22.4
Seniors or older adults	11	19.0
LGBT ¹	11	19.0
Veterans	13	22.4
Clients living with HIV/AIDS	10	17.2
Members of military families	8	13.8
Active duty military	9	15.5
Other	3	5.2
No program or group offered	4	6.9

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

S. Halling A. SERVICES. ICO.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Tennessee National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Tennessee, 217 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 16,765 clients in substance abuse treatment on March 31, 2017. The survey response rate in Tennessee was 92.4 percent.

Facility operation, by number and percent						
			Clients i	n treatmen	t on March 31,	2017
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	140	64.5	7,580	45.2	372	47.2
Private for-profit	71	32.7	8,539	50.9	416	52.8
Local, county, or community government	1	0.5	8	*	_	_
State government	1	0.5	48	0.3	_	_
Federal government	4	1.8	590	3.5	_	_
Tribal government	_	_	_	_	_	_
Total	217	100.0	16,765	100.0	788	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017					nt on March 31, 2017	
	Faciliti	es¹	Clients ² Clients ² per 100			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	177	91.7	5,158	31.1	90	
Clients with drug abuse only	163	84.5	9,481	57.1	178	
Clients with alcohol abuse only	141	73.1	1,955	11.8	35	
Total			16,594	100.0	303	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	194	89.4	14,821	88.4	755	28	578	73.4
Regular	155	71.4	7,167	42.7	782	20		
Intensive	116	53.5	2,041	12.2	_	15		
Day treatment/partial hospitalization	40	18.4	264	1.6	_	5		
Detoxification	19	8.8	164	1.0	20	4		
Methadone maintenance	33	15.2	5,185	30.9	754	14		
Residential (non-hospital)	61	28.1	1,485	8.9	_	18	175	22.2
Short term (<30 days)	43	19.8	757	4.5	_	19		
Long term (30+ days)	54	24.9	563	3.4	_	15		
Detoxification	26	12.0	165	1.0	_	7		
Hospital inpatient	16	7.4	459	2.7	_	20	35	4.4
Treatment	13	6.0	302	1.8	_	20		
Detoxification	16	7.4	157	0.9	_	10		
Total	217		16,765	100.0	755	31	788	100.0

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	8	0.6
Oliver 4 - 1 - 5 - 11141 141- OTD - 2		
Clients in facilities with OTPs ²		
Any MAT	5,187	1.3
Methadone	4,776	1.2
Buprenorphine	411	1.5
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	1,374	1.3
Buprenorphine	1,217	1.4
Naltrexone	157	8.0

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	205	94.5
Private health insurance	165	76.0
Medicare	97	44.7
Medicaid	137	63.1
State-financed health insurance	126	58.1
Federal military insurance	99	45.6
No payment accepted	3	1.4
Access to Recovery (ATR) vouchers ²	27	12.4
IHS/Tribal/Urban (ITU) funds	6	2.8
Other payments	_	_
Sliding fee scale	139	64.1
Treatment at no charge for clients who can't pay	97	44.7
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	207	95.4
State substance abuse agency	144	66.4
State mental health department	174	80.2
State department of health	68	31.3
Hospital licensing authority	11	5.1
The Joint Commission	65	30.0
Commission on Accreditation of Rehabilitation Facilities	71	32.7
National Committee for Quality Assurance	6	2.8
Council on Accreditation	17	7.8
Healthcare Facilities Accreditation Program	3	1.4
Other state/local agency/organization	6	2.8

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 136 62.7

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	Faci	1:4:
	No.	lities %
Assessment and pre-treatment services	NO.	70
Screening for substance abuse	212	97.7
Screening for mental health disorders	187	86.2
Comprehensive substance abuse assessment or diagnosis	203	93.5
Comprehensive mental health assessment or diagnosis	138	63.6
Screening for tobacco use	115	53.0
Outreach to persons in the community who may need treatment	160	73.7
Interim services for clients when immediate admission is not possible	94	43.3
No services offered	2	0.9
	Δ	0.9
Testing Prostholyzer or other blood clookel testing	116	53.5
Breathalyzer or other blood alcohol testing		
Drug or alcohol urine screening	200	92.2
Screening for hepatitis B	55	25.3
Screening for hepatitis C	67	30.9
HIV testing	81	37.3
STD testing	56	25.8
TB screening	145	66.8
No services offered	13	6.0
Counseling		
Individual counseling	214	98.6
Group counseling	210	96.8
Family counseling	195	89.9
Marital/couples counseling	149	68.7
Transitional services		
Discharge planning	214	98.6
Aftercare/continuing care	204	94.0
No services offered	2	0.9
Pharmacotherapies		
Disulfiram (Antabuse®)	40	18.4
Naltrexone (oral)	51	23.5
Extended-release, injectable naltrexone/Vivitrol®	58	26.7
Acamprosate (Campral®)	33	15.2
Nicotine replacement	56	25.8
Non-nicotine smoking/tobacco cessation medications	55	25.3
Medications for psychiatric disorders	131	60.4
Methadone	8	3.7
Buprenorphine with naloxone (Suboxone®)	47	21.7
Buprenorphine without naloxone	34	15.7
Buprenorphine subdermal implant (Probuphine®)	2	0.9
No services offered	60	27.6
Ancillary services		
Case management services	179	82.5
Social skills development	170	78.3
Mentoring/peer support	123	56.7
Child care for clients' children	9	4.1
Assistance with obtaining social services	113	52.1
Employment counseling or training for clients	86	39.6
Continued		

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	134	61.8
Domestic violence services	96	44.2
Early intervention for HIV	53	24.4
HIV or AIDS education, counseling, or support	123	56.7
Hepatitis education, counseling, or support	93	42.9
Health education other than HIV/AIDS or hepatitis	127	58.5
Substance abuse education	214	98.6
Transportation assistance to treatment	85	39.2
Mental health services	176	81.1
Acupuncture	11	5.1
Residential beds for clients' children	4	1.8
Self-help groups	118	54.4
Smoking/tobacco cessation counseling	76	35.0
No services offered	_	_
Other services		
Treatment for gambling disorder	21	9.7
Treatment for Internet use disorder	22	10.1
Treatment for other addiction disorder	50	23.0
No services offered	164	75.6

	Fac	ilities
	No.	%
Substance abuse counseling	217	100.0
Relapse prevention	212	97.7
Cognitive behavioral therapy	198	91.2
Motivational interviewing	202	93.1
Anger management	189	87.1
Brief intervention	185	85.3
Trauma-related counseling	195	89.9
12-step facilitation	171	78.8
Contingency management/motivational incentives	103	47.5
Dialectical behavior therapy	121	55.8
Rational emotive behavioral therapy	97	44.7
Matrix model	112	51.6
Computerized substance abuse treatment	46	21.2
Community reinforcement plus vouchers	20	9.2
Other treatment approaches	6	2.8

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	56	10		
Number of clients ²	1,415	330		
Number of designated beds	1,738	156		
Utilization rate ³	81.4	211.5		
Average number of designated beds per facility	31	16		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	77
Methadone	71
Buprenorphine	6
Naltrexone	_

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	117	53.9
Any language other than English	136	62.7
Non-English language provided by		
Staff counselor only	6	4.4
On-call interpreter only	113	83.1
Both staff counselor and on-call interpreter	17	12.5
Languages provided by staff counselor ¹		
Spanish	21	91.3
American Indian/Alaskan Native languages	_	_
Other	4	17 4
Other	4	17.4

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	174	80.2
Adult women	77	35.5
Clients with co-occurring disorders	122	56.2
Adult men	67	30.9
Clients who have experienced trauma	59	27.2
Criminal justice clients	47	21.7
DUI/DWI clients	38	17.5
Young adults	44	20.3
Adolescents	48	22.1
Clients who have experienced domestic violence	32	14.7
Clients who have experienced sexual		
abuse	39	18.0
Pregnant or postpartum women	42	19.4
Seniors or older adults	32	14.7
LGBT ¹	24	11.1
Veterans	28	12.9
Clients living with HIV/AIDS	26	12.0
Members of military families	17	7.8
Active duty military	14	6.5
Other	2	0.9
No program or group offered	43	19.8

¹ Lesbian, gay, bisexual, or transgender clients.

Location of treatment facilities

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at: https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

2017 State Profile — Texas National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Texas, 431 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 35,474 clients in substance abuse treatment on March 31, 2017. The survey response rate in Texas was 82 percent.

Facility operation, by number and percei	nt					
	Clients in treatment on March 31, 201				2017	
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	187	43.4	11,403	32.1	905	52.4
Private for-profit	190	44.1	17,219	48.5	548	31.7
Local, county, or community government	27	6.3	2,537	7.2	202	11.7
State government	7	1.6	1,821	5.1	72	4.2
Federal government	19	4.4	2,476	7.0	_	_
Tribal government	1	0.2	18	0.1	_	_
Total	431	100.0	35,474	100.0	1,727	100.0

Substance abuse problem treated, by number and percent						
			Clients i	n treatmer	nt on March 31, 2017	
_	Faciliti	es¹	Client	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	345	85.4	13,382	37.7	59	
Clients with drug abuse only	329	81.4	16,874	47.6	78	
Clients with alcohol abuse only	269	66.6	5,218	14.7	24	
Total			35,474	100.0	161	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no.	Median no. of		
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%
Outpatient	362	84.0	30,140	85.0	149	32	1,066	61.7
Regular	301	69.8	12,398	34.9	122	25		
Intensive	232	53.8	4,787	13.5	98	15		
Day treatment/partial hospitalization	65	15.1	928	2.6	200	12		
Detoxification	41	9.5	299	8.0	3	8		
Methadone maintenance	91	21.1	11,728	33.1	140	20		
Residential (non-hospital)	108	25.1	4,224	11.9	40	27	445	25.8
Short term (<30 days)	81	18.8	1,511	4.3	29	20		
Long term (30+ days)	94	21.8	2,432	6.9	_	16		
Detoxification	36	8.4	281	8.0	100	6		
Hospital inpatient	41	9.5	1,110	3.1	26	15	216	12.5
Treatment	35	8.1	810	2.3	21	16		
Detoxification	38	8.8	300	8.0	5	5		
Total	431		35,474	100.0	152	35	1,727	100.0

¹Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	62	4.7
Clients in facilities with OTPs ²		
Any MAT	11,701	2.8
Methadone	10,973	2.9
Buprenorphine	684	2.5
Naltrexone	44	1.3
Clients in facilities without OTPs ²		
Any MAT	1,029	1.0
Buprenorphine	718	8.0
Naltrexone	311	1.6

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹ No. % Cash or self-payment 389 90.3 Private health insurance 271 62.9 Medicare 77 17.9 Medicaid 246 57.1 State-financed health insurance 165 38.3 23.7 Federal military insurance 102 No payment accepted 7 1.6 Access to Recovery (ATR) vouchers2 21 4.9 IHS/Tribal/Urban (ITU) funds 20 4.6 Other payments 4 0.9 49.0 Sliding fee scale 211 206 47.8 Treatment at no charge for clients who can't pay

Facility licensing, certification, or accreditation, by number and percent

Facilities ¹	
No.	%
413	95.8
334	77.5
106	24.6
303	70.3
32	7.4
119	27.6
102	23.7
11	2.6
11	2.6
6	1.4
13	3.0
	No. 413 334 106 303 32 119 102 11 11 6

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent			
	Facilities		
	No.	%	
Receives federal, state, county, or local government funds for substance abuse treatment programs	230	53.4	

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services effered, by flumber and percent	Eaci	lities
	No.	%
Assessment and pre-treatment services	110.	70
Screening for substance abuse	427	99.1
Screening for mental health disorders	255	59.2
Comprehensive substance abuse assessment or diagnosis	403	93.5
Comprehensive mental health assessment or diagnosis	156	36.2
Screening for tobacco use	302	70.1
Outreach to persons in the community who may need treatment	256	59.4
Interim services for clients when immediate admission is not possible	215	49.9
No services offered	2	0.5
Testing		0.5
Breathalyzer or other blood alcohol testing	231	53.6
Drug or alcohol urine screening	387	89.8
	124	28.8
Screening for hepatitis B	153	35.5
Screening for hepatitis C	173	35.5 40.1
HIV testing		
STD testing	145	33.6
TB screening	177	41.1
No services offered	35	8.1
Counseling	407	00.4
Individual counseling	427	99.1
Group counseling	397	92.1
Family counseling	367	85.2
Marital/couples counseling	220	51.0
Transitional services	100	00.4
Discharge planning	423	98.1
Aftercare/continuing care	377	87.5
No services offered	4	0.9
Pharmacotherapies District (And Long (And Lon	50	40.0
Disulfiram (Antabuse®)	53	12.3
Naltrexone (oral)	80	18.6
Extended-release, injectable naltrexone/Vivitrol®	59	13.7
Acamprosate (Campral®)	69	16.0
Nicotine replacement	123	28.5
Non-nicotine smoking/tobacco cessation medications	77	17.9
Medications for psychiatric disorders	153	35.5
Methadone	62	14.4
Buprenorphine with naloxone (Suboxone®)	101	23.4
Buprenorphine without naloxone	60	13.9
Buprenorphine subdermal implant (Probuphine®)	3	0.7
No services offered	197	45.7
Ancillary services		22.2
Case management services	389	90.3
Social skills development	337	78.2
Mentoring/peer support	264	61.3
Child care for clients' children	24	5.6
Assistance with obtaining social services	209	48.5
Employment counseling or training for clients	163	37.8

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	217	50.3
Domestic violence services	117	27.1
Early intervention for HIV	135	31.3
HIV or AIDS education, counseling, or support	291	67.5
Hepatitis education, counseling, or support	273	63.3
Health education other than HIV/AIDS or hepatitis	260	60.3
Substance abuse education	424	98.4
Transportation assistance to treatment	156	36.2
Mental health services	232	53.8
Acupuncture	26	6.0
Residential beds for clients' children	9	2.1
Self-help groups	200	46.4
Smoking/tobacco cessation counseling	264	61.3
No services offered	2	0.5
Other services		
Treatment for gambling disorder	39	9.0
Treatment for Internet use disorder	32	7.4
Treatment for other addiction disorder	79	18.3
No services offered	345	80.0

	Faci	lities
	No.	%
Substance abuse counseling	427	99.1
Relapse prevention	417	96.8
Cognitive behavioral therapy	405	94.0
Motivational interviewing	396	91.9
Anger management	350	81.2
Brief intervention	351	81.4
Frauma-related counseling	310	71.9
12-step facilitation	335	77.7
Contingency management/motivational incentives	236	54.8
Dialectical behavior therapy	190	44.1
Rational emotive behavioral therapy	245	56.8
Matrix model	179	41.5
Computerized substance abuse treatment	62	14.4
Community reinforcement plus vouchers	54	12.5
Other treatment approaches	32	7.4

Facility capacity and utilization rate ¹				
	Residential	Hospital inpatient		
Number of facilities	102	25		
Number of clients ²	4,077	866		
Number of designated beds	4,460	711		
Utilization rate ³	91.4	121.8		
Average number of designated beds per facility	44	28		

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	41
Methadone	39
Buprenorphine	2
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

_	Facili	ties
	No.	%
Sign language	148	34.3
Any language other than English	250	58.0
Non-English language provided by		
Staff counselor only	98	39.2
On-call interpreter only	60	24.0
Both staff counselor and on-call interpreter	92	36.8
Languages provided by staff counselor ¹		
Spanish	188	98.9
American Indian/Alaskan Native languages	_	_
Other	8	4.2

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	352	81.7
Adult women	207	48.0
Clients with co-occurring disorders	193	44.8
Adult men	195	45.2
Clients who have experienced trauma	130	30.2
Criminal justice clients	147	34.1
DUI/DWI clients	53	12.3
Young adults	111	25.8
Adolescents	115	26.7
Clients who have experienced domestic violence	98	22.7
Clients who have experienced sexual		
abuse	94	21.8
Pregnant or postpartum women	108	25.1
Seniors or older adults	92	21.3
LGBT ¹	86	20.0
Veterans	90	20.9
Clients living with HIV/AIDS	76	17.6
Members of military families	62	14.4
Active duty military	58	13.5
Other	12	2.8
No program or group offered	79	18.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; *n/a* Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Utah National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Utah, 239 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 14,326 clients in substance abuse treatment on March 31, 2017. The survey response rate in Utah was 94.9 percent.

Facility operation, by number and percent							
	Clients in treatment on March					2017	
	Facilities All clients			Facilities All clients C		Clients und	ler age 18
	No.	%	No.	%	No.	%	
Private non-profit	58	24.3	4,510	31.5	497	36.4	
Private for-profit	151	63.2	7,264	50.7	653	47.8	
Local, county, or community government	24	10.0	2,106	14.7	181	13.3	
State government	2	8.0	22	0.2	2	0.1	
Federal government	2	8.0	275	1.9	_	—	
Tribal government	2	8.0	149	1.0	33	2.4	
Total	239	100.0	14,326	100.0	1,366	100.0	

Substance abuse problem treated, by number and percent						
Clients in treatment					nt on March 31, 2017	
	Facilities ¹		Clients	S ²	Clients ² per 100,000 pop.	
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	206	93.6	6,173	43.1	247	
Clients with drug abuse only	179	81.4	6,010	42.0	260	
Clients with alcohol abuse only	162	73.6	2,143	15.0	89	
Total			14,326	100.0	596	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	192	80.3	12,491	87.2	180	26	697	51.0
Regular	183	76.6	6,658	46.5	38	21		
Intensive	123	51.5	1,640	11.4	1	10		
Day treatment/partial hospitalization	60	25.1	356	2.5	_	6		
Detoxification	26	10.9	92	0.6	2	5		
Methadone maintenance	61	25.5	3,745	26.1	177	15		
Residential (non-hospital)	65	27.2	1,706	11.9	17	16	669	49.0
Short term (<30 days)	44	18.4	437	3.1	_	10		
Long term (30+ days)	63	26.4	1,198	8.4	16	14		
Detoxification	22	9.2	71	0.5	1	1		
Hospital inpatient	8	3.3	129	0.9	_	12	_	_
Treatment	6	2.5	44	0.3	_	4		
Detoxification	5	2.1	85	0.6	<u> </u>	6		
Total	239		14,326	100.0	180	25	1,366	100.0

¹ Facilities may provide more than one type of care.

Ор	ioid treatment programs (OTPs),
bv	number and percent

,		
	No.	%
Facilities with OTPs ¹	14	1.1
Clients in facilities with OTPs ²		
Chefits in facilities with OTPS		
Any MAT	2,785	0.7
Methadone	2,557	0.7
Buprenorphine	224	8.0
Naltrexone	4	0.1
Clients in facilities without OTPs ²		
Any MAT	1,619	1.6
Buprenorphine	1,193	1.4
Naltrexone	426	2.2
4B		

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	•	
	No.	%
Cash or self-payment	231	96.7
Private health insurance	201	84.1
Medicare	82	34.3
Medicaid	110	46.0
State-financed health insurance	98	41.0
Federal military insurance	119	49.8
No payment accepted	1	0.4
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	37	15.5
Other payments	4	1.7
Sliding fee scale	124	51.9
Treatment at no charge for clients who can't pay	65	27.2

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	225	94.1
State substance abuse agency	179	74.9
State mental health department	141	59.0
State department of health	136	56.9
Hospital licensing authority	9	3.8
The Joint Commission	64	26.8
Commission on Accreditation of Rehabilitation Facilities	17	7.1
National Committee for Quality Assurance	4	1.7
Council on Accreditation	2	0.8
Healthcare Facilities Accreditation Program	1	0.4
Other state/local agency/organization	12	5.0

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 86 36.0

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by names and percent	Faci	lities
	No.	%
Assessment and pre-treatment services	110.	78
Screening for substance abuse	230	96.2
Screening for mental health disorders	201	84.1
Comprehensive substance abuse assessment or diagnosis	222	92.9
Comprehensive mental health assessment or diagnosis	160	66.9
Screening for tobacco use	160	66.9
Outreach to persons in the community who may need treatment	139	58.2
Interim services for clients when immediate admission is not possible	98	41.0
No services offered	_	_
Testing		
Breathalyzer or other blood alcohol testing	138	57.7
Drug or alcohol urine screening	209	87.4
Screening for hepatitis B	46	19.2
Screening for hepatitis C	49	20.5
HIV testing	41	17.2
STD testing	51	21.3
TB screening	99	41.4
No services offered	26	10.9
Counseling		
Individual counseling	236	98.7
Group counseling	231	96.7
Family counseling	215	90.0
Marital/couples counseling	181	75.7
Transitional services		
Discharge planning	227	95.0
Aftercare/continuing care	207	86.6
No services offered	4	1.7
Pharmacotherapies		
Disulfiram (Antabuse®)	69	28.9
Naltrexone (oral)	82	34.3
Extended-release, injectable naltrexone/Vivitrol®	87	36.4
Acamprosate (Campral®)	52	21.8
Nicotine replacement	85	35.6
Non-nicotine smoking/tobacco cessation medications	81	33.9
Medications for psychiatric disorders	127	53.1
Methadone	14	5.9
Buprenorphine with naloxone (Suboxone®)	81	33.9
Buprenorphine without naloxone	64	26.8
Buprenorphine subdermal implant (Probuphine®)	7	2.9
No services offered	84	35.1
Ancillary services		
Case management services	204	85.4
Social skills development	203	84.9
Mentoring/peer support	140	58.6
Child care for clients' children	14	5.9
Assistance with obtaining social services	111	46.4
Employment counseling or training for clients	92	38.5

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	112	46.9
Domestic violence services	116	48.5
Early intervention for HIV	30	12.6
HIV or AIDS education, counseling, or support	58	24.3
Hepatitis education, counseling, or support	66	27.6
Health education other than HIV/AIDS or hepatitis	98	41.0
Substance abuse education	228	95.4
Transportation assistance to treatment	90	37.7
Mental health services	204	85.4
Acupuncture	6	2.5
Residential beds for clients' children	6	2.5
Self-help groups	99	41.4
Smoking/tobacco cessation counseling	145	60.7
No services offered	1	0.4
Other services		
Treatment for gambling disorder	54	22.6
Treatment for Internet use disorder	73	30.5
Treatment for other addiction disorder	135	56.5
No services offered	103	43.1

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Facil	ities		
	No.	%		
Substance abuse counseling	236	98.7		
Relapse prevention	232	97.1		
Cognitive behavioral therapy	231	96.7		
Motivational interviewing	215	90.0		
Anger management	211	88.3		
Brief intervention	184	77.0		
Trauma-related counseling	208	87.0		
12-step facilitation	158	66.1		
Contingency management/motivational incentives	167	69.9		
Dialectical behavior therapy	190	79.5		
Rational emotive behavioral therapy	145	60.7		
Matrix model	95	39.7		
Computerized substance abuse treatment	40	16.7		
Community reinforcement plus vouchers	41	17.2		
Other treatment approaches	31	13.0		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	46	3			
Number of clients ²	1,121	52			
Number of designated beds	1,287	51			
Utilization rate ³	87.1	102.0			
Average number of designated beds per facility	28	17			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	90
Methadone	82
Buprenorphine	7
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	65	27.2
Any language other than English	99	41.4
Non-English language provided by		
Staff counselor only	35	35.4
On-call interpreter only	20	20.2
Both staff counselor and on-call interpreter	44	44.4
Languages provided by staff counselor ¹		
Spanish	79	100.0
American Indian/Alaskan Native		
languages	_	_
Other	14	17.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facili	ties
	No.	%
Any program or group	214	89.5
Adult women	124	51.9
Clients with co-occurring disorders	139	58.2
Adult men	122	51.0
Clients who have experienced trauma	133	55.6
Criminal justice clients	111	46.4
DUI/DWI clients	99	41.4
Young adults	78	32.6
Adolescents	68	28.5
Clients who have experienced domestic violence	97	40.6
Clients who have experienced sexual		
abuse	98	41.0
Pregnant or postpartum women	50	20.9
Seniors or older adults	53	22.2
LGBT ¹	56	23.4
Veterans	55	23.0
Clients living with HIV/AIDS	40	16.7
Members of military families	36	15.1
Active duty military	34	14.2
Other	6	2.5
No program or group offered	25	10.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Vermont National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Vermont, 42 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 7,015 clients in substance abuse treatment on March 31, 2017. The survey response rate in Vermont was 93.8 percent.

Facility operation, by number and percen	nt					
	Clients in treatment on March 31, 2017				2017	
	Faciliti	es	All clie	nts	Clients und	ler age 18
	No.	%	No.	%	No.	%
Private non-profit	35	83.3	4,702	67.0	346	95.6
Private for-profit	5	11.9	1,691	24.1	16	4.4
Local, county, or community government	_	_	_	_	_	_
State government	_	_	_	_	_	_
Federal government	2	4.8	622	8.9	_	_
Tribal government	_	_	_	_	_	_
Total	42	100.0	7,015	100.0	362	100.0

Substance abuse problem treated, by number and percent						
Clients in treatment on March 31, 2017						
	Faciliti	es¹	Clients ² Clients ² per 100,000 pc			
	No.	%	No.	%	age 18 or older	
Clients with both alcohol and drug abuse	38	92.7	2,321	33.1	408	
Clients with drug abuse only	38	92.7	3,657	52.1	705	
Clients with alcohol abuse only	31	75.6	1,037	14.8	199	
Total			7,015	100.0	1,313	

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
				Clie	nts in treatmen	t on March 31, 20	17	
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	36	85.7	6,796	96.9	354	98	346	95.6
Regular	33	78.6	2,870	40.9	82	94		
Intensive	15	35.7	218	3.1	23	12		
Day treatment/partial hospitalization	3	7.1	64	0.9	_	10		
Detoxification	3	7.1	15	0.2	_	15		
Methadone maintenance	21	50.0	3,629	51.7	354	16		
Residential (non-hospital)	6	14.3	148	2.1	67	17	8	2.2
Short term (<30 days)	3	7.1	65	0.9	48	17		
Long term (30+ days)	4	9.5	62	0.9	5	17		
Detoxification	3	7.1	21	0.3	14	4		
Hospital inpatient	4	9.5	71	1.0	29	7	8	2.2
Treatment	4	9.5	34	0.5	12	5		
Detoxification	4	9.5	37	0.5	17	2		
Total	42		7,015	100.0	269	55	362	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	11	0.8
Clients in facilities with OTPs ²		
Any MAT	3,306	8.0
Methadone	2,151	0.6
Buprenorphine	1,111	4.0
Naltrexone	44	1.3
Clients in facilities without OTPs ²		
Any MAT	459	0.4
Buprenorphine	348	0.4
Naltrexone	111	0.6

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	,,		
		No.	%
Cash or se	elf-payment	37	88.1
Private he	alth insurance	38	90.5
Medicare		24	57.1
Medicaid		40	95.2
State-finar	nced health insurance	37	88.1
Federal m	ilitary insurance	25	59.5
No payme	nt accepted	1	2.4
Access to	Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal	/Urban (ITU) funds	3	7.1
Other pay	ments	_	_
Sliding fee	scale	28	66.7
Treatment	at no charge for clients who can't pay	27	64.3
1 = -000			

Facility licensing, certification, or accreditation, by number and percent

	Faci	lities¹
	No.	%
Any listed agency/organization	42	100.0
State substance abuse agency	36	85.7
State mental health department	22	52.4
State department of health	32	76.2
Hospital licensing authority	7	16.7
The Joint Commission	13	31.0
Commission on Accreditation of Rehabilitation Facilities	9	21.4
National Committee for Quality Assurance	5	11.9
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	1	2.4

¹ Facilities may be licensed by more than one agency/organization.

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Assessment and pre-freatment services No. % 1 Screening for substance abuse 41 97.6 Screening for substance abuse 41 97.6 Comprehensive substance abuse assessment or diagnosis 31 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 Comprehensive mental health assessment or diagnosis 30 71.4 Outreach to persons in the community who may need treatment 35 83.3 Interim services for clients when immediate admission is not possible 2 7 Interim services for clients when immediate admission is not possible 2 63.3 Interim services for clients when immediate admission is not possible 2 64.3 No services offered 27 64.3 Screening for hepatitis S 7 64.3 Screening for hepatitis S 17 40.5 Screening for hepatitis S 18 42.9 HIV testing 15 55.7 Storewing for hepatitis C 18 42.9 HIV testing 18 42.9 Group courseling	Types of services offered, by number and percent		
Assessment and pre-treatment services No. % Screening for substance abuse 41 97.6 Screening for mental health disorders 37 88.1 Comprehensive substance abuse assessment or diagnosis 41 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 97.6 63.3 33.3 11.6 33.3 30 92.9 48.2 30 92.9 48.3 92.9 49.2 49.5 49.5 55.7 57.5 57.7 TB screening for hepatitis expression for p	Types of services effered, by framiser and percent	Fac	ilitios
Assessment and pre-treatment services 41 97.6 Screening for substance abuse 41 97.6 Screening for mental health disorders 37 88.1 Comprehensive substance abuse assessment or diagnosis 41 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interior services for clients when immediate admission is not possible 30 71.4 No services offered 27 64.3 Presting 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV Lesting 15 35.7 STD testing 15 35.7 STD testing 16 35.7 Storeening for hepatitis C 18 42.9 HIV Lesting 15 <td< th=""><th></th><th></th><th></th></td<>			
Screening for substance abuse 41 97.6 Screening for mental health disorders 37 88.1 Comprehensive substance abuse assessment or diagnosis 41 97.6 Comprehensive substance abuse assessment or diagnosis 30 71.4 Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interior services for clients when immediate admission is not possible 30 71.4 No services offered - - Testing - - Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Streening for hepatitis B 17 40.5 ST besting 18 42.9 HIV testing 17 40.5 ST besting 17	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 37 88.1 Comprehensive substance abuse assessment or diagnosis 30 71.4 Comprehensive mental health assessment or diagnosis 30 71.4 Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interim services for clients when immediate admission is not possible 30 71.4 No services offered 27 64.3 Testing 27 64.3 Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol time screening 39 92.9 Screening for hepatitis C 18 42.9 HIV testing 15 55.7 STD testing 15 55.7 TB screening 15 55.7 TB screening 16 55.7 TB screening 16 55.7 TB screening 40 95.2 Group counseling 41 97.6 Family counseling 41 97.6 F	·	41	97.6
Comprehensive substance abuse assessment or diagnosis 41 97.6 Comprehensive mental health assessment or diagnosis 30 71.4 Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interim services for clients when immediate admission is not possible 30 71.4 No services offered 27 64.3 Presting to the possible of the possible	•		
Comprehensive mental health assessment or diagnosis 30 71.4 Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interin services for clients when immediate admission is not possible 30 71.4 No services offered 2 64.3 Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis B 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 STD testing 16 35.7 STD testing 17 40.5 No services offered 2 4.8 Coreuning for hepatitis B 40 95.6 Moservices offered 40 40.5 Coreening for hepatitis B 41 40.5 Coreening for hepatitis B 40 40.5 Coreening for hepatitis B 40	-		
Screening for tobacco use 41 97.6 Outreach to persons in the community who may need treatment 35 83.3 Interim services offered - - No services offered benefits when immediate admission is not possible 30 71.4 No services offered benefits when immediate admission is not possible - 64.3 Presting 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis B 18 42.9 HIV testing 15 35.7 TS to reening 15 35.7 TS screening for hepatitis B 17 40.5 No services offered 18 42.9 HIV testing 15 35.7 TS screening for hepatitis B 17 40.5 No services offered 24 40.5 Ourseling 40 95.2 TS screening for hepatitis B 40 95.2 Barnily counseling 40 95.2 Family counseling 41 97.6 Family counseling	· · · · · · · · · · · · · · · · · · ·		
Outreach to persons in the community who may need treatment 35 83.3 Interin services for clients when immediate admission is not possible 30 71.4 No services offered - - Testing - - Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 TD testing 15 35.7 TS Screening of repatitis B 40 95.2 No services offered 2 4.8 Counciling 40 95.2 No services offered 40 95.2 Group counseling 41 97.6 Family counseling 41 97.6 Family counseling 41 97.6 Family counseling 41 97.6 Aftercare/continuing care 2 10 No services offered 2 5 </td <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Interim services for clients when immediate admission is not possible 30 71.4 No services offered − − Tosting − 64.3 Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis S creening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening offered 2 40.5 No services offered 2 40.5 Services offered 40 95.2 Group courseling 41 97.6 Group courseling 41 97.6 Family counseling 41 97.6 After care/continuing care 42 100.0 After care/continuing care 42 100.0 No services offered 2 54.8 Nattrexone (oral) 25 55.5 Standed-release, injectable natirexone/Vivitrol® 23 54.8 Natire care probline with nalixone (Subxone®)<	-		
No services offered — — Testing — — Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening 15 35.7 TB screening 15 35.7 No services offered 2 4.8 Counseling 40 95.2 Group counseling 41 97.6 Sernily counseling 41 97.6 Family couples counseling 41 97.6 Family couples counseling 41 97.6 Brailitian (Souples counseling 41 97.6 Aftercare/continuing care 42 100.0 Alter care/continuing care 42 100.0 No services offered 2 59.5 Pharmacothrapies 23 54.8 Disulfiram (Antabuse ⁶) 25	· · · · · · · · · · · · · · · · · · ·		
Testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening 15 35.7 TB screening 16 35.7 TB screening 17 40.5 No services offered 2 4.8 Counseling 40 95.2 Group counseling 40 95.2 Group counseling 41 97.6 Family counseling 41 97.6 Martical Couples counseling 41 97.6 Martical Couples counseling 41 97.6	·	_	_
Breathalyzer or other blood alcohol testing 27 64.3 Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 17 40.5 St STD testing 17 40.5 No services offered 2 4.8 Counseling 40 95.2 Individual counseling 41 97.6 Group counseling 41 97.6 Family counseling 30 92.9 Marital/couples counseling 36 85.7 Tamsittonal services 36 85.7 Tassistional services 30 92.9 Marital/couples counseling 41 97.6 Aftercare/continuing care 42 100.0 No services offered 2 5 59.5 Ibusifiran (Antabuse*) 25 59.5 59.5 Extended-release, injectable naltrexone/vivitol* 17			
Drug or alcohol urine screening 39 92.9 Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening 17 40.5 No services offered 2 4.8 Consuling Individual counseling 40 95.2 Group counseling 41 97.6 Family counseling 41 97.6 Asting conservices 2 100.0 Barrilly counseling 41 97.6 Aftercare/continuing care 2 100.0 No services offere		27	64.3
Screening for hepatitis B 17 40.5 Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening 17 40.5 No services offered 2 4.8 Courseling 40 95.2 Group counseling 40 95.2 Group counseling 39 92.9 Bramily counseling 39 92.9 Marital/couples counseling 39 92.9 Marital/couples counseling 40 85.7 Transitional services Use of services offered 41 97.6 Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered 23 54.8 Naltrexone (contil) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable nattrexone/Vivitrol® 19 45.2 Nicotine replacement 22 <t< td=""><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td></t<>	· · · · · · · · · · · · · · · · · · ·		
Screening for hepatitis C 18 42.9 HIV testing 15 35.7 STD testing 15 35.7 TB screening 17 40.5 No services offered 2 4.8 Counseling 40 95.2 Individual counseling 40 95.2 Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 36 85.7 Family counseling 41 97.6 Family counseling 41 97.6 Aftercare/continuing care 42 100.0 No services offered 42 100.0 No services offered 23 54.8 Naltexone (oral) 23 54.8 Naltexone (oral) 17 40.5 Extended-release, injectable nattrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Non-nicotine smoking/tobacco cessation medications 18 42.9 Methadone <td></td> <td></td> <td></td>			
HIV testing 15 35.7 STD testing 15 35.7 TB screening 17 40.5 No services offered 2 4.8 Courseling Individual counseling 40 95.2 Family counseling 41 97.6 Family counseling 39 92.9 Martal/couples counseling 39 92.9 Martal/couples counseling 41 97.6 Family counseling 41 97.6 Family services 2 100.0 National services Transitional services Transitional services After care/continuing care 41 97.6 After care/continuing care 42 100.0 No services offered 2 54.8 Natire care/continuing care 42 100.0 No services offered 23 54.8 Natire care/continuing care 23 54.8 Natire care/continuing care 23 54.8<	•		
STD testing 15 35.7 TB screening 17 40.5 No services offered 2 4.8 Courseling 40 95.2 Group counseling 41 97.6 Family counseling 41 97.6 Family counseling 36 85.7 Transitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered 2 1 No services offered 2 1 Nulltrexnoe (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Non-nicotine smoking/fobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Bupren			
TB screening 17 40.5 No services offered 2 4.8 Counseling 40 95.2 Individual counseling 40 95.2 Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 39 92.9 Marital/couples counseling 41 97.6 Family counseling 41 97.6 Marital/couples counseling 41 97.6 Parmacotheric 22 100.0 Aftercare/continuing care 42 100.0 No services offered 2 100.0 Pharmacotherapies 2 100.0 Pharmacotherapies 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable nattrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 17 40.5 Acamprosate (Campral®) 19 45.2 Non-nicotine smoking/tobacco cessation medications 18 42.9 Me			
No services offered 2 4.8 Counseling 40 95.2 Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 36 85.7 Transitional services Usisharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered 42 100.0 Pharmacotherapies 2 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) 7 <td< td=""><td>•</td><td></td><td></td></td<>	•		
Counseling 40 95.2 Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 36 85.7 Transitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered - - Pharmacotherapies 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine subdermal implant (Probuphine®) - - No services offered 40 95.2 <td>S Comment of the comm</td> <td></td> <td></td>	S Comment of the comm		
Individual counseling 40 95.2 Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 36 85.7 Transitional services Userlange planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse*) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol* 17 40.5 Acamprosate (Campral*) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone*) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine without problemal implant (Probuphine*) 7 16.7		_	1.0
Group counseling 41 97.6 Family counseling 39 92.9 Marital/couples counseling 36 85.7 Transitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered		40	95.2
Family counseling 39 92.9 Marital/couples counseling 36 85.7 Transitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Accillatery services Case management serv	· ·		
Marital/couples counseling 36 85.7 Transitional services Fransitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered Pharmacotherapies Disulfiram (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) - - No services offered 7 16.7 Accillary services 3 90.5 Social skills development 31 <td>,</td> <td></td> <td></td>	,		
Transitional services Discharge planning 41 97.6 Aftercare/continuing care 42 100.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Accillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8	·		
Aftercare/continuing care 42 100.0 No services offered — — Pharmacotherapies Secondary of the part of			
Aftercare/continuing care 42 100.0 No services offered — — Pharmacotherapies Stream (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 9	Discharge planning	41	97.6
No services offered — — Pharmacotherapies Usulfiram (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) 2 7 16.7 No services offered 7 16.7 7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9			
Disulfiram (Antabuse®) 23 54.8 Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	· · · · · · · · · · · · · · · · · · ·	_	_
Naltrexone (oral) 25 59.5 Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 17 40.5 Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Disulfiram (Antabuse®)	23	54.8
Acamprosate (Campral®) 19 45.2 Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Naltrexone (oral)	25	59.5
Nicotine replacement 22 52.4 Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Extended-release, injectable naltrexone/Vivitrol®	17	40.5
Non-nicotine smoking/tobacco cessation medications 18 42.9 Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Acamprosate (Campral®)	19	45.2
Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Nicotine replacement	22	52.4
Medications for psychiatric disorders 27 64.3 Methadone 9 21.4 Buprenorphine with naloxone (Suboxone®) 25 59.5 Buprenorphine without naloxone 24 57.1 Buprenorphine subdermal implant (Probuphine®) — — No services offered 7 16.7 Ancillary services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Non-nicotine smoking/tobacco cessation medications	18	42.9
Buprenorphine with naloxone (Suboxone®)2559.5Buprenorphine without naloxone2457.1Buprenorphine subdermal implant (Probuphine®)——No services offered716.7Ancillary servicesCase management services4095.2Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9		27	64.3
Buprenorphine without naloxone2457.1Buprenorphine subdermal implant (Probuphine®)——No services offered716.7Ancillary servicesCase management services4095.2Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	Methadone	9	21.4
Buprenorphine subdermal implant (Probuphine®) — — — — No services offered 7 16.7 Ancillary services Case management services 40 95.2 Social skills development 38 90.5 Mentoring/peer support 31 73.8 Child care for clients' children 5 11.9 Assistance with obtaining social services 39 92.9	Buprenorphine with naloxone (Suboxone®)	25	59.5
No services offered716.7Ancillary servicesVCase management services4095.2Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	Buprenorphine without naloxone	24	57.1
Ancillary servicesCase management services4095.2Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	Buprenorphine subdermal implant (Probuphine®)	_	_
Case management services4095.2Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	No services offered	7	16.7
Social skills development3890.5Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	Ancillary services		
Mentoring/peer support3173.8Child care for clients' children511.9Assistance with obtaining social services3992.9	Case management services	40	95.2
Child care for clients' children511.9Assistance with obtaining social services3992.9	Social skills development	38	90.5
Assistance with obtaining social services 39 92.9	Mentoring/peer support	31	73.8
	Child care for clients' children	5	11.9
Employment counseling or training for clients 25 59.5	Assistance with obtaining social services	39	92.9
	Employment counseling or training for clients	25	59.5

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	34	81.0
Domestic violence services	16	38.1
Early intervention for HIV	12	28.6
HIV or AIDS education, counseling, or support	31	73.8
Hepatitis education, counseling, or support	27	64.3
Health education other than HIV/AIDS or hepatitis	25	59.5
Substance abuse education	41	97.6
Transportation assistance to treatment	24	57.1
Mental health services	34	81.0
Acupuncture	3	7.1
Residential beds for clients' children	1	2.4
Self-help groups	16	38.1
Smoking/tobacco cessation counseling	30	71.4
No services offered	_	_
Other services		
Treatment for gambling disorder	19	45.2
Treatment for Internet use disorder	14	33.3
Treatment for other addiction disorder	26	61.9
No services offered	15	35.7

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent				
	Fac	ilities		
	No.	%		
Substance abuse counseling	42	100.0		
Relapse prevention	42	100.0		
Cognitive behavioral therapy	41	97.6		
Motivational interviewing	41	97.6		
Anger management	37	88.1		
Brief intervention	37	88.1		
Trauma-related counseling	39	92.9		
12-step facilitation	33	78.6		
Contingency management/motivational incentives	22	52.4		
Dialectical behavior therapy	26	61.9		
Rational emotive behavioral therapy	11	26.2		
Matrix model	21	50.0		
Computerized substance abuse treatment	2	4.8		
Community reinforcement plus vouchers	7	16.7		
Other treatment approaches	8	19.0		

Facility capacity and utilization rate ¹					
	Residential	Hospital inpatient			
Number of facilities	5	2			
Number of clients ²	131	58			
Number of designated beds	123	120			
Utilization rate ³	106.5	48.3			
Average number of designated beds per facility	25	60			

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	530
Methadone	345
Buprenorphine	178
Naltrexone	7

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	28	66.7
Any language other than English	26	61.9
Non-English language provided by		
Staff counselor only	_	_
On-call interpreter only	21	80.8
Both staff counselor and on-call interpreter	5	19.2
Languages provided by staff counselor ¹		
Spanish	4	80.0
American Indian/Alaskan Native		
languages	_	_
Other	3	60.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	38	90.5
Adult women	21	50.0
Clients with co-occurring disorders	21	50.0
Adult men	20	47.6
Clients who have experienced trauma	21	50.0
Criminal justice clients	21	50.0
DUI/DWI clients	12	28.6
Young adults	19	45.2
Adolescents	10	23.8
Clients who have experienced domestic violence	12	28.6
Clients who have experienced sexual abuse	8	19.0
Pregnant or postpartum women	16	38.1
Seniors or older adults	7	16.7
LGBT ¹	4	9.5
Veterans	6	14.3
Clients living with HIV/AIDS	3	7.1
Members of military families	3	7.1
Active duty military	4	9.5
Other	3	7.1
No program or group offered	4	9.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Virginia National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Virginia, 223 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 22,413 clients in substance abuse treatment on March 31, 2017. The survey response rate in Virginia was 89.7 percent.

Facility operation, by number and percent							
	Clients in treatment on March 31, 2017				2017		
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	50	22.4	2,781	12.4	266	14.9	
Private for-profit	68	30.5	11,280	50.3	857	48.0	
Local, county, or community government	88	39.5	7,230	32.3	614	34.4	
State government	7	3.1	541	2.4	47	2.6	
Federal government	10	4.5	581	2.6	_	-	
Tribal government	_	_	_	_	_	_	
Total	223	100.0	22,413	100.0	1,784	100.0	

Substance abuse problem treated, by number and percent							
Clients in treatment on March 31, 2017							
_	Faciliti	es¹	Clients ² Clients ² per 100,000				
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	161	86.1	7,233	32.0	99		
Clients with drug abuse only	165	88.2	12,384	54.8	174		
Clients with alcohol abuse only	143	76.5	2,965	13.1	42		
Total			22,582	100.0	315		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
			Clients in treatment on March 31, 2017					
_	Facili	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of		
	No.	%	No.	%	OTP facility	clients per non-OTP facility	No.	%
Outpatient	193	86.5	21,306	95.1	250	53	1,739	97.5
Regular	170	76.2	10,186	45.4	91	40		
Intensive	83	37.2	1,738	7.8	16	14		
Day treatment/partial hospitalization	32	14.3	450	2.0	18	12		
Detoxification	30	13.5	117	0.5	3	10		
Methadone maintenance	69	30.9	8,815	39.3	250	48		
Residential (non-hospital)	35	15.7	908	4.1	12	14	40	2.2
Short term (<30 days)	23	10.3	289	1.3	12	8		
Long term (30+ days)	24	10.8	461	2.1	_	8		
Detoxification	15	6.7	158	0.7	31	10		
Hospital inpatient	13	5.8	199	0.9	16	13	5	0.3
Treatment	11	4.9	62	0.3	_	7		
Detoxification	13	5.8	137	0.6	16	8		
Total	223		22,413	100.0	259	49	1,784	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs),
by number and percent

•		
	No.	%
Facilities with OTPs ¹	30	2.3
Clients in facilities with OTPs ²		
Any MAT	7,326	1.8
Methadone	6,650	1.7
Buprenorphine	604	2.2
Naltrexone	72	2.1
Clients in facilities without OTPs ²		
Any MAT	2,216	2.1
Buprenorphine	1,997	2.4
Naltrexone	219	1.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	205	91.9
Private health insurance	173	77.6
Medicare	111	49.8
Medicaid	144	64.6
State-financed health insurance	93	41.7
Federal military insurance	122	54.7
No payment accepted	3	1.3
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	4	1.8
Other payments	2	0.9
Sliding fee scale	119	53.4
Treatment at no charge for clients who can't pay	72	32.3
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	205	91.9
State substance abuse agency	172	77.1
State mental health department	151	67.7
State department of health	56	25.1
Hospital licensing authority	20	9.0
The Joint Commission	33	14.8
Commission on Accreditation of Rehabilitation Facilities	50	22.4
National Committee for Quality Assurance	5	2.2
Council on Accreditation	4	1.8
Healthcare Facilities Accreditation Program	1	0.4
Other state/local agency/organization	7	3.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 124 55.6

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Facility No. No. Assessment and pre-freatment services Screening for substance abuse 214 96.0 Screening for mental health disorders 177 79.4 Comprehensive substance abuse assessment or diagnosis 203 91.0 Comprehensive mental health assessment or diagnosis 137 61.4 Outreach to persons in the community who may need treatment 138 61.9 Interin services for clients when immediate admission is not possible 17 52.5 No services offered 2 9.9 Testing 2 9.9 Streathalyzer or other blood alcohol testing 195 87.4 Drug or alcohol urine screening 195 87.4 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 Screening for hepatitis C 68 30.5 Streening for hepatitis C 82 42.7 Streening for hepatitis C 82 42.7 Bis screening for bepatitis C 82 42.1	Types of services offered, by number and percent		
No. No.	Types of services offered, by flumber and percent	Eaci	litios
Screening for substance abuse 214 96.0			
Screening for substance abuse 214 96.0 Screening for mental health disorders 177 79.4 Comprehensive substance abuse assessment or diagnosis 203 91.0 Comprehensive substance abuse assessment or diagnosis 137 61.4 Screening for tobacco use 144 64.6 Outreach to persons in the community who may need treatment 138 61.9 Interin services for clients when immediate admission is not possible 117 52.5 No services offered 2 0.9 Testing 15 87.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 30.5 16.1 B screening for hepatitis B 30.5 16.1 Streening for hepatitis B 30.5 24.7 STD testing 36 16.1 18 TB screening for hepatitis B 30.5 24.7 STD testing 36 16.1 18	Assessment and pre-treatment services	140.	70
Screening for mental health disorders 177 79.4 Comprehensive substance abuse assessment or diagnosis 203 91.0 Comprehensive mental health assessment or diagnosis 137 61.4 Screening for tobacco use 144 64.6 Outreach to persons in the community who may need treatment 138 61.9 Interim services for clients when immediate admission is not possible 117 52.5 No services offered 20 9.7 Testing 195 87.4 Drug or alcohol urine screening 209 3.7 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV I vesting 36 16.1 TB screening 36 16.1 TB screening 4 1.8 Councilier 4 1.8 Enditional counseling 218 8.6 Group counseling 216 6.9 Family counseling 218 8.3 Martial-couples courseling 218 8.3		214	96.0
Comprehensive substance abuse assessment or diagnosis 203 91.0 Comprehensive mental health assessment or diagnosis 137 61.4 Screening for tobacco use 144 64.6 Outreach to persons in the community who may need treatment 138 61.9 Interim services for clients when immediate admission is not possible 2 0.9 Tosting Tosting 209 93.7 Breathalyzer or other blood alcohol testing 195 8.7.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 55 24.7 Storeening for hepatitis B 36 16.1 TB screening 36 16.1 TB screening 36 16.1 TB screening 217 24.7 No services offered 4 18.8 Group counseling 218 97.8 Group counseling 218 97.8 <td< td=""><td></td><td></td><td></td></td<>			
Comprehensive mental health assessment or diagnosis 137 61.4 Screening for tobacco use 144 6.6 Outreach to persons in the community who may need treatment 138 61.9 Interim services for clients when immediate admission is not possible 117 52.5 No services offered 2 0.9 Breathalyzer or other blood alcohol testing 195 87.4 Breathalyzer or other blood alcohol testing 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 68 30.5 Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening for hepatitis B 30.5 14.7 Storeening for hepatitis B 95 24.7 Storeening for hepatitis B 30.5 16.1 TB screening for hepatitis B 30.5 16.1 Storeening for hepatitis B 30.5 16.1 TB screening for hepatitis B 30.5 16.1 Store screening for	•		
Screening for tobacco use 144 64.6 Outreach to persons in the community who may need treatment 138 61.9 Interim services for clients when immediate admission is not possible 17 52.5 No services offered 2 0.9 Testing Breathalyzer or other blood alcohol testing 195 87.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 55 24.7 Screening for hepatitis B 68 30.5 HIV testing 36 16.1 TB screening for hepatitis B 47 24.7 Streening for hepatitis B 55 24.7 Streening for hepatitis B 30.5 24.7 No services offered 4 18.8 Counseling 28 4.4 Roservices offered 218 97.8 Group counseling 218 82.5 Martial/couples counseling 213 95.5 Family counseling 213 <td>·</td> <td></td> <td></td>	·		
Outreach to persons in the community who may need treatment 138 61.9 Interim services for clients when immediate admission is not possible 17 52.5 No services offered 2 0.9 Testing Breathalyzer or other blood alcohol testing 195 87.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV testing 36 16.1 TB screening 39 44.4 No services offered 4 1.8 Counciling 218 97.8 Group counseling 218 97.8 Group counseling 218 96.9 Family counseling 218 95.5 Group counseling 218 95.5 Family counseling 218 95.5 Family counseling 218 95.5 Aftercare/continuing care 218 95.5 Aftercare/continuing care 218 95.5 <tr< td=""><td>·</td><td></td><td></td></tr<>	·		
Interim services for clients when immediate admission is not possible 117 52.5 No services offered 2			
No services offered 2 0.9 Testins 87.4 Breathalyzer or other blood alcohol testing 195 8.7.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 18 Counseling 218 97.8 Group counseling 218 97.8 Group counseling 218 97.8 Group counseling 218 97.8 Group counseling 218 95.9 Bramily counseling 218 95.5	· · · · · · · · · · · · · · · · · · ·		
Testing 195 87.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 184 82.5 Marital/couples counseling 213 95.5 Family counseling 213 95.5 Aftercare/continuing care 185 83.0 No services offered 2 - Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered - - Disulfiram (Antabuse*) 53 23.8 Nalltersone (oral) 74	·		
Breathalyzer or other blood alcohol testing 195 87.4 Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counseling Individual counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Group counseling 130 58.3 Tarnity counseling 184 82.5 Marital/couples counseling 130 58.3 Tarnity counseling 184 82.5 Marital/couples counseling 130 58.3 Tarnity counseling 218 95.5 Family counseling 218 95.5 Rafecare/continuing care 185 83.0 Discharge planning <t< td=""><td></td><td>_</td><td></td></t<>		_	
Drug or alcohol urine screening 209 93.7 Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counciling Individual counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Family counseling 185 83.0 Marital couples counseling 218 95.8 Family counseling 218 95.8 Family counseling 218 95.8 Family counseling 218 95.8 After		195	87.4
Screening for hepatitis B 55 24.7 Screening for hepatitis C 68 30.5 HIV testing 36 16.1 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 130 58.3 Transitional services 5 53 Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies 33 23.8 Disulfiram (Antabuse*) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol* 46 20.6 Acamprosate (Campral*) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medic	•		
Screening for hepatitis C 68 30.5 HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Courseling Individual counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 180 95.3 Family counseling 213 95.5 Family counseling 213 95.5 Aftercare/continuing care 185 83.0 No services offered 2 - Disulfiram (Antabuse*) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol* 46 20.6 Acamprosate (Campral*) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Methadone 30 <td< td=""><td></td><td></td><td></td></td<>			
HIV testing 55 24.7 STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counseling 31 97.8 Group counseling 216 96.9 Family counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 184 82.5 Marital/couples counseling 185 83.0 Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered 2 2 Pharmacotherapies 2 Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 144 6.3 Assistance with obtaining social services 127 57.0	· · · · · · · · · · · · · · · · · · ·		
STD testing 36 16.1 TB screening 99 44.4 No services offered 4 1.8 Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 213 95.5 Aftercare/continuing care 185 83.0 No services offered 5 83.0 No services offered 5 33 23.8 Extended-release, injectable naltrexone/vivitrol® 46 20.6 No-nicotine emoking/tobacco cessation medications	· · · · · · · · · · · · · · · · · · ·		
TB screening 99 44.4 No services offered 4 1.8 Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 180 58.3 Transitional services Transitional services Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered —			
No services offered 4 1.8 Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 180 58.3 Transitional services *** *** Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered - - Pharmacotherapies *** *** Disulfiram (Antabuse*) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol** 46 20.6 Acamprosate (Campral**) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone*) 80 35.9 Buprenorphine with naloxone (Suboxone*) 80	•		
Counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 130 58.3 Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine subdermal implant (Probuphine®) 1 0.4 <			
Individual counseling 218 97.8 Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 130 58.3 Transitional services Userpane planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse*) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol* 46 20.6 Acamprosate (Campral*) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone*) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine without paloxone 58 26.0 <			1.0
Group counseling 216 96.9 Family counseling 184 82.5 Marital/couples counseling 130 58.3 Transitional services Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/vivitrol® 46 20.6 Acamprosate (Campra®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine without naloxone 50 22.4 Ancillary services 50 22.4		218	97.8
Family counseling 184 82.5 Marital/couples counseling 130 58.3 Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4			
Marital/couples counseling 130 58.3 Transitional services Use factor planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies — — Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Transitional services Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Accillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8	· · · · · · · · · · · · · · · · · · ·		
Discharge planning 213 95.5 Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children <td< td=""><td></td><td></td><td></td></td<>			
Aftercare/continuing care 185 83.0 No services offered — — Pharmacotherapies Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Discharge planning	213	95.5
No services offered — — Pharmacotherapies S 23.8 Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0			
Disulfiram (Antabuse®) 53 23.8 Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	· · · · · · · · · · · · · · · · · · ·	_	_
Naltrexone (oral) 74 33.2 Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Pharmacotherapies		
Extended-release, injectable naltrexone/Vivitrol® 46 20.6 Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Disulfiram (Antabuse®)	53	23.8
Acamprosate (Campral®) 68 30.5 Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Naltrexone (oral)	74	33.2
Nicotine replacement 54 24.2 Non-nicotine smoking/tobacco cessation medications 48 21.5 Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 50 22.4 Ancillary services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Extended-release, injectable naltrexone/Vivitrol®	46	20.6
Non-nicotine smoking/tobacco cessation medications4821.5Medications for psychiatric disorders14062.8Methadone3013.5Buprenorphine with naloxone (Suboxone®)8035.9Buprenorphine without naloxone5826.0Buprenorphine subdermal implant (Probuphine®)10.4No services offered5022.4Ancillary services19587.4Case management services19587.4Social skills development16373.1Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	Acamprosate (Campral®)	68	30.5
Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 50 22.4 Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Nicotine replacement	54	24.2
Medications for psychiatric disorders 140 62.8 Methadone 30 13.5 Buprenorphine with naloxone (Suboxone®) 80 35.9 Buprenorphine without naloxone 58 26.0 Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services 50 22.4 Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services 127 57.0	Non-nicotine smoking/tobacco cessation medications	48	21.5
Buprenorphine with naloxone (Suboxone®) Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) No services offered 50 22.4 Ancillary services Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services		140	62.8
Buprenorphine without naloxone Buprenorphine subdermal implant (Probuphine®) 1 0.4 No services offered 50 22.4 Ancillary services Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services	Methadone	30	13.5
Buprenorphine subdermal implant (Probuphine®) No services offered 50 22.4 Ancillary services Case management services 195 87.4 Social skills development 163 73.1 Mentoring/peer support 129 57.8 Child care for clients' children 14 6.3 Assistance with obtaining social services	Buprenorphine with naloxone (Suboxone®)	80	35.9
No services offered5022.4Ancillary services87.4Case management services19587.4Social skills development16373.1Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	Buprenorphine without naloxone	58	26.0
Ancillary servicesCase management services19587.4Social skills development16373.1Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	Buprenorphine subdermal implant (Probuphine®)	1	0.4
Case management services19587.4Social skills development16373.1Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	No services offered	50	22.4
Social skills development16373.1Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	Ancillary services		
Mentoring/peer support12957.8Child care for clients' children146.3Assistance with obtaining social services12757.0	Case management services	195	87.4
Child care for clients' children146.3Assistance with obtaining social services12757.0	Social skills development	163	73.1
Assistance with obtaining social services 127 57.0	Mentoring/peer support	129	57.8
	Child care for clients' children	14	6.3
Employment counseling or training for clients 82 36.8	Assistance with obtaining social services	127	57.0
, , , , , , , , , , , , , , , , , , , ,	Employment counseling or training for clients	82	36.8

Types of services offered, by number and percent (continued)				
	Facilities			
	No.	%		
Assistance in locating housing for clients	125	56.1		
Domestic violence services	86	38.6		
Early intervention for HIV	50	22.4		
HIV or AIDS education, counseling, or support	113	50.7		
Hepatitis education, counseling, or support	101	45.3		
Health education other than HIV/AIDS or hepatitis	120	53.8		
Substance abuse education	219	98.2		
Transportation assistance to treatment	89	39.9		
Mental health services	179	80.3		
Acupuncture	41	18.4		
Residential beds for clients' children	2	0.9		
Self-help groups	101	45.3		
Smoking/tobacco cessation counseling	102	45.7		
No services offered	1	0.4		
Other services				
Treatment for gambling disorder	27	12.1		
Treatment for Internet use disorder	30	13.5		
Treatment for other addiction disorder	61	27.4		
No services offered	160	71.7		

	Faci	lities
	No.	%
Substance abuse counseling	221	99.1
Relapse prevention	217	97.3
Cognitive behavioral therapy	217	97.3
Motivational interviewing	210	94.2
Anger management	198	88.8
Brief intervention	188	84.3
Trauma-related counseling	188	84.3
12-step facilitation	164	73.5
Contingency management/motivational incentives	123	55.2
Dialectical behavior therapy	126	56.5
Rational emotive behavioral therapy	89	39.9
Matrix model	101	45.3
Computerized substance abuse treatment	33	14.8
Community reinforcement plus vouchers	13	5.8
Other treatment approaches	10	4.5

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	25	9				
Number of clients ²	659	161				
Number of designated beds	728	152				
Utilization rate ³	90.5	105.9				
Average number of designated beds per facility	29	17				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	86
Methadone	79
Buprenorphine	7
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facili	ties
	No.	%
Sign language	97	43.5
Any language other than English	108	48.4
Non-English language provided by		
Staff counselor only	14	13.0
On-call interpreter only	67	62.0
Both staff counselor and on-call interpreter	27	25.0
Languages provided by staff counselor ¹		
Spanish	38	92.7
American Indian/Alaskan Native languages	_	_
Other	8	19.5

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	175	78.5
Adult women	111	49.8
Clients with co-occurring disorders	113	50.7
Adult men	101	45.3
Clients who have experienced trauma	81	36.3
Criminal justice clients	67	30.0
DUI/DWI clients	38	17.0
Young adults	46	20.6
Adolescents	54	24.2
Clients who have experienced domestic violence	34	15.2
Clients who have experienced sexual		10.1
abuse	41	18.4
Pregnant or postpartum women	64	28.7
Seniors or older adults	20	9.0
LGBT ¹	25	11.2
Veterans	31	13.9
Clients living with HIV/AIDS	25	11.2
Members of military families	17	7.6
Active duty military	21	9.4
Other	10	4.5
No program or group offered	48	21.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

SO HILINGA PAGE COLOR OF THE P

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



2017 State Profile — Washington National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Washington, 396 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 43,846 clients in substance abuse treatment on March 31, 2017. The survey response rate in Washington was 89.4 percent.

Facility operation, by number and percent							
			Clients i	n treatmen	t on March 31,	2017	
	Facilities		All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	176	44.4	21,103	48.1	1,713	71.8	
Private for-profit	158	39.9	14,922	34.0	193	8.1	
Local, county, or community government	23	5.8	2,990	6.8	256	10.7	
State government	5	1.3	346	0.8	152	6.4	
Federal government	6	1.5	1,919	4.4	_	_	
Tribal government	28	7.1	2,566	5.9	72	3.0	
Total	396	100.0	43,846	100.0	2,386	100.0	

Substance abuse problem treated, by number and percent							
	nt on March 31, 2017						
_	Facilities ¹ C				Clients ² per 100,000 pop.		
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	354	95.7	18,708	41.0	302		
Clients with drug abuse only	307	83.0	18,569	40.7	310		
Clients with alcohol abuse only	299	80.8	8,354	18.3	139		
Total			45,631	100.0	751		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent								
			Clients in treatment on March 31, 20				17	
_	Facil	ities¹		All clients			Clients age < 18	
_				Median no. Median no. of of clients per				
	No.	%	No.	%	OTP facility	non-OTP facility	No.	%
Outpatient	346	87.4	41,390	94.4	533	61	2,237	93.8
Regular	342	86.4	18,804	42.9	142	39		
Intensive	298	75.3	10,096	23.0	52	22		
Day treatment/partial hospitalization	22	5.6	94	0.2	_	12		
Detoxification	24	6.1	125	0.3	11	5		
Methadone maintenance	72	18.2	12,271	28.0	371	31		
Residential (non-hospital)	64	16.2	2,265	5.2	20	16	149	6.2
Short term (<30 days)	47	11.9	1,409	3.2	20	18		
Long term (30+ days)	33	8.3	669	1.5	_	15		
Detoxification	18	4.5	187	0.4	_	10		
Hospital inpatient	11	2.8	191	0.4	2	16	_	_
Treatment	8	2.0	83	0.2	_	20		
Detoxification	11	2.8	108	0.2	2	9		
Total	396		43,846	100.0	533	55	2,386	100.0

¹ Facilities may provide more than one type of care.

	No.	%
Facilities with OTPs ¹	25	1.9
Clients in facilities with OTPs ²		
Any MAT	11,795	2.8
Methadone	10,903	2.8
Buprenorphine	853	3.1
Naltrexone	39	1.1
Clients in facilities without OTPs ²		
Any MAT	4,039	3.9
Buprenorphine	3,817	4.5
Naltrexone	222	1.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	358	90.4
Private health insurance	325	82.1
Medicare	80	20.2
Medicaid	267	67.4
State-financed health insurance	216	54.5
Federal military insurance	97	24.5
No payment accepted	5	1.3
Access to Recovery (ATR) vouchers ²	53	13.4
IHS/Tribal/Urban (ITU) funds	81	20.5
Other payments	3	0.8
Sliding fee scale	232	58.6
Treatment at no charge for clients who can't pay	152	38.4

Facility licensing, certification, or accreditation, by number and percent

Facil	ities¹
No.	%
388	98.0
372	93.9
141	35.6
297	75.0
10	2.5
51	12.9
70	17.7
4	1.0
7	1.8
2	0.5
4	1.0
	388 372 141 297 10 51 70 4 7

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 195 49.2

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by fidiliber and percent	Facilities	
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	371	93.7
Screening for mental health disorders	270	68.2
Comprehensive substance abuse assessment or diagnosis	380	96.0
Comprehensive mental health assessment or diagnosis	172	43.4
Screening for tobacco use	323	81.6
Outreach to persons in the community who may need treatment	255	64.4
Interim services for clients when immediate admission is not possible	248	62.6
No services offered	4	1.0
Testing		
Breathalyzer or other blood alcohol testing	230	58.1
Drug or alcohol urine screening	386	97.5
Screening for hepatitis B	85	21.5
Screening for hepatitis C	86	21.7
HIV testing	43	10.9
STD testing	45	11.4
TB screening	208	52.5
No services offered	8	2.0
Counseling		
Individual counseling	395	99.7
Group counseling	391	98.7
Family counseling	312	78.8
Marital/couples counseling	197	49.7
Fransitional services		
Discharge planning	393	99.2
Aftercare/continuing care	346	87.4
No services offered	_	
Pharmacotherapies		
Disulfiram (Antabuse®)	45	11.4
Naltrexone (oral)	65	16.4
Extended-release, injectable naltrexone/Vivitrol®	59	14.9
Acamprosate (Campral®)	38	9.6
Nicotine replacement	67	16.9
Non-nicotine smoking/tobacco cessation medications	46	11.6
Medications for psychiatric disorders	122	30.8
Methadone	24	6.1
Buprenorphine with naloxone (Suboxone®)	80	20.2
Buprenorphine without naloxone	41	10.4
Buprenorphine subdermal implant (Probuphine®)	4	1.0
No services offered	229	57.8
Ancillary services		
Case management services	358	90.4
Social skills development	314	79.3
Mentoring/peer support	193	48.7
Child care for clients' children	31	7.8
Assistance with obtaining social services	230	58.1
Employment counseling or training for clients	132	33.3

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	239	60.4
Domestic violence services	119	30.1
Early intervention for HIV	122	30.8
HIV or AIDS education, counseling, or support	238	60.1
Hepatitis education, counseling, or support	208	52.5
Health education other than HIV/AIDS or hepatitis	210	53.0
Substance abuse education	391	98.7
Transportation assistance to treatment	190	48.0
Mental health services	225	56.8
Acupuncture	22	5.6
Residential beds for clients' children	9	2.3
Self-help groups	159	40.2
Smoking/tobacco cessation counseling	213	53.8
No services offered	1	0.3
Other services		
Treatment for gambling disorder	58	14.6
Treatment for Internet use disorder	11	2.8
Treatment for other addiction disorder	49	12.4
No services offered	312	78.8

Clinical/therapeutic approaches (used 'always,' 'often,' or 'sometimes'), by number and percent					
	Faci	lities			
	No.	%			
Substance abuse counseling	390	98.5			
Relapse prevention	385	97.2			
Cognitive behavioral therapy	361	91.2			
Motivational interviewing	372	93.9			
Anger management	244	61.6			
Brief intervention	334	84.3			
Trauma-related counseling	253	63.9			
12-step facilitation	255	64.4			
Contingency management/motivational incentives	193	48.7			
Dialectical behavior therapy	215	54.3			
Rational emotive behavioral therapy	163	41.2			
Matrix model	164	41.4			
Computerized substance abuse treatment	31	7.8			
Community reinforcement plus vouchers	33	8.3			
Other treatment approaches	44	11.1			

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	61	10				
Number of clients ²	2,224	175				
Number of designated beds	2,464	242				
Utilization rate ³	90.3	72.3				
Average number of designated beds per facility	40	24				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	159
Methadone	147
Buprenorphine	12
Naltrexone	†

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

Facilities	
No.	%
180	45.5
213	53.8
25	11.7
126	59.2
62	29.1
75	86.2
1	1.1
17	19.5
	No. 180 213 25 126 62 75

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	320	80.8
Adult women	167	42.2
Clients with co-occurring disorders	139	35.1
Adult men	143	36.1
Clients who have experienced trauma	92	23.2
Criminal justice clients	97	24.5
DUI/DWI clients	126	31.8
Young adults	93	23.5
Adolescents	115	29.0
Clients who have experienced domestic violence	59	14.9
Clients who have experienced sexual		
abuse	59	14.9
Pregnant or postpartum women	73	18.4
Seniors or older adults	51	12.9
LGBT ¹	39	9.8
Veterans	42	10.6
Clients living with HIV/AIDS	27	6.8
Members of military families	26	6.6
Active duty military	25	6.3
Other	14	3.5
No program or group offered	76	19.2

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

PHANT SERVICES ITS

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — West Virginia National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In West Virginia, 102 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 18,115 clients in substance abuse treatment on March 31, 2017. The survey response rate in West Virginia was 92.2 percent.

Facility operation, by number and percent								
			Clients i	n treatmen	t on March 31,	2017		
	Faciliti	es	All clie	nts	Clients und	ler age 18		
	No.	%	No.	%	No.	%		
Private non-profit	78	76.5	10,925	60.3	1,326	91.6		
Private for-profit	19	18.6	6,672	36.8	121	8.4		
Local, county, or community government	_	_	_	_	_	_		
State government	2	2.0	63	0.3	_	_		
Federal government	3	2.9	455	2.5	_			
Tribal government	_	_	_	_	_	_		
Total	102	100.0	18,115	100.0	1,447	100.0		

Substance abuse problem treated, by number and percent								
	it on March 31, 2017							
	Facilities ¹ Clients ² Clie				Clients ² per 100,000 pop.			
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	82	90.1	4,704	26.0	297			
Clients with drug abuse only	79	86.8	10,104	55.8	657			
Clients with alcohol abuse only	67	73.6	3,307	18.3	198			
Total			18,115	100.0	1,153			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report substance abuse problem treated in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent										
				Clients in treatment on March 31, 20						
_	Facil	ities¹		All clients				age < 18		
				Median no. Median no. of						
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%		
Outpatient	72	70.6	17,283	95.4	540	78	1,407	97.2		
Regular	68	66.7	9,654	53.3	295	50				
Intensive	34	33.3	615	3.4	6	15				
Day treatment/partial hospitalization	4	3.9	66	0.4	_	15				
Detoxification	19	18.6	149	8.0	10	8				
Methadone maintenance	46	45.1	6,799	37.5	525	20				
Residential (non-hospital)	29	28.4	698	3.9	_	12	39	2.7		
Short term (<30 days)	12	11.8	117	0.6	_	8				
Long term (30+ days)	21	20.6	508	2.8	_	13				
Detoxification	7	6.9	73	0.4	_	7				
Hospital inpatient	12	11.8	134	0.7	_	10	1	0.1		
Treatment	8	7.8	82	0.5	_	6				
Detoxification	12	11.8	52	0.3	<u>—</u>	5				
Total	102		18,115	100.0	540	40	1,447	100.0		

¹ Facilities may provide more than one type of care.

•		
	No.	%
Facilities with OTPs ¹	9	0.7
Clients in facilities with OTPs ²		
Olients in lacilities with O 11 3		
Any MAT	5,406	1.3
Methadone	3,109	0.8
Buprenorphine	2,051	7.4
Naltrexone	246	7.2
Clients in facilities without OTPs ²		
Any MAT	1,726	1.7
Buprenorphine	1,488	1.8
Naltrexone	238	1.2

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	92	90.2
Private health insurance	82	80.4
Medicare	62	60.8
Medicaid	84	82.4
State-financed health insurance	74	72.5
Federal military insurance	61	59.8
No payment accepted	6	5.9
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	5	4.9
Other payments	1	1.0
Sliding fee scale	43	42.2
Treatment at no charge for clients who can't pay	72	70.6

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	89	87.3
State substance abuse agency	61	59.8
State mental health department	54	52.9
State department of health	66	64.7
Hospital licensing authority	6	5.9
The Joint Commission	11	10.8
Commission on Accreditation of		
Rehabilitation Facilities	20	19.6
National Committee for Quality Assurance	4	3.9
Council on Accreditation	3	2.9
Healthcare Facilities Accreditation Program	4	3.9
Other state/local agency/organization	2	2.0

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 64 62.7

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services energy, by number and percent	Faci	lities
	No.	%
Assessment and pre-treatment services	110.	70
Screening for substance abuse	93	91.2
Screening for mental health disorders	84	82.4
Comprehensive substance abuse assessment or diagnosis	87	85.3
Comprehensive mental health assessment or diagnosis	68	66.7
Screening for tobacco use	55	53.9
Outreach to persons in the community who may need treatment	69	67.6
Interim services for clients when immediate admission is not possible	55	53.9
No services offered	4	3.9
Testing		
Breathalyzer or other blood alcohol testing	85	83.3
Drug or alcohol urine screening	94	92.2
Screening for hepatitis B	29	28.4
Screening for hepatitis C	30	29.4
HIV testing	25	24.5
STD testing	21	20.6
TB screening	28	27.5
No services offered	4	3.9
Counseling		0.0
Individual counseling	100	98.0
Group counseling	94	92.2
Family counseling	84	82.4
Marital/couples counseling	62	60.8
Transitional services		
Discharge planning	97	95.1
Aftercare/continuing care	88	86.3
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	30	29.4
Naltrexone (oral)	44	43.1
Extended-release, injectable naltrexone/Vivitrol®	43	42.2
Acamprosate (Campral®)	32	31.4
Nicotine replacement	32	31.4
Non-nicotine smoking/tobacco cessation medications	24	23.5
Medications for psychiatric disorders	67	65.7
Methadone	9	8.8
Buprenorphine with naloxone (Suboxone®)	35	34.3
Buprenorphine without naloxone	28	27.5
Buprenorphine subdermal implant (Probuphine®)	1	1.0
No services offered	23	22.5
Ancillary services		
Case management services	86	84.3
Social skills development	74	72.5
Mentoring/peer support	53	52.0
Child care for clients' children	2	2.0
Assistance with obtaining social services	82	80.4
Employment counseling or training for clients	28	27.5

Types of services offered, by number and percent (continued)						
	Facilities					
	No.	%				
Assistance in locating housing for clients	70	68.6				
Domestic violence services	44	43.1				
Early intervention for HIV	22	21.6				
HIV or AIDS education, counseling, or support	43	42.2				
Hepatitis education, counseling, or support	44	43.1				
Health education other than HIV/AIDS or hepatitis	51	50.0				
Substance abuse education	97	95.1				
Transportation assistance to treatment	59	57.8				
Mental health services	83	81.4				
Acupuncture	1	1.0				
Residential beds for clients' children	4	3.9				
Self-help groups	44	43.1				
Smoking/tobacco cessation counseling	41	40.2				
No services offered	_	-				
Other services						
Treatment for gambling disorder	39	38.2				
Treatment for Internet use disorder	18	17.6				
Treatment for other addiction disorder	39	38.2				
No services offered	47	46.1				

	Faci	lities
	No.	%
Substance abuse counseling	100	98.0
Relapse prevention	99	97.1
Cognitive behavioral therapy	97	95.1
Motivational interviewing	96	94.1
Anger management	93	91.2
Brief intervention	90	88.2
Trauma-related counseling	88	86.3
12-step facilitation	79	77.5
Contingency management/motivational incentives	50	49.0
Dialectical behavior therapy	57	55.9
Rational emotive behavioral therapy	77	75.5
Matrix model	37	36.3
Computerized substance abuse treatment	19	18.6
Community reinforcement plus vouchers	7	6.9
Other treatment approaches	1	1.0

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	24	5				
Number of clients ²	399	94				
Number of designated beds	437	69				
Utilization rate ³	91.3	136.2				
Average number of designated beds per facility	18	14				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	298
Methadone	171
Buprenorphine	113
Naltrexone	14

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	39	38.2
Any language other than English	24	23.5
Non-English language provided by		
Staff counselor only	_	_
On-call interpreter only	23	95.8
Both staff counselor and on-call interpreter	1	4.2
Languages provided by staff counselor ¹		
Spanish	1	100.0
American Indian/Alaskan Native		
languages	_	_
Other	_	_

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	77	75.5
Adult women	38	37.3
Clients with co-occurring disorders	36	35.3
Adult men	39	38.2
Clients who have experienced trauma	32	31.4
Criminal justice clients	23	22.5
DUI/DWI clients	28	27.5
Young adults	17	16.7
Adolescents	17	16.7
Clients who have experienced domestic violence	25	24.5
Clients who have experienced sexual		
abuse	23	22.5
Pregnant or postpartum women	21	20.6
Seniors or older adults	15	14.7
LGBT ¹	20	19.6
Veterans	20	19.6
Clients living with HIV/AIDS	18	17.6
Members of military families	11	10.8
Active duty military	8	7.8
Other	1	1.0
No program or group offered	25	24.5

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Wisconsin National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Wisconsin, 273 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 22,628 clients in substance abuse treatment on March 31, 2017. The survey response rate in Wisconsin was 91.4 percent.

Facility operation, by number and percent									
			Clients i	n treatmen	t on March 31,	2017			
	Faciliti	Facilities All clients		nts	Clients under age 18				
	No.	%	No.	%	No.	%			
Private non-profit	117	42.9	7,038	31.1	714	45.0			
Private for-profit	95	34.8	9,249	40.9	483	30.4			
Local, county, or community government	44	16.1	3,813	16.9	156	9.8			
State government	1	0.4	46	0.2	6	0.4			
Federal government	3	1.1	794	3.5	_	_			
Tribal government	13	4.8	1,688	7.5	229	14.4			
Total	273	100.0	22,628	100.0	1,588	100.0			

Substance abuse problem treated, by number and percent								
	n treatmer	nt on March 31, 2017						
_	Facilities ¹		Clients ²		Clients ² per 100,000 pop.			
	No.	%	No.	%	age 18 or older			
Clients with both alcohol and drug abuse	244	94.6	9,278	41.2	189			
Clients with drug abuse only	223	86.4	8,411	37.3	178			
Clients with alcohol abuse only	222	86.0	4,832	21.5	97			
Total			22,521	100.0	464			

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and percent										
				Clients in treatment on March 31, 20						
_	Facil	ities¹	All clients					Clients age < 18		
				Median no. Median no. of						
	No.	%	No.	%	of clients per OTP facility	clients per non-OTP facility	No.	%		
Outpatient	232	85.0	20,885	92.3	407	40	1,521	95.8		
Regular	222	81.3	14,235	62.9	197	35				
Intensive	97	35.5	2,020	8.9	19	16				
Day treatment/partial hospitalization	23	8.4	143	0.6	_	10				
Detoxification	16	5.9	64	0.3	3	15				
Methadone maintenance	73	26.7	4,423	19.5	368	20				
Residential (non-hospital)	43	15.8	950	4.2	_	16	46	2.9		
Short term (<30 days)	24	8.8	354	1.6	_	14				
Long term (30+ days)	39	14.3	586	2.6	_	15				
Detoxification	4	1.5	10	*	_	2				
Hospital inpatient	27	9.9	793	3.5	_	14	21	1.3		
Treatment	15	5.5	281	1.2	_	11				
Detoxification	25	9.2	512	2.3	_	8				
Total	273		22,628	100.0	407	36	1,588	100.0		

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹	13	1.0
Clients in facilities with OTPs ²		
Any MAT	4,353	1.1
Methadone	4,101	1.1
Buprenorphine	181	0.7
Naltrexone	71	2.1
Clients in facilities without OTPs ²		
Any MAT	1,883	1.8
Buprenorphine	1,268	1.5
Naltrexone	615	3.1

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	255	93.4
Private health insurance	245	89.7
Medicare	162	59.3
Medicaid	235	86.1
State-financed health insurance	155	56.8
Federal military insurance	161	59.0
No payment accepted	2	0.7
Access to Recovery (ATR) vouchers ²	33	12.1
IHS/Tribal/Urban (ITU) funds	37	13.6
Other payments	1	0.4
Sliding fee scale	116	42.5
Treatment at no charge for clients who can't pay	86	31.5
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	252	92.3
State substance abuse agency	217	79.5
State mental health department	180	65.9
State department of health	130	47.6
Hospital licensing authority	37	13.6
The Joint Commission	57	20.9
Commission on Accreditation of Rehabilitation Facilities	18	6.6
National Committee for Quality Assurance	12	4.4
Council on Accreditation	22	8.1
Healthcare Facilities Accreditation Program	3	1.1
Other state/local agency/organization	4	1.5

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 140 51.3

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of cervices energy, by number and personic	Faci	lities
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	262	96.0
Screening for mental health disorders	234	85.7
Comprehensive substance abuse assessment or diagnosis	256	93.8
Comprehensive mental health assessment or diagnosis	192	70.3
Screening for tobacco use	174	63.7
Outreach to persons in the community who may need treatment	140	51.3
Interim services for clients when immediate admission is not possible	109	39.9
No services offered	1	0.4
Testing		
Breathalyzer or other blood alcohol testing	173	63.4
Drug or alcohol urine screening	204	74.7
Screening for hepatitis B	66	24.2
Screening for hepatitis C	69	25.3
HIV testing	61	22.3
STD testing	55	20.1
TB screening	106	38.8
No services offered	43	15.8
Counseling		10.0
Individual counseling	268	98.2
Group counseling	230	84.2
Family counseling	244	89.4
Marital/couples counseling	214	78.4
Transitional services		
Discharge planning	258	94.5
Aftercare/continuing care	243	89.0
No services offered	1	0.4
Pharmacotherapies		
Disulfiram (Antabuse®)	69	25.3
Naltrexone (oral)	86	31.5
Extended-release, injectable naltrexone/Vivitrol®	79	28.9
Acamprosate (Campral®)	89	32.6
Nicotine replacement	81	29.7
Non-nicotine smoking/tobacco cessation medications	87	31.9
Medications for psychiatric disorders	144	52.7
Methadone	13	4.8
Buprenorphine with naloxone (Suboxone®)	60	22.0
Buprenorphine without naloxone	39	14.3
Buprenorphine subdermal implant (Probuphine®)	2	0.7
No services offered	107	39.2
Ancillary services		
Case management services	191	70.0
Social skills development	192	70.3
Mentoring/peer support	111	40.7
Child care for clients' children	13	4.8
Assistance with obtaining social services	137	50.2
Employment counseling or training for clients	81	29.7

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	111	40.7
Domestic violence services	127	46.5
Early intervention for HIV	30	11.0
HIV or AIDS education, counseling, or support	78	28.6
Hepatitis education, counseling, or support	82	30.0
Health education other than HIV/AIDS or hepatitis	103	37.7
Substance abuse education	261	95.6
Transportation assistance to treatment	89	32.6
Mental health services	224	82.1
Acupuncture	4	1.5
Residential beds for clients' children	2	0.7
Self-help groups	92	33.7
Smoking/tobacco cessation counseling	133	48.7
No services offered	2	0.7
Other services		
Treatment for gambling disorder	111	40.7
Treatment for Internet use disorder	69	25.3
Treatment for other addiction disorder	142	52.0
No services offered	114	41.8

	Faci	lities
	No.	%
Substance abuse counseling	267	97.8
Relapse prevention	263	96.3
Cognitive behavioral therapy	259	94.9
Motivational interviewing	248	90.8
Anger management	227	83.2
Brief intervention	225	82.4
Trauma-related counseling	247	90.5
12-step facilitation	190	69.6
Contingency management/motivational incentives	145	53.1
Dialectical behavior therapy	153	56.0
Rational emotive behavioral therapy	141	51.6
Matrix model	90	33.0
Computerized substance abuse treatment	35	12.8
Community reinforcement plus vouchers	31	11.4
Other treatment approaches	24	8.8

Facility capacity and utilization rate ¹							
	Residential	Hospital inpatient					
Number of facilities	37	7					
Number of clients ²	803	167					
Number of designated beds	840	188					
Utilization rate ³	95.6	88.8					
Average number of designated beds per facility	23	27					

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	75
Methadone	71
Buprenorphine	3
Naltrexone	1

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	115	42.1
Any language other than English	134	49.1
Non-English language provided by		
Staff counselor only	8	6.0
On-call interpreter only	109	81.3
Both staff counselor and on-call interpreter	17	12.7
Languages provided by staff counselor ¹		
Spanish	22	88.0
American Indian/Alaskan Native		
languages	_	_
Other	7	28.0

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	190	69.6
Adult women	111	40.7
Clients with co-occurring disorders	97	35.5
Adult men	97	35.5
Clients who have experienced trauma	86	31.5
Criminal justice clients	86	31.5
DUI/DWI clients	81	29.7
Young adults	62	22.7
Adolescents	54	19.8
Clients who have experienced domestic violence	58	21.2
Clients who have experienced sexual		
abuse	62	22.7
Pregnant or postpartum women	40	14.7
Seniors or older adults	45	16.5
LGBT ¹	44	16.1
Veterans	47	17.2
Clients living with HIV/AIDS	38	13.9
Members of military families	33	12.1
Active duty military	29	10.6
Other	10	3.7
No program or group offered	83	30.4

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — Wyoming National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report:

https://www.samhsa.gov/data/all-reports

In Wyoming, 47 substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 3,236 clients in substance abuse treatment on March 31, 2017. The survey response rate in Wyoming was 90.4 percent.

Facility operation, by number and percent							
	Clients in treatment on March 31, 2017						
	Faciliti	es	All clie	nts	Clients und	ler age 18	
	No.	%	No.	%	No.	%	
Private non-profit	28	59.6	1,492	46.1	106	54.9	
Private for-profit	9	19.1	235	7.3	38	19.7	
Local, county, or community government	8	17.0	1,394	43.1	43	22.3	
State government	_	_	_	_	_	_	
Federal government	1	2.1	80	2.5	_	_	
Tribal government	1	2.1	35	1.1	6	3.1	
Total	47	100.0	3,236	100.0	193	100.0	

Substance abuse problem treated, by number and percent							
			Clients in	n treatmer	it on March 31, 2017		
	Faciliti	Facilities ¹		Clients ² Clients ² per 100,00			
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	38	88.4	1,177	36.4	244		
Clients with drug abuse only	34	79.1	972	30.0	207		
Clients with alcohol abuse only	40	93.0	1,088	33.6	236		
Total			3,236	100.0	687		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report substance abuse problem treated in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹			All clients		Clients	age < 18
					Median no. of clients per	Median no. of clients per		
	No.	%	No.	%		non-OTP facility	No.	%
Outpatient	38	80.9	2,689	83.1	_	25	173	89.6
Regular	38	80.9	1,513	46.8	_	18		
Intensive	33	70.2	936	28.9	_	11		
Day treatment/partial hospitalization	5	10.6	20	0.6	_	8		
Detoxification	3	6.4	20	0.6	_	4		
Methadone maintenance	11	23.4	200	6.2	_	28		
Residential (non-hospital)	12	25.5	543	16.8	_	22	20	10.4
Short term (<30 days)	10	21.3	255	7.9	_	17		
Long term (30+ days)	11	23.4	180	5.6	_	12		
Detoxification	10	21.3	108	3.3	_	1		
Hospital inpatient	4	8.5	4	0.1	_	1	_	_
Treatment	4	8.5	_	_	_	_		
Detoxification	4	8.5	4	0.1	<u> </u>	1		
Total	47		3,236	100.0	_	25	193	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

,		
	No.	%
Facilities with OTPs ¹	_	_
Cliente in facilities with OTDs?		
Clients in facilities with OTPs ²		
Any MAT		
Methadone	_	_
Buprenorphine	_	_
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	256	0.2
Buprenorphine	171	0.2
Naltrexone	85	0.4
15		

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

r dome, payment options, by manner and		
	No.	%
Cash or self-payment	46	97.9
Private health insurance	46	97.9
Medicare	28	59.6
Medicaid	41	87.2
State-financed health insurance	35	74.5
Federal military insurance	39	83.0
No payment accepted	1	2.1
Access to Recovery (ATR) vouchers ²	5	10.6
IHS/Tribal/Urban (ITU) funds	14	29.8
Other payments	1	2.1
Sliding fee scale	38	80.9
Treatment at no charge for clients who can't pay	33	70.2
1 = -1141		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	46	97.9
State substance abuse agency	40	85.1
State mental health department	38	80.9
State department of health	43	91.5
Hospital licensing authority	5	10.6
The Joint Commission	5	10.6
Commission on Accreditation of Rehabilitation Facilities	37	78.7
National Committee for Quality Assurance	_	_
Council on Accreditation	_	-
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	1	2.1

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 36 76.6

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of services offered, by flumber and percent	Fac	ilities
	No.	%
Assessment and pre-treatment services	1101	
Screening for substance abuse	44	93.6
Screening for mental health disorders	40	85.1
Comprehensive substance abuse assessment or diagnosis	46	97.9
Comprehensive mental health assessment or diagnosis	33	70.2
Screening for tobacco use	34	72.3
Outreach to persons in the community who may need treatment	36	76.6
Interim services for clients when immediate admission is not possible	30	63.8
No services offered	_	_
Testing		
Breathalyzer or other blood alcohol testing	35	74.5
Drug or alcohol urine screening	33	70.2
Screening for hepatitis B	13	27.7
Screening for hepatitis C	13	27.7
HIV testing	10	21.3
STD testing	10	21.3
TB screening	15	31.9
No services offered	8	17.0
Counseling		
Individual counseling	47	100.0
Group counseling	47	100.0
Family counseling	46	97.9
Marital/couples counseling	41	87.2
Fransitional services		
Discharge planning	46	97.9
Aftercare/continuing care	45	95.7
No services offered	_	_
Pharmacotherapies		
Disulfiram (Antabuse®)	19	40.4
Naltrexone (oral)	22	46.8
Extended-release, injectable naltrexone/Vivitrol®	18	38.3
Acamprosate (Campral®)	17	36.2
Nicotine replacement	21	44.7
Non-nicotine smoking/tobacco cessation medications	17	36.2
Medications for psychiatric disorders	33	70.2
Methadone	_	_
Buprenorphine with naloxone (Suboxone®)	13	27.7
Buprenorphine without naloxone	10	21.3
Buprenorphine subdermal implant (Probuphine®)	1	2.1
No services offered	11	23.4
Ancillary services		
Case management services	45	95.7
Social skills development	40	85.1
Mentoring/peer support	29	61.7
Child care for clients' children	9	19.1
Assistance with obtaining social services	40	85.1
Employment counseling or training for clients	25	53.2
Continued		

Types of services offered, by number and percent (continued)		
	Faci	lities
	No.	%
Assistance in locating housing for clients	38	80.9
Domestic violence services	31	66.0
Early intervention for HIV	15	31.9
HIV or AIDS education, counseling, or support	27	57.4
Hepatitis education, counseling, or support	22	46.8
Health education other than HIV/AIDS or hepatitis	27	57.4
Substance abuse education	46	97.9
Transportation assistance to treatment	33	70.2
Mental health services	45	95.7
Acupuncture	4	8.5
Residential beds for clients' children	6	12.8
Self-help groups	18	38.3
Smoking/tobacco cessation counseling	33	70.2
No services offered	_	_
Other services		
Treatment for gambling disorder	20	42.6
Treatment for Internet use disorder	10	21.3
Treatment for other addiction disorder	27	57.4
No services offered	15	31.9

	Fac	ilities
	No.	%
Substance abuse counseling	47	100.0
Relapse prevention	47	100.0
Cognitive behavioral therapy	46	97.9
Motivational interviewing	46	97.9
Anger management	43	91.5
Brief intervention	43	91.5
Frauma-related counseling	47	100.0
12-step facilitation	34	72.3
Contingency management/motivational incentives	34	72.3
Dialectical behavior therapy	41	87.2
Rational emotive behavioral therapy	28	59.6
Matrix model	26	55.3
Computerized substance abuse treatment	14	29.8
Community reinforcement plus vouchers	7	14.9
Other treatment approaches	6	12.8

Facility capacity and utilization rate ¹						
	Residential	Hospital inpatient				
Number of facilities	8	2				
Number of clients ²	195	3				
Number of designated beds	224	18				
Utilization rate ³	87.1	16.7				
Average number of designated beds per facility	28	9				

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

² Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	‡
Methadone	‡
Buprenorphine	‡
Naltrexone	‡

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	16	34.0
Any language other than English	25	53.2
Non-English language provided by		
Staff counselor only	3	12.0
On-call interpreter only	12	48.0
Both staff counselor and on-call interpreter	10	40.0
Languages provided by staff counselor ¹		
Spanish	12	92.3
American Indian/Alaskan Native languages	1	7.7
Other	_	_

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	37	78.7
Adult women	24	51.1
Clients with co-occurring disorders	27	57.4
Adult men	24	51.1
Clients who have experienced trauma	25	53.2
Criminal justice clients	26	55.3
DUI/DWI clients	25	53.2
Young adults	17	36.2
Adolescents	19	40.4
Clients who have experienced domestic violence	19	40.4
Clients who have experienced sexual		
abuse	18	38.3
Pregnant or postpartum women	14	29.8
Seniors or older adults	10	21.3
LGBT ¹	11	23.4
Veterans	12	25.5
Clients living with HIV/AIDS	8	17.0
Members of military families	8	17.0
Active duty military	6	12.8
Other	1	2.1
No program or group offered	10	21.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at:

https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at:

https://wwwdasis.samhsa.gov/


For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:

https://findtreatment.samhsa.gov/

O HINTON SERVICES USES

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities



https://wwwdasis.samhsa.gov/webt/newmapv1.htm

2017 State Profile — U.S. Territories and Other Jurisdictions National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2017 N-SSATS report: https://www.samhsa.gov/data/all-reports

The U.S. territories and other jurisdictions presented in this profile consist of data from Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, and the U.S. Virgin Islands. This profile does not include data for the District of Columbia and Puerto Rico. In these U.S. territories and other jurisdictions, seven substance abuse treatment facilities were included in the 2017 N-SSATS, which reported a total of 473 clients in substance abuse treatment on March 31, 2017. The survey response rate in these U.S. territories and other jurisdictions, combined, was 58.3 percent.

Facility operation, by number and percent								
			Clients in treatment on March 31, 2017					
	Faciliti	es	All clier	nts	Clients und	ler age 18		
	No.	%	No.	%	No.	%		
Private non-profit	4	57.1	168	35.5	49	69.0		
Private for-profit	1	14.3	80	16.9	_	_		
Local, county, or community government	_	_	_	_	_	_		
State government	2	28.6	225	47.6	22	31.0		
Federal government	_	_	_	_	_	_		
Tribal government	_	_	_	_	_	_		
Total	7	100.0	473	100.0	71	100.0		

Substance abuse problem treated, by number and percent							
Clients in treatment on March 3							
	Facilities ¹ Clients ² Clients ² pe						
	No.	%	No.	%	age 18 or older		
Clients with both alcohol and drug abuse	7	100.0	173	36.6	42		
Clients with drug abuse only	6	85.7	121	25.5	39		
Clients with alcohol abuse only	7	100.0	179	37.9	54		
Total			473	100.0	136		

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Type of care, by number and per	cent							
			Clients in treatment on March 31, 2017					
_	Facil	ities¹		All clients				
					Median no.	Median no. of		
	No.	%	No.	%	of clients per	clients per non-OTP facility	No.	%
Outpatient	7	100.0	410	86.7	—	38	57	80.3
Regular	7	100.0	348	73.6		21	31	00.5
Intensive	5	71.4	62	13.1	_	16		
Day treatment/partial hospitalization	1	14.3	_	_	_	_		
Detoxification	3	42.9	_	_	_	_		
Methadone maintenance	1	14.3	_	_	_	_		
Residential (non-hospital)	4	57.1	63	13.3	_	16	14	19.7
Short term (<30 days)	4	57.1	1	0.2	_	1		
Long term (30+ days)	4	57.1	55	11.6	_	15		
Detoxification	3	42.9	7	1.5	_	2		
Hospital inpatient	_	_	_	_	_	_	_	_
Treatment	_	_	_	_	_	_		
Detoxification	_	_	_	_	_	_		
Total	7		473	100.0	_	52	71	100.0

¹ Facilities may provide more than one type of care.

Opioid treatment programs (OTPs), by number and percent

	No.	%
Facilities with OTPs ¹		
Clients in facilities with OTPs ²		
Any MAT	_	_
Methadone	_	_
Buprenorphine	_	_
Naltrexone	_	_
Clients in facilities without OTPs ²		
Any MAT	1	*
Buprenorphine	_	_
Naltrexone	1	*

¹ Percentage of all OTP facilities in the U.S. ² Percentage of all methadone, buprenorphine, or naltrexone clients in the U.S. See 2017 N-SSATS report for details.

Facility payment options, by number and percent¹

	No.	%
Cash or self-payment	2	28.6
Private health insurance	1	14.3
Medicare	—	
Medicaid	_	
State-financed health insurance	_	_
Federal military insurance	1	14.3
No payment accepted	5	71.4
Access to Recovery (ATR) vouchers ²	n/a	n/a
IHS/Tribal/Urban (ITU) funds	_	
Other payments	_	_
Sliding fee scale	1	14.3
Treatment at no charge for clients who can't pay	7	100.0
4 = 100		

Facility licensing, certification, or accreditation, by number and percent

	Facilities ¹	
	No.	%
Any listed agency/organization	4	57.1
State substance abuse agency	2	28.6
State mental health department	3	42.9
State department of health	3	42.9
Hospital licensing authority	1	14.3
The Joint Commission	_	_
Commission on Accreditation of Rehabilitation Facilities	1	14.3
National Committee for Quality Assurance	1	14.3
Council on Accreditation	_	_
Healthcare Facilities Accreditation Program	_	_
Other state/local agency/organization	_	_

¹ Facilities may be licensed by more than one agency/organization.

Facility funding, by number and percent Facilities No. % Receives federal, state, county, or local government funds for substance abuse treatment programs 7 100.0

¹ Facilities may accept more than one type of payment.

² Available in AK, AR, AZ, CA, CO, CT, DC, FL, HI, IA, ID, IL, IN, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SD, TN, TX, WA, WI, and WY.

Types of services offered, by number and percent		
Types of Services offered, by flumber and percent	F	ilitioo
	No.	ilities %
Assessment and pre-treatment services	NO.	
Screening for substance abuse	7	100.0
Screening for mental health disorders	6	85.7
Comprehensive substance abuse assessment or diagnosis	7	100.0
Comprehensive mental health assessment or diagnosis	3	42.9
Screening for tobacco use	6	85.7
Outreach to persons in the community who may need treatment	6	85.7
Interim services for clients when immediate admission is not possible	6	85.7
No services offered	<u> </u>	—
Testing		
Breathalyzer or other blood alcohol testing	7	100.0
Drug or alcohol urine screening	7	100.0
Screening for hepatitis B	2	28.6
Screening for hepatitis C	2	28.6
HIV testing	3	42.9
STD testing	2	28.6
TB screening	2	28.6
No services offered	Z	20.0
	_	
Counseling Individual counseling	7	100.0
Group counseling	7	100.0
· · · · · · · · · · · · · · · · · · ·	7	100.0
Family counseling Marital/couples counseling	4	57.1
Transitional services	4	57.1
Discharge planning	7	100.0
Aftercare/continuing care	7	100.0
No services offered	1	100.0
Pharmacotherapies	_	
Disulfiram (Antabuse®)	1	14.3
Naltrexone (oral)	2	28.6
Extended-release, injectable naltrexone/Vivitrol®	2	28.6
Acamprosate (Campral®)	1	14.3
Nicotine replacement	2	28.6
Non-nicotine smoking/tobacco cessation medications	2	28.6
Medications for psychiatric disorders	3	42.9
Methadone	_	42.5 —
Buprenorphine with naloxone (Suboxone®)	 1	14.3
Buprenorphine with naloxone Buprenorphine without naloxone	1	14.3
Buprenorphine subdermal implant (Probuphine®)	_	<u> </u>
No services offered	<u> </u>	— 57.1
Ancillary services	-	37.1
Case management services	6	85.7
Social skills development	7	100.0
Mentoring/peer support	6	85.7
Child care for clients' children	2	28.6
Assistance with obtaining social services	4	57.1
Employment counseling or training for clients	6	85.7
Continued	U	00.1

Types of services offered, by number and percent (continued)		
	Facilities	
	No.	%
Assistance in locating housing for clients	5	71.4
Domestic violence services	4	57.1
Early intervention for HIV	4	57.1
HIV or AIDS education, counseling, or support	4	57.1
Hepatitis education, counseling, or support	1	14.3
Health education other than HIV/AIDS or hepatitis	3	42.9
Substance abuse education	7	100.0
Transportation assistance to treatment	6	85.7
Mental health services	5	71.4
Acupuncture	_	_
Residential beds for clients' children		_
Self-help groups	5	71.4
Smoking/tobacco cessation counseling	3	42.9
No services offered	_	_
Other services		
Treatment for gambling disorder	2	28.6
Treatment for Internet use disorder	1	14.3
Treatment for other addiction disorder	2	28.6
No services offered	4	57.1

	Fac	ilities
	No.	%
Substance abuse counseling	7	100.0
Relapse prevention	7	100.0
Cognitive behavioral therapy	6	85.7
Motivational interviewing	7	100.0
Anger management	7	100.0
Brief intervention	7	100.0
Trauma-related counseling	6	85.7
12-step facilitation	6	85.7
Contingency management/motivational incentives	6	85.7
Dialectical behavior therapy	3	42.9
Rational emotive behavioral therapy	4	57.1
Matrix model	5	71.4
Computerized substance abuse treatment	-	<u> </u>
Community reinforcement plus vouchers	3	42.9
Other treatment approaches	_	_

Facility capacity and utilization rate ¹			
	Residential	Hospital inpatient	
Number of facilities	4	_	
Number of clients ²	63		
Number of designated beds	68	_	
Utilization rate ³	92.6	_	
Average number of designated beds per facility	17	_	

¹ Excludes facilities not reporting both client counts and number of beds; facilities whose client counts were reported by another facility; facilities that included client counts from other facilities; and facilities that did not respond to this question.

 $^{^{\}rm 2}$ Number of clients on March 31, 2017.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

	No.
Any type of medication-assisted therapy	‡
Methadone	‡
Buprenorphine	‡
Naltrexone	‡

Services in sign language for the deaf and hard-ofhearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	_	_
Any language other than English	4	57.1
Non-English language provided by		
Staff counselor only	2	50.0
On-call interpreter only	1	25.0
Both staff counselor and on-call interpreter	1	25.0
Languages provided by staff counselor ¹		
Spanish	1	33.3
American Indian/Alaskan Native languages	_	_
Other	2	66.7

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	6	85.7
Adult women	5	71.4
Clients with co-occurring disorders	5	71.4
Adult men	5	71.4
Clients who have experienced trauma	4	57.1
Criminal justice clients	4	57.1
DUI/DWI clients	2	28.6
Young adults	2	28.6
Adolescents	1	14.3
Clients who have experienced domestic violence	2	28.6
Clients who have experienced sexual		
abuse	3	42.9
Pregnant or postpartum women	1	14.3
Seniors or older adults	2	28.6
LGBT ¹	1	14.3
Veterans	1	14.3
Clients living with HIV/AIDS	2	28.6
Members of military families	_	_
Active duty military	_	_
Other	_	_
No program or group offered	1	14.3

¹ Lesbian, gay, bisexual, or transgender clients.

Symbol key

— Quantity is zero; * Less than 0.05 percent; n/a Not applicable; ‡ No facilities in this category; † Less than 1 per 100,000 population.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 31, 2017. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: https://www.samhsa.gov/data/all-reports

Access the latest N-SSATS public use files at: https://datafiles.samhsa.gov

Access N-SSATS profiles for individual states at: https://wwwdasis.samhsa.gov/

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at: https://findtreatment.samhsa.gov/

HITTONIAN SERVICES LOG

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality www.samhsa.gov/data

Location of treatment facilities

No image available for U.S. territories and other jurisdictions.